id	sid	tid	token	lemma	pos
cana-5141	1	1	communications	communication	NOUN
cana-5141	1	2	on	on	ADP
cana-5141	1	3	applied	apply	VERB
cana-5141	1	4	nonlinear	nonlinear	ADJ
cana-5141	1	5	analysis	analysis	NOUN
cana-5141	1	6	issn	issn	NOUN
cana-5141	1	7	:	:	PUNCT
cana-5141	1	8	1074	1074	NUM
cana-5141	1	9	-	-	PUNCT
cana-5141	1	10	133x	133x	NUM
cana-5141	1	11	vol	vol	NOUN
cana-5141	1	12	32	32	NUM
cana-5141	1	13	no	no	NOUN
cana-5141	1	14	.	.	PUNCT
cana-5141	2	1	icmasd	icmasd	NOUN
cana-5141	2	2	(	(	PUNCT
cana-5141	2	3	2025	2025	NUM
cana-5141	2	4	)	)	PUNCT
cana-5141	2	5	1137	1137	NUM
cana-5141	2	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	3	1	"	"	PUNCT
cana-5141	3	2	transformative	transformative	ADJ
cana-5141	3	3	approaches	approach	NOUN
cana-5141	3	4	to	to	ADP
cana-5141	3	5	alzheimer	alzheimer	PROPN
cana-5141	3	6	disease	disease	PROPN
cana-5141	3	7	treatment	treatment	NOUN
cana-5141	3	8	:	:	PUNCT
cana-5141	3	9	current	current	ADJ
cana-5141	3	10	progress	progress	NOUN
cana-5141	3	11	and	and	CCONJ
cana-5141	3	12	future	future	ADJ
cana-5141	3	13	direction	direction	NOUN
cana-5141	3	14	”	"	PUNCT
cana-5141	3	15	vandana	vandana	PROPN
cana-5141	3	16	bhatia1	bhatia1	PROPN
cana-5141	3	17	*	*	PROPN
cana-5141	3	18	,	,	PUNCT
cana-5141	3	19	vir	vir	PROPN
cana-5141	3	20	vikram	vikram	PROPN
cana-5141	3	21	sharma1	sharma1	PROPN
cana-5141	3	22	,	,	PUNCT
cana-5141	3	23	swati	swati	PROPN
cana-5141	3	24	rana2	rana2	PROPN
cana-5141	3	25	,	,	PUNCT
cana-5141	3	26	shagun	shagun	VERB
cana-5141	3	27	thakur2	thakur2	PROPN
cana-5141	3	28	,	,	PUNCT
cana-5141	3	29	yavnika	yavnika	PROPN
cana-5141	3	30	minhas2	minhas2	PROPN
cana-5141	3	31	,	,	PUNCT
cana-5141	3	32	aditya	aditya	PROPN
cana-5141	3	33	rattan2	rattan2	PROPN
cana-5141	3	34	1	1	NUM
cana-5141	3	35	department	department	NOUN
cana-5141	3	36	of	of	ADP
cana-5141	3	37	pharmacology	pharmacology	NOUN
cana-5141	3	38	,	,	PUNCT
cana-5141	3	39	ct	ct	PROPN
cana-5141	3	40	university	university	PROPN
cana-5141	3	41	ludhiana	ludhiana	PROPN
cana-5141	3	42	,	,	PUNCT
cana-5141	3	43	punjab	punjab	PROPN
cana-5141	3	44	,	,	PUNCT
cana-5141	3	45	142024	142024	NUM
cana-5141	3	46	2	2	NUM
cana-5141	3	47	department	department	NOUN
cana-5141	3	48	of	of	ADP
cana-5141	3	49	pharmacology	pharmacology	NOUN
cana-5141	3	50	,	,	PUNCT
cana-5141	3	51	laureate	laureate	PROPN
cana-5141	3	52	institute	institute	PROPN
cana-5141	3	53	of	of	ADP
cana-5141	3	54	pharmacy	pharmacy	PROPN
cana-5141	3	55	kathog	kathog	VERB
cana-5141	3	56	,	,	PUNCT
cana-5141	3	57	177101	177101	NUM
cana-5141	3	58	address	address	NOUN
cana-5141	3	59	of	of	ADP
cana-5141	3	60	correspondence	correspondence	NOUN
cana-5141	3	61	:	:	PUNCT
cana-5141	3	62	mrs	mrs	PROPN
cana-5141	3	63	.	.	PROPN
cana-5141	3	64	vandana	vandana	PROPN
cana-5141	3	65	bhatia	bhatia	PROPN
cana-5141	3	66	(	(	PUNCT
cana-5141	3	67	research	research	NOUN
cana-5141	3	68	scholar	scholar	NOUN
cana-5141	3	69	)	)	PUNCT
cana-5141	3	70	,	,	PUNCT
cana-5141	3	71	department	department	NOUN
cana-5141	3	72	of	of	ADP
cana-5141	3	73	pharmacology	pharmacology	NOUN
cana-5141	3	74	,	,	PUNCT
cana-5141	3	75	ct	ct	PROPN
cana-5141	3	76	university	university	PROPN
cana-5141	3	77	ludhiana	ludhiana	PROPN
cana-5141	3	78	,	,	PUNCT
cana-5141	3	79	punjab	punjab	ADJ
cana-5141	3	80	,	,	PUNCT
cana-5141	3	81	142024	142024	NUM
cana-5141	3	82	email	email	NOUN
cana-5141	3	83	:	:	PUNCT
cana-5141	3	84	vandana.bhatia40@gmail.com	vandana.bhatia40@gmail.com	PROPN
cana-5141	3	85	,	,	PUNCT
cana-5141	3	86	orcid	orcid	NOUN
cana-5141	4	1	i	i	PRON
cana-5141	4	2	d	d	NOUN
cana-5141	4	3	:	:	PUNCT
cana-5141	4	4	0000	0000	NUM
cana-5141	4	5	-	-	PUNCT
cana-5141	4	6	0002	0002	NUM
cana-5141	4	7	-	-	PUNCT
cana-5141	4	8	1614	1614	NUM
cana-5141	4	9	-	-	PUNCT
cana-5141	4	10	7192	7192	NUM
cana-5141	4	11	article	article	NOUN
cana-5141	4	12	history	history	NOUN
cana-5141	4	13	:	:	PUNCT
cana-5141	4	14	received	receive	VERB
cana-5141	4	15	:	:	PUNCT
cana-5141	4	16	12	12	NUM
cana-5141	4	17	-	-	SYM
cana-5141	4	18	12	12	NUM
cana-5141	4	19	-	-	PUNCT
cana-5141	4	20	2024	2024	NUM
cana-5141	4	21	revised	revise	VERB
cana-5141	4	22	:	:	PUNCT
cana-5141	4	23	25	25	NUM
cana-5141	4	24	-	-	PUNCT
cana-5141	4	25	01	01	NUM
cana-5141	4	26	-	-	PUNCT
cana-5141	4	27	2025	2025	NUM
cana-5141	4	28	accepted	accept	VERB
cana-5141	4	29	:	:	PUNCT
cana-5141	4	30	05	05	NUM
cana-5141	4	31	-	-	PUNCT
cana-5141	4	32	02	02	NUM
cana-5141	4	33	-	-	PUNCT
cana-5141	4	34	2025	2025	NUM
cana-5141	4	35	abstract	abstract	NOUN
cana-5141	4	36	:	:	PUNCT
cana-5141	4	37	alzheimer	alzheimer	PROPN
cana-5141	4	38	's	's	PART
cana-5141	4	39	disease	disease	NOUN
cana-5141	4	40	(	(	PUNCT
cana-5141	4	41	ad	ad	NOUN
cana-5141	4	42	)	)	PUNCT
cana-5141	4	43	is	be	AUX
cana-5141	4	44	a	a	DET
cana-5141	4	45	neurological	neurological	ADJ
cana-5141	4	46	condition	condition	NOUN
cana-5141	4	47	that	that	PRON
cana-5141	4	48	worsens	worsen	VERB
cana-5141	4	49	over	over	ADP
cana-5141	4	50	time	time	NOUN
cana-5141	4	51	and	and	CCONJ
cana-5141	4	52	is	be	AUX
cana-5141	4	53	characterised	characterise	VERB
cana-5141	4	54	by	by	ADP
cana-5141	4	55	tau	tau	PROPN
cana-5141	4	56	tangles	tangle	NOUN
cana-5141	4	57	and	and	CCONJ
cana-5141	4	58	amyloid	amyloid	NOUN
cana-5141	4	59	plaques	plaque	NOUN
cana-5141	4	60	.	.	PUNCT
cana-5141	5	1	current	current	ADJ
cana-5141	5	2	medications	medication	NOUN
cana-5141	5	3	mostly	mostly	ADV
cana-5141	5	4	address	address	VERB
cana-5141	5	5	symptoms	symptom	NOUN
cana-5141	5	6	,	,	PUNCT
cana-5141	5	7	despite	despite	SCONJ
cana-5141	5	8	significant	significant	ADJ
cana-5141	5	9	research	research	NOUN
cana-5141	5	10	advancement	advancement	NOUN
cana-5141	5	11	,	,	PUNCT
cana-5141	5	12	leaving	leave	VERB
cana-5141	5	13	a	a	DET
cana-5141	5	14	demand	demand	NOUN
cana-5141	5	15	for	for	ADP
cana-5141	5	16	disease	disease	NOUN
cana-5141	5	17	-	-	PUNCT
cana-5141	5	18	modifying	modify	VERB
cana-5141	5	19	therapy	therapy	NOUN
cana-5141	5	20	unfulfilled	unfulfilled	ADJ
cana-5141	5	21	.	.	PUNCT
cana-5141	6	1	new	new	ADJ
cana-5141	6	2	treatment	treatment	NOUN
cana-5141	6	3	approaches	approach	NOUN
cana-5141	6	4	target	target	VERB
cana-5141	6	5	the	the	DET
cana-5141	6	6	genetic	genetic	ADJ
cana-5141	6	7	and	and	CCONJ
cana-5141	6	8	molecular	molecular	ADJ
cana-5141	6	9	causes	cause	NOUN
cana-5141	6	10	of	of	ADP
cana-5141	6	11	ad	ad	NOUN
cana-5141	6	12	by	by	ADP
cana-5141	6	13	focussing	focusse	VERB
cana-5141	6	14	on	on	ADP
cana-5141	6	15	gene	gene	NOUN
cana-5141	6	16	editing	editing	NOUN
cana-5141	6	17	,	,	PUNCT
cana-5141	6	18	specifically	specifically	ADV
cana-5141	6	19	the	the	DET
cana-5141	6	20	crispr	crispr	ADJ
cana-5141	6	21	-	-	PUNCT
cana-5141	6	22	cas9	cas9	NOUN
cana-5141	6	23	system	system	NOUN
cana-5141	6	24	.	.	PUNCT
cana-5141	7	1	by	by	ADP
cana-5141	7	2	specifically	specifically	ADV
cana-5141	7	3	editing	edit	VERB
cana-5141	7	4	genes	gene	NOUN
cana-5141	7	5	linked	link	VERB
cana-5141	7	6	to	to	ADP
cana-5141	7	7	disease	disease	NOUN
cana-5141	7	8	,	,	PUNCT
cana-5141	7	9	including	include	VERB
cana-5141	7	10	app	app	NOUN
cana-5141	7	11	,	,	PUNCT
cana-5141	7	12	psen1	psen1	ADJ
cana-5141	7	13	,	,	PUNCT
cana-5141	7	14	psen2	psen2	NOUN
cana-5141	7	15	,	,	PUNCT
cana-5141	7	16	and	and	CCONJ
cana-5141	7	17	apoe4	apoe4	ADJ
cana-5141	7	18	,	,	PUNCT
cana-5141	7	19	crispr	crispr	ADJ
cana-5141	7	20	-	-	PUNCT
cana-5141	7	21	cas9	cas9	NOUN
cana-5141	7	22	aims	aim	VERB
cana-5141	7	23	to	to	PART
cana-5141	7	24	improve	improve	VERB
cana-5141	7	25	neuronal	neuronal	ADJ
cana-5141	7	26	protection	protection	NOUN
cana-5141	7	27	and	and	CCONJ
cana-5141	7	28	lessen	lessen	VERB
cana-5141	7	29	tau	tau	PROPN
cana-5141	7	30	and	and	CCONJ
cana-5141	7	31	amyloid	amyloid	NOUN
cana-5141	7	32	-	-	PUNCT
cana-5141	7	33	beta	beta	NOUN
cana-5141	7	34	pathology	pathology	NOUN
cana-5141	7	35	.	.	PUNCT
cana-5141	8	1	base	base	NOUN
cana-5141	8	2	and	and	CCONJ
cana-5141	8	3	prime	prime	ADJ
cana-5141	8	4	editing	editing	NOUN
cana-5141	8	5	are	be	AUX
cana-5141	8	6	two	two	NUM
cana-5141	8	7	recent	recent	ADJ
cana-5141	8	8	developments	development	NOUN
cana-5141	8	9	in	in	ADP
cana-5141	8	10	crispr	crispr	ADJ
cana-5141	8	11	technology	technology	NOUN
cana-5141	8	12	that	that	PRON
cana-5141	8	13	have	have	AUX
cana-5141	8	14	increased	increase	VERB
cana-5141	8	15	therapeutic	therapeutic	ADJ
cana-5141	8	16	potential	potential	NOUN
cana-5141	8	17	,	,	PUNCT
cana-5141	8	18	decreased	decrease	VERB
cana-5141	8	19	off	off	ADP
cana-5141	8	20	-	-	PUNCT
cana-5141	8	21	target	target	NOUN
cana-5141	8	22	effects	effect	NOUN
cana-5141	8	23	,	,	PUNCT
cana-5141	8	24	and	and	CCONJ
cana-5141	8	25	improved	improve	VERB
cana-5141	8	26	editing	edit	VERB
cana-5141	8	27	specificity	specificity	NOUN
cana-5141	8	28	.	.	PUNCT
cana-5141	9	1	in	in	ADP
cana-5141	9	2	cellular	cellular	ADJ
cana-5141	9	3	and	and	CCONJ
cana-5141	9	4	animal	animal	NOUN
cana-5141	9	5	models	model	NOUN
cana-5141	9	6	,	,	PUNCT
cana-5141	9	7	preclinical	preclinical	ADJ
cana-5141	9	8	research	research	NOUN
cana-5141	9	9	shows	show	VERB
cana-5141	9	10	that	that	SCONJ
cana-5141	9	11	it	it	PRON
cana-5141	9	12	is	be	AUX
cana-5141	9	13	effective	effective	ADJ
cana-5141	9	14	in	in	ADP
cana-5141	9	15	repairing	repair	VERB
cana-5141	9	16	mutations	mutation	NOUN
cana-5141	9	17	,	,	PUNCT
cana-5141	9	18	modifying	modify	VERB
cana-5141	9	19	gene	gene	NOUN
cana-5141	9	20	expression	expression	NOUN
cana-5141	9	21	,	,	PUNCT
cana-5141	9	22	and	and	CCONJ
cana-5141	9	23	lowering	lower	VERB
cana-5141	9	24	the	the	DET
cana-5141	9	25	synthesis	synthesis	NOUN
cana-5141	9	26	of	of	ADP
cana-5141	9	27	neurotoxic	neurotoxic	ADJ
cana-5141	9	28	proteins	protein	NOUN
cana-5141	9	29	.	.	PUNCT
cana-5141	10	1	adeno	adeno	NOUN
cana-5141	10	2	-	-	PUNCT
cana-5141	10	3	associated	associate	VERB
cana-5141	10	4	viruses	virus	NOUN
cana-5141	10	5	(	(	PUNCT
cana-5141	10	6	aavs	aavs	ADV
cana-5141	10	7	)	)	PUNCT
cana-5141	10	8	and	and	CCONJ
cana-5141	10	9	lipid	lipid	NOUN
cana-5141	10	10	nanoparticles	nanoparticle	NOUN
cana-5141	10	11	are	be	AUX
cana-5141	10	12	two	two	NUM
cana-5141	10	13	delivery	delivery	NOUN
cana-5141	10	14	systems	system	NOUN
cana-5141	10	15	that	that	PRON
cana-5141	10	16	have	have	AUX
cana-5141	10	17	been	be	AUX
cana-5141	10	18	created	create	VERB
cana-5141	10	19	to	to	PART
cana-5141	10	20	get	get	VERB
cana-5141	10	21	across	across	ADP
cana-5141	10	22	the	the	DET
cana-5141	10	23	blood	blood	NOUN
cana-5141	10	24	-	-	PUNCT
cana-5141	10	25	brain	brain	NOUN
cana-5141	10	26	barrier	barrier	NOUN
cana-5141	10	27	's	's	PART
cana-5141	10	28	obstacles	obstacle	NOUN
cana-5141	10	29	.	.	PUNCT
cana-5141	11	1	clinical	clinical	ADJ
cana-5141	11	2	use	use	NOUN
cana-5141	11	3	is	be	AUX
cana-5141	11	4	nevertheless	nevertheless	ADV
cana-5141	11	5	hampered	hamper	VERB
cana-5141	11	6	by	by	ADP
cana-5141	11	7	concerns	concern	NOUN
cana-5141	11	8	about	about	ADP
cana-5141	11	9	long	long	ADJ
cana-5141	11	10	-	-	PUNCT
cana-5141	11	11	term	term	NOUN
cana-5141	11	12	safety	safety	NOUN
cana-5141	11	13	,	,	PUNCT
cana-5141	11	14	distribution	distribution	NOUN
cana-5141	11	15	efficiency	efficiency	NOUN
cana-5141	11	16	,	,	PUNCT
cana-5141	11	17	and	and	CCONJ
cana-5141	11	18	ethical	ethical	ADJ
cana-5141	11	19	issues	issue	NOUN
cana-5141	11	20	,	,	PUNCT
cana-5141	11	21	despite	despite	SCONJ
cana-5141	11	22	encouraging	encourage	VERB
cana-5141	11	23	results	result	NOUN
cana-5141	11	24	.	.	PUNCT
cana-5141	12	1	crispr	crispr	ADJ
cana-5141	12	2	-	-	PUNCT
cana-5141	12	3	cas9	cas9	NOUN
cana-5141	12	4	's	's	PART
cana-5141	12	5	combination	combination	NOUN
cana-5141	12	6	with	with	ADP
cana-5141	12	7	immunotherapy	immunotherapy	NOUN
cana-5141	12	8	and	and	CCONJ
cana-5141	12	9	artificial	artificial	ADJ
cana-5141	12	10	intelligence	intelligence	NOUN
cana-5141	12	11	has	have	AUX
cana-5141	12	12	created	create	VERB
cana-5141	12	13	new	new	ADJ
cana-5141	12	14	opportunities	opportunity	NOUN
cana-5141	12	15	for	for	ADP
cana-5141	12	16	precision	precision	NOUN
cana-5141	12	17	medicine	medicine	NOUN
cana-5141	12	18	by	by	ADP
cana-5141	12	19	providing	provide	VERB
cana-5141	12	20	specialised	specialised	ADJ
cana-5141	12	21	methods	method	NOUN
cana-5141	12	22	to	to	PART
cana-5141	12	23	address	address	VERB
cana-5141	12	24	the	the	DET
cana-5141	12	25	pathological	pathological	ADJ
cana-5141	12	26	and	and	CCONJ
cana-5141	12	27	genetic	genetic	ADJ
cana-5141	12	28	characteristics	characteristic	NOUN
cana-5141	12	29	of	of	ADP
cana-5141	12	30	ad	ad	NOUN
cana-5141	12	31	.	.	PUNCT
cana-5141	13	1	with	with	ADP
cana-5141	13	2	its	its	PRON
cana-5141	13	3	potential	potential	NOUN
cana-5141	13	4	to	to	PART
cana-5141	13	5	shift	shift	VERB
cana-5141	13	6	ad	ad	NOUN
cana-5141	13	7	treatment	treatment	NOUN
cana-5141	13	8	from	from	ADP
cana-5141	13	9	symptomatic	symptomatic	ADJ
cana-5141	13	10	management	management	NOUN
cana-5141	13	11	to	to	PART
cana-5141	13	12	curative	curative	ADJ
cana-5141	13	13	approaches	approach	NOUN
cana-5141	13	14	,	,	PUNCT
cana-5141	13	15	this	this	DET
cana-5141	13	16	review	review	NOUN
cana-5141	13	17	focusses	focusse	VERB
cana-5141	13	18	on	on	ADP
cana-5141	13	19	the	the	DET
cana-5141	13	20	advancements	advancement	NOUN
cana-5141	13	21	,	,	PUNCT
cana-5141	13	22	difficulties	difficulty	NOUN
cana-5141	13	23	,	,	PUNCT
cana-5141	13	24	and	and	CCONJ
cana-5141	13	25	prospects	prospect	NOUN
cana-5141	13	26	of	of	ADP
cana-5141	13	27	crispr	crispr	NOUN
cana-5141	13	28	-	-	PUNCT
cana-5141	13	29	cas9	cas9	NOUN
cana-5141	13	30	in	in	ADP
cana-5141	13	31	ad	ad	NOUN
cana-5141	13	32	therapies	therapy	NOUN
cana-5141	13	33	.	.	PUNCT
cana-5141	14	1	to	to	PART
cana-5141	14	2	advance	advance	VERB
cana-5141	14	3	crispr	crispr	NOUN
cana-5141	14	4	-	-	PUNCT
cana-5141	14	5	based	base	VERB
cana-5141	14	6	medicines	medicine	NOUN
cana-5141	14	7	into	into	ADP
cana-5141	14	8	clinical	clinical	ADJ
cana-5141	14	9	practice	practice	NOUN
cana-5141	14	10	,	,	PUNCT
cana-5141	14	11	ongoing	ongoing	ADJ
cana-5141	14	12	innovation	innovation	NOUN
cana-5141	14	13	in	in	ADP
cana-5141	14	14	gene	gene	NOUN
cana-5141	14	15	-	-	PUNCT
cana-5141	14	16	editing	edit	VERB
cana-5141	14	17	technologies	technology	NOUN
cana-5141	14	18	,	,	PUNCT
cana-5141	14	19	delivery	delivery	NOUN
cana-5141	14	20	methods	method	NOUN
cana-5141	14	21	,	,	PUNCT
cana-5141	14	22	and	and	CCONJ
cana-5141	14	23	ethical	ethical	ADJ
cana-5141	14	24	frameworks	framework	NOUN
cana-5141	14	25	will	will	AUX
cana-5141	14	26	be	be	AUX
cana-5141	14	27	essential	essential	ADJ
cana-5141	14	28	.	.	PUNCT
cana-5141	15	1	keywords	keyword	NOUN
cana-5141	15	2	:	:	PUNCT
cana-5141	15	3	alzheimer	alzheimer	PROPN
cana-5141	15	4	's	's	PART
cana-5141	15	5	disease	disease	NOUN
cana-5141	15	6	,	,	PUNCT
cana-5141	15	7	gene	gene	NOUN
cana-5141	15	8	editing	editing	NOUN
cana-5141	15	9	,	,	PUNCT
cana-5141	15	10	amyloid	amyloid	NOUN
cana-5141	15	11	-	-	PUNCT
cana-5141	15	12	β	β	NOUN
cana-5141	15	13	,	,	PUNCT
cana-5141	15	14	nanoparticle	nanoparticle	NOUN
cana-5141	15	15	delivery	delivery	NOUN
cana-5141	15	16	,	,	PUNCT
cana-5141	15	17	off	off	ADP
cana-5141	15	18	-	-	PUNCT
cana-5141	15	19	target	target	NOUN
cana-5141	15	20	effects	effect	NOUN
cana-5141	15	21	,	,	PUNCT
cana-5141	15	22	crispr	crispr	NOUN
cana-5141	15	23	-	-	PUNCT
cana-5141	15	24	cas9	cas9	NOUN
cana-5141	15	25	.	.	PUNCT
cana-5141	16	1	1	1	X
cana-5141	16	2	.	.	X
cana-5141	16	3	introduction	introduction	PROPN
cana-5141	16	4	alzheimer	alzheimer	PROPN
cana-5141	16	5	’s	’s	PART
cana-5141	16	6	disease	disease	NOUN
cana-5141	16	7	(	(	PUNCT
cana-5141	16	8	ad	ad	NOUN
cana-5141	16	9	)	)	PUNCT
cana-5141	16	10	is	be	AUX
cana-5141	16	11	a	a	DET
cana-5141	16	12	progressive	progressive	ADJ
cana-5141	16	13	neurodegenerative	neurodegenerative	ADJ
cana-5141	16	14	condition	condition	NOUN
cana-5141	16	15	primarily	primarily	ADV
cana-5141	16	16	affecting	affect	VERB
cana-5141	16	17	individuals	individual	NOUN
cana-5141	16	18	over	over	ADP
cana-5141	16	19	65	65	NUM
cana-5141	16	20	.	.	PUNCT
cana-5141	17	1	early	early	ADJ
cana-5141	17	2	-	-	PUNCT
cana-5141	17	3	onset	onset	NOUN
cana-5141	17	4	ad	ad	NOUN
cana-5141	17	5	,	,	PUNCT
cana-5141	17	6	occurring	occur	VERB
cana-5141	17	7	before	before	ADP
cana-5141	17	8	this	this	DET
cana-5141	17	9	age	age	NOUN
cana-5141	17	10	,	,	PUNCT
cana-5141	17	11	accounts	account	VERB
cana-5141	17	12	for	for	ADP
cana-5141	17	13	less	less	ADJ
cana-5141	17	14	than	than	ADP
cana-5141	17	15	5	5	NUM
cana-5141	17	16	%	%	NOUN
cana-5141	17	17	of	of	ADP
cana-5141	17	18	cases	case	NOUN
cana-5141	17	19	mailto:vandana.bhatia40@gmail.com	mailto:vandana.bhatia40@gmail.com	X
cana-5141	17	20	communications	communication	NOUN
cana-5141	17	21	on	on	ADP
cana-5141	17	22	applied	apply	VERB
cana-5141	17	23	nonlinear	nonlinear	ADJ
cana-5141	17	24	analysis	analysis	NOUN
cana-5141	17	25	issn	issn	NOUN
cana-5141	17	26	:	:	PUNCT
cana-5141	17	27	1074	1074	NUM
cana-5141	17	28	-	-	PUNCT
cana-5141	17	29	133x	133x	NUM
cana-5141	17	30	vol	vol	NOUN
cana-5141	17	31	32	32	NUM
cana-5141	17	32	no	no	NOUN
cana-5141	17	33	.	.	PUNCT
cana-5141	18	1	icmasd	icmasd	NOUN
cana-5141	18	2	(	(	PUNCT
cana-5141	18	3	2025	2025	NUM
cana-5141	18	4	)	)	PUNCT
cana-5141	18	5	1138	1138	NUM
cana-5141	18	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	18	7	and	and	CCONJ
cana-5141	18	8	is	be	AUX
cana-5141	18	9	often	often	ADV
cana-5141	18	10	familial	familial	ADJ
cana-5141	18	11	,	,	PUNCT
cana-5141	18	12	driven	drive	VERB
cana-5141	18	13	by	by	ADP
cana-5141	18	14	inherited	inherit	VERB
cana-5141	18	15	genetic	genetic	ADJ
cana-5141	18	16	mutations	mutation	NOUN
cana-5141	19	1	[	[	X
cana-5141	19	2	1	1	NUM
cana-5141	19	3	]	]	PUNCT
cana-5141	19	4	.	.	PUNCT
cana-5141	20	1	in	in	ADP
cana-5141	20	2	contrast	contrast	NOUN
cana-5141	20	3	,	,	PUNCT
cana-5141	20	4	late	late	ADJ
cana-5141	20	5	-	-	PUNCT
cana-5141	20	6	onset	onset	NOUN
cana-5141	20	7	ad	ad	NOUN
cana-5141	20	8	,	,	PUNCT
cana-5141	20	9	usually	usually	ADV
cana-5141	20	10	sporadic	sporadic	ADJ
cana-5141	20	11	,	,	PUNCT
cana-5141	20	12	lacks	lack	VERB
cana-5141	20	13	identifiable	identifiable	ADJ
cana-5141	20	14	genetic	genetic	ADJ
cana-5141	20	15	mutations	mutation	NOUN
cana-5141	20	16	.	.	PUNCT
cana-5141	21	1	familial	familial	ADJ
cana-5141	21	2	ad	ad	NOUN
cana-5141	21	3	is	be	AUX
cana-5141	21	4	linked	link	VERB
cana-5141	21	5	to	to	ADP
cana-5141	21	6	mutations	mutation	NOUN
cana-5141	21	7	in	in	ADP
cana-5141	21	8	the	the	DET
cana-5141	21	9	amyloid	amyloid	NOUN
cana-5141	21	10	precursor	precursor	NOUN
cana-5141	21	11	protein	protein	NOUN
cana-5141	21	12	(	(	PUNCT
cana-5141	21	13	app	app	NOUN
cana-5141	21	14	)	)	PUNCT
cana-5141	21	15	gene	gene	NOUN
cana-5141	21	16	and	and	CCONJ
cana-5141	21	17	the	the	DET
cana-5141	21	18	presenilin	presenilin	PROPN
cana-5141	21	19	(	(	PUNCT
cana-5141	21	20	psen	psen	NOUN
cana-5141	21	21	)	)	PUNCT
cana-5141	21	22	genes	gene	NOUN
cana-5141	21	23	,	,	PUNCT
cana-5141	21	24	psen1	psen1	NOUN
cana-5141	21	25	and	and	CCONJ
cana-5141	21	26	psen2	psen2	NOUN
cana-5141	21	27	,	,	PUNCT
cana-5141	21	28	which	which	PRON
cana-5141	21	29	play	play	VERB
cana-5141	21	30	critical	critical	ADJ
cana-5141	21	31	roles	role	NOUN
cana-5141	21	32	in	in	ADP
cana-5141	21	33	amyloid	amyloid	NOUN
cana-5141	21	34	-	-	PUNCT
cana-5141	21	35	beta	beta	NOUN
cana-5141	21	36	(	(	PUNCT
cana-5141	21	37	aβ	aβ	NOUN
cana-5141	21	38	)	)	PUNCT
cana-5141	21	39	production	production	NOUN
cana-5141	21	40	via	via	ADP
cana-5141	21	41	gamma	gamma	NOUN
cana-5141	21	42	-	-	PUNCT
cana-5141	21	43	secretase	secretase	NOUN
cana-5141	21	44	activity	activity	NOUN
cana-5141	21	45	.	.	PUNCT
cana-5141	22	1	a	a	DET
cana-5141	22	2	hallmark	hallmark	NOUN
cana-5141	22	3	of	of	ADP
cana-5141	22	4	ad	ad	NOUN
cana-5141	22	5	includes	include	VERB
cana-5141	22	6	the	the	DET
cana-5141	22	7	formation	formation	NOUN
cana-5141	22	8	of	of	ADP
cana-5141	22	9	extracellular	extracellular	ADJ
cana-5141	22	10	aβ	aβ	NOUN
cana-5141	22	11	plaques	plaque	NOUN
cana-5141	22	12	and	and	CCONJ
cana-5141	22	13	hyperphosphorylated	hyperphosphorylate	VERB
cana-5141	22	14	tau	tau	PROPN
cana-5141	22	15	protein	protein	NOUN
cana-5141	22	16	aggregates	aggregate	NOUN
cana-5141	22	17	,	,	PUNCT
cana-5141	22	18	leading	lead	VERB
cana-5141	22	19	to	to	ADP
cana-5141	22	20	cognitive	cognitive	ADJ
cana-5141	22	21	decline	decline	NOUN
cana-5141	22	22	,	,	PUNCT
cana-5141	22	23	motor	motor	NOUN
cana-5141	22	24	dysfunction	dysfunction	NOUN
cana-5141	22	25	,	,	PUNCT
cana-5141	22	26	and	and	CCONJ
cana-5141	22	27	impaired	impaired	ADJ
cana-5141	22	28	daily	daily	ADJ
cana-5141	22	29	living	living	NOUN
cana-5141	22	30	[	[	X
cana-5141	22	31	2	2	NUM
cana-5141	22	32	]	]	PUNCT
cana-5141	22	33	.	.	PUNCT
cana-5141	23	1	ad	ad	NOUN
cana-5141	23	2	progression	progression	NOUN
cana-5141	23	3	is	be	AUX
cana-5141	23	4	categorized	categorize	VERB
cana-5141	23	5	into	into	ADP
cana-5141	23	6	stages	stage	NOUN
cana-5141	23	7	,	,	PUNCT
cana-5141	23	8	beginning	begin	VERB
cana-5141	23	9	with	with	ADP
cana-5141	23	10	mild	mild	ADJ
cana-5141	23	11	mental	mental	ADJ
cana-5141	23	12	decline	decline	NOUN
cana-5141	23	13	,	,	PUNCT
cana-5141	23	14	advancing	advance	VERB
cana-5141	23	15	to	to	ADP
cana-5141	23	16	mild	mild	ADJ
cana-5141	23	17	cognitive	cognitive	ADJ
cana-5141	23	18	impairment	impairment	NOUN
cana-5141	23	19	,	,	PUNCT
cana-5141	23	20	and	and	CCONJ
cana-5141	23	21	culminating	culminate	VERB
cana-5141	23	22	in	in	ADP
cana-5141	23	23	severe	severe	ADJ
cana-5141	23	24	symptoms	symptom	NOUN
cana-5141	23	25	like	like	ADP
cana-5141	23	26	hallucinations	hallucination	NOUN
cana-5141	23	27	,	,	PUNCT
cana-5141	23	28	anxiety	anxiety	NOUN
cana-5141	23	29	,	,	PUNCT
cana-5141	23	30	and	and	CCONJ
cana-5141	23	31	sleep	sleep	VERB
cana-5141	23	32	disorders	disorder	NOUN
cana-5141	23	33	.	.	PUNCT
cana-5141	24	1	beyond	beyond	ADP
cana-5141	24	2	genetic	genetic	ADJ
cana-5141	24	3	factors	factor	NOUN
cana-5141	24	4	,	,	PUNCT
cana-5141	24	5	oxidative	oxidative	ADJ
cana-5141	24	6	stress	stress	NOUN
cana-5141	24	7	and	and	CCONJ
cana-5141	24	8	neuroinflammation	neuroinflammation	NOUN
cana-5141	24	9	also	also	ADV
cana-5141	24	10	play	play	VERB
cana-5141	24	11	significant	significant	ADJ
cana-5141	24	12	roles	role	NOUN
cana-5141	24	13	in	in	ADP
cana-5141	24	14	ad	ad	NOUN
cana-5141	24	15	pathogenesis	pathogenesis	NOUN
cana-5141	24	16	,	,	PUNCT
cana-5141	24	17	complicating	complicate	VERB
cana-5141	24	18	treatment	treatment	NOUN
cana-5141	24	19	efforts	effort	NOUN
cana-5141	24	20	.	.	PUNCT
cana-5141	25	1	current	current	ADJ
cana-5141	25	2	clinical	clinical	ADJ
cana-5141	25	3	approaches	approach	NOUN
cana-5141	25	4	focus	focus	VERB
cana-5141	25	5	on	on	ADP
cana-5141	25	6	slowing	slow	VERB
cana-5141	25	7	symptom	symptom	NOUN
cana-5141	25	8	progression	progression	NOUN
cana-5141	25	9	and	and	CCONJ
cana-5141	25	10	cognitive	cognitive	ADJ
cana-5141	25	11	decline	decline	NOUN
cana-5141	25	12	,	,	PUNCT
cana-5141	25	13	but	but	CCONJ
cana-5141	25	14	no	no	DET
cana-5141	25	15	cure	cure	NOUN
cana-5141	25	16	exists	exist	VERB
cana-5141	25	17	,	,	PUNCT
cana-5141	25	18	and	and	CCONJ
cana-5141	25	19	patients	patient	NOUN
cana-5141	25	20	often	often	ADV
cana-5141	25	21	progress	progress	VERB
cana-5141	25	22	to	to	ADP
cana-5141	25	23	advanced	advanced	ADJ
cana-5141	25	24	stages	stage	NOUN
cana-5141	25	25	.	.	PUNCT
cana-5141	26	1	the	the	DET
cana-5141	26	2	heterogeneity	heterogeneity	NOUN
cana-5141	26	3	of	of	ADP
cana-5141	26	4	ad	ad	NOUN
cana-5141	26	5	presentations	presentation	NOUN
cana-5141	26	6	highlights	highlight	VERB
cana-5141	26	7	the	the	DET
cana-5141	26	8	need	need	NOUN
cana-5141	26	9	for	for	ADP
cana-5141	26	10	personalized	personalized	ADJ
cana-5141	26	11	treatments	treatment	NOUN
cana-5141	26	12	,	,	PUNCT
cana-5141	26	13	emphasizing	emphasize	VERB
cana-5141	26	14	the	the	DET
cana-5141	26	15	urgency	urgency	NOUN
cana-5141	26	16	of	of	ADP
cana-5141	26	17	innovative	innovative	ADJ
cana-5141	26	18	research	research	NOUN
cana-5141	26	19	targeting	target	VERB
cana-5141	26	20	disease	disease	NOUN
cana-5141	26	21	-	-	PUNCT
cana-5141	26	22	modifying	modify	VERB
cana-5141	26	23	therapies	therapy	NOUN
cana-5141	26	24	[	[	X
cana-5141	26	25	3	3	NUM
cana-5141	26	26	]	]	PUNCT
cana-5141	26	27	.	.	PUNCT
cana-5141	27	1	alzheimer	alzheimer	PROPN
cana-5141	27	2	’s	’s	PART
cana-5141	27	3	disease	disease	NOUN
cana-5141	27	4	(	(	PUNCT
cana-5141	27	5	ad	ad	NOUN
cana-5141	27	6	)	)	PUNCT
cana-5141	27	7	research	research	NOUN
cana-5141	27	8	has	have	AUX
cana-5141	27	9	made	make	VERB
cana-5141	27	10	significant	significant	ADJ
cana-5141	27	11	strides	stride	NOUN
cana-5141	27	12	,	,	PUNCT
cana-5141	27	13	particularly	particularly	ADV
cana-5141	27	14	through	through	ADP
cana-5141	27	15	clinical	clinical	ADJ
cana-5141	27	16	trials	trial	NOUN
cana-5141	27	17	targeting	target	VERB
cana-5141	27	18	its	its	PRON
cana-5141	27	19	complex	complex	ADJ
cana-5141	27	20	pathology	pathology	NOUN
cana-5141	27	21	.	.	PUNCT
cana-5141	28	1	amyloid	amyloid	NOUN
cana-5141	28	2	-	-	PUNCT
cana-5141	28	3	centric	centric	ADJ
cana-5141	28	4	therapies	therapy	NOUN
cana-5141	28	5	,	,	PUNCT
cana-5141	28	6	such	such	ADJ
cana-5141	28	7	as	as	ADP
cana-5141	28	8	aducanumab	aducanumab	NOUN
cana-5141	28	9	by	by	ADP
cana-5141	28	10	biogen	biogen	PROPN
cana-5141	28	11	,	,	PUNCT
cana-5141	28	12	lecanemab	lecanemab	NOUN
cana-5141	28	13	by	by	ADP
cana-5141	28	14	eisai	eisai	NOUN
cana-5141	28	15	and	and	CCONJ
cana-5141	28	16	biogen	biogen	PROPN
cana-5141	28	17	,	,	PUNCT
cana-5141	28	18	gantenerumab	gantenerumab	NOUN
cana-5141	28	19	by	by	ADP
cana-5141	28	20	roche	roche	PROPN
cana-5141	28	21	,	,	PUNCT
cana-5141	28	22	and	and	CCONJ
cana-5141	28	23	donanemab	donanemab	VERB
cana-5141	28	24	by	by	ADP
cana-5141	28	25	eli	eli	PROPN
cana-5141	28	26	lilly	lilly	PROPN
cana-5141	28	27	,	,	PUNCT
cana-5141	28	28	have	have	AUX
cana-5141	28	29	focused	focus	VERB
cana-5141	28	30	on	on	ADP
cana-5141	28	31	reducing	reduce	VERB
cana-5141	28	32	amyloid	amyloid	NOUN
cana-5141	28	33	plaques	plaque	NOUN
cana-5141	28	34	to	to	PART
cana-5141	28	35	slow	slow	VERB
cana-5141	28	36	cognitive	cognitive	ADJ
cana-5141	28	37	decline	decline	NOUN
cana-5141	29	1	[	[	X
cana-5141	29	2	4].while	4].while	NUM
cana-5141	29	3	promising	promise	VERB
cana-5141	29	4	,	,	PUNCT
cana-5141	29	5	these	these	DET
cana-5141	29	6	approaches	approach	NOUN
cana-5141	29	7	have	have	AUX
cana-5141	29	8	faced	face	VERB
cana-5141	29	9	challenges	challenge	NOUN
cana-5141	29	10	,	,	PUNCT
cana-5141	29	11	as	as	SCONJ
cana-5141	29	12	seen	see	VERB
cana-5141	29	13	in	in	ADP
cana-5141	29	14	the	the	DET
cana-5141	29	15	failures	failure	NOUN
cana-5141	29	16	of	of	ADP
cana-5141	29	17	semagacestat	semagacestat	NOUN
cana-5141	29	18	,	,	PUNCT
cana-5141	29	19	a	a	DET
cana-5141	29	20	gamma	gamma	NOUN
cana-5141	29	21	-	-	PUNCT
cana-5141	29	22	secretase	secretase	NOUN
cana-5141	29	23	inhibitor	inhibitor	NOUN
cana-5141	29	24	,	,	PUNCT
cana-5141	29	25	and	and	CCONJ
cana-5141	29	26	bace	bace	PROPN
cana-5141	29	27	inhibitors	inhibitor	NOUN
cana-5141	29	28	like	like	ADP
cana-5141	29	29	elenbecestat	elenbecestat	NOUN
cana-5141	29	30	and	and	CCONJ
cana-5141	29	31	atabecestat	atabecestat	ADJ
cana-5141	29	32	.	.	PUNCT
cana-5141	30	1	tau	tau	NOUN
cana-5141	30	2	-	-	PUNCT
cana-5141	30	3	targeting	target	VERB
cana-5141	30	4	therapies	therapy	NOUN
cana-5141	30	5	,	,	PUNCT
cana-5141	30	6	such	such	ADJ
cana-5141	30	7	as	as	ADP
cana-5141	30	8	lmtx	lmtx	NOUN
cana-5141	30	9	by	by	ADP
cana-5141	30	10	taurx	taurx	NOUN
cana-5141	30	11	pharmaceuticals	pharmaceutical	NOUN
cana-5141	30	12	,	,	PUNCT
cana-5141	30	13	aim	aim	VERB
cana-5141	30	14	to	to	PART
cana-5141	30	15	mitigate	mitigate	VERB
cana-5141	30	16	tau	tau	PROPN
cana-5141	30	17	tangle	tangle	NOUN
cana-5141	30	18	progression	progression	NOUN
cana-5141	30	19	,	,	PUNCT
cana-5141	30	20	while	while	SCONJ
cana-5141	30	21	alternative	alternative	ADJ
cana-5141	30	22	approaches	approach	NOUN
cana-5141	30	23	like	like	ADP
cana-5141	30	24	anavex	anavex	PROPN
cana-5141	30	25	2–73	2–73	PROPN
cana-5141	30	26	,	,	PUNCT
cana-5141	30	27	targeting	target	VERB
cana-5141	30	28	the	the	DET
cana-5141	30	29	sigma-1	sigma-1	NUM
cana-5141	30	30	receptor	receptor	NOUN
cana-5141	30	31	,	,	PUNCT
cana-5141	30	32	and	and	CCONJ
cana-5141	30	33	alzt	alzt	PROPN
cana-5141	30	34	-	-	PUNCT
cana-5141	30	35	op1	op1	PROPN
cana-5141	30	36	,	,	PUNCT
cana-5141	30	37	which	which	PRON
cana-5141	30	38	combines	combine	VERB
cana-5141	30	39	anti	anti	ADJ
cana-5141	30	40	-	-	ADJ
cana-5141	30	41	inflammatory	inflammatory	ADJ
cana-5141	30	42	and	and	CCONJ
cana-5141	30	43	anti	anti	ADJ
cana-5141	30	44	-	-	ADJ
cana-5141	30	45	amyloid	amyloid	ADJ
cana-5141	30	46	strategies	strategy	NOUN
cana-5141	30	47	,	,	PUNCT
cana-5141	30	48	offer	offer	VERB
cana-5141	30	49	innovative	innovative	ADJ
cana-5141	30	50	solutions	solution	NOUN
cana-5141	30	51	[	[	X
cana-5141	30	52	5	5	NUM
cana-5141	30	53	]	]	PUNCT
cana-5141	30	54	.	.	PUNCT
cana-5141	31	1	among	among	ADP
cana-5141	31	2	these	these	PRON
cana-5141	31	3	,	,	PUNCT
cana-5141	31	4	lecanemab	lecanemab	NOUN
cana-5141	31	5	,	,	PUNCT
cana-5141	31	6	a	a	DET
cana-5141	31	7	monoclonal	monoclonal	NOUN
cana-5141	31	8	antibody	antibody	NOUN
cana-5141	31	9	targeting	target	VERB
cana-5141	31	10	amyloid	amyloid	NOUN
cana-5141	31	11	-	-	PUNCT
cana-5141	31	12	beta	beta	NOUN
cana-5141	31	13	protofibrils	protofibril	NOUN
cana-5141	31	14	,	,	PUNCT
cana-5141	31	15	has	have	AUX
cana-5141	31	16	emerged	emerge	VERB
cana-5141	31	17	as	as	ADP
cana-5141	31	18	a	a	DET
cana-5141	31	19	promising	promising	ADJ
cana-5141	31	20	therapy	therapy	NOUN
cana-5141	31	21	[	[	X
cana-5141	31	22	6	6	NUM
cana-5141	31	23	]	]	PUNCT
cana-5141	31	24	.	.	PUNCT
cana-5141	32	1	clinical	clinical	ADJ
cana-5141	32	2	trials	trial	NOUN
cana-5141	32	3	have	have	AUX
cana-5141	32	4	shown	show	VERB
cana-5141	32	5	it	it	PRON
cana-5141	32	6	reduces	reduce	VERB
cana-5141	32	7	amyloid	amyloid	NOUN
cana-5141	32	8	levels	level	NOUN
cana-5141	32	9	and	and	CCONJ
cana-5141	32	10	moderately	moderately	ADV
cana-5141	32	11	slows	slow	VERB
cana-5141	32	12	cognitive	cognitive	ADJ
cana-5141	32	13	decline	decline	NOUN
cana-5141	32	14	in	in	ADP
cana-5141	32	15	patients	patient	NOUN
cana-5141	32	16	with	with	ADP
cana-5141	32	17	mild	mild	ADJ
cana-5141	32	18	cognitive	cognitive	ADJ
cana-5141	32	19	impairment	impairment	NOUN
cana-5141	32	20	or	or	CCONJ
cana-5141	32	21	mild	mild	ADJ
cana-5141	32	22	ad	ad	NOUN
cana-5141	32	23	dementia	dementia	NOUN
cana-5141	32	24	,	,	PUNCT
cana-5141	32	25	leading	lead	VERB
cana-5141	32	26	to	to	ADP
cana-5141	32	27	its	its	PRON
cana-5141	32	28	approval	approval	NOUN
cana-5141	32	29	.	.	PUNCT
cana-5141	33	1	however	however	ADV
cana-5141	33	2	,	,	PUNCT
cana-5141	33	3	challenges	challenge	NOUN
cana-5141	33	4	remain	remain	VERB
cana-5141	33	5	,	,	PUNCT
cana-5141	33	6	including	include	VERB
cana-5141	33	7	its	its	PRON
cana-5141	33	8	high	high	ADJ
cana-5141	33	9	cost	cost	NOUN
cana-5141	33	10	,	,	PUNCT
cana-5141	33	11	moderate	moderate	ADJ
cana-5141	33	12	efficacy	efficacy	NOUN
cana-5141	33	13	,	,	PUNCT
cana-5141	33	14	potential	potential	ADJ
cana-5141	33	15	side	side	NOUN
cana-5141	33	16	effects	effect	NOUN
cana-5141	33	17	such	such	ADJ
cana-5141	33	18	as	as	ADP
cana-5141	33	19	amyloid	amyloid	NOUN
cana-5141	33	20	-	-	PUNCT
cana-5141	33	21	related	relate	VERB
cana-5141	33	22	imaging	imaging	NOUN
cana-5141	33	23	abnormalities	abnormality	NOUN
cana-5141	33	24	(	(	PUNCT
cana-5141	33	25	aria	aria	NOUN
cana-5141	33	26	)	)	PUNCT
cana-5141	33	27	,	,	PUNCT
cana-5141	33	28	and	and	CCONJ
cana-5141	33	29	the	the	DET
cana-5141	33	30	need	need	NOUN
cana-5141	33	31	for	for	ADP
cana-5141	33	32	further	further	ADJ
cana-5141	33	33	investigation	investigation	NOUN
cana-5141	33	34	into	into	ADP
cana-5141	33	35	its	its	PRON
cana-5141	33	36	long	long	ADJ
cana-5141	33	37	-	-	PUNCT
cana-5141	33	38	term	term	NOUN
cana-5141	33	39	effects	effect	NOUN
cana-5141	33	40	.	.	PUNCT
cana-5141	34	1	lecanemab	lecanemab	NOUN
cana-5141	34	2	represents	represent	VERB
cana-5141	34	3	a	a	DET
cana-5141	34	4	critical	critical	ADJ
cana-5141	34	5	step	step	NOUN
cana-5141	34	6	forward	forward	ADV
cana-5141	34	7	in	in	ADP
cana-5141	34	8	precision	precision	NOUN
cana-5141	34	9	medicine	medicine	NOUN
cana-5141	34	10	for	for	ADP
cana-5141	34	11	ad	ad	NOUN
cana-5141	34	12	,	,	PUNCT
cana-5141	34	13	highlighting	highlight	VERB
cana-5141	34	14	the	the	DET
cana-5141	34	15	importance	importance	NOUN
cana-5141	34	16	of	of	ADP
cana-5141	34	17	targeted	target	VERB
cana-5141	34	18	therapies	therapy	NOUN
cana-5141	34	19	while	while	SCONJ
cana-5141	34	20	emphasizing	emphasize	VERB
cana-5141	34	21	the	the	DET
cana-5141	34	22	need	need	NOUN
cana-5141	34	23	for	for	ADP
cana-5141	34	24	ongoing	ongoing	ADJ
cana-5141	34	25	research	research	NOUN
cana-5141	34	26	to	to	PART
cana-5141	34	27	optimize	optimize	VERB
cana-5141	34	28	treatment	treatment	NOUN
cana-5141	34	29	strategies	strategy	NOUN
cana-5141	34	30	and	and	CCONJ
cana-5141	34	31	explore	explore	VERB
cana-5141	34	32	combination	combination	NOUN
cana-5141	34	33	therapies	therapy	NOUN
cana-5141	34	34	for	for	ADP
cana-5141	34	35	improved	improved	ADJ
cana-5141	34	36	outcomes	outcome	NOUN
cana-5141	34	37	[	[	X
cana-5141	34	38	7	7	NUM
cana-5141	34	39	]	]	PUNCT
cana-5141	34	40	.	.	PUNCT
cana-5141	35	1	the	the	DET
cana-5141	35	2	advent	advent	NOUN
cana-5141	35	3	of	of	ADP
cana-5141	35	4	gene	gene	NOUN
cana-5141	35	5	-	-	PUNCT
cana-5141	35	6	editing	edit	VERB
cana-5141	35	7	technologies	technology	NOUN
cana-5141	35	8	,	,	PUNCT
cana-5141	35	9	particularly	particularly	ADV
cana-5141	35	10	crispr	crispr	ADJ
cana-5141	35	11	-	-	PUNCT
cana-5141	35	12	cas9	cas9	NOUN
cana-5141	35	13	,	,	PUNCT
cana-5141	35	14	offers	offer	VERB
cana-5141	35	15	new	new	ADJ
cana-5141	35	16	hope	hope	NOUN
cana-5141	35	17	in	in	ADP
cana-5141	35	18	addressing	address	VERB
cana-5141	35	19	ad	ad	NOUN
cana-5141	35	20	's	's	PART
cana-5141	35	21	complexities	complexity	NOUN
cana-5141	35	22	.	.	PUNCT
cana-5141	36	1	crispr	crispr	PROPN
cana-5141	36	2	-	-	PUNCT
cana-5141	36	3	cas9	cas9	NOUN
cana-5141	36	4	has	have	AUX
cana-5141	36	5	shown	show	VERB
cana-5141	36	6	significant	significant	ADJ
cana-5141	36	7	promise	promise	NOUN
cana-5141	36	8	in	in	ADP
cana-5141	36	9	treating	treat	VERB
cana-5141	36	10	genetic	genetic	ADJ
cana-5141	36	11	disorders	disorder	NOUN
cana-5141	36	12	in	in	ADP
cana-5141	36	13	animal	animal	NOUN
cana-5141	36	14	models	model	NOUN
cana-5141	36	15	,	,	PUNCT
cana-5141	36	16	suggesting	suggest	VERB
cana-5141	36	17	its	its	PRON
cana-5141	36	18	potential	potential	NOUN
cana-5141	36	19	for	for	ADP
cana-5141	36	20	developing	develop	VERB
cana-5141	36	21	ad	ad	NOUN
cana-5141	36	22	therapies	therapy	NOUN
cana-5141	36	23	.	.	PUNCT
cana-5141	37	1	this	this	DET
cana-5141	37	2	review	review	NOUN
cana-5141	37	3	explores	explore	VERB
cana-5141	37	4	the	the	DET
cana-5141	37	5	evolution	evolution	NOUN
cana-5141	37	6	of	of	ADP
cana-5141	37	7	crispr	crispr	NOUN
cana-5141	37	8	-	-	PUNCT
cana-5141	37	9	cas9	cas9	NOUN
cana-5141	37	10	,	,	PUNCT
cana-5141	37	11	compares	compare	VERB
cana-5141	37	12	it	it	PRON
cana-5141	37	13	with	with	ADP
cana-5141	37	14	other	other	ADJ
cana-5141	37	15	gene	gene	NOUN
cana-5141	37	16	-	-	PUNCT
cana-5141	37	17	editing	edit	VERB
cana-5141	37	18	tools	tool	NOUN
cana-5141	37	19	,	,	PUNCT
cana-5141	37	20	and	and	CCONJ
cana-5141	37	21	summarizes	summarize	VERB
cana-5141	37	22	its	its	PRON
cana-5141	37	23	current	current	ADJ
cana-5141	37	24	applications	application	NOUN
cana-5141	37	25	in	in	ADP
cana-5141	37	26	advancing	advance	VERB
cana-5141	37	27	ad	ad	NOUN
cana-5141	37	28	treatment	treatment	NOUN
cana-5141	37	29	strategies[8].crispr	strategies[8].crispr	NOUN
cana-5141	37	30	-	-	PUNCT
cana-5141	37	31	cas9	cas9	NOUN
cana-5141	37	32	,	,	PUNCT
cana-5141	37	33	a	a	DET
cana-5141	37	34	bacterial	bacterial	ADJ
cana-5141	37	35	immune	immune	ADJ
cana-5141	37	36	system	system	NOUN
cana-5141	37	37	component	component	NOUN
cana-5141	37	38	,	,	PUNCT
cana-5141	37	39	defends	defend	VERB
cana-5141	37	40	against	against	ADP
cana-5141	37	41	mobile	mobile	ADJ
cana-5141	37	42	genetic	genetic	ADJ
cana-5141	37	43	elements	element	NOUN
cana-5141	37	44	like	like	ADP
cana-5141	37	45	plasmids	plasmid	NOUN
cana-5141	37	46	and	and	CCONJ
cana-5141	37	47	viruses	virus	NOUN
cana-5141	37	48	.	.	PUNCT
cana-5141	38	1	initially	initially	ADV
cana-5141	38	2	identified	identify	VERB
cana-5141	38	3	by	by	ADP
cana-5141	38	4	ishino	ishino	NOUN
cana-5141	38	5	in	in	ADP
cana-5141	38	6	1987	1987	NUM
cana-5141	38	7	,	,	PUNCT
cana-5141	38	8	it	it	PRON
cana-5141	38	9	gained	gain	VERB
cana-5141	38	10	laboratory	laboratory	NOUN
cana-5141	38	11	application	application	NOUN
cana-5141	38	12	through	through	ADP
cana-5141	38	13	doudna	doudna	NOUN
cana-5141	38	14	and	and	CCONJ
cana-5141	38	15	charpentier	charpentier	NOUN
cana-5141	38	16	's	's	PART
cana-5141	38	17	efforts	effort	NOUN
cana-5141	38	18	[	[	X
cana-5141	38	19	9	9	NUM
cana-5141	38	20	]	]	PUNCT
cana-5141	38	21	.	.	PUNCT
cana-5141	39	1	the	the	DET
cana-5141	39	2	system	system	NOUN
cana-5141	39	3	's	's	PART
cana-5141	39	4	core	core	NOUN
cana-5141	39	5	components	component	NOUN
cana-5141	39	6	are	be	AUX
cana-5141	39	7	the	the	DET
cana-5141	39	8	cas9	cas9	NOUN
cana-5141	39	9	enzyme	enzyme	NOUN
cana-5141	39	10	,	,	PUNCT
cana-5141	39	11	functioning	function	VERB
cana-5141	39	12	as	as	ADP
cana-5141	39	13	a	a	DET
cana-5141	39	14	molecular	molecular	ADJ
cana-5141	39	15	scissor	scissor	NOUN
cana-5141	39	16	,	,	PUNCT
cana-5141	39	17	and	and	CCONJ
cana-5141	39	18	singleguide	singleguide	PROPN
cana-5141	39	19	rna	rna	PROPN
cana-5141	39	20	(	(	PUNCT
cana-5141	39	21	sgrna	sgrna	PROPN
cana-5141	39	22	)	)	PUNCT
cana-5141	39	23	,	,	PUNCT
cana-5141	39	24	which	which	PRON
cana-5141	39	25	targets	target	VERB
cana-5141	39	26	specific	specific	ADJ
cana-5141	39	27	dna	dna	NOUN
cana-5141	39	28	sequences	sequence	NOUN
cana-5141	39	29	.	.	PUNCT
cana-5141	40	1	crispr	crispr	ADJ
cana-5141	40	2	-	-	PUNCT
cana-5141	40	3	cas9	cas9	NOUN
cana-5141	40	4	operates	operate	VERB
cana-5141	40	5	via	via	ADP
cana-5141	40	6	two	two	NUM
cana-5141	40	7	dna	dna	PROPN
cana-5141	40	8	repair	repair	NOUN
cana-5141	40	9	pathways	pathway	NOUN
cana-5141	40	10	:	:	PUNCT
cana-5141	40	11	non	non	ADJ
cana-5141	40	12	-	-	ADJ
cana-5141	40	13	homologous	homologous	ADJ
cana-5141	40	14	end	end	NOUN
cana-5141	40	15	joining	join	VERB
cana-5141	40	16	(	(	PUNCT
cana-5141	40	17	nhej	nhej	ADJ
cana-5141	40	18	)	)	PUNCT
cana-5141	40	19	,	,	PUNCT
cana-5141	40	20	which	which	PRON
cana-5141	40	21	induces	induce	VERB
cana-5141	40	22	insertions	insertion	NOUN
cana-5141	40	23	or	or	CCONJ
cana-5141	40	24	deletions	deletion	NOUN
cana-5141	40	25	,	,	PUNCT
cana-5141	40	26	and	and	CCONJ
cana-5141	40	27	homology	homology	NOUN
cana-5141	40	28	-	-	PUNCT
cana-5141	40	29	directed	direct	VERB
cana-5141	40	30	repair	repair	NOUN
cana-5141	40	31	(	(	PUNCT
cana-5141	40	32	hdr	hdr	NOUN
cana-5141	40	33	)	)	PUNCT
cana-5141	40	34	,	,	PUNCT
cana-5141	40	35	which	which	PRON
cana-5141	40	36	enables	enable	VERB
cana-5141	40	37	precise	precise	ADJ
cana-5141	40	38	sequence	sequence	NOUN
cana-5141	40	39	replacement	replacement	NOUN
cana-5141	41	1	[	[	X
cana-5141	41	2	10].crisprcas9	10].crisprcas9	NOUN
cana-5141	41	3	's	's	PART
cana-5141	41	4	genome	genome	NOUN
cana-5141	41	5	-	-	PUNCT
cana-5141	41	6	editing	edit	VERB
cana-5141	41	7	capabilities	capability	NOUN
cana-5141	41	8	hold	hold	VERB
cana-5141	41	9	promise	promise	NOUN
cana-5141	41	10	for	for	ADP
cana-5141	41	11	treating	treat	VERB
cana-5141	41	12	alzheimer	alzheimer	NOUN
cana-5141	41	13	's	's	PART
cana-5141	41	14	disease	disease	NOUN
cana-5141	41	15	(	(	PUNCT
cana-5141	41	16	ad	ad	NOUN
cana-5141	41	17	)	)	PUNCT
cana-5141	42	1	[	[	X
cana-5141	42	2	11	11	NUM
cana-5141	42	3	]	]	PUNCT
cana-5141	42	4	.	.	PUNCT
cana-5141	43	1	communications	communication	NOUN
cana-5141	43	2	on	on	ADP
cana-5141	43	3	applied	apply	VERB
cana-5141	43	4	nonlinear	nonlinear	ADJ
cana-5141	43	5	analysis	analysis	NOUN
cana-5141	43	6	issn	issn	NOUN
cana-5141	43	7	:	:	PUNCT
cana-5141	43	8	1074	1074	NUM
cana-5141	43	9	-	-	PUNCT
cana-5141	43	10	133x	133x	NUM
cana-5141	43	11	vol	vol	NOUN
cana-5141	43	12	32	32	NUM
cana-5141	43	13	no	no	NOUN
cana-5141	43	14	.	.	PUNCT
cana-5141	44	1	icmasd	icmasd	NOUN
cana-5141	44	2	(	(	PUNCT
cana-5141	44	3	2025	2025	NUM
cana-5141	44	4	)	)	PUNCT
cana-5141	44	5	1139	1139	NUM
cana-5141	44	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	44	7	delivery	delivery	NOUN
cana-5141	44	8	methods	method	NOUN
cana-5141	44	9	include	include	VERB
cana-5141	44	10	viral	viral	ADJ
cana-5141	44	11	vectors	vector	NOUN
cana-5141	44	12	like	like	ADP
cana-5141	44	13	adeno	adeno	NOUN
cana-5141	44	14	-	-	PUNCT
cana-5141	44	15	associated	associate	VERB
cana-5141	44	16	viruses	virus	NOUN
cana-5141	44	17	(	(	PUNCT
cana-5141	44	18	aavs	aavs	PROPN
cana-5141	44	19	)	)	PUNCT
cana-5141	44	20	,	,	PUNCT
cana-5141	44	21	which	which	PRON
cana-5141	44	22	efficiently	efficiently	ADV
cana-5141	44	23	reduce	reduce	VERB
cana-5141	44	24	amyloid	amyloid	NOUN
cana-5141	44	25	-	-	PUNCT
cana-5141	44	26	beta	beta	NOUN
cana-5141	44	27	(	(	PUNCT
cana-5141	44	28	aβ	aβ	NOUN
cana-5141	44	29	)	)	PUNCT
cana-5141	44	30	production	production	NOUN
cana-5141	44	31	,	,	PUNCT
cana-5141	44	32	and	and	CCONJ
cana-5141	44	33	non	non	ADJ
cana-5141	44	34	-	-	ADJ
cana-5141	44	35	viral	viral	ADJ
cana-5141	44	36	techniques	technique	NOUN
cana-5141	44	37	,	,	PUNCT
cana-5141	44	38	such	such	ADJ
cana-5141	44	39	as	as	ADP
cana-5141	44	40	nanocomplexes	nanocomplexe	NOUN
cana-5141	44	41	,	,	PUNCT
cana-5141	44	42	offering	offer	VERB
cana-5141	44	43	lower	low	ADJ
cana-5141	44	44	immunogenicity	immunogenicity	NOUN
cana-5141	44	45	and	and	CCONJ
cana-5141	44	46	targeted	target	VERB
cana-5141	44	47	delivery	delivery	NOUN
cana-5141	44	48	[	[	X
cana-5141	44	49	12	12	NUM
cana-5141	44	50	]	]	PUNCT
cana-5141	44	51	.	.	PUNCT
cana-5141	45	1	for	for	ADP
cana-5141	45	2	instance	instance	NOUN
cana-5141	45	3	,	,	PUNCT
cana-5141	45	4	nanocomplexes	nanocomplexe	NOUN
cana-5141	45	5	targeting	target	VERB
cana-5141	45	6	the	the	DET
cana-5141	45	7	bace1	bace1	NOUN
cana-5141	45	8	gene	gene	NOUN
cana-5141	45	9	effectively	effectively	ADV
cana-5141	45	10	reduced	reduce	VERB
cana-5141	45	11	β	β	NOUN
cana-5141	45	12	-	-	ADJ
cana-5141	45	13	cleavage	cleavage	NOUN
cana-5141	45	14	products	product	NOUN
cana-5141	45	15	in	in	ADP
cana-5141	45	16	ad	ad	NOUN
cana-5141	45	17	models	model	NOUN
cana-5141	45	18	[	[	X
cana-5141	45	19	13	13	NUM
cana-5141	45	20	]	]	PUNCT
cana-5141	45	21	.	.	PUNCT
cana-5141	46	1	gene	gene	NOUN
cana-5141	46	2	-	-	PUNCT
cana-5141	46	3	editing	edit	VERB
cana-5141	46	4	strategies	strategy	NOUN
cana-5141	46	5	have	have	AUX
cana-5141	46	6	addressed	address	VERB
cana-5141	46	7	various	various	ADJ
cana-5141	46	8	ad	ad	NOUN
cana-5141	46	9	-	-	PUNCT
cana-5141	46	10	associated	associate	VERB
cana-5141	46	11	genetic	genetic	ADJ
cana-5141	46	12	mutations	mutation	NOUN
cana-5141	46	13	.	.	PUNCT
cana-5141	47	1	targeting	target	VERB
cana-5141	47	2	app	app	NOUN
cana-5141	47	3	mutations	mutation	NOUN
cana-5141	47	4	and	and	CCONJ
cana-5141	47	5	enhancing	enhance	VERB
cana-5141	47	6	protective	protective	ADJ
cana-5141	47	7	pathways	pathway	NOUN
cana-5141	47	8	has	have	AUX
cana-5141	47	9	shown	show	VERB
cana-5141	47	10	success	success	NOUN
cana-5141	47	11	in	in	ADP
cana-5141	47	12	reducing	reduce	VERB
cana-5141	47	13	aβ	aβ	DET
cana-5141	47	14	production	production	NOUN
cana-5141	47	15	.	.	PUNCT
cana-5141	48	1	crispr	crispr	PROPN
cana-5141	48	2	-	-	PUNCT
cana-5141	48	3	cas9	cas9	NOUN
cana-5141	48	4	has	have	AUX
cana-5141	48	5	also	also	ADV
cana-5141	48	6	been	be	AUX
cana-5141	48	7	used	use	VERB
cana-5141	48	8	to	to	PART
cana-5141	48	9	delete	delete	VERB
cana-5141	48	10	toxic	toxic	ADJ
cana-5141	48	11	forms	form	NOUN
cana-5141	48	12	of	of	ADP
cana-5141	48	13	tau	tau	PROPN
cana-5141	48	14	,	,	PUNCT
cana-5141	48	15	implicated	implicate	VERB
cana-5141	48	16	in	in	ADP
cana-5141	48	17	neurodegeneration	neurodegeneration	NOUN
cana-5141	48	18	,	,	PUNCT
cana-5141	48	19	and	and	CCONJ
cana-5141	48	20	to	to	PART
cana-5141	48	21	modulate	modulate	VERB
cana-5141	48	22	genes	gene	NOUN
cana-5141	48	23	like	like	ADP
cana-5141	48	24	cyslt1r	cyslt1r	NOUN
cana-5141	48	25	,	,	PUNCT
cana-5141	48	26	which	which	PRON
cana-5141	48	27	contributes	contribute	VERB
cana-5141	48	28	to	to	ADP
cana-5141	48	29	inflammation	inflammation	NOUN
cana-5141	48	30	,	,	PUNCT
cana-5141	48	31	and	and	CCONJ
cana-5141	48	32	mt1	mt1	PROPN
cana-5141	48	33	,	,	PUNCT
cana-5141	48	34	enhancing	enhance	VERB
cana-5141	48	35	neuroprotection	neuroprotection	NOUN
cana-5141	48	36	through	through	ADP
cana-5141	48	37	melatonin	melatonin	NOUN
cana-5141	48	38	receptors[14	receptors[14	PROPN
cana-5141	48	39	]	]	PUNCT
cana-5141	48	40	.	.	PUNCT
cana-5141	49	1	studies	study	NOUN
cana-5141	49	2	demonstrate	demonstrate	VERB
cana-5141	49	3	crispr	crispr	ADJ
cana-5141	49	4	-	-	PUNCT
cana-5141	49	5	cas9	cas9	NOUN
cana-5141	49	6	’s	’s	PART
cana-5141	49	7	potential	potential	NOUN
cana-5141	49	8	in	in	ADP
cana-5141	49	9	familial	familial	ADJ
cana-5141	49	10	ad	ad	NOUN
cana-5141	49	11	by	by	ADP
cana-5141	49	12	correcting	correct	VERB
cana-5141	49	13	mutations	mutation	NOUN
cana-5141	49	14	in	in	ADP
cana-5141	49	15	genes	gene	NOUN
cana-5141	49	16	like	like	ADP
cana-5141	49	17	psen2	psen2	NOUN
cana-5141	49	18	and	and	CCONJ
cana-5141	49	19	improving	improve	VERB
cana-5141	49	20	neuronal	neuronal	ADJ
cana-5141	49	21	resilience	resilience	NOUN
cana-5141	49	22	by	by	ADP
cana-5141	49	23	editing	edit	VERB
cana-5141	49	24	apoe4	apoe4	ADJ
cana-5141	49	25	alleles	allele	NOUN
cana-5141	49	26	in	in	ADP
cana-5141	49	27	induced	induced	ADJ
cana-5141	49	28	pluripotent	pluripotent	ADJ
cana-5141	49	29	stem	stem	NOUN
cana-5141	49	30	cells	cell	NOUN
cana-5141	49	31	(	(	PUNCT
cana-5141	49	32	ipscs	ipscs	NOUN
cana-5141	49	33	)	)	PUNCT
cana-5141	49	34	.	.	PUNCT
cana-5141	50	1	these	these	DET
cana-5141	50	2	advancements	advancement	NOUN
cana-5141	50	3	provide	provide	VERB
cana-5141	50	4	insights	insight	NOUN
cana-5141	50	5	into	into	ADP
cana-5141	50	6	ad	ad	NOUN
cana-5141	50	7	mechanisms	mechanism	NOUN
cana-5141	50	8	and	and	CCONJ
cana-5141	50	9	suggest	suggest	VERB
cana-5141	50	10	a	a	DET
cana-5141	50	11	path	path	NOUN
cana-5141	50	12	toward	toward	ADP
cana-5141	50	13	innovative	innovative	ADJ
cana-5141	50	14	therapeutic	therapeutic	ADJ
cana-5141	50	15	strategies	strategy	NOUN
cana-5141	50	16	[	[	X
cana-5141	50	17	15	15	NUM
cana-5141	50	18	]	]	PUNCT
cana-5141	50	19	.	.	PUNCT
cana-5141	51	1	2	2	X
cana-5141	51	2	.	.	X
cana-5141	51	3	current	current	ADJ
cana-5141	51	4	landscape	landscape	NOUN
cana-5141	51	5	of	of	ADP
cana-5141	51	6	alzheimer	alzheimer	PROPN
cana-5141	51	7	’s	’s	PART
cana-5141	51	8	therapeutics	therapeutic	NOUN
cana-5141	51	9	the	the	DET
cana-5141	51	10	fda	fda	PROPN
cana-5141	51	11	approval	approval	NOUN
cana-5141	51	12	of	of	ADP
cana-5141	51	13	amyloid	amyloid	NOUN
cana-5141	51	14	-	-	PUNCT
cana-5141	51	15	targeting	target	VERB
cana-5141	51	16	therapies	therapy	NOUN
cana-5141	51	17	significantly	significantly	ADV
cana-5141	51	18	impacts	impact	VERB
cana-5141	51	19	the	the	DET
cana-5141	51	20	design	design	NOUN
cana-5141	51	21	and	and	CCONJ
cana-5141	51	22	conduct	conduct	NOUN
cana-5141	51	23	of	of	ADP
cana-5141	51	24	alzheimer	alzheimer	PROPN
cana-5141	51	25	’s	’s	PART
cana-5141	51	26	disease	disease	NOUN
cana-5141	51	27	(	(	PUNCT
cana-5141	51	28	ad	ad	NOUN
cana-5141	51	29	)	)	PUNCT
cana-5141	51	30	clinical	clinical	ADJ
cana-5141	51	31	trials	trial	NOUN
cana-5141	51	32	,	,	PUNCT
cana-5141	51	33	influencing	influence	VERB
cana-5141	51	34	study	study	NOUN
cana-5141	51	35	design	design	NOUN
cana-5141	51	36	,	,	PUNCT
cana-5141	51	37	statistical	statistical	ADJ
cana-5141	51	38	analysis	analysis	NOUN
cana-5141	51	39	,	,	PUNCT
cana-5141	51	40	safety	safety	NOUN
cana-5141	51	41	monitoring	monitoring	NOUN
cana-5141	51	42	,	,	PUNCT
cana-5141	51	43	and	and	CCONJ
cana-5141	51	44	participant	participant	ADJ
cana-5141	51	45	recruitment	recruitment	NOUN
cana-5141	51	46	and	and	CCONJ
cana-5141	51	47	retention	retention	NOUN
cana-5141	51	48	.	.	PUNCT
cana-5141	52	1	a	a	DET
cana-5141	52	2	key	key	ADJ
cana-5141	52	3	question	question	NOUN
cana-5141	52	4	is	be	AUX
cana-5141	52	5	whether	whether	SCONJ
cana-5141	52	6	a	a	DET
cana-5141	52	7	placebo	placebo	NOUN
cana-5141	52	8	arm	arm	NOUN
cana-5141	52	9	remains	remain	VERB
cana-5141	52	10	appropriate	appropriate	ADJ
cana-5141	52	11	for	for	ADP
cana-5141	52	12	trials	trial	NOUN
cana-5141	52	13	involving	involve	VERB
cana-5141	52	14	amyloid	amyloid	NOUN
cana-5141	52	15	-	-	PUNCT
cana-5141	52	16	targeting	target	VERB
cana-5141	52	17	therapies	therapy	NOUN
cana-5141	52	18	or	or	CCONJ
cana-5141	52	19	combination	combination	VERB
cana-5141	52	20	interventions[16	interventions[16	PROPN
cana-5141	52	21	]	]	PUNCT
cana-5141	52	22	.	.	PUNCT
cana-5141	53	1	a	a	DET
cana-5141	53	2	potential	potential	ADJ
cana-5141	53	3	alternative	alternative	NOUN
cana-5141	53	4	,	,	PUNCT
cana-5141	53	5	commonly	commonly	ADV
cana-5141	53	6	used	use	VERB
cana-5141	53	7	in	in	ADP
cana-5141	53	8	psychiatry	psychiatry	NOUN
cana-5141	53	9	trials	trial	NOUN
cana-5141	53	10	for	for	ADP
cana-5141	53	11	conditions	condition	NOUN
cana-5141	53	12	like	like	ADP
cana-5141	53	13	major	major	ADJ
cana-5141	53	14	depressive	depressive	ADJ
cana-5141	53	15	disorder	disorder	NOUN
cana-5141	53	16	or	or	CCONJ
cana-5141	53	17	schizophrenia	schizophrenia	NOUN
cana-5141	53	18	,	,	PUNCT
cana-5141	53	19	is	be	AUX
cana-5141	53	20	a	a	DET
cana-5141	53	21	factorial	factorial	ADJ
cana-5141	53	22	or	or	CCONJ
cana-5141	53	23	multi	multi	ADJ
cana-5141	53	24	-	-	ADJ
cana-5141	53	25	arm	arm	ADJ
cana-5141	53	26	design	design	NOUN
cana-5141	53	27	with	with	ADP
cana-5141	53	28	both	both	DET
cana-5141	53	29	placebo	placebo	NOUN
cana-5141	53	30	and	and	CCONJ
cana-5141	53	31	approved	approve	VERB
cana-5141	53	32	-	-	PUNCT
cana-5141	53	33	drug	drug	NOUN
cana-5141	53	34	control	control	NOUN
cana-5141	53	35	groups	group	NOUN
cana-5141	53	36	.	.	PUNCT
cana-5141	54	1	however	however	ADV
cana-5141	54	2	,	,	PUNCT
cana-5141	54	3	such	such	ADJ
cana-5141	54	4	designs	design	NOUN
cana-5141	54	5	increase	increase	VERB
cana-5141	54	6	sample	sample	NOUN
cana-5141	54	7	size	size	NOUN
cana-5141	54	8	requirements	requirement	NOUN
cana-5141	54	9	,	,	PUNCT
cana-5141	54	10	complicate	complicate	VERB
cana-5141	54	11	statistical	statistical	ADJ
cana-5141	54	12	analysis	analysis	NOUN
cana-5141	54	13	,	,	PUNCT
cana-5141	54	14	and	and	CCONJ
cana-5141	54	15	escalate	escalate	VERB
cana-5141	54	16	costs	cost	NOUN
cana-5141	54	17	and	and	CCONJ
cana-5141	54	18	trial	trial	NOUN
cana-5141	54	19	duration[16],[17].safety	duration[16],[17].safety	NOUN
cana-5141	54	20	monitoring	monitoring	NOUN
cana-5141	54	21	in	in	ADP
cana-5141	54	22	trials	trial	NOUN
cana-5141	54	23	using	use	VERB
cana-5141	54	24	amyloid	amyloid	NOUN
cana-5141	54	25	-	-	PUNCT
cana-5141	54	26	targeting	target	VERB
cana-5141	54	27	therapies	therapy	NOUN
cana-5141	54	28	poses	pose	VERB
cana-5141	54	29	unique	unique	ADJ
cana-5141	54	30	challenges	challenge	NOUN
cana-5141	54	31	.	.	PUNCT
cana-5141	55	1	amyloid	amyloid	NOUN
cana-5141	55	2	-	-	PUNCT
cana-5141	55	3	related	relate	VERB
cana-5141	55	4	imaging	imaging	NOUN
cana-5141	55	5	abnormalities	abnormality	NOUN
cana-5141	55	6	(	(	PUNCT
cana-5141	55	7	aria	aria	NOUN
cana-5141	55	8	)	)	PUNCT
cana-5141	55	9	,	,	PUNCT
cana-5141	55	10	the	the	DET
cana-5141	55	11	main	main	ADJ
cana-5141	55	12	adverse	adverse	ADJ
cana-5141	55	13	events	event	NOUN
cana-5141	55	14	associated	associate	VERB
cana-5141	55	15	with	with	ADP
cana-5141	55	16	plaque	plaque	NOUN
cana-5141	55	17	-	-	PUNCT
cana-5141	55	18	lowering	lower	VERB
cana-5141	55	19	monoclonal	monoclonal	NOUN
cana-5141	55	20	antibodies	antibodie	VERB
cana-5141	55	21	,	,	PUNCT
cana-5141	55	22	require	require	VERB
cana-5141	55	23	close	close	ADJ
cana-5141	55	24	monitoring	monitoring	NOUN
cana-5141	55	25	through	through	ADP
cana-5141	55	26	surveillance	surveillance	NOUN
cana-5141	55	27	mris	mris	PROPN
cana-5141	55	28	.	.	PUNCT
cana-5141	56	1	aria	aria	PROPN
cana-5141	56	2	can	can	AUX
cana-5141	56	3	manifest	manifest	VERB
cana-5141	56	4	as	as	ADP
cana-5141	56	5	edema	edema	NOUN
cana-5141	56	6	/	/	SYM
cana-5141	56	7	effusion	effusion	NOUN
cana-5141	56	8	(	(	PUNCT
cana-5141	56	9	aria	aria	NOUN
cana-5141	56	10	-	-	PUNCT
cana-5141	56	11	e	e	NOUN
cana-5141	56	12	)	)	PUNCT
cana-5141	56	13	or	or	CCONJ
cana-5141	56	14	hemorrhage	hemorrhage	NOUN
cana-5141	56	15	(	(	PUNCT
cana-5141	56	16	aria	aria	NOUN
cana-5141	56	17	-	-	PUNCT
cana-5141	56	18	h	h	NOUN
cana-5141	56	19	)	)	PUNCT
cana-5141	56	20	and	and	CCONJ
cana-5141	56	21	is	be	AUX
cana-5141	56	22	often	often	ADV
cana-5141	56	23	asymptomatic	asymptomatic	ADJ
cana-5141	56	24	.	.	PUNCT
cana-5141	57	1	additional	additional	ADJ
cana-5141	57	2	safety	safety	NOUN
cana-5141	57	3	considerations	consideration	NOUN
cana-5141	57	4	arise	arise	VERB
cana-5141	57	5	when	when	SCONJ
cana-5141	57	6	distinguishing	distinguish	VERB
cana-5141	57	7	adverse	adverse	ADJ
cana-5141	57	8	events	event	NOUN
cana-5141	57	9	caused	cause	VERB
cana-5141	57	10	by	by	ADP
cana-5141	57	11	experimental	experimental	ADJ
cana-5141	57	12	drugs	drug	NOUN
cana-5141	57	13	versus	versus	ADP
cana-5141	57	14	approved	approve	VERB
cana-5141	57	15	therapies[18].the	therapies[18].the	DET
cana-5141	57	16	availability	availability	NOUN
cana-5141	57	17	of	of	ADP
cana-5141	57	18	fda	fda	PROPN
cana-5141	57	19	-	-	PUNCT
cana-5141	57	20	approved	approve	VERB
cana-5141	57	21	amyloid	amyloid	NOUN
cana-5141	57	22	-	-	PUNCT
cana-5141	57	23	targeting	target	VERB
cana-5141	57	24	treatments	treatment	NOUN
cana-5141	57	25	also	also	ADV
cana-5141	57	26	affects	affect	VERB
cana-5141	57	27	recruitment	recruitment	NOUN
cana-5141	57	28	and	and	CCONJ
cana-5141	57	29	retention	retention	NOUN
cana-5141	57	30	for	for	ADP
cana-5141	57	31	future	future	ADJ
cana-5141	57	32	ad	ad	NOUN
cana-5141	57	33	trials	trial	NOUN
cana-5141	57	34	.	.	PUNCT
cana-5141	58	1	barriers	barrier	NOUN
cana-5141	58	2	such	such	ADJ
cana-5141	58	3	as	as	ADP
cana-5141	58	4	cost	cost	NOUN
cana-5141	58	5	,	,	PUNCT
cana-5141	58	6	limited	limited	ADJ
cana-5141	58	7	access	access	NOUN
cana-5141	58	8	,	,	PUNCT
cana-5141	58	9	and	and	CCONJ
cana-5141	58	10	stringent	stringent	ADJ
cana-5141	58	11	eligibility	eligibility	NOUN
cana-5141	58	12	criteria	criterion	NOUN
cana-5141	58	13	reduce	reduce	VERB
cana-5141	58	14	patient	patient	ADJ
cana-5141	58	15	availability	availability	NOUN
cana-5141	58	16	.	.	PUNCT
cana-5141	59	1	furthermore	furthermore	ADV
cana-5141	59	2	,	,	PUNCT
cana-5141	59	3	participants	participant	NOUN
cana-5141	59	4	from	from	ADP
cana-5141	59	5	early	early	ADJ
cana-5141	59	6	amyloid	amyloid	NOUN
cana-5141	59	7	-	-	PUNCT
cana-5141	59	8	targeting	target	VERB
cana-5141	59	9	trials	trial	NOUN
cana-5141	59	10	may	may	AUX
cana-5141	59	11	no	no	ADV
cana-5141	59	12	longer	long	ADV
cana-5141	59	13	meet	meet	VERB
cana-5141	59	14	biomarker	biomarker	NOUN
cana-5141	59	15	criteria	criterion	NOUN
cana-5141	59	16	due	due	ADP
cana-5141	59	17	to	to	ADP
cana-5141	59	18	reduced	reduce	VERB
cana-5141	59	19	amyloid	amyloid	NOUN
cana-5141	59	20	burden	burden	NOUN
cana-5141	59	21	,	,	PUNCT
cana-5141	59	22	shrinking	shrink	VERB
cana-5141	59	23	the	the	DET
cana-5141	59	24	pool	pool	NOUN
cana-5141	59	25	of	of	ADP
cana-5141	59	26	eligible	eligible	ADJ
cana-5141	59	27	candidates	candidate	NOUN
cana-5141	59	28	.	.	PUNCT
cana-5141	60	1	to	to	PART
cana-5141	60	2	address	address	VERB
cana-5141	60	3	these	these	DET
cana-5141	60	4	challenges	challenge	NOUN
cana-5141	60	5	,	,	PUNCT
cana-5141	60	6	decentralized	decentralize	VERB
cana-5141	60	7	clinical	clinical	ADJ
cana-5141	60	8	trials	trial	NOUN
cana-5141	60	9	(	(	PUNCT
cana-5141	60	10	dcts	dct	NOUN
cana-5141	60	11	)	)	PUNCT
cana-5141	60	12	offer	offer	VERB
cana-5141	60	13	a	a	DET
cana-5141	60	14	promising	promising	ADJ
cana-5141	60	15	solution	solution	NOUN
cana-5141	60	16	.	.	PUNCT
cana-5141	61	1	dcts	dct	NOUN
cana-5141	61	2	can	can	AUX
cana-5141	61	3	enhance	enhance	VERB
cana-5141	61	4	recruitment	recruitment	NOUN
cana-5141	61	5	by	by	ADP
cana-5141	61	6	reaching	reach	VERB
cana-5141	61	7	diverse	diverse	ADJ
cana-5141	61	8	populations	population	NOUN
cana-5141	61	9	,	,	PUNCT
cana-5141	61	10	providing	provide	VERB
cana-5141	61	11	greater	great	ADJ
cana-5141	61	12	flexibility	flexibility	NOUN
cana-5141	61	13	,	,	PUNCT
cana-5141	61	14	and	and	CCONJ
cana-5141	61	15	allowing	allow	VERB
cana-5141	61	16	home	home	NOUN
cana-5141	61	17	-	-	PUNCT
cana-5141	61	18	based	base	VERB
cana-5141	61	19	screening	screening	NOUN
cana-5141	61	20	and	and	CCONJ
cana-5141	61	21	administration	administration	NOUN
cana-5141	61	22	of	of	ADP
cana-5141	61	23	therapies	therapy	NOUN
cana-5141	61	24	.	.	PUNCT
cana-5141	62	1	expanding	expand	VERB
cana-5141	62	2	geographic	geographic	ADJ
cana-5141	62	3	accessibility	accessibility	NOUN
cana-5141	62	4	for	for	ADP
cana-5141	62	5	trials	trial	NOUN
cana-5141	62	6	can	can	AUX
cana-5141	62	7	further	far	ADV
cana-5141	62	8	improve	improve	VERB
cana-5141	62	9	participation	participation	NOUN
cana-5141	62	10	.	.	PUNCT
cana-5141	63	1	however	however	ADV
cana-5141	63	2	,	,	PUNCT
cana-5141	63	3	global	global	ADJ
cana-5141	63	4	variations	variation	NOUN
cana-5141	63	5	in	in	ADP
cana-5141	63	6	regulatory	regulatory	ADJ
cana-5141	63	7	approvals	approval	NOUN
cana-5141	63	8	and	and	CCONJ
cana-5141	63	9	access	access	NOUN
cana-5141	63	10	to	to	ADP
cana-5141	63	11	treatments	treatment	NOUN
cana-5141	63	12	may	may	AUX
cana-5141	63	13	complicate	complicate	VERB
cana-5141	63	14	trial	trial	NOUN
cana-5141	63	15	design	design	NOUN
cana-5141	63	16	and	and	CCONJ
cana-5141	63	17	limit	limit	VERB
cana-5141	63	18	patient	patient	ADJ
cana-5141	63	19	diversity	diversity	NOUN
cana-5141	63	20	,	,	PUNCT
cana-5141	63	21	underscoring	underscore	VERB
cana-5141	63	22	the	the	DET
cana-5141	63	23	need	need	NOUN
cana-5141	63	24	for	for	ADP
cana-5141	63	25	innovative	innovative	ADJ
cana-5141	63	26	strategies	strategy	NOUN
cana-5141	63	27	to	to	PART
cana-5141	63	28	overcome	overcome	VERB
cana-5141	63	29	these	these	DET
cana-5141	63	30	barriers[19	barriers[19	NOUN
cana-5141	63	31	]	]	PUNCT
cana-5141	63	32	.	.	PUNCT
cana-5141	64	1	while	while	SCONJ
cana-5141	64	2	fda	fda	PROPN
cana-5141	64	3	-	-	PUNCT
cana-5141	64	4	approved	approve	VERB
cana-5141	64	5	amyloid	amyloid	NOUN
cana-5141	64	6	-	-	PUNCT
cana-5141	64	7	targeting	target	VERB
cana-5141	64	8	therapies	therapy	NOUN
cana-5141	64	9	have	have	AUX
cana-5141	64	10	shown	show	VERB
cana-5141	64	11	clinically	clinically	ADV
cana-5141	64	12	meaningful	meaningful	ADJ
cana-5141	64	13	benefits	benefit	NOUN
cana-5141	64	14	in	in	ADP
cana-5141	64	15	trials	trial	NOUN
cana-5141	64	16	,	,	PUNCT
cana-5141	64	17	implementing	implement	VERB
cana-5141	64	18	them	they	PRON
cana-5141	64	19	as	as	SCONJ
cana-5141	64	20	standard	standard	PROPN
cana-5141	64	21	care	care	NOUN
cana-5141	64	22	poses	pose	VERB
cana-5141	64	23	significant	significant	ADJ
cana-5141	64	24	challenges	challenge	NOUN
cana-5141	64	25	.	.	PUNCT
cana-5141	65	1	these	these	PRON
cana-5141	65	2	include	include	VERB
cana-5141	65	3	healthcare	healthcare	NOUN
cana-5141	65	4	system	system	NOUN
cana-5141	65	5	infrastructure	infrastructure	NOUN
cana-5141	65	6	,	,	PUNCT
cana-5141	65	7	clinician	clinician	NOUN
cana-5141	65	8	training	training	NOUN
cana-5141	65	9	,	,	PUNCT
cana-5141	65	10	screening	screening	NOUN
cana-5141	65	11	and	and	CCONJ
cana-5141	65	12	monitoring	monitoring	NOUN
cana-5141	65	13	methods	method	NOUN
cana-5141	65	14	,	,	PUNCT
cana-5141	65	15	and	and	CCONJ
cana-5141	65	16	limited	limited	ADJ
cana-5141	65	17	real	real	ADJ
cana-5141	65	18	-	-	PUNCT
cana-5141	65	19	world	world	NOUN
cana-5141	65	20	data	datum	NOUN
cana-5141	65	21	.	.	PUNCT
cana-5141	66	1	clinicians	clinician	NOUN
cana-5141	66	2	must	must	AUX
cana-5141	66	3	carefully	carefully	ADV
cana-5141	66	4	weigh	weigh	VERB
cana-5141	66	5	the	the	DET
cana-5141	66	6	risks	risk	NOUN
cana-5141	66	7	and	and	CCONJ
cana-5141	66	8	burdens	burden	NOUN
cana-5141	66	9	of	of	ADP
cana-5141	66	10	these	these	DET
cana-5141	66	11	treatments	treatment	NOUN
cana-5141	66	12	against	against	ADP
cana-5141	66	13	their	their	PRON
cana-5141	66	14	communications	communication	NOUN
cana-5141	66	15	on	on	ADP
cana-5141	66	16	applied	apply	VERB
cana-5141	66	17	nonlinear	nonlinear	ADJ
cana-5141	66	18	analysis	analysis	NOUN
cana-5141	66	19	issn	issn	NOUN
cana-5141	66	20	:	:	PUNCT
cana-5141	66	21	1074	1074	NUM
cana-5141	66	22	-	-	PUNCT
cana-5141	66	23	133x	133x	NUM
cana-5141	66	24	vol	vol	NOUN
cana-5141	66	25	32	32	NUM
cana-5141	66	26	no	no	NOUN
cana-5141	66	27	.	.	PUNCT
cana-5141	67	1	icmasd	icmasd	NOUN
cana-5141	67	2	(	(	PUNCT
cana-5141	67	3	2025	2025	NUM
cana-5141	67	4	)	)	PUNCT
cana-5141	67	5	1140	1140	NUM
cana-5141	67	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	67	7	potential	potential	ADJ
cana-5141	67	8	benefits	benefit	NOUN
cana-5141	67	9	and	and	CCONJ
cana-5141	67	10	engage	engage	VERB
cana-5141	67	11	patients	patient	NOUN
cana-5141	67	12	and	and	CCONJ
cana-5141	67	13	caregivers	caregiver	NOUN
cana-5141	67	14	in	in	ADP
cana-5141	67	15	shared	shared	ADJ
cana-5141	67	16	decision	decision	NOUN
cana-5141	67	17	-	-	PUNCT
cana-5141	67	18	making	making	NOUN
cana-5141	67	19	processes[20	processes[20	NOUN
cana-5141	67	20	]	]	PUNCT
cana-5141	67	21	.	.	PUNCT
cana-5141	68	1	the	the	DET
cana-5141	68	2	eligible	eligible	ADJ
cana-5141	68	3	patient	patient	ADJ
cana-5141	68	4	population	population	NOUN
cana-5141	68	5	for	for	ADP
cana-5141	68	6	amyloid	amyloid	NOUN
cana-5141	68	7	-	-	PUNCT
cana-5141	68	8	targeting	target	VERB
cana-5141	68	9	therapies	therapy	NOUN
cana-5141	68	10	is	be	AUX
cana-5141	68	11	diverse	diverse	ADJ
cana-5141	68	12	,	,	PUNCT
cana-5141	68	13	including	include	VERB
cana-5141	68	14	those	those	PRON
cana-5141	68	15	with	with	ADP
cana-5141	68	16	prior	prior	ADJ
cana-5141	68	17	exposure	exposure	NOUN
cana-5141	68	18	to	to	ADP
cana-5141	68	19	plaque	plaque	NOUN
cana-5141	68	20	-	-	PUNCT
cana-5141	68	21	lowering	lower	VERB
cana-5141	68	22	treatments	treatment	NOUN
cana-5141	68	23	,	,	PUNCT
cana-5141	68	24	varying	vary	VERB
cana-5141	68	25	amyloid	amyloid	NOUN
cana-5141	68	26	burdens	burden	NOUN
cana-5141	68	27	,	,	PUNCT
cana-5141	68	28	and	and	CCONJ
cana-5141	68	29	altered	altered	ADJ
cana-5141	68	30	biomarkers	biomarker	NOUN
cana-5141	68	31	.	.	PUNCT
cana-5141	69	1	these	these	DET
cana-5141	69	2	subpopulations	subpopulation	NOUN
cana-5141	69	3	require	require	VERB
cana-5141	69	4	tailored	tailor	VERB
cana-5141	69	5	approaches	approach	NOUN
cana-5141	69	6	.	.	PUNCT
cana-5141	70	1	furthermore	furthermore	ADV
cana-5141	70	2	,	,	PUNCT
cana-5141	70	3	barriers	barrier	NOUN
cana-5141	70	4	such	such	ADJ
cana-5141	70	5	as	as	ADP
cana-5141	70	6	inequitable	inequitable	ADJ
cana-5141	70	7	access	access	NOUN
cana-5141	70	8	,	,	PUNCT
cana-5141	70	9	financial	financial	ADJ
cana-5141	70	10	burden	burden	NOUN
cana-5141	70	11	,	,	PUNCT
cana-5141	70	12	safety	safety	NOUN
cana-5141	70	13	risks	risk	NOUN
cana-5141	70	14	,	,	PUNCT
cana-5141	70	15	comorbidities	comorbiditie	NOUN
cana-5141	70	16	,	,	PUNCT
cana-5141	70	17	and	and	CCONJ
cana-5141	70	18	the	the	DET
cana-5141	70	19	invasive	invasive	ADJ
cana-5141	70	20	nature	nature	NOUN
cana-5141	70	21	of	of	ADP
cana-5141	70	22	iv	iv	NUM
cana-5141	70	23	infusions	infusion	NOUN
cana-5141	70	24	which	which	PRON
cana-5141	70	25	involve	involve	VERB
cana-5141	70	26	high	high	ADJ
cana-5141	70	27	doses	dose	NOUN
cana-5141	70	28	due	due	ADJ
cana-5141	70	29	to	to	ADP
cana-5141	70	30	limited	limited	ADJ
cana-5141	70	31	blood	blood	NOUN
cana-5141	70	32	-	-	PUNCT
cana-5141	70	33	brain	brain	NOUN
cana-5141	70	34	barrier	barrier	NOUN
cana-5141	70	35	penetration	penetration	NOUN
cana-5141	70	36	may	may	AUX
cana-5141	70	37	lead	lead	VERB
cana-5141	70	38	some	some	DET
cana-5141	70	39	patients	patient	NOUN
cana-5141	70	40	to	to	PART
cana-5141	70	41	prefer	prefer	VERB
cana-5141	70	42	enrolling	enrolling	NOUN
cana-5141	70	43	in	in	ADP
cana-5141	70	44	clinical	clinical	ADJ
cana-5141	70	45	trials	trial	NOUN
cana-5141	70	46	over	over	ADP
cana-5141	70	47	starting	start	VERB
cana-5141	70	48	approved	approve	VERB
cana-5141	70	49	treatments	treatment	NOUN
cana-5141	70	50	[	[	X
cana-5141	70	51	21	21	NUM
cana-5141	70	52	]	]	PUNCT
cana-5141	70	53	.	.	PUNCT
cana-5141	71	1	for	for	ADP
cana-5141	71	2	individuals	individual	NOUN
cana-5141	71	3	with	with	ADP
cana-5141	71	4	unique	unique	ADJ
cana-5141	71	5	conditions	condition	NOUN
cana-5141	71	6	like	like	ADP
cana-5141	71	7	early	early	ADJ
cana-5141	71	8	symptomatic	symptomatic	ADJ
cana-5141	71	9	ad	ad	NOUN
cana-5141	71	10	,	,	PUNCT
cana-5141	71	11	diad	diad	NOUN
cana-5141	71	12	,	,	PUNCT
cana-5141	71	13	or	or	CCONJ
cana-5141	71	14	down	down	ADP
cana-5141	71	15	syndrome	syndrome	NOUN
cana-5141	71	16	,	,	PUNCT
cana-5141	71	17	the	the	DET
cana-5141	71	18	risks	risk	NOUN
cana-5141	71	19	and	and	CCONJ
cana-5141	71	20	benefits	benefit	NOUN
cana-5141	71	21	of	of	ADP
cana-5141	71	22	amyloid	amyloid	NOUN
cana-5141	71	23	-	-	PUNCT
cana-5141	71	24	targeting	target	VERB
cana-5141	71	25	therapies	therapy	NOUN
cana-5141	71	26	remain	remain	VERB
cana-5141	71	27	uncertain	uncertain	ADJ
cana-5141	71	28	.	.	PUNCT
cana-5141	72	1	offering	offer	VERB
cana-5141	72	2	multiple	multiple	ADJ
cana-5141	72	3	treatment	treatment	NOUN
cana-5141	72	4	options	option	NOUN
cana-5141	72	5	,	,	PUNCT
cana-5141	72	6	including	include	VERB
cana-5141	72	7	clinical	clinical	ADJ
cana-5141	72	8	trials	trial	NOUN
cana-5141	72	9	,	,	PUNCT
cana-5141	72	10	supports	support	VERB
cana-5141	72	11	patient	patient	ADJ
cana-5141	72	12	autonomy	autonomy	NOUN
cana-5141	72	13	and	and	CCONJ
cana-5141	72	14	ensures	ensure	VERB
cana-5141	72	15	equitable	equitable	ADJ
cana-5141	72	16	care	care	NOUN
cana-5141	73	1	[	[	X
cana-5141	73	2	22	22	NUM
cana-5141	73	3	]	]	PUNCT
cana-5141	73	4	.	.	PUNCT
cana-5141	74	1	trials	trial	NOUN
cana-5141	74	2	of	of	ADP
cana-5141	74	3	monoclonal	monoclonal	NOUN
cana-5141	74	4	antibodies	antibody	NOUN
cana-5141	74	5	targeting	target	VERB
cana-5141	74	6	amyloid	amyloid	NOUN
cana-5141	74	7	show	show	VERB
cana-5141	74	8	these	these	DET
cana-5141	74	9	therapies	therapy	NOUN
cana-5141	74	10	reduce	reduce	VERB
cana-5141	74	11	amyloid	amyloid	NOUN
cana-5141	74	12	burden	burden	NOUN
cana-5141	74	13	,	,	PUNCT
cana-5141	74	14	as	as	SCONJ
cana-5141	74	15	measured	measure	VERB
cana-5141	74	16	by	by	ADP
cana-5141	74	17	amyloid	amyloid	NOUN
cana-5141	74	18	-	-	PUNCT
cana-5141	74	19	pet	pet	NOUN
cana-5141	74	20	,	,	PUNCT
cana-5141	74	21	and	and	CCONJ
cana-5141	74	22	slow	slow	ADJ
cana-5141	74	23	cognitive	cognitive	ADJ
cana-5141	74	24	and	and	CCONJ
cana-5141	74	25	functional	functional	ADJ
cana-5141	74	26	decline	decline	NOUN
cana-5141	74	27	.	.	PUNCT
cana-5141	75	1	they	they	PRON
cana-5141	75	2	also	also	ADV
cana-5141	75	3	affect	affect	VERB
cana-5141	75	4	biomarkers	biomarker	NOUN
cana-5141	75	5	such	such	ADJ
cana-5141	75	6	as	as	ADP
cana-5141	75	7	soluble	soluble	ADJ
cana-5141	75	8	amyloid	amyloid	NOUN
cana-5141	75	9	species	specie	NOUN
cana-5141	75	10	,	,	PUNCT
cana-5141	75	11	total	total	ADJ
cana-5141	75	12	and	and	CCONJ
cana-5141	75	13	phosphorylated	phosphorylate	VERB
cana-5141	75	14	tau	tau	PROPN
cana-5141	75	15	,	,	PUNCT
cana-5141	75	16	and	and	CCONJ
cana-5141	75	17	markers	marker	NOUN
cana-5141	75	18	of	of	ADP
cana-5141	75	19	neurodegeneration	neurodegeneration	NOUN
cana-5141	75	20	and	and	CCONJ
cana-5141	75	21	neuroinflammation	neuroinflammation	NOUN
cana-5141	75	22	[	[	X
cana-5141	75	23	23	23	NUM
cana-5141	75	24	]	]	PUNCT
cana-5141	75	25	.	.	PUNCT
cana-5141	76	1	however	however	ADV
cana-5141	76	2	,	,	PUNCT
cana-5141	76	3	amyloid	amyloid	NOUN
cana-5141	76	4	-	-	PUNCT
cana-5141	76	5	pet	pet	NOUN
cana-5141	76	6	imaging	imaging	NOUN
cana-5141	76	7	is	be	AUX
cana-5141	76	8	costly	costly	ADJ
cana-5141	76	9	and	and	CCONJ
cana-5141	76	10	not	not	PART
cana-5141	76	11	widely	widely	ADV
cana-5141	76	12	accessible	accessible	ADJ
cana-5141	76	13	,	,	PUNCT
cana-5141	76	14	highlighting	highlight	VERB
cana-5141	76	15	the	the	DET
cana-5141	76	16	need	need	NOUN
cana-5141	76	17	for	for	ADP
cana-5141	76	18	more	more	ADV
cana-5141	76	19	affordable	affordable	ADJ
cana-5141	76	20	and	and	CCONJ
cana-5141	76	21	practical	practical	ADJ
cana-5141	76	22	biomarkers	biomarker	NOUN
cana-5141	76	23	to	to	PART
cana-5141	76	24	assess	assess	VERB
cana-5141	76	25	clinical	clinical	ADJ
cana-5141	76	26	efficacy	efficacy	NOUN
cana-5141	76	27	,	,	PUNCT
cana-5141	76	28	safety	safety	NOUN
cana-5141	76	29	(	(	PUNCT
cana-5141	76	30	e.g.	e.g.	ADV
cana-5141	76	31	,	,	PUNCT
cana-5141	76	32	aria	aria	NOUN
cana-5141	76	33	)	)	PUNCT
cana-5141	76	34	,	,	PUNCT
cana-5141	76	35	and	and	CCONJ
cana-5141	76	36	treatment	treatment	NOUN
cana-5141	76	37	risks	risk	NOUN
cana-5141	76	38	as	as	SCONJ
cana-5141	76	39	these	these	DET
cana-5141	76	40	therapies	therapy	NOUN
cana-5141	76	41	become	become	VERB
cana-5141	76	42	more	more	ADV
cana-5141	76	43	prevalent	prevalent	ADJ
cana-5141	76	44	[	[	X
cana-5141	76	45	24	24	NUM
cana-5141	76	46	]	]	PUNCT
cana-5141	76	47	.	.	PUNCT
cana-5141	77	1	in	in	ADP
cana-5141	77	2	combination	combination	NOUN
cana-5141	77	3	therapy	therapy	NOUN
cana-5141	77	4	trials	trial	NOUN
cana-5141	77	5	,	,	PUNCT
cana-5141	77	6	attributing	attribute	VERB
cana-5141	77	7	biomarker	biomarker	NOUN
cana-5141	77	8	changes	change	NOUN
cana-5141	77	9	to	to	ADP
cana-5141	77	10	specific	specific	ADJ
cana-5141	77	11	treatments	treatment	NOUN
cana-5141	77	12	can	can	AUX
cana-5141	77	13	be	be	AUX
cana-5141	77	14	challenging	challenge	VERB
cana-5141	77	15	[	[	PUNCT
cana-5141	77	16	25	25	NUM
cana-5141	77	17	]	]	PUNCT
cana-5141	77	18	.	.	PUNCT
cana-5141	78	1	fluid	fluid	ADJ
cana-5141	78	2	biomarkers	biomarker	NOUN
cana-5141	78	3	like	like	ADP
cana-5141	78	4	cerebrospinal	cerebrospinal	ADJ
cana-5141	78	5	fluid	fluid	NOUN
cana-5141	78	6	(	(	PUNCT
cana-5141	78	7	csf	csf	NOUN
cana-5141	78	8	)	)	PUNCT
cana-5141	78	9	and	and	CCONJ
cana-5141	78	10	plasma	plasma	NOUN
cana-5141	78	11	enable	enable	VERB
cana-5141	78	12	profiling	profiling	NOUN
cana-5141	78	13	of	of	ADP
cana-5141	78	14	multiple	multiple	ADJ
cana-5141	78	15	markers	marker	NOUN
cana-5141	78	16	from	from	ADP
cana-5141	78	17	a	a	DET
cana-5141	78	18	single	single	ADJ
cana-5141	78	19	sample	sample	NOUN
cana-5141	78	20	.	.	PUNCT
cana-5141	79	1	research	research	NOUN
cana-5141	79	2	suggests	suggest	VERB
cana-5141	79	3	plasma	plasma	NOUN
cana-5141	79	4	biomarkers	biomarker	NOUN
cana-5141	79	5	,	,	PUNCT
cana-5141	79	6	particularly	particularly	ADV
cana-5141	79	7	p	p	NOUN
cana-5141	79	8	-	-	PUNCT
cana-5141	79	9	tau217	tau217	NOUN
cana-5141	79	10	,	,	PUNCT
cana-5141	79	11	may	may	AUX
cana-5141	79	12	outperform	outperform	VERB
cana-5141	79	13	csf	csf	ADJ
cana-5141	79	14	in	in	ADP
cana-5141	79	15	identifying	identify	VERB
cana-5141	79	16	amyloid	amyloid	NOUN
cana-5141	79	17	-	-	PUNCT
cana-5141	79	18	positive	positive	ADJ
cana-5141	79	19	patients	patient	NOUN
cana-5141	79	20	.	.	PUNCT
cana-5141	80	1	plasma	plasma	VERB
cana-5141	80	2	p	p	NOUN
cana-5141	80	3	-	-	PUNCT
cana-5141	80	4	tau217	tau217	NOUN
cana-5141	80	5	also	also	ADV
cana-5141	80	6	offers	offer	VERB
cana-5141	80	7	a	a	DET
cana-5141	80	8	cost	cost	NOUN
cana-5141	80	9	-	-	PUNCT
cana-5141	80	10	effective	effective	ADJ
cana-5141	80	11	option	option	NOUN
cana-5141	80	12	for	for	ADP
cana-5141	80	13	monitoring	monitor	VERB
cana-5141	80	14	amyloid	amyloid	NOUN
cana-5141	80	15	burden	burden	NOUN
cana-5141	80	16	and	and	CCONJ
cana-5141	80	17	eligibility	eligibility	NOUN
cana-5141	80	18	screening	screen	VERB
cana-5141	80	19	for	for	ADP
cana-5141	80	20	trials	trial	NOUN
cana-5141	80	21	requiring	require	VERB
cana-5141	80	22	amyloid	amyloid	NOUN
cana-5141	80	23	positivity	positivity	NOUN
cana-5141	80	24	.	.	PUNCT
cana-5141	81	1	this	this	DET
cana-5141	81	2	approach	approach	NOUN
cana-5141	81	3	could	could	AUX
cana-5141	81	4	streamline	streamline	VERB
cana-5141	81	5	combination	combination	NOUN
cana-5141	81	6	trials	trial	NOUN
cana-5141	81	7	and	and	CCONJ
cana-5141	81	8	expand	expand	VERB
cana-5141	81	9	accessibility	accessibility	NOUN
cana-5141	81	10	as	as	SCONJ
cana-5141	81	11	shown	show	VERB
cana-5141	81	12	in	in	ADP
cana-5141	81	13	table	table	NOUN
cana-5141	81	14	1	1	NUM
cana-5141	81	15	.	.	PUNCT
cana-5141	81	16	table	table	NOUN
cana-5141	81	17	1	1	NUM
cana-5141	81	18	:	:	PUNCT
cana-5141	81	19	evidence	evidence	NOUN
cana-5141	81	20	and	and	CCONJ
cana-5141	81	21	biomarker	biomarker	VERB
cana-5141	81	22	insights	insight	NOUN
cana-5141	81	23	for	for	ADP
cana-5141	81	24	amyloid	amyloid	NOUN
cana-5141	81	25	-	-	PUNCT
cana-5141	81	26	targeting	target	VERB
cana-5141	81	27	therapies	therapy	NOUN
cana-5141	81	28	in	in	ADP
cana-5141	81	29	ad	ad	NOUN
cana-5141	81	30	aspect	aspect	NOUN
cana-5141	81	31	details	detail	NOUN
cana-5141	81	32	references	reference	VERB
cana-5141	81	33	therapeutic	therapeutic	ADJ
cana-5141	81	34	impact	impact	NOUN
cana-5141	81	35	monoclonal	monoclonal	NOUN
cana-5141	81	36	antibodies	antibodie	VERB
cana-5141	81	37	targeting	target	VERB
cana-5141	81	38	amyloid	amyloid	NOUN
cana-5141	81	39	lower	low	ADJ
cana-5141	81	40	amyloid	amyloid	NOUN
cana-5141	81	41	burden	burden	NOUN
cana-5141	81	42	(	(	PUNCT
cana-5141	81	43	measured	measure	VERB
cana-5141	81	44	via	via	ADP
cana-5141	81	45	amyloid	amyloid	NOUN
cana-5141	81	46	-	-	PUNCT
cana-5141	81	47	pet	pet	NOUN
cana-5141	81	48	)	)	PUNCT
cana-5141	81	49	and	and	CCONJ
cana-5141	81	50	slow	slow	ADJ
cana-5141	81	51	cognitive	cognitive	ADJ
cana-5141	81	52	and	and	CCONJ
cana-5141	81	53	functional	functional	ADJ
cana-5141	81	54	decline	decline	NOUN
cana-5141	81	55	.	.	PUNCT
cana-5141	82	1	they	they	PRON
cana-5141	82	2	also	also	ADV
cana-5141	82	3	influence	influence	VERB
cana-5141	82	4	biomarkers	biomarker	NOUN
cana-5141	82	5	like	like	ADP
cana-5141	82	6	soluble	soluble	ADJ
cana-5141	82	7	amyloid	amyloid	NOUN
cana-5141	82	8	species	specie	NOUN
cana-5141	82	9	,	,	PUNCT
cana-5141	82	10	tau	tau	PROPN
cana-5141	82	11	proteins	protein	NOUN
cana-5141	82	12	,	,	PUNCT
cana-5141	82	13	and	and	CCONJ
cana-5141	82	14	neurodegeneration	neurodegeneration	NOUN
cana-5141	82	15	processes	process	NOUN
cana-5141	82	16	.	.	PUNCT
cana-5141	83	1	[	[	X
cana-5141	83	2	25	25	NUM
cana-5141	83	3	]	]	PUNCT
cana-5141	83	4	limitations	limitation	NOUN
cana-5141	83	5	of	of	ADP
cana-5141	83	6	amyloidpet	amyloidpet	NOUN
cana-5141	83	7	✓	✓	ADJ
cana-5141	83	8	high	high	ADJ
cana-5141	83	9	cost	cost	NOUN
cana-5141	83	10	and	and	CCONJ
cana-5141	83	11	limited	limited	ADJ
cana-5141	83	12	accessibility	accessibility	NOUN
cana-5141	83	13	.	.	PUNCT
cana-5141	84	1	✓	✓	ADJ
cana-5141	84	2	need	need	NOUN
cana-5141	84	3	for	for	ADP
cana-5141	84	4	less	less	ADV
cana-5141	84	5	expensive	expensive	ADJ
cana-5141	84	6	,	,	PUNCT
cana-5141	84	7	widely	widely	ADV
cana-5141	84	8	available	available	ADJ
cana-5141	84	9	biomarkers	biomarker	NOUN
cana-5141	84	10	for	for	ADP
cana-5141	84	11	measuring	measure	VERB
cana-5141	84	12	clinical	clinical	ADJ
cana-5141	84	13	efficacy	efficacy	NOUN
cana-5141	84	14	,	,	PUNCT
cana-5141	84	15	risk	risk	NOUN
cana-5141	84	16	(	(	PUNCT
cana-5141	84	17	e.g.	e.g.	ADV
cana-5141	84	18	,	,	PUNCT
cana-5141	84	19	aria	aria	NOUN
cana-5141	84	20	)	)	PUNCT
cana-5141	84	21	,	,	PUNCT
cana-5141	84	22	and	and	CCONJ
cana-5141	84	23	safety	safety	NOUN
cana-5141	84	24	.	.	PUNCT
cana-5141	85	1	[	[	X
cana-5141	85	2	21	21	NUM
cana-5141	85	3	]	]	PUNCT
cana-5141	85	4	fluid	fluid	ADJ
cana-5141	85	5	biomarkers	biomarker	NOUN
cana-5141	85	6	✓	✓	ADJ
cana-5141	85	7	csf	csf	ADJ
cana-5141	85	8	and	and	CCONJ
cana-5141	85	9	plasma	plasma	NOUN
cana-5141	85	10	biomarkers	biomarker	NOUN
cana-5141	85	11	allow	allow	VERB
cana-5141	85	12	for	for	ADP
cana-5141	85	13	profiling	profile	VERB
cana-5141	85	14	multiple	multiple	ADJ
cana-5141	85	15	markers	marker	NOUN
cana-5141	85	16	from	from	ADP
cana-5141	85	17	a	a	DET
cana-5141	85	18	single	single	ADJ
cana-5141	85	19	sample	sample	NOUN
cana-5141	85	20	.	.	PUNCT
cana-5141	86	1	✓	✓	ADJ
cana-5141	86	2	plasma	plasma	NOUN
cana-5141	86	3	p	p	NOUN
cana-5141	86	4	-	-	PUNCT
cana-5141	86	5	tau217	tau217	NOUN
cana-5141	86	6	shows	show	VERB
cana-5141	86	7	higher	high	ADJ
cana-5141	86	8	accuracy	accuracy	NOUN
cana-5141	86	9	in	in	ADP
cana-5141	86	10	identifying	identify	VERB
cana-5141	86	11	amyloid	amyloid	NOUN
cana-5141	86	12	positivity	positivity	NOUN
cana-5141	86	13	compared	compare	VERB
cana-5141	86	14	to	to	ADP
cana-5141	86	15	csf	csf	ADJ
cana-5141	86	16	biomarkers	biomarker	NOUN
cana-5141	86	17	.	.	PUNCT
cana-5141	87	1	[	[	X
cana-5141	87	2	22	22	NUM
cana-5141	87	3	]	]	PUNCT
cana-5141	87	4	possible	possible	ADJ
cana-5141	87	5	alternative	alternative	ADJ
cana-5141	87	6	endpoints	endpoint	NOUN
cana-5141	87	7	✓	✓	ADV
cana-5141	87	8	csf	csf	X
cana-5141	87	9	aβ42/40	aβ42/40	PRON
cana-5141	87	10	shows	show	VERB
cana-5141	87	11	potential	potential	NOUN
cana-5141	87	12	for	for	ADP
cana-5141	87	13	determining	determine	VERB
cana-5141	87	14	amyloid	amyloid	NOUN
cana-5141	87	15	negativity	negativity	NOUN
cana-5141	87	16	but	but	CCONJ
cana-5141	87	17	with	with	ADP
cana-5141	87	18	higher	high	ADJ
cana-5141	87	19	accuracy	accuracy	NOUN
cana-5141	87	20	in	in	ADP
cana-5141	87	21	csf	csf	ADJ
cana-5141	87	22	samples	sample	NOUN
cana-5141	87	23	.	.	PUNCT
cana-5141	88	1	✓	✓	ADJ
cana-5141	88	2	plasma	plasma	NOUN
cana-5141	88	3	p	p	NOUN
cana-5141	88	4	-	-	PUNCT
cana-5141	88	5	tau217	tau217	NOUN
cana-5141	88	6	could	could	AUX
cana-5141	88	7	serve	serve	VERB
cana-5141	88	8	as	as	ADP
cana-5141	88	9	a	a	DET
cana-5141	88	10	cost	cost	NOUN
cana-5141	88	11	-	-	PUNCT
cana-5141	88	12	effective	effective	ADJ
cana-5141	88	13	alternative	alternative	NOUN
cana-5141	88	14	for	for	ADP
cana-5141	88	15	eligibility	eligibility	NOUN
cana-5141	88	16	screening	screening	NOUN
cana-5141	88	17	and	and	CCONJ
cana-5141	88	18	monitoring	monitoring	NOUN
cana-5141	88	19	.	.	PUNCT
cana-5141	89	1	[	[	X
cana-5141	89	2	24	24	NUM
cana-5141	89	3	]	]	PUNCT
cana-5141	89	4	communications	communication	NOUN
cana-5141	89	5	on	on	ADP
cana-5141	89	6	applied	apply	VERB
cana-5141	89	7	nonlinear	nonlinear	ADJ
cana-5141	89	8	analysis	analysis	NOUN
cana-5141	89	9	issn	issn	NOUN
cana-5141	89	10	:	:	PUNCT
cana-5141	89	11	1074	1074	NUM
cana-5141	89	12	-	-	PUNCT
cana-5141	89	13	133x	133x	NUM
cana-5141	89	14	vol	vol	NOUN
cana-5141	89	15	32	32	NUM
cana-5141	89	16	no	no	NOUN
cana-5141	89	17	.	.	PUNCT
cana-5141	90	1	icmasd	icmasd	NOUN
cana-5141	90	2	(	(	PUNCT
cana-5141	90	3	2025	2025	NUM
cana-5141	90	4	)	)	PUNCT
cana-5141	90	5	1141	1141	NUM
cana-5141	90	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	90	7	combination	combination	NOUN
cana-5141	90	8	therapy	therapy	NOUN
cana-5141	90	9	challenges	challenge	VERB
cana-5141	90	10	✓	✓	ADJ
cana-5141	90	11	attributing	attribute	VERB
cana-5141	90	12	biomarker	biomarker	NOUN
cana-5141	90	13	changes	change	NOUN
cana-5141	90	14	to	to	ADP
cana-5141	90	15	specific	specific	ADJ
cana-5141	90	16	treatments	treatment	NOUN
cana-5141	90	17	in	in	ADP
cana-5141	90	18	combination	combination	NOUN
cana-5141	90	19	therapies	therapy	NOUN
cana-5141	90	20	is	be	AUX
cana-5141	90	21	complex	complex	ADJ
cana-5141	90	22	.	.	PUNCT
cana-5141	91	1	✓	✓	ADJ
cana-5141	91	2	research	research	NOUN
cana-5141	91	3	is	be	AUX
cana-5141	91	4	needed	need	VERB
cana-5141	91	5	to	to	PART
cana-5141	91	6	refine	refine	VERB
cana-5141	91	7	the	the	DET
cana-5141	91	8	use	use	NOUN
cana-5141	91	9	of	of	ADP
cana-5141	91	10	plasma	plasma	NOUN
cana-5141	91	11	amyloid	amyloid	NOUN
cana-5141	91	12	markers	marker	NOUN
cana-5141	91	13	for	for	ADP
cana-5141	91	14	guiding	guide	VERB
cana-5141	91	15	treatment	treatment	NOUN
cana-5141	91	16	decisions	decision	NOUN
cana-5141	91	17	in	in	ADP
cana-5141	91	18	combination	combination	NOUN
cana-5141	91	19	trials	trial	NOUN
cana-5141	91	20	.	.	PUNCT
cana-5141	92	1	[	[	X
cana-5141	92	2	26	26	NUM
cana-5141	92	3	]	]	SYM
cana-5141	92	4	3	3	NUM
cana-5141	92	5	.	.	X
cana-5141	92	6	pathophysiology	pathophysiology	NOUN
cana-5141	92	7	of	of	ADP
cana-5141	92	8	alzheimer	alzheimer	PROPN
cana-5141	92	9	's	's	PART
cana-5141	92	10	disease	disease	NOUN
cana-5141	92	11	the	the	DET
cana-5141	92	12	pathophysiology	pathophysiology	NOUN
cana-5141	92	13	of	of	ADP
cana-5141	92	14	ad	ad	NOUN
cana-5141	92	15	is	be	AUX
cana-5141	92	16	primarily	primarily	ADV
cana-5141	92	17	characterized	characterize	VERB
cana-5141	92	18	by	by	ADP
cana-5141	92	19	the	the	DET
cana-5141	92	20	accumulation	accumulation	NOUN
cana-5141	92	21	of	of	ADP
cana-5141	92	22	amyloid	amyloid	NOUN
cana-5141	92	23	plaques	plaque	NOUN
cana-5141	92	24	and	and	CCONJ
cana-5141	92	25	neurofibrillary	neurofibrillary	ADJ
cana-5141	92	26	tangles	tangle	NOUN
cana-5141	92	27	,	,	PUNCT
cana-5141	92	28	which	which	PRON
cana-5141	92	29	are	be	AUX
cana-5141	92	30	critical	critical	ADJ
cana-5141	92	31	neuropathological	neuropathological	ADJ
cana-5141	92	32	features	feature	NOUN
cana-5141	92	33	of	of	ADP
cana-5141	92	34	the	the	DET
cana-5141	92	35	disorder	disorder	NOUN
cana-5141	92	36	.	.	PUNCT
cana-5141	93	1	amyloid	amyloid	NOUN
cana-5141	93	2	β	β	X
cana-5141	93	3	protein	protein	NOUN
cana-5141	93	4	undergoes	undergo	VERB
cana-5141	93	5	aberrant	aberrant	NOUN
cana-5141	93	6	folding	folding	NOUN
cana-5141	93	7	and	and	CCONJ
cana-5141	93	8	aggregation	aggregation	NOUN
cana-5141	93	9	as	as	SCONJ
cana-5141	93	10	shown	show	VERB
cana-5141	93	11	in	in	ADP
cana-5141	93	12	(	(	PUNCT
cana-5141	93	13	fig.1	fig.1	PROPN
cana-5141	93	14	)	)	PUNCT
cana-5141	93	15	,	,	PUNCT
cana-5141	93	16	leading	lead	VERB
cana-5141	93	17	to	to	ADP
cana-5141	93	18	the	the	DET
cana-5141	93	19	formation	formation	NOUN
cana-5141	93	20	of	of	ADP
cana-5141	93	21	senile	senile	ADJ
cana-5141	93	22	plaques	plaque	NOUN
cana-5141	93	23	,	,	PUNCT
cana-5141	93	24	a	a	DET
cana-5141	93	25	hallmark	hallmark	NOUN
cana-5141	93	26	of	of	ADP
cana-5141	93	27	ad	ad	NOUN
cana-5141	93	28	[	[	X
cana-5141	93	29	27	27	NUM
cana-5141	93	30	]	]	PUNCT
cana-5141	93	31	,	,	PUNCT
cana-5141	93	32	[	[	X
cana-5141	93	33	28	28	NUM
cana-5141	93	34	]	]	PUNCT
cana-5141	93	35	.	.	PUNCT
cana-5141	94	1	these	these	DET
cana-5141	94	2	plaques	plaque	NOUN
cana-5141	94	3	result	result	VERB
cana-5141	94	4	from	from	ADP
cana-5141	94	5	the	the	DET
cana-5141	94	6	cleavage	cleavage	NOUN
cana-5141	94	7	of	of	ADP
cana-5141	94	8	app	app	NOUN
cana-5141	94	9	by	by	ADP
cana-5141	94	10	secretases	secretase	NOUN
cana-5141	94	11	,	,	PUNCT
cana-5141	94	12	contributing	contribute	VERB
cana-5141	94	13	to	to	ADP
cana-5141	94	14	neuronal	neuronal	ADJ
cana-5141	94	15	dysfunction	dysfunction	NOUN
cana-5141	94	16	and	and	CCONJ
cana-5141	94	17	loss	loss	NOUN
cana-5141	94	18	[	[	X
cana-5141	94	19	28	28	NUM
cana-5141	94	20	]	]	PUNCT
cana-5141	94	21	.	.	PUNCT
cana-5141	95	1	additionally	additionally	ADV
cana-5141	95	2	,	,	PUNCT
cana-5141	95	3	tau	tau	PROPN
cana-5141	95	4	protein	protein	NOUN
cana-5141	95	5	plays	play	VERB
cana-5141	95	6	a	a	DET
cana-5141	95	7	significant	significant	ADJ
cana-5141	95	8	role	role	NOUN
cana-5141	95	9	in	in	ADP
cana-5141	95	10	the	the	DET
cana-5141	95	11	disease	disease	NOUN
cana-5141	95	12	's	's	PART
cana-5141	95	13	progression	progression	NOUN
cana-5141	95	14	,	,	PUNCT
cana-5141	95	15	as	as	SCONJ
cana-5141	95	16	its	its	PRON
cana-5141	95	17	abnormal	abnormal	ADJ
cana-5141	95	18	aggregation	aggregation	NOUN
cana-5141	95	19	forms	form	NOUN
cana-5141	95	20	neurofibrillary	neurofibrillary	ADJ
cana-5141	95	21	tangles	tangle	NOUN
cana-5141	95	22	,	,	PUNCT
cana-5141	95	23	further	far	ADV
cana-5141	95	24	disrupting	disrupt	VERB
cana-5141	95	25	synaptic	synaptic	ADJ
cana-5141	95	26	integrity	integrity	NOUN
cana-5141	95	27	and	and	CCONJ
cana-5141	95	28	neuronal	neuronal	ADJ
cana-5141	95	29	health[29	health[29	NOUN
cana-5141	95	30	]	]	PUNCT
cana-5141	95	31	.	.	PUNCT
cana-5141	96	1	the	the	DET
cana-5141	96	2	convergence	convergence	NOUN
cana-5141	96	3	of	of	ADP
cana-5141	96	4	these	these	DET
cana-5141	96	5	pathological	pathological	ADJ
cana-5141	96	6	processes	process	NOUN
cana-5141	96	7	,	,	PUNCT
cana-5141	96	8	including	include	VERB
cana-5141	96	9	mitochondrial	mitochondrial	ADJ
cana-5141	96	10	damage	damage	NOUN
cana-5141	96	11	and	and	CCONJ
cana-5141	96	12	selective	selective	ADJ
cana-5141	96	13	neuronal	neuronal	ADJ
cana-5141	96	14	loss	loss	NOUN
cana-5141	96	15	,	,	PUNCT
cana-5141	96	16	underpins	underpin	VERB
cana-5141	96	17	the	the	DET
cana-5141	96	18	cognitive	cognitive	ADJ
cana-5141	96	19	decline	decline	NOUN
cana-5141	96	20	observed	observe	VERB
cana-5141	96	21	in	in	ADP
cana-5141	96	22	affected	affect	VERB
cana-5141	96	23	individuals[30	individuals[30	PROPN
cana-5141	96	24	]	]	PUNCT
cana-5141	96	25	.	.	PUNCT
cana-5141	97	1	moreover	moreover	ADV
cana-5141	97	2	,	,	PUNCT
cana-5141	97	3	the	the	DET
cana-5141	97	4	interplay	interplay	NOUN
cana-5141	97	5	between	between	ADP
cana-5141	97	6	genetic	genetic	ADJ
cana-5141	97	7	and	and	CCONJ
cana-5141	97	8	environmental	environmental	ADJ
cana-5141	97	9	factors	factor	NOUN
cana-5141	97	10	exacerbates	exacerbate	VERB
cana-5141	97	11	the	the	DET
cana-5141	97	12	disease	disease	NOUN
cana-5141	97	13	's	's	PART
cana-5141	97	14	progression	progression	NOUN
cana-5141	97	15	,	,	PUNCT
cana-5141	97	16	highlighting	highlight	VERB
cana-5141	97	17	the	the	DET
cana-5141	97	18	complexity	complexity	NOUN
cana-5141	97	19	of	of	ADP
cana-5141	97	20	its	its	PRON
cana-5141	97	21	etiology[29	etiology[29	NOUN
cana-5141	97	22	]	]	PUNCT
cana-5141	97	23	.	.	PUNCT
cana-5141	98	1	ultimately	ultimately	ADV
cana-5141	98	2	,	,	PUNCT
cana-5141	98	3	the	the	DET
cana-5141	98	4	loss	loss	NOUN
cana-5141	98	5	of	of	ADP
cana-5141	98	6	synapses	synapsis	NOUN
cana-5141	98	7	and	and	CCONJ
cana-5141	98	8	the	the	DET
cana-5141	98	9	resultant	resultant	NOUN
cana-5141	98	10	cognitive	cognitive	ADJ
cana-5141	98	11	impairment	impairment	NOUN
cana-5141	98	12	are	be	AUX
cana-5141	98	13	central	central	ADJ
cana-5141	98	14	to	to	ADP
cana-5141	98	15	the	the	DET
cana-5141	98	16	clinical	clinical	ADJ
cana-5141	98	17	manifestations	manifestation	NOUN
cana-5141	98	18	of	of	ADP
cana-5141	98	19	alzheimer	alzheimer	PROPN
cana-5141	98	20	's	's	PART
cana-5141	98	21	disease	disease	NOUN
cana-5141	98	22	,	,	PUNCT
cana-5141	98	23	making	make	VERB
cana-5141	98	24	the	the	DET
cana-5141	98	25	understanding	understanding	NOUN
cana-5141	98	26	of	of	ADP
cana-5141	98	27	these	these	DET
cana-5141	98	28	molecular	molecular	ADJ
cana-5141	98	29	mechanisms	mechanism	NOUN
cana-5141	98	30	crucial	crucial	ADJ
cana-5141	98	31	for	for	ADP
cana-5141	98	32	developing	develop	VERB
cana-5141	98	33	effective	effective	ADJ
cana-5141	98	34	therapies	therapy	NOUN
cana-5141	98	35	[	[	X
cana-5141	98	36	29	29	NUM
cana-5141	98	37	]	]	PUNCT
cana-5141	98	38	,	,	PUNCT
cana-5141	98	39	[	[	X
cana-5141	98	40	31	31	NUM
cana-5141	98	41	]	]	PUNCT
cana-5141	98	42	.	.	PUNCT
cana-5141	99	1	fig.1	fig.1	ADJ
cana-5141	99	2	:	:	PUNCT
cana-5141	99	3	pathogenesis	pathogenesis	NOUN
cana-5141	99	4	of	of	ADP
cana-5141	99	5	alzheimer	alzheimer	PROPN
cana-5141	99	6	's	's	PART
cana-5141	99	7	disease	disease	NOUN
cana-5141	99	8	4	4	NUM
cana-5141	99	9	.	.	PUNCT
cana-5141	99	10	advances	advance	NOUN
cana-5141	99	11	in	in	ADP
cana-5141	99	12	crisper	crisp	ADJ
cana-5141	99	13	/	/	SYM
cana-5141	99	14	cas9	cas9	NOUN
cana-5141	99	15	technology	technology	NOUN
cana-5141	99	16	for	for	ADP
cana-5141	99	17	ad	ad	NOUN
cana-5141	99	18	the	the	DET
cana-5141	99	19	crispr	crispr	ADJ
cana-5141	99	20	-	-	PUNCT
cana-5141	99	21	cas9	cas9	NOUN
cana-5141	99	22	system	system	NOUN
cana-5141	99	23	has	have	AUX
cana-5141	99	24	emerged	emerge	VERB
cana-5141	99	25	as	as	ADP
cana-5141	99	26	a	a	DET
cana-5141	99	27	pivotal	pivotal	ADJ
cana-5141	99	28	tool	tool	NOUN
cana-5141	99	29	for	for	ADP
cana-5141	99	30	genetic	genetic	ADJ
cana-5141	99	31	modification	modification	NOUN
cana-5141	99	32	,	,	PUNCT
cana-5141	99	33	offering	offer	VERB
cana-5141	99	34	promising	promise	VERB
cana-5141	99	35	therapeutic	therapeutic	ADJ
cana-5141	99	36	strategies	strategy	NOUN
cana-5141	99	37	for	for	ADP
cana-5141	99	38	managing	manage	VERB
cana-5141	99	39	genetic	genetic	ADJ
cana-5141	99	40	diseases	disease	NOUN
cana-5141	99	41	like	like	ADP
cana-5141	99	42	alzheimer	alzheimer	PROPN
cana-5141	99	43	's	's	PART
cana-5141	99	44	disease	disease	NOUN
cana-5141	99	45	(	(	PUNCT
cana-5141	99	46	ad	ad	NOUN
cana-5141	99	47	)	)	PUNCT
cana-5141	99	48	.	.	PUNCT
cana-5141	100	1	scientists	scientist	NOUN
cana-5141	100	2	are	be	AUX
cana-5141	100	3	leveraging	leverage	VERB
cana-5141	100	4	crispr	crispr	NOUN
cana-5141	100	5	to	to	PART
cana-5141	100	6	target	target	VERB
cana-5141	100	7	specific	specific	ADJ
cana-5141	100	8	genes	gene	NOUN
cana-5141	100	9	implicated	implicate	VERB
cana-5141	100	10	in	in	ADP
cana-5141	100	11	ad	ad	NOUN
cana-5141	100	12	,	,	PUNCT
cana-5141	100	13	such	such	ADJ
cana-5141	100	14	as	as	ADP
cana-5141	100	15	amyloid	amyloid	NOUN
cana-5141	100	16	communications	communication	NOUN
cana-5141	100	17	on	on	ADP
cana-5141	100	18	applied	apply	VERB
cana-5141	100	19	nonlinear	nonlinear	ADJ
cana-5141	100	20	analysis	analysis	NOUN
cana-5141	100	21	issn	issn	NOUN
cana-5141	100	22	:	:	PUNCT
cana-5141	100	23	1074	1074	NUM
cana-5141	100	24	-	-	PUNCT
cana-5141	100	25	133x	133x	NUM
cana-5141	100	26	vol	vol	NOUN
cana-5141	100	27	32	32	NUM
cana-5141	100	28	no	no	NOUN
cana-5141	100	29	.	.	PUNCT
cana-5141	101	1	icmasd	icmasd	NOUN
cana-5141	101	2	(	(	PUNCT
cana-5141	101	3	2025	2025	NUM
cana-5141	101	4	)	)	PUNCT
cana-5141	101	5	1142	1142	NUM
cana-5141	101	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	101	7	precursor	precursor	NOUN
cana-5141	101	8	protein	protein	NOUN
cana-5141	101	9	(	(	PUNCT
cana-5141	101	10	app	app	NOUN
cana-5141	101	11	)	)	PUNCT
cana-5141	101	12	,	,	PUNCT
cana-5141	101	13	presenilin	presenilin	PROPN
cana-5141	101	14	(	(	PUNCT
cana-5141	101	15	psen1	psen1	ADJ
cana-5141	101	16	,	,	PUNCT
cana-5141	101	17	psen2	psen2	NOUN
cana-5141	101	18	)	)	PUNCT
cana-5141	101	19	,	,	PUNCT
cana-5141	101	20	and	and	CCONJ
cana-5141	101	21	apolipoprotein	apolipoprotein	ADJ
cana-5141	101	22	e	e	PROPN
cana-5141	101	23	(	(	PUNCT
cana-5141	101	24	apoe	apoe	ADJ
cana-5141	101	25	)	)	PUNCT
cana-5141	101	26	.	.	PUNCT
cana-5141	102	1	recent	recent	ADJ
cana-5141	102	2	advancements	advancement	NOUN
cana-5141	102	3	,	,	PUNCT
cana-5141	102	4	including	include	VERB
cana-5141	102	5	base	base	NOUN
cana-5141	102	6	editing	editing	NOUN
cana-5141	102	7	and	and	CCONJ
cana-5141	102	8	prime	prime	ADJ
cana-5141	102	9	editing	editing	NOUN
cana-5141	102	10	,	,	PUNCT
cana-5141	102	11	have	have	AUX
cana-5141	102	12	significantly	significantly	ADV
cana-5141	102	13	improved	improve	VERB
cana-5141	102	14	the	the	DET
cana-5141	102	15	precision	precision	NOUN
cana-5141	102	16	and	and	CCONJ
cana-5141	102	17	specificity	specificity	NOUN
cana-5141	102	18	of	of	ADP
cana-5141	102	19	gene	gene	NOUN
cana-5141	102	20	editing	editing	NOUN
cana-5141	102	21	,	,	PUNCT
cana-5141	102	22	minimized	minimize	VERB
cana-5141	102	23	off	off	ADP
cana-5141	102	24	-	-	PUNCT
cana-5141	102	25	target	target	NOUN
cana-5141	102	26	effects	effect	NOUN
cana-5141	102	27	and	and	CCONJ
cana-5141	102	28	enhanced	enhance	VERB
cana-5141	102	29	the	the	DET
cana-5141	102	30	accuracy	accuracy	NOUN
cana-5141	102	31	of	of	ADP
cana-5141	102	32	targeting	target	VERB
cana-5141	102	33	mutations	mutation	NOUN
cana-5141	102	34	associated	associate	VERB
cana-5141	102	35	with	with	ADP
cana-5141	102	36	ad	ad	NOUN
cana-5141	102	37	[	[	X
cana-5141	102	38	32	32	NUM
cana-5141	102	39	]	]	PUNCT
cana-5141	102	40	.	.	PUNCT
cana-5141	103	1	preclinical	preclinical	ADJ
cana-5141	103	2	studies	study	NOUN
cana-5141	103	3	have	have	AUX
cana-5141	103	4	compared	compare	VERB
cana-5141	103	5	various	various	ADJ
cana-5141	103	6	crispr	crispr	ADJ
cana-5141	103	7	variants	variant	NOUN
cana-5141	103	8	,	,	PUNCT
cana-5141	103	9	such	such	ADJ
cana-5141	103	10	as	as	ADP
cana-5141	103	11	spcas9	spcas9	NOUN
cana-5141	103	12	,	,	PUNCT
cana-5141	103	13	sacas9	sacas9	NOUN
cana-5141	103	14	,	,	PUNCT
cana-5141	103	15	and	and	CCONJ
cana-5141	103	16	ascas12a	ascas12a	ADV
cana-5141	103	17	,	,	PUNCT
cana-5141	103	18	revealing	reveal	VERB
cana-5141	103	19	differing	differ	VERB
cana-5141	103	20	success	success	NOUN
cana-5141	103	21	rates	rate	NOUN
cana-5141	103	22	in	in	ADP
cana-5141	103	23	editing	edit	VERB
cana-5141	103	24	ad	ad	NOUN
cana-5141	103	25	-	-	PUNCT
cana-5141	103	26	related	relate	VERB
cana-5141	103	27	genes[33	genes[33	NOUN
cana-5141	103	28	]	]	PUNCT
cana-5141	103	29	.	.	PUNCT
cana-5141	104	1	a	a	DET
cana-5141	104	2	2019	2019	NUM
cana-5141	104	3	study	study	NOUN
cana-5141	104	4	demonstrated	demonstrate	VERB
cana-5141	104	5	the	the	DET
cana-5141	104	6	efficacy	efficacy	NOUN
cana-5141	104	7	of	of	ADP
cana-5141	104	8	crispr	crispr	NOUN
cana-5141	104	9	-	-	PUNCT
cana-5141	104	10	cas9	cas9	NOUN
cana-5141	104	11	in	in	ADP
cana-5141	104	12	reducing	reduce	VERB
cana-5141	104	13	bace1	bace1	NOUN
cana-5141	104	14	expression	expression	NOUN
cana-5141	104	15	,	,	PUNCT
cana-5141	104	16	aβ	aβ	PRON
cana-5141	104	17	levels	level	NOUN
cana-5141	104	18	,	,	PUNCT
cana-5141	104	19	and	and	CCONJ
cana-5141	104	20	cognitive	cognitive	ADJ
cana-5141	104	21	deficits	deficit	NOUN
cana-5141	104	22	in	in	ADP
cana-5141	104	23	mouse	mouse	NOUN
cana-5141	104	24	models	model	NOUN
cana-5141	104	25	of	of	ADP
cana-5141	104	26	ad	ad	NOUN
cana-5141	104	27	,	,	PUNCT
cana-5141	104	28	highlighting	highlight	VERB
cana-5141	104	29	its	its	PRON
cana-5141	104	30	therapeutic	therapeutic	ADJ
cana-5141	104	31	potential	potential	NOUN
cana-5141	104	32	.	.	PUNCT
cana-5141	105	1	despite	despite	SCONJ
cana-5141	105	2	these	these	DET
cana-5141	105	3	advances	advance	NOUN
cana-5141	105	4	,	,	PUNCT
cana-5141	105	5	technical	technical	ADJ
cana-5141	105	6	and	and	CCONJ
cana-5141	105	7	ethical	ethical	ADJ
cana-5141	105	8	challenges	challenge	NOUN
cana-5141	105	9	persist[34	persist[34	NOUN
cana-5141	105	10	]	]	PUNCT
cana-5141	105	11	.	.	PUNCT
cana-5141	106	1	long	long	ADJ
cana-5141	106	2	-	-	PUNCT
cana-5141	106	3	term	term	NOUN
cana-5141	106	4	effects	effect	NOUN
cana-5141	106	5	on	on	ADP
cana-5141	106	6	the	the	DET
cana-5141	106	7	brain	brain	NOUN
cana-5141	106	8	,	,	PUNCT
cana-5141	106	9	potential	potential	ADJ
cana-5141	106	10	unintended	unintended	ADJ
cana-5141	106	11	genetic	genetic	ADJ
cana-5141	106	12	modifications	modification	NOUN
cana-5141	106	13	,	,	PUNCT
cana-5141	106	14	and	and	CCONJ
cana-5141	106	15	ethical	ethical	ADJ
cana-5141	106	16	concerns	concern	NOUN
cana-5141	106	17	regarding	regard	VERB
cana-5141	106	18	human	human	ADJ
cana-5141	106	19	genome	genome	NOUN
cana-5141	106	20	editing	editing	NOUN
cana-5141	106	21	must	must	AUX
cana-5141	106	22	be	be	AUX
cana-5141	106	23	thoroughly	thoroughly	ADV
cana-5141	106	24	addressed	address	VERB
cana-5141	106	25	before	before	SCONJ
cana-5141	106	26	clinical	clinical	ADJ
cana-5141	106	27	application	application	NOUN
cana-5141	106	28	can	can	AUX
cana-5141	106	29	proceed[35	proceed[35	X
cana-5141	106	30	]	]	PUNCT
cana-5141	107	1	the	the	DET
cana-5141	107	2	apoe4	apoe4	PROPN
cana-5141	107	3	allele	allele	NOUN
cana-5141	107	4	is	be	AUX
cana-5141	107	5	strongly	strongly	ADV
cana-5141	107	6	associated	associate	VERB
cana-5141	107	7	with	with	ADP
cana-5141	107	8	alzheimer	alzheimer	PROPN
cana-5141	107	9	's	's	PART
cana-5141	107	10	disease	disease	NOUN
cana-5141	107	11	(	(	PUNCT
cana-5141	107	12	ad	ad	NOUN
cana-5141	107	13	)	)	PUNCT
cana-5141	107	14	pathogenesis	pathogenesis	NOUN
cana-5141	107	15	,	,	PUNCT
cana-5141	107	16	significantly	significantly	ADV
cana-5141	107	17	increasing	increase	VERB
cana-5141	107	18	the	the	DET
cana-5141	107	19	risk	risk	NOUN
cana-5141	107	20	of	of	ADP
cana-5141	107	21	developing	develop	VERB
cana-5141	107	22	ad	ad	NOUN
cana-5141	107	23	by	by	ADP
cana-5141	107	24	promoting	promote	VERB
cana-5141	107	25	tau	tau	PROPN
cana-5141	107	26	protein	protein	NOUN
cana-5141	107	27	hyperphosphorylation	hyperphosphorylation	NOUN
cana-5141	107	28	.	.	PUNCT
cana-5141	108	1	individuals	individual	NOUN
cana-5141	108	2	with	with	ADP
cana-5141	108	3	one	one	NUM
cana-5141	108	4	apoe4	apoe4	ADJ
cana-5141	108	5	allele	allele	NOUN
cana-5141	108	6	have	have	VERB
cana-5141	108	7	approximately	approximately	ADV
cana-5141	108	8	a	a	DET
cana-5141	108	9	threefold	threefold	ADV
cana-5141	108	10	higher	high	ADJ
cana-5141	108	11	risk	risk	NOUN
cana-5141	108	12	,	,	PUNCT
cana-5141	108	13	while	while	SCONJ
cana-5141	108	14	those	those	PRON
cana-5141	108	15	with	with	ADP
cana-5141	108	16	two	two	NUM
cana-5141	108	17	alleles	allele	NOUN
cana-5141	108	18	face	face	VERB
cana-5141	108	19	up	up	ADP
cana-5141	108	20	to	to	ADP
cana-5141	108	21	a	a	DET
cana-5141	108	22	15	15	NUM
cana-5141	108	23	-	-	ADJ
cana-5141	108	24	fold	fold	ADJ
cana-5141	108	25	increased	increased	ADJ
cana-5141	108	26	risk	risk	NOUN
cana-5141	108	27	.	.	PUNCT
cana-5141	109	1	about	about	ADV
cana-5141	109	2	80	80	NUM
cana-5141	109	3	%	%	NOUN
cana-5141	109	4	of	of	ADP
cana-5141	109	5	ad	ad	NOUN
cana-5141	109	6	patients	patient	NOUN
cana-5141	109	7	carry	carry	VERB
cana-5141	109	8	at	at	ADV
cana-5141	109	9	least	least	ADV
cana-5141	109	10	one	one	NUM
cana-5141	109	11	apoe4	apoe4	ADJ
cana-5141	109	12	allele	allele	NOUN
cana-5141	109	13	.	.	PUNCT
cana-5141	110	1	a	a	DET
cana-5141	110	2	single	single	ADJ
cana-5141	110	3	amino	amino	NOUN
cana-5141	110	4	acid	acid	NOUN
cana-5141	110	5	substitution	substitution	NOUN
cana-5141	110	6	can	can	AUX
cana-5141	110	7	convert	convert	VERB
cana-5141	110	8	apoe4	apoe4	NOUN
cana-5141	110	9	into	into	ADP
cana-5141	110	10	the	the	DET
cana-5141	110	11	protective	protective	ADJ
cana-5141	110	12	apoe2	apoe2	NOUN
cana-5141	110	13	allele	allele	NOUN
cana-5141	110	14	or	or	CCONJ
cana-5141	110	15	the	the	DET
cana-5141	110	16	neutral	neutral	ADJ
cana-5141	110	17	apoe3	apoe3	PROPN
cana-5141	110	18	allele	allele	PROPN
cana-5141	110	19	,	,	PUNCT
cana-5141	110	20	providing	provide	VERB
cana-5141	110	21	a	a	DET
cana-5141	110	22	foundation	foundation	NOUN
cana-5141	110	23	for	for	ADP
cana-5141	110	24	targeted	target	VERB
cana-5141	110	25	therapies[36	therapies[36	NOUN
cana-5141	110	26	]	]	PUNCT
cana-5141	110	27	.	.	PUNCT
cana-5141	111	1	recent	recent	ADJ
cana-5141	111	2	advancements	advancement	NOUN
cana-5141	111	3	in	in	ADP
cana-5141	111	4	crispr	crispr	NOUN
cana-5141	111	5	-	-	PUNCT
cana-5141	111	6	cas9based	cas9base	VERB
cana-5141	111	7	"	"	PUNCT
cana-5141	111	8	base	base	NOUN
cana-5141	111	9	editing	editing	NOUN
cana-5141	111	10	"	"	PUNCT
cana-5141	111	11	have	have	AUX
cana-5141	111	12	demonstrated	demonstrate	VERB
cana-5141	111	13	promising	promising	ADJ
cana-5141	111	14	results	result	NOUN
cana-5141	111	15	for	for	ADP
cana-5141	111	16	modifying	modify	VERB
cana-5141	111	17	apoe4	apoe4	PROPN
cana-5141	111	18	.	.	PUNCT
cana-5141	112	1	in	in	ADP
cana-5141	112	2	mouse	mouse	NOUN
cana-5141	112	3	astrocytic	astrocytic	ADJ
cana-5141	112	4	cells	cell	NOUN
cana-5141	112	5	,	,	PUNCT
cana-5141	112	6	lentivirus	lentivirus	NOUN
cana-5141	112	7	-	-	PUNCT
cana-5141	112	8	delivered	deliver	VERB
cana-5141	112	9	crispr	crispr	NOUN
cana-5141	112	10	-	-	PUNCT
cana-5141	112	11	cas9	cas9	NOUN
cana-5141	112	12	selectively	selectively	ADV
cana-5141	112	13	reduced	reduce	VERB
cana-5141	112	14	apoe4	apoe4	ADJ
cana-5141	112	15	protein	protein	NOUN
cana-5141	112	16	production	production	NOUN
cana-5141	112	17	by	by	ADP
cana-5141	112	18	60	60	NUM
cana-5141	112	19	%	%	NOUN
cana-5141	112	20	,	,	PUNCT
cana-5141	112	21	sparing	spare	VERB
cana-5141	112	22	apoe3	apoe3	PROPN
cana-5141	112	23	.	.	PUNCT
cana-5141	113	1	similarly	similarly	ADV
cana-5141	113	2	,	,	PUNCT
cana-5141	113	3	in	in	ADP
cana-5141	113	4	hek293	hek293	PROPN
cana-5141	113	5	t	t	NOUN
cana-5141	113	6	cells	cell	NOUN
cana-5141	113	7	,	,	PUNCT
cana-5141	113	8	the	the	DET
cana-5141	113	9	system	system	NOUN
cana-5141	113	10	fused	fuse	VERB
cana-5141	113	11	with	with	ADP
cana-5141	113	12	cytidine	cytidine	NOUN
cana-5141	113	13	deaminase	deaminase	NOUN
cana-5141	113	14	irreversibly	irreversibly	ADV
cana-5141	113	15	converted	convert	VERB
cana-5141	113	16	apoe4	apoe4	NOUN
cana-5141	113	17	into	into	ADP
cana-5141	113	18	apoe3	apoe3	PROPN
cana-5141	113	19	,	,	PUNCT
cana-5141	113	20	mitigating	mitigate	VERB
cana-5141	113	21	tau	tau	PROPN
cana-5141	113	22	hyperphosphorylation	hyperphosphorylation	NOUN
cana-5141	113	23	and	and	CCONJ
cana-5141	113	24	correcting	correct	VERB
cana-5141	113	25	mutations	mutation	NOUN
cana-5141	113	26	linked	link	VERB
cana-5141	113	27	to	to	ADP
cana-5141	113	28	ad[36].the	ad[36].the	DET
cana-5141	113	29	app	app	PROPN
cana-5141	113	30	gene	gene	NOUN
cana-5141	113	31	is	be	AUX
cana-5141	113	32	another	another	DET
cana-5141	113	33	critical	critical	ADJ
cana-5141	113	34	target	target	NOUN
cana-5141	113	35	for	for	ADP
cana-5141	113	36	sporadic	sporadic	ADJ
cana-5141	113	37	ad	ad	NOUN
cana-5141	113	38	.	.	PUNCT
cana-5141	114	1	lentiviral	lentiviral	ADJ
cana-5141	114	2	crispr	crispr	NOUN
cana-5141	114	3	-	-	PUNCT
cana-5141	114	4	cas9	cas9	NOUN
cana-5141	114	5	selectively	selectively	ADV
cana-5141	114	6	edits	edit	VERB
cana-5141	114	7	the	the	DET
cana-5141	114	8	c	c	NOUN
cana-5141	114	9	-	-	PUNCT
cana-5141	114	10	terminus	terminus	NOUN
cana-5141	114	11	of	of	ADP
cana-5141	114	12	the	the	DET
cana-5141	114	13	app	app	NOUN
cana-5141	114	14	gene	gene	NOUN
cana-5141	114	15	,	,	PUNCT
cana-5141	114	16	reducing	reduce	VERB
cana-5141	114	17	amyloidogenic	amyloidogenic	ADJ
cana-5141	114	18	pathway	pathway	NOUN
cana-5141	114	19	activity	activity	NOUN
cana-5141	114	20	while	while	SCONJ
cana-5141	114	21	preserving	preserve	VERB
cana-5141	114	22	its	its	PRON
cana-5141	114	23	physiological	physiological	ADJ
cana-5141	114	24	roles	role	NOUN
cana-5141	114	25	.	.	PUNCT
cana-5141	115	1	this	this	DET
cana-5141	115	2	strategy	strategy	NOUN
cana-5141	115	3	has	have	AUX
cana-5141	115	4	effectively	effectively	ADV
cana-5141	115	5	reduced	reduce	VERB
cana-5141	115	6	aβ	aβ	PRON
cana-5141	115	7	production	production	NOUN
cana-5141	115	8	and	and	CCONJ
cana-5141	115	9	ad	ad	NOUN
cana-5141	115	10	-	-	PUNCT
cana-5141	115	11	like	like	ADJ
cana-5141	115	12	pathology	pathology	NOUN
cana-5141	115	13	in	in	ADP
cana-5141	115	14	mouse	mouse	NOUN
cana-5141	115	15	models	model	NOUN
cana-5141	115	16	and	and	CCONJ
cana-5141	115	17	cell	cell	NOUN
cana-5141	115	18	lines	line	NOUN
cana-5141	115	19	,	,	PUNCT
cana-5141	115	20	demonstrating	demonstrate	VERB
cana-5141	115	21	its	its	PRON
cana-5141	115	22	therapeutic	therapeutic	ADJ
cana-5141	115	23	potential[37	potential[37	NOUN
cana-5141	115	24	]	]	PUNCT
cana-5141	115	25	.	.	PUNCT
cana-5141	116	1	crispr	crispr	PROPN
cana-5141	116	2	-	-	PUNCT
cana-5141	116	3	cas9	cas9	NOUN
cana-5141	116	4	has	have	AUX
cana-5141	116	5	transformed	transform	VERB
cana-5141	116	6	gene	gene	NOUN
cana-5141	116	7	editing	edit	VERB
cana-5141	116	8	with	with	ADP
cana-5141	116	9	its	its	PRON
cana-5141	116	10	vast	vast	ADJ
cana-5141	116	11	potential	potential	NOUN
cana-5141	116	12	for	for	ADP
cana-5141	116	13	clinical	clinical	ADJ
cana-5141	116	14	applications	application	NOUN
cana-5141	116	15	,	,	PUNCT
cana-5141	116	16	but	but	CCONJ
cana-5141	116	17	offtarget	offtarget	NOUN
cana-5141	116	18	effects	effect	NOUN
cana-5141	116	19	remain	remain	VERB
cana-5141	116	20	a	a	DET
cana-5141	116	21	significant	significant	ADJ
cana-5141	116	22	challenge	challenge	NOUN
cana-5141	116	23	.	.	PUNCT
cana-5141	117	1	these	these	DET
cana-5141	117	2	effects	effect	NOUN
cana-5141	117	3	occur	occur	VERB
cana-5141	117	4	when	when	SCONJ
cana-5141	117	5	the	the	DET
cana-5141	117	6	cas9	cas9	NOUN
cana-5141	117	7	protein	protein	NOUN
cana-5141	117	8	unintentionally	unintentionally	ADV
cana-5141	117	9	cleaves	cleave	VERB
cana-5141	117	10	dna	dna	NOUN
cana-5141	117	11	at	at	ADP
cana-5141	117	12	unintended	unintended	ADJ
cana-5141	117	13	sites	site	NOUN
cana-5141	117	14	,	,	PUNCT
cana-5141	117	15	potentially	potentially	ADV
cana-5141	117	16	disrupting	disrupt	VERB
cana-5141	117	17	normal	normal	ADJ
cana-5141	117	18	gene	gene	NOUN
cana-5141	117	19	functions	function	NOUN
cana-5141	117	20	and	and	CCONJ
cana-5141	117	21	compromising	compromise	VERB
cana-5141	117	22	genomic	genomic	ADJ
cana-5141	117	23	stability	stability	NOUN
cana-5141	117	24	.	.	PUNCT
cana-5141	118	1	precision	precision	NOUN
cana-5141	118	2	in	in	ADP
cana-5141	118	3	therapeutic	therapeutic	ADJ
cana-5141	118	4	applications	application	NOUN
cana-5141	118	5	,	,	PUNCT
cana-5141	118	6	such	such	ADJ
cana-5141	118	7	as	as	ADP
cana-5141	118	8	those	those	PRON
cana-5141	118	9	for	for	ADP
cana-5141	118	10	alzheimer	alzheimer	PROPN
cana-5141	118	11	’s	’s	PART
cana-5141	118	12	disease	disease	NOUN
cana-5141	118	13	(	(	PUNCT
cana-5141	118	14	ad	ad	NOUN
cana-5141	118	15	)	)	PUNCT
cana-5141	118	16	,	,	PUNCT
cana-5141	118	17	depends	depend	VERB
cana-5141	118	18	heavily	heavily	ADV
cana-5141	118	19	on	on	ADP
cana-5141	118	20	the	the	DET
cana-5141	118	21	accurate	accurate	ADJ
cana-5141	118	22	interaction	interaction	NOUN
cana-5141	118	23	between	between	ADP
cana-5141	118	24	the	the	DET
cana-5141	118	25	single	single	ADJ
cana-5141	118	26	-	-	PUNCT
cana-5141	118	27	guide	guide	NOUN
cana-5141	118	28	rna	rna	NOUN
cana-5141	118	29	(	(	PUNCT
cana-5141	118	30	sgrna	sgrna	PROPN
cana-5141	118	31	)	)	PUNCT
cana-5141	118	32	and	and	CCONJ
cana-5141	118	33	the	the	DET
cana-5141	118	34	target	target	NOUN
cana-5141	118	35	dna	dna	NOUN
cana-5141	118	36	sequence[38	sequence[38	VERB
cana-5141	118	37	]	]	PUNCT
cana-5141	118	38	.	.	PUNCT
cana-5141	119	1	factors	factor	NOUN
cana-5141	119	2	influencing	influence	VERB
cana-5141	119	3	off	off	ADP
cana-5141	119	4	-	-	PUNCT
cana-5141	119	5	target	target	NOUN
cana-5141	119	6	effects	effect	NOUN
cana-5141	119	7	include	include	VERB
cana-5141	119	8	the	the	DET
cana-5141	119	9	length	length	NOUN
cana-5141	119	10	and	and	CCONJ
cana-5141	119	11	composition	composition	NOUN
cana-5141	119	12	of	of	ADP
cana-5141	119	13	sgrnas	sgrna	NOUN
cana-5141	119	14	.	.	PUNCT
cana-5141	120	1	truncated	truncate	VERB
cana-5141	120	2	sgrnas	sgrnas	NOUN
cana-5141	120	3	shorter	short	ADJ
cana-5141	120	4	than	than	SCONJ
cana-5141	120	5	17	17	NUM
cana-5141	120	6	nucleotides	nucleotide	NOUN
cana-5141	120	7	show	show	VERB
cana-5141	120	8	reduced	reduce	VERB
cana-5141	120	9	activity	activity	NOUN
cana-5141	120	10	compared	compare	VERB
cana-5141	120	11	to	to	ADP
cana-5141	120	12	the	the	DET
cana-5141	120	13	standard	standard	ADJ
cana-5141	120	14	20	20	NUM
cana-5141	120	15	-	-	PUNCT
cana-5141	120	16	nucleotide	nucleotide	NOUN
cana-5141	120	17	sgrnas	sgrna	NOUN
cana-5141	120	18	,	,	PUNCT
cana-5141	120	19	emphasizing	emphasize	VERB
cana-5141	120	20	the	the	DET
cana-5141	120	21	importance	importance	NOUN
cana-5141	120	22	of	of	ADP
cana-5141	120	23	maintaining	maintain	VERB
cana-5141	120	24	fulllength	fulllength	NOUN
cana-5141	120	25	sequences	sequence	NOUN
cana-5141	120	26	to	to	PART
cana-5141	120	27	minimize	minimize	VERB
cana-5141	120	28	mismatches	mismatch	NOUN
cana-5141	120	29	.	.	PUNCT
cana-5141	121	1	additionally	additionally	ADV
cana-5141	121	2	,	,	PUNCT
cana-5141	121	3	the	the	DET
cana-5141	121	4	gc	gc	PROPN
cana-5141	121	5	content	content	NOUN
cana-5141	121	6	of	of	ADP
cana-5141	121	7	sgrnas	sgrnas	PROPN
cana-5141	121	8	plays	play	VERB
cana-5141	121	9	a	a	DET
cana-5141	121	10	critical	critical	ADJ
cana-5141	121	11	role	role	NOUN
cana-5141	121	12	;	;	PUNCT
cana-5141	121	13	extremes	extreme	NOUN
cana-5141	121	14	in	in	ADP
cana-5141	121	15	gc	gc	PROPN
cana-5141	121	16	content	content	NOUN
cana-5141	121	17	can	can	AUX
cana-5141	121	18	increase	increase	VERB
cana-5141	121	19	the	the	DET
cana-5141	121	20	likelihood	likelihood	NOUN
cana-5141	121	21	of	of	ADP
cana-5141	121	22	off	off	ADP
cana-5141	121	23	-	-	PUNCT
cana-5141	121	24	target	target	NOUN
cana-5141	121	25	effects	effect	NOUN
cana-5141	121	26	,	,	PUNCT
cana-5141	121	27	with	with	SCONJ
cana-5141	121	28	optimal	optimal	ADJ
cana-5141	121	29	performance	performance	NOUN
cana-5141	121	30	achieved	achieve	VERB
cana-5141	121	31	at	at	ADP
cana-5141	121	32	a	a	DET
cana-5141	121	33	gc	gc	PROPN
cana-5141	121	34	content	content	NOUN
cana-5141	121	35	of	of	ADP
cana-5141	121	36	40–60%.[39].to	40–60%.[39].to	NUM
cana-5141	121	37	address	address	NOUN
cana-5141	121	38	these	these	DET
cana-5141	121	39	challenges	challenge	NOUN
cana-5141	121	40	,	,	PUNCT
cana-5141	121	41	advanced	advanced	ADJ
cana-5141	121	42	cas9	cas9	NOUN
cana-5141	121	43	variants	variant	NOUN
cana-5141	121	44	,	,	PUNCT
cana-5141	121	45	such	such	ADJ
cana-5141	121	46	as	as	ADP
cana-5141	121	47	spcas9	spcas9	NOUN
cana-5141	121	48	-	-	PUNCT
cana-5141	121	49	hf1	hf1	NOUN
cana-5141	121	50	,	,	PUNCT
cana-5141	121	51	sniper	sniper	NOUN
cana-5141	121	52	-	-	PUNCT
cana-5141	121	53	cas9	cas9	NOUN
cana-5141	121	54	,	,	PUNCT
cana-5141	121	55	espcas9	espcas9	NOUN
cana-5141	121	56	1.1	1.1	NUM
cana-5141	121	57	,	,	PUNCT
cana-5141	121	58	hypacas9	hypacas9	NOUN
cana-5141	121	59	,	,	PUNCT
cana-5141	121	60	and	and	CCONJ
cana-5141	121	61	xcas9	xcas9	NOUN
cana-5141	121	62	,	,	PUNCT
cana-5141	121	63	have	have	AUX
cana-5141	121	64	been	be	AUX
cana-5141	121	65	developed	develop	VERB
cana-5141	121	66	to	to	PART
cana-5141	121	67	enhance	enhance	VERB
cana-5141	121	68	dna	dna	PROPN
cana-5141	121	69	cleavage	cleavage	NOUN
cana-5141	121	70	specificity	specificity	NOUN
cana-5141	121	71	while	while	SCONJ
cana-5141	121	72	preserving	preserve	VERB
cana-5141	121	73	on	on	ADP
cana-5141	121	74	-	-	PUNCT
cana-5141	121	75	target	target	NOUN
cana-5141	121	76	activity	activity	NOUN
cana-5141	121	77	.	.	PUNCT
cana-5141	122	1	computational	computational	ADJ
cana-5141	122	2	algorithms	algorithm	NOUN
cana-5141	122	3	further	far	ADV
cana-5141	122	4	improve	improve	VERB
cana-5141	122	5	precision	precision	NOUN
cana-5141	122	6	by	by	ADP
cana-5141	122	7	enabling	enable	VERB
cana-5141	122	8	the	the	DET
cana-5141	122	9	selection	selection	NOUN
cana-5141	122	10	of	of	ADP
cana-5141	122	11	highly	highly	ADV
cana-5141	122	12	specific	specific	ADJ
cana-5141	122	13	sgrna	sgrna	ADJ
cana-5141	122	14	sequences	sequence	NOUN
cana-5141	122	15	,	,	PUNCT
cana-5141	122	16	reducing	reduce	VERB
cana-5141	122	17	unintended	unintended	ADJ
cana-5141	122	18	dna	dna	NOUN
cana-5141	122	19	cleavage	cleavage	NOUN
cana-5141	122	20	.	.	PUNCT
cana-5141	123	1	ongoing	ongoing	ADJ
cana-5141	123	2	innovations	innovation	NOUN
cana-5141	123	3	in	in	ADP
cana-5141	123	4	cas9	cas9	NOUN
cana-5141	123	5	protein	protein	NOUN
cana-5141	123	6	engineering	engineering	NOUN
cana-5141	123	7	and	and	CCONJ
cana-5141	123	8	sgrna	sgrna	PROPN
cana-5141	123	9	design	design	NOUN
cana-5141	123	10	are	be	AUX
cana-5141	123	11	critical	critical	ADJ
cana-5141	123	12	to	to	ADP
cana-5141	123	13	mitigating	mitigate	VERB
cana-5141	123	14	off	off	ADP
cana-5141	123	15	-	-	PUNCT
cana-5141	123	16	target	target	NOUN
cana-5141	123	17	effects	effect	NOUN
cana-5141	123	18	,	,	PUNCT
cana-5141	123	19	paving	pave	VERB
cana-5141	123	20	the	the	DET
cana-5141	123	21	way	way	NOUN
cana-5141	123	22	for	for	ADP
cana-5141	123	23	the	the	DET
cana-5141	123	24	safe	safe	ADJ
cana-5141	123	25	and	and	CCONJ
cana-5141	123	26	effective	effective	ADJ
cana-5141	123	27	clinical	clinical	ADJ
cana-5141	123	28	use	use	NOUN
cana-5141	123	29	of	of	ADP
cana-5141	123	30	crispr	crispr	NOUN
cana-5141	123	31	-	-	PUNCT
cana-5141	123	32	cas9	cas9	NOUN
cana-5141	123	33	in	in	ADP
cana-5141	123	34	ad	ad	NOUN
cana-5141	123	35	and	and	CCONJ
cana-5141	123	36	other	other	ADJ
cana-5141	123	37	diseases	disease	NOUN
cana-5141	123	38	[	[	X
cana-5141	123	39	40	40	NUM
cana-5141	123	40	]	]	PUNCT
cana-5141	123	41	.	.	PUNCT
cana-5141	124	1	communications	communication	NOUN
cana-5141	124	2	on	on	ADP
cana-5141	124	3	applied	apply	VERB
cana-5141	124	4	nonlinear	nonlinear	ADJ
cana-5141	124	5	analysis	analysis	NOUN
cana-5141	124	6	issn	issn	NOUN
cana-5141	124	7	:	:	PUNCT
cana-5141	124	8	1074	1074	NUM
cana-5141	124	9	-	-	PUNCT
cana-5141	124	10	133x	133x	NUM
cana-5141	124	11	vol	vol	NOUN
cana-5141	124	12	32	32	NUM
cana-5141	124	13	no	no	NOUN
cana-5141	124	14	.	.	PUNCT
cana-5141	125	1	icmasd	icmasd	NOUN
cana-5141	125	2	(	(	PUNCT
cana-5141	125	3	2025	2025	NUM
cana-5141	125	4	)	)	PUNCT
cana-5141	125	5	1143	1143	NUM
cana-5141	125	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	125	7	5	5	X
cana-5141	125	8	.	.	PUNCT
cana-5141	125	9	mechanism	mechanism	NOUN
cana-5141	125	10	of	of	ADP
cana-5141	125	11	crispr	crispr	ADJ
cana-5141	125	12	cas9	cas9	NOUN
cana-5141	125	13	in	in	ADP
cana-5141	125	14	alzheimer	alzheimer	PROPN
cana-5141	125	15	’s	’s	PART
cana-5141	125	16	therapy	therapy	NOUN
cana-5141	125	17	the	the	DET
cana-5141	125	18	adaptive	adaptive	ADJ
cana-5141	125	19	immune	immune	ADJ
cana-5141	125	20	system	system	NOUN
cana-5141	125	21	of	of	ADP
cana-5141	125	22	prokaryotes	prokaryote	NOUN
cana-5141	125	23	-	-	PUNCT
cana-5141	125	24	which	which	PRON
cana-5141	125	25	are	be	AUX
cana-5141	125	26	primarily	primarily	ADV
cana-5141	125	27	descended	descend	VERB
cana-5141	125	28	from	from	ADP
cana-5141	125	29	bacteria	bacteria	NOUN
cana-5141	125	30	and	and	CCONJ
cana-5141	125	31	archaea	archaea	NOUN
cana-5141	125	32	is	be	AUX
cana-5141	125	33	where	where	SCONJ
cana-5141	125	34	the	the	DET
cana-5141	125	35	crispr	crispr	NOUN
cana-5141	125	36	-	-	PUNCT
cana-5141	125	37	cas9	cas9	NOUN
cana-5141	125	38	(	(	PUNCT
cana-5141	125	39	fig.2	fig.2	PROPN
cana-5141	125	40	)	)	PUNCT
cana-5141	125	41	system	system	NOUN
cana-5141	125	42	was	be	AUX
cana-5141	125	43	discovered	discover	VERB
cana-5141	125	44	[	[	X
cana-5141	125	45	41	41	NUM
cana-5141	125	46	]	]	PUNCT
cana-5141	125	47	.	.	PUNCT
cana-5141	126	1	enzyme	enzyme	NOUN
cana-5141	126	2	cas9	cas9	NOUN
cana-5141	126	3	,	,	PUNCT
cana-5141	126	4	transactivating	transactivate	VERB
cana-5141	126	5	crrna	crrna	NOUN
cana-5141	126	6	and	and	CCONJ
cana-5141	126	7	tracrrna	tracrrna	NOUN
cana-5141	126	8	are	be	AUX
cana-5141	126	9	the	the	DET
cana-5141	126	10	three	three	NUM
cana-5141	126	11	primary	primary	ADJ
cana-5141	126	12	components	component	NOUN
cana-5141	126	13	of	of	ADP
cana-5141	126	14	the	the	DET
cana-5141	126	15	extensively	extensively	ADV
cana-5141	126	16	used	use	VERB
cana-5141	126	17	type	type	NOUN
cana-5141	126	18	ii	ii	PROPN
cana-5141	126	19	crispr	crispr	ADJ
cana-5141	126	20	-	-	PUNCT
cana-5141	126	21	cas9	cas9	NOUN
cana-5141	126	22	system	system	NOUN
cana-5141	126	23	.	.	PUNCT
cana-5141	127	1	among	among	ADP
cana-5141	127	2	these	these	DET
cana-5141	127	3	three	three	NUM
cana-5141	127	4	components	component	NOUN
cana-5141	127	5	,	,	PUNCT
cana-5141	127	6	cas9	cas9	PROPN
cana-5141	127	7	is	be	AUX
cana-5141	127	8	an	an	DET
cana-5141	127	9	enzyme	enzyme	NOUN
cana-5141	127	10	that	that	PRON
cana-5141	127	11	cleaves	cleave	VERB
cana-5141	127	12	the	the	DET
cana-5141	127	13	target	target	NOUN
cana-5141	127	14	dna	dna	NOUN
cana-5141	127	15	through	through	ADP
cana-5141	127	16	six	six	NUM
cana-5141	127	17	domains	domain	NOUN
cana-5141	127	18	:	:	PUNCT
cana-5141	127	19	the	the	DET
cana-5141	127	20	bridge	bridge	NOUN
cana-5141	127	21	helix	helix	NOUN
cana-5141	127	22	,	,	PUNCT
cana-5141	127	23	the	the	DET
cana-5141	127	24	pam	pam	NOUN
cana-5141	127	25	-	-	PUNCT
cana-5141	127	26	interacting	interact	VERB
cana-5141	127	27	domain	domain	NOUN
cana-5141	127	28	,	,	PUNCT
cana-5141	127	29	the	the	DET
cana-5141	127	30	recombination	recombination	NOUN
cana-5141	127	31	enhancer	enhancer	NOUN
cana-5141	127	32	cis	cis	NOUN
cana-5141	127	33	-	-	PUNCT
cana-5141	127	34	acting	act	VERB
cana-5141	127	35	element	element	NOUN
cana-5141	127	36	(	(	PUNCT
cana-5141	127	37	rec	rec	PROPN
cana-5141	127	38	i	i	PROPN
cana-5141	127	39	,	,	PUNCT
cana-5141	127	40	ii	ii	PROPN
cana-5141	127	41	)	)	PUNCT
cana-5141	127	42	the	the	DET
cana-5141	127	43	hnh	hnh	NOUN
cana-5141	127	44	,	,	PUNCT
cana-5141	127	45	and	and	CCONJ
cana-5141	127	46	the	the	DET
cana-5141	127	47	ruvc	ruvc	PROPN
cana-5141	127	48	.	.	PUNCT
cana-5141	128	1	the	the	DET
cana-5141	128	2	guide	guide	PROPN
cana-5141	128	3	rna	rna	PROPN
cana-5141	128	4	's	's	PART
cana-5141	128	5	binding	binding	NOUN
cana-5141	128	6	to	to	ADP
cana-5141	128	7	the	the	DET
cana-5141	128	8	target	target	NOUN
cana-5141	128	9	sequence	sequence	NOUN
cana-5141	128	10	is	be	AUX
cana-5141	128	11	facilitated	facilitate	VERB
cana-5141	128	12	by	by	ADP
cana-5141	128	13	the	the	DET
cana-5141	128	14	rec	rec	NOUN
cana-5141	128	15	i	i	PRON
cana-5141	128	16	domain	domain	VERB
cana-5141	128	17	.	.	PUNCT
cana-5141	129	1	the	the	DET
cana-5141	129	2	arginine	arginine	NOUN
cana-5141	129	3	rich	rich	ADJ
cana-5141	129	4	bridge	bridge	NOUN
cana-5141	129	5	helix	helix	NOUN
cana-5141	129	6	is	be	AUX
cana-5141	129	7	necessary	necessary	ADJ
cana-5141	129	8	to	to	PART
cana-5141	129	9	initiate	initiate	VERB
cana-5141	129	10	the	the	DET
cana-5141	129	11	cleavage	cleavage	NOUN
cana-5141	129	12	activity	activity	NOUN
cana-5141	129	13	,	,	PUNCT
cana-5141	129	14	and	and	CCONJ
cana-5141	129	15	the	the	DET
cana-5141	129	16	pam	pam	NOUN
cana-5141	129	17	-	-	PUNCT
cana-5141	129	18	interacting	interact	VERB
cana-5141	129	19	domain	domain	NOUN
cana-5141	129	20	is	be	AUX
cana-5141	129	21	responsible	responsible	ADJ
cana-5141	129	22	for	for	ADP
cana-5141	129	23	initiating	initiate	VERB
cana-5141	129	24	the	the	DET
cana-5141	129	25	binding	bind	VERB
cana-5141	129	26	process	process	NOUN
cana-5141	129	27	with	with	ADP
cana-5141	129	28	the	the	DET
cana-5141	129	29	target	target	NOUN
cana-5141	129	30	dna	dna	NOUN
cana-5141	129	31	once	once	SCONJ
cana-5141	129	32	it	it	PRON
cana-5141	129	33	has	have	AUX
cana-5141	129	34	been	be	AUX
cana-5141	129	35	bound	bind	VERB
cana-5141	129	36	.	.	PUNCT
cana-5141	130	1	a	a	DET
cana-5141	130	2	chimeric	chimeric	ADJ
cana-5141	130	3	single	single	NOUN
cana-5141	130	4	can	can	AUX
cana-5141	130	5	be	be	AUX
cana-5141	130	6	created	create	VERB
cana-5141	130	7	by	by	ADP
cana-5141	130	8	joining	join	VERB
cana-5141	130	9	the	the	DET
cana-5141	130	10	crrna	crrna	NOUN
cana-5141	130	11	-	-	PUNCT
cana-5141	130	12	tracrrna	tracrrna	NOUN
cana-5141	130	13	duplex	duplex	NOUN
cana-5141	130	14	,	,	PUNCT
cana-5141	130	15	which	which	PRON
cana-5141	130	16	will	will	AUX
cana-5141	130	17	effectively	effectively	ADV
cana-5141	130	18	progress	progress	VERB
cana-5141	130	19	genome	genome	NOUN
cana-5141	130	20	engineering	engineering	NOUN
cana-5141	131	1	[	[	X
cana-5141	131	2	42	42	NUM
cana-5141	131	3	]	]	PUNCT
cana-5141	131	4	,	,	PUNCT
cana-5141	131	5	[	[	X
cana-5141	131	6	43].the	43].the	DET
cana-5141	131	7	synthetic	synthetic	ADJ
cana-5141	131	8	rna	rna	NOUN
cana-5141	131	9	's	's	PART
cana-5141	131	10	20	20	NUM
cana-5141	131	11	-	-	PUNCT
cana-5141	131	12	nucleotide	nucleotide	NOUN
cana-5141	131	13	guide	guide	NOUN
cana-5141	131	14	sequence	sequence	NOUN
cana-5141	131	15	is	be	AUX
cana-5141	131	16	complementary	complementary	ADJ
cana-5141	131	17	to	to	ADP
cana-5141	131	18	the	the	DET
cana-5141	131	19	target	target	NOUN
cana-5141	131	20	site	site	NOUN
cana-5141	131	21	.	.	PUNCT
cana-5141	132	1	once	once	SCONJ
cana-5141	132	2	the	the	DET
cana-5141	132	3	target	target	NOUN
cana-5141	132	4	sequence	sequence	NOUN
cana-5141	132	5	is	be	AUX
cana-5141	132	6	identified	identify	VERB
cana-5141	132	7	,	,	PUNCT
cana-5141	132	8	the	the	DET
cana-5141	132	9	sgrna	sgrna	NOUN
cana-5141	132	10	attaches	attach	VERB
cana-5141	132	11	by	by	ADP
cana-5141	132	12	base	base	NOUN
cana-5141	132	13	-	-	PUNCT
cana-5141	132	14	pairing	pairing	NOUN
cana-5141	132	15	via	via	ADP
cana-5141	132	16	watson	watson	PROPN
cana-5141	132	17	-	-	PUNCT
cana-5141	132	18	crick	crick	PROPN
cana-5141	132	19	method	method	NOUN
cana-5141	132	20	,	,	PUNCT
cana-5141	132	21	which	which	PRON
cana-5141	132	22	instructs	instruct	VERB
cana-5141	132	23	cas9	cas9	NOUN
cana-5141	132	24	to	to	PART
cana-5141	132	25	cut	cut	VERB
cana-5141	132	26	the	the	DET
cana-5141	132	27	dna	dna	PROPN
cana-5141	132	28	strand	strand	NOUN
cana-5141	132	29	and	and	CCONJ
cana-5141	132	30	form	form	VERB
cana-5141	132	31	a	a	DET
cana-5141	132	32	double	double	ADJ
cana-5141	132	33	strand	strand	NOUN
cana-5141	132	34	break	break	NOUN
cana-5141	132	35	(	(	PUNCT
cana-5141	132	36	dsb	dsb	PROPN
cana-5141	132	37	)	)	PUNCT
cana-5141	132	38	at	at	ADP
cana-5141	132	39	the	the	DET
cana-5141	132	40	intended	intended	ADJ
cana-5141	132	41	site	site	NOUN
cana-5141	132	42	.	.	PUNCT
cana-5141	133	1	the	the	DET
cana-5141	133	2	nuclease	nuclease	NOUN
cana-5141	133	3	domains	domain	NOUN
cana-5141	133	4	of	of	ADP
cana-5141	133	5	hnh	hnh	NOUN
cana-5141	133	6	and	and	CCONJ
cana-5141	133	7	ruvc	ruvc	PROPN
cana-5141	133	8	cleave	cleave	PROPN
cana-5141	133	9	target	target	PROPN
cana-5141	133	10	dna	dna	PROPN
cana-5141	133	11	.	.	PUNCT
cana-5141	134	1	non	non	ADJ
cana-5141	134	2	-	-	ADJ
cana-5141	134	3	homologous	homologous	ADJ
cana-5141	134	4	end	end	NOUN
cana-5141	134	5	joining	join	VERB
cana-5141	134	6	(	(	PUNCT
cana-5141	134	7	nhej	nhej	ADJ
cana-5141	134	8	)	)	PUNCT
cana-5141	134	9	and	and	CCONJ
cana-5141	134	10	homology	homology	NOUN
cana-5141	134	11	-	-	PUNCT
cana-5141	134	12	directed	direct	VERB
cana-5141	134	13	repair	repair	NOUN
cana-5141	134	14	(	(	PUNCT
cana-5141	134	15	hdr	hdr	NOUN
cana-5141	134	16	)	)	PUNCT
cana-5141	134	17	are	be	AUX
cana-5141	134	18	the	the	DET
cana-5141	134	19	two	two	NUM
cana-5141	134	20	main	main	ADJ
cana-5141	134	21	techniques	technique	NOUN
cana-5141	134	22	for	for	ADP
cana-5141	134	23	mending	mend	VERB
cana-5141	134	24	the	the	DET
cana-5141	134	25	fractures	fracture	NOUN
cana-5141	134	26	(	(	PUNCT
cana-5141	134	27	fig.3	fig.3	PROPN
cana-5141	134	28	)	)	PUNCT
cana-5141	135	1	[	[	X
cana-5141	135	2	44	44	NUM
cana-5141	135	3	]	]	PUNCT
cana-5141	135	4	.	.	PUNCT
cana-5141	136	1	when	when	SCONJ
cana-5141	136	2	dsbs	dsbs	ADJ
cana-5141	136	3	are	be	AUX
cana-5141	136	4	damaged	damage	VERB
cana-5141	136	5	for	for	ADP
cana-5141	136	6	gene	gene	NOUN
cana-5141	136	7	alteration	alteration	NOUN
cana-5141	136	8	,	,	PUNCT
cana-5141	136	9	the	the	DET
cana-5141	136	10	hdr	hdr	NOUN
cana-5141	136	11	repair	repair	NOUN
cana-5141	136	12	mechanism	mechanism	NOUN
cana-5141	136	13	correctly	correctly	ADV
cana-5141	136	14	repairs	repair	VERB
cana-5141	136	15	them	they	PRON
cana-5141	136	16	using	use	VERB
cana-5141	136	17	a	a	DET
cana-5141	136	18	donor	donor	NOUN
cana-5141	136	19	dna	dna	NOUN
cana-5141	136	20	template	template	NOUN
cana-5141	136	21	,	,	PUNCT
cana-5141	136	22	while	while	SCONJ
cana-5141	136	23	the	the	DET
cana-5141	136	24	nhej	nhej	ADJ
cana-5141	136	25	repair	repair	NOUN
cana-5141	136	26	mechanism	mechanism	NOUN
cana-5141	136	27	often	often	ADV
cana-5141	136	28	causes	cause	VERB
cana-5141	136	29	genomic	genomic	ADJ
cana-5141	136	30	insertions	insertion	NOUN
cana-5141	136	31	or	or	CCONJ
cana-5141	136	32	deletions	deletion	NOUN
cana-5141	136	33	(	(	PUNCT
cana-5141	136	34	indels	indel	NOUN
cana-5141	136	35	)	)	PUNCT
cana-5141	136	36	for	for	ADP
cana-5141	136	37	gene	gene	NOUN
cana-5141	136	38	disruption	disruption	NOUN
cana-5141	136	39	,	,	PUNCT
cana-5141	136	40	which	which	PRON
cana-5141	136	41	is	be	AUX
cana-5141	136	42	more	more	ADV
cana-5141	136	43	efficient	efficient	ADJ
cana-5141	136	44	.	.	PUNCT
cana-5141	137	1	normally	normally	ADV
cana-5141	137	2	,	,	PUNCT
cana-5141	137	3	the	the	DET
cana-5141	137	4	nhej	nhej	ADJ
cana-5141	137	5	is	be	AUX
cana-5141	137	6	prone	prone	ADJ
cana-5141	137	7	to	to	ADP
cana-5141	137	8	errors	error	NOUN
cana-5141	137	9	and	and	CCONJ
cana-5141	137	10	has	have	VERB
cana-5141	137	11	the	the	DET
cana-5141	137	12	ability	ability	NOUN
cana-5141	137	13	to	to	PART
cana-5141	137	14	join	join	VERB
cana-5141	137	15	break	break	VERB
cana-5141	137	16	sequences	sequence	NOUN
cana-5141	137	17	directly	directly	ADV
cana-5141	137	18	.	.	PUNCT
cana-5141	138	1	it	it	PRON
cana-5141	138	2	can	can	AUX
cana-5141	138	3	also	also	ADV
cana-5141	138	4	introduce	introduce	VERB
cana-5141	138	5	arbitrary	arbitrary	ADJ
cana-5141	138	6	insertions	insertion	NOUN
cana-5141	138	7	or	or	CCONJ
cana-5141	138	8	deletions	deletion	NOUN
cana-5141	138	9	(	(	PUNCT
cana-5141	138	10	indels	indel	NOUN
cana-5141	138	11	)	)	PUNCT
cana-5141	138	12	at	at	ADP
cana-5141	138	13	the	the	DET
cana-5141	138	14	dsb	dsb	NOUN
cana-5141	138	15	site[45	site[45	NOUN
cana-5141	138	16	]	]	PUNCT
cana-5141	138	17	.	.	PUNCT
cana-5141	139	1	when	when	SCONJ
cana-5141	139	2	sgrna	sgrna	NOUN
cana-5141	139	3	and	and	CCONJ
cana-5141	139	4	cas9	cas9	NOUN
cana-5141	139	5	are	be	AUX
cana-5141	139	6	expressed	express	VERB
cana-5141	139	7	together	together	ADV
cana-5141	139	8	,	,	PUNCT
cana-5141	139	9	high	high	ADJ
cana-5141	139	10	-	-	PUNCT
cana-5141	139	11	efficiency	efficiency	NOUN
cana-5141	139	12	cleavage	cleavage	NOUN
cana-5141	139	13	of	of	ADP
cana-5141	139	14	any	any	DET
cana-5141	139	15	target	target	NOUN
cana-5141	139	16	sequence	sequence	NOUN
cana-5141	139	17	is	be	AUX
cana-5141	139	18	readily	readily	ADV
cana-5141	139	19	accomplished	accomplish	VERB
cana-5141	139	20	[	[	X
cana-5141	139	21	46	46	NUM
cana-5141	139	22	]	]	PUNCT
cana-5141	139	23	.	.	PUNCT
cana-5141	140	1	sgrna	sgrna	PROPN
cana-5141	140	2	attaches	attach	VERB
cana-5141	140	3	to	to	ADP
cana-5141	140	4	a	a	DET
cana-5141	140	5	complementary	complementary	ADJ
cana-5141	140	6	genomic	genomic	NOUN
cana-5141	140	7	dna	dna	NOUN
cana-5141	140	8	fragment	fragment	VERB
cana-5141	140	9	through	through	ADP
cana-5141	140	10	an	an	DET
cana-5141	140	11	rna	rna	NOUN
cana-5141	140	12	–	–	PUNCT
cana-5141	140	13	dna	dna	NOUN
cana-5141	140	14	complex	complex	NOUN
cana-5141	140	15	after	after	SCONJ
cana-5141	140	16	cas9	cas9	NOUN
cana-5141	140	17	locates	locate	VERB
cana-5141	140	18	its	its	PRON
cana-5141	140	19	dna	dna	NOUN
cana-5141	140	20	-	-	PUNCT
cana-5141	140	21	binding	bind	VERB
cana-5141	140	22	sites	site	NOUN
cana-5141	140	23	.	.	PUNCT
cana-5141	141	1	cas9	cas9	NOUN
cana-5141	141	2	endonucleases	endonuclease	NOUN
cana-5141	141	3	cause	cause	VERB
cana-5141	141	4	a	a	DET
cana-5141	141	5	double	double	ADJ
cana-5141	141	6	-	-	PUNCT
cana-5141	141	7	strand	strand	NOUN
cana-5141	141	8	break	break	NOUN
cana-5141	141	9	that	that	PRON
cana-5141	141	10	can	can	AUX
cana-5141	141	11	be	be	AUX
cana-5141	141	12	repaired	repair	VERB
cana-5141	141	13	via	via	ADP
cana-5141	141	14	the	the	DET
cana-5141	141	15	hrr	hrr	PROPN
cana-5141	141	16	route	route	NOUN
cana-5141	141	17	or	or	CCONJ
cana-5141	141	18	the	the	DET
cana-5141	141	19	error	error	NOUN
cana-5141	141	20	-	-	PUNCT
cana-5141	141	21	prone	prone	ADJ
cana-5141	141	22	nhej	nhej	ADJ
cana-5141	141	23	,	,	PUNCT
cana-5141	141	24	both	both	PRON
cana-5141	141	25	of	of	ADP
cana-5141	141	26	which	which	PRON
cana-5141	141	27	can	can	AUX
cana-5141	141	28	cause	cause	VERB
cana-5141	141	29	dna	dna	PROPN
cana-5141	141	30	mutagenesis	mutagenesis	NOUN
cana-5141	141	31	.	.	PUNCT
cana-5141	142	1	frameshift	frameshift	NOUN
cana-5141	142	2	mutations	mutation	NOUN
cana-5141	142	3	can	can	AUX
cana-5141	142	4	result	result	VERB
cana-5141	142	5	from	from	ADP
cana-5141	142	6	insertion	insertion	NOUN
cana-5141	142	7	or	or	CCONJ
cana-5141	142	8	deletion	deletion	NOUN
cana-5141	142	9	(	(	PUNCT
cana-5141	142	10	indel	indel	NOUN
cana-5141	142	11	)	)	PUNCT
cana-5141	142	12	mutations	mutation	NOUN
cana-5141	142	13	,	,	PUNCT
cana-5141	142	14	which	which	PRON
cana-5141	142	15	cause	cause	VERB
cana-5141	142	16	nhej	nhej	ADJ
cana-5141	142	17	repair	repair	NOUN
cana-5141	142	18	.	.	PUNCT
cana-5141	143	1	on	on	ADP
cana-5141	143	2	the	the	DET
cana-5141	143	3	other	other	ADJ
cana-5141	143	4	hand	hand	NOUN
cana-5141	143	5	,	,	PUNCT
cana-5141	143	6	in	in	ADP
cana-5141	143	7	the	the	DET
cana-5141	143	8	presence	presence	NOUN
cana-5141	143	9	of	of	ADP
cana-5141	143	10	a	a	DET
cana-5141	143	11	homologous	homologous	ADJ
cana-5141	143	12	dna	dna	NOUN
cana-5141	143	13	template	template	NOUN
cana-5141	143	14	,	,	PUNCT
cana-5141	143	15	the	the	DET
cana-5141	143	16	hdr	hdr	NOUN
cana-5141	143	17	process	process	NOUN
cana-5141	143	18	can	can	AUX
cana-5141	143	19	be	be	AUX
cana-5141	143	20	utilized	utilize	VERB
cana-5141	143	21	to	to	PART
cana-5141	143	22	induce	induce	VERB
cana-5141	143	23	precise	precise	ADJ
cana-5141	143	24	genetic	genetic	ADJ
cana-5141	143	25	alterations	alteration	NOUN
cana-5141	143	26	.	.	PUNCT
cana-5141	144	1	fig.2	fig.2	NOUN
cana-5141	144	2	:	:	PUNCT
cana-5141	144	3	an	an	DET
cana-5141	144	4	outline	outline	NOUN
cana-5141	144	5	of	of	ADP
cana-5141	144	6	the	the	DET
cana-5141	144	7	cas9	cas9	NOUN
cana-5141	144	8	endonuclease	endonuclease	NOUN
cana-5141	144	9	.	.	PUNCT
cana-5141	145	1	single	single	ADJ
cana-5141	145	2	guide	guide	PROPN
cana-5141	145	3	rna	rna	PROPN
cana-5141	145	4	(	(	PUNCT
cana-5141	145	5	sgrna	sgrna	PROPN
cana-5141	145	6	)	)	PUNCT
cana-5141	145	7	is	be	AUX
cana-5141	145	8	the	the	DET
cana-5141	145	9	name	name	NOUN
cana-5141	145	10	given	give	VERB
cana-5141	145	11	to	to	ADP
cana-5141	145	12	this	this	DET
cana-5141	145	13	combined	combine	VERB
cana-5141	145	14	rna	rna	NOUN
cana-5141	145	15	molecule	molecule	NOUN
cana-5141	145	16	,	,	PUNCT
cana-5141	145	17	which	which	PRON
cana-5141	145	18	is	be	AUX
cana-5141	145	19	connected	connect	VERB
cana-5141	145	20	to	to	ADP
cana-5141	145	21	the	the	DET
cana-5141	145	22	3′	3′	NUM
cana-5141	145	23	end	end	NOUN
cana-5141	145	24	of	of	ADP
cana-5141	145	25	crrna	crrna	NOUN
cana-5141	145	26	and	and	CCONJ
cana-5141	145	27	functions	function	NOUN
cana-5141	145	28	as	as	ADP
cana-5141	145	29	an	an	DET
cana-5141	145	30	anchor	anchor	NOUN
cana-5141	145	31	to	to	ADP
cana-5141	145	32	the	the	DET
cana-5141	145	33	cas9	cas9	NOUN
cana-5141	145	34	endonuclease	endonuclease	NOUN
cana-5141	145	35	.	.	PUNCT
cana-5141	146	1	cas9	cas9	NOUN
cana-5141	146	2	looks	look	VERB
cana-5141	146	3	for	for	ADP
cana-5141	146	4	the	the	DET
cana-5141	146	5	proper	proper	ADJ
cana-5141	146	6	protospacer	protospacer	NOUN
cana-5141	146	7	adjacent	adjacent	ADJ
cana-5141	146	8	motif	motif	NOUN
cana-5141	146	9	(	(	PUNCT
cana-5141	146	10	pam	pam	NOUN
cana-5141	146	11	)	)	PUNCT
cana-5141	146	12	in	in	ADP
cana-5141	146	13	possible	possible	ADJ
cana-5141	146	14	targets	target	NOUN
cana-5141	146	15	'	'	PART
cana-5141	146	16	dna	dna	NOUN
cana-5141	146	17	.	.	PUNCT
cana-5141	147	1	upon	upon	SCONJ
cana-5141	147	2	locating	locate	VERB
cana-5141	147	3	the	the	DET
cana-5141	147	4	pam	pam	NOUN
cana-5141	147	5	,	,	PUNCT
cana-5141	147	6	the	the	DET
cana-5141	147	7	protein	protein	NOUN
cana-5141	147	8	undergoes	undergo	VERB
cana-5141	147	9	a	a	DET
cana-5141	147	10	confirmation	confirmation	NOUN
cana-5141	147	11	alteration	alteration	NOUN
cana-5141	147	12	that	that	PRON
cana-5141	147	13	causes	cause	VERB
cana-5141	147	14	the	the	DET
cana-5141	147	15	dna	dna	NOUN
cana-5141	147	16	to	to	PART
cana-5141	147	17	unravel	unravel	VERB
cana-5141	147	18	,	,	PUNCT
cana-5141	147	19	hence	hence	ADV
cana-5141	147	20	facilitating	facilitate	VERB
cana-5141	147	21	communications	communication	NOUN
cana-5141	147	22	on	on	ADP
cana-5141	147	23	applied	apply	VERB
cana-5141	147	24	nonlinear	nonlinear	ADJ
cana-5141	147	25	analysis	analysis	NOUN
cana-5141	147	26	issn	issn	NOUN
cana-5141	147	27	:	:	PUNCT
cana-5141	147	28	1074	1074	NUM
cana-5141	147	29	-	-	PUNCT
cana-5141	147	30	133x	133x	NUM
cana-5141	147	31	vol	vol	NOUN
cana-5141	147	32	32	32	NUM
cana-5141	147	33	no	no	NOUN
cana-5141	147	34	.	.	PUNCT
cana-5141	148	1	icmasd	icmasd	NOUN
cana-5141	148	2	(	(	PUNCT
cana-5141	148	3	2025	2025	NUM
cana-5141	148	4	)	)	PUNCT
cana-5141	148	5	1144	1144	NUM
cana-5141	148	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	148	7	communication	communication	NOUN
cana-5141	148	8	between	between	ADP
cana-5141	148	9	the	the	DET
cana-5141	148	10	crrna	crrna	NOUN
cana-5141	148	11	and	and	CCONJ
cana-5141	148	12	dna	dna	NOUN
cana-5141	148	13	.	.	PUNCT
cana-5141	149	1	if	if	SCONJ
cana-5141	149	2	complementary	complementary	ADJ
cana-5141	149	3	binding	bind	VERB
cana-5141	149	4	takes	take	VERB
cana-5141	149	5	place	place	NOUN
cana-5141	149	6	between	between	ADP
cana-5141	149	7	the	the	DET
cana-5141	149	8	guide	guide	NOUN
cana-5141	149	9	and	and	CCONJ
cana-5141	149	10	seed	seed	NOUN
cana-5141	149	11	area	area	NOUN
cana-5141	149	12	,	,	PUNCT
cana-5141	149	13	the	the	DET
cana-5141	149	14	ruvc	ruvc	PROPN
cana-5141	149	15	and	and	CCONJ
cana-5141	149	16	hnh	hnh	NOUN
cana-5141	149	17	domains	domain	NOUN
cana-5141	149	18	subsequently	subsequently	ADV
cana-5141	149	19	cut	cut	VERB
cana-5141	149	20	the	the	DET
cana-5141	149	21	target	target	NOUN
cana-5141	149	22	dna	dna	NOUN
cana-5141	149	23	.	.	PUNCT
cana-5141	150	1	fig.3	fig.3	ADJ
cana-5141	150	2	:	:	PUNCT
cana-5141	151	1	the	the	DET
cana-5141	151	2	crispr	crispr	ADJ
cana-5141	151	3	-	-	PUNCT
cana-5141	151	4	cas9	cas9	NOUN
cana-5141	151	5	mechanism	mechanism	NOUN
cana-5141	151	6	for	for	ADP
cana-5141	151	7	genome	genome	NOUN
cana-5141	151	8	editing	editing	NOUN
cana-5141	151	9	6	6	NUM
cana-5141	151	10	.	.	PUNCT
cana-5141	151	11	proposed	propose	VERB
cana-5141	151	12	crispr	crispr	ADJ
cana-5141	151	13	-	-	PUNCT
cana-5141	151	14	cas9	cas9	NOUN
cana-5141	151	15	delivery	delivery	NOUN
cana-5141	151	16	method	method	NOUN
cana-5141	151	17	for	for	ADP
cana-5141	151	18	alzheimer	alzheimer	PROPN
cana-5141	151	19	’s	’s	PART
cana-5141	151	20	disease	disease	NOUN
cana-5141	151	21	the	the	DET
cana-5141	151	22	delivery	delivery	NOUN
cana-5141	151	23	of	of	ADP
cana-5141	151	24	crispr	crispr	ADJ
cana-5141	151	25	/	/	SYM
cana-5141	151	26	cas9	cas9	NOUN
cana-5141	151	27	systems	system	NOUN
cana-5141	151	28	for	for	ADP
cana-5141	151	29	applications	application	NOUN
cana-5141	151	30	in	in	ADP
cana-5141	151	31	ad	ad	NOUN
cana-5141	151	32	can	can	AUX
cana-5141	151	33	be	be	AUX
cana-5141	151	34	approached	approach	VERB
cana-5141	151	35	through	through	ADP
cana-5141	151	36	various	various	ADJ
cana-5141	151	37	methods	method	NOUN
cana-5141	151	38	,	,	PUNCT
cana-5141	151	39	each	each	PRON
cana-5141	151	40	with	with	ADP
cana-5141	151	41	its	its	PRON
cana-5141	151	42	advantages	advantage	NOUN
cana-5141	151	43	and	and	CCONJ
cana-5141	151	44	challenges	challenge	NOUN
cana-5141	151	45	.	.	PUNCT
cana-5141	152	1	adenoviral	adenoviral	ADJ
cana-5141	152	2	vectors	vector	NOUN
cana-5141	152	3	(	(	PUNCT
cana-5141	152	4	advs	advs	PROPN
cana-5141	152	5	)	)	PUNCT
cana-5141	152	6	are	be	AUX
cana-5141	152	7	recognized	recognize	VERB
cana-5141	152	8	as	as	ADP
cana-5141	152	9	effective	effective	ADJ
cana-5141	152	10	delivery	delivery	NOUN
cana-5141	152	11	vehicles	vehicle	NOUN
cana-5141	152	12	for	for	ADP
cana-5141	152	13	introducing	introduce	VERB
cana-5141	152	14	rna	rna	NOUN
cana-5141	152	15	-	-	PUNCT
cana-5141	152	16	guided	guide	VERB
cana-5141	152	17	nucleases	nuclease	NOUN
cana-5141	152	18	into	into	ADP
cana-5141	152	19	human	human	ADJ
cana-5141	152	20	somatic	somatic	ADJ
cana-5141	152	21	cells	cell	NOUN
cana-5141	152	22	,	,	PUNCT
cana-5141	152	23	making	make	VERB
cana-5141	152	24	them	they	PRON
cana-5141	152	25	suitable	suitable	ADJ
cana-5141	152	26	for	for	ADP
cana-5141	152	27	targeting	target	VERB
cana-5141	152	28	neuronal	neuronal	ADJ
cana-5141	152	29	cells	cell	NOUN
cana-5141	152	30	in	in	ADP
cana-5141	152	31	ad	ad	NOUN
cana-5141	152	32	research	research	NOUN
cana-5141	152	33	[	[	X
cana-5141	152	34	47	47	NUM
cana-5141	152	35	]	]	PUNCT
cana-5141	152	36	.	.	PUNCT
cana-5141	153	1	these	these	DET
cana-5141	153	2	viral	viral	ADJ
cana-5141	153	3	vectors	vector	NOUN
cana-5141	153	4	can	can	AUX
cana-5141	153	5	package	package	VERB
cana-5141	153	6	genetic	genetic	ADJ
cana-5141	153	7	material	material	NOUN
cana-5141	153	8	efficiently	efficiently	ADV
cana-5141	153	9	,	,	PUNCT
cana-5141	153	10	broadening	broaden	VERB
cana-5141	153	11	the	the	DET
cana-5141	153	12	applicability	applicability	NOUN
cana-5141	153	13	of	of	ADP
cana-5141	153	14	crispr	crispr	NOUN
cana-5141	153	15	/	/	SYM
cana-5141	153	16	cas9	cas9	NOUN
cana-5141	153	17	to	to	ADP
cana-5141	153	18	different	different	ADJ
cana-5141	153	19	cell	cell	NOUN
cana-5141	153	20	types	type	NOUN
cana-5141	153	21	,	,	PUNCT
cana-5141	153	22	including	include	VERB
cana-5141	153	23	those	those	PRON
cana-5141	153	24	that	that	PRON
cana-5141	153	25	are	be	AUX
cana-5141	153	26	quiescent	quiescent	ADJ
cana-5141	153	27	or	or	CCONJ
cana-5141	153	28	dividing	divide	VERB
cana-5141	153	29	[	[	X
cana-5141	153	30	48	48	NUM
cana-5141	153	31	]	]	PUNCT
cana-5141	153	32	.	.	PUNCT
cana-5141	154	1	however	however	ADV
cana-5141	154	2	,	,	PUNCT
cana-5141	154	3	safety	safety	NOUN
cana-5141	154	4	concerns	concern	NOUN
cana-5141	154	5	associated	associate	VERB
cana-5141	154	6	with	with	ADP
cana-5141	154	7	viral	viral	ADJ
cana-5141	154	8	vectors	vector	NOUN
cana-5141	154	9	necessitate	necessitate	ADJ
cana-5141	154	10	the	the	DET
cana-5141	154	11	exploration	exploration	NOUN
cana-5141	154	12	of	of	ADP
cana-5141	154	13	nonviral	nonviral	ADJ
cana-5141	154	14	drug	drug	NOUN
cana-5141	154	15	delivery	delivery	NOUN
cana-5141	154	16	systems	system	NOUN
cana-5141	154	17	.	.	PUNCT
cana-5141	155	1	recent	recent	ADJ
cana-5141	155	2	advancements	advancement	NOUN
cana-5141	155	3	in	in	ADP
cana-5141	155	4	lipid	lipid	NOUN
cana-5141	155	5	or	or	CCONJ
cana-5141	155	6	polymer	polymer	NOUN
cana-5141	155	7	-	-	PUNCT
cana-5141	155	8	based	base	VERB
cana-5141	155	9	nanocarriers	nanocarrier	NOUN
cana-5141	155	10	present	present	VERB
cana-5141	155	11	promising	promising	ADJ
cana-5141	155	12	alternatives	alternative	NOUN
cana-5141	155	13	for	for	ADP
cana-5141	155	14	in	in	ADP
cana-5141	155	15	vivo	vivo	ADJ
cana-5141	155	16	delivery	delivery	NOUN
cana-5141	155	17	of	of	ADP
cana-5141	155	18	crispr	crispr	ADJ
cana-5141	155	19	/	/	SYM
cana-5141	155	20	cas9	cas9	NOUN
cana-5141	155	21	components	component	NOUN
cana-5141	155	22	,	,	PUNCT
cana-5141	155	23	addressing	address	VERB
cana-5141	155	24	the	the	DET
cana-5141	155	25	challenges	challenge	NOUN
cana-5141	155	26	faced	face	VERB
cana-5141	155	27	in	in	ADP
cana-5141	155	28	effectively	effectively	ADV
cana-5141	155	29	targeting	target	VERB
cana-5141	155	30	the	the	DET
cana-5141	155	31	brain	brain	NOUN
cana-5141	155	32	[	[	X
cana-5141	155	33	49	49	NUM
cana-5141	155	34	]	]	PUNCT
cana-5141	155	35	.	.	PUNCT
cana-5141	156	1	the	the	DET
cana-5141	156	2	combination	combination	NOUN
cana-5141	156	3	of	of	ADP
cana-5141	156	4	these	these	DET
cana-5141	156	5	delivery	delivery	NOUN
cana-5141	156	6	methods	method	NOUN
cana-5141	156	7	could	could	AUX
cana-5141	156	8	enhance	enhance	VERB
cana-5141	156	9	the	the	DET
cana-5141	156	10	precision	precision	NOUN
cana-5141	156	11	and	and	CCONJ
cana-5141	156	12	safety	safety	NOUN
cana-5141	156	13	of	of	ADP
cana-5141	156	14	crispr	crispr	ADJ
cana-5141	156	15	/	/	SYM
cana-5141	156	16	cas9	cas9	NOUN
cana-5141	156	17	applications	application	NOUN
cana-5141	156	18	in	in	ADP
cana-5141	156	19	ad	ad	NOUN
cana-5141	156	20	,	,	PUNCT
cana-5141	156	21	ultimately	ultimately	ADV
cana-5141	156	22	contributing	contribute	VERB
cana-5141	156	23	to	to	ADP
cana-5141	156	24	more	more	ADV
cana-5141	156	25	effective	effective	ADJ
cana-5141	156	26	gene	gene	NOUN
cana-5141	156	27	editing	edit	VERB
cana-5141	156	28	strategies	strategy	NOUN
cana-5141	156	29	in	in	ADP
cana-5141	156	30	therapeutic	therapeutic	ADJ
cana-5141	156	31	contexts	context	NOUN
cana-5141	157	1	[	[	X
cana-5141	157	2	50	50	NUM
cana-5141	157	3	]	]	PUNCT
cana-5141	157	4	,	,	PUNCT
cana-5141	157	5	[	[	X
cana-5141	157	6	51	51	NUM
cana-5141	157	7	]	]	PUNCT
cana-5141	157	8	.	.	PUNCT
cana-5141	158	1	thus	thus	ADV
cana-5141	158	2	,	,	PUNCT
cana-5141	158	3	a	a	DET
cana-5141	158	4	multifaceted	multifaceted	ADJ
cana-5141	158	5	approach	approach	NOUN
cana-5141	158	6	utilizing	utilize	VERB
cana-5141	158	7	both	both	DET
cana-5141	158	8	viral	viral	ADJ
cana-5141	158	9	and	and	CCONJ
cana-5141	158	10	nonviral	nonviral	ADJ
cana-5141	158	11	systems	system	NOUN
cana-5141	158	12	may	may	AUX
cana-5141	158	13	be	be	AUX
cana-5141	158	14	essential	essential	ADJ
cana-5141	158	15	for	for	ADP
cana-5141	158	16	optimizing	optimize	VERB
cana-5141	158	17	crispr	crispr	ADJ
cana-5141	158	18	/	/	SYM
cana-5141	158	19	cas9	cas9	NOUN
cana-5141	158	20	delivery	delivery	NOUN
cana-5141	158	21	in	in	ADP
cana-5141	158	22	the	the	DET
cana-5141	158	23	treatment	treatment	NOUN
cana-5141	158	24	of	of	ADP
cana-5141	158	25	alzheimer	alzheimer	PROPN
cana-5141	158	26	's	's	PART
cana-5141	158	27	disease	disease	NOUN
cana-5141	158	28	.	.	PUNCT
cana-5141	159	1	lipid	lipid	ADJ
cana-5141	159	2	nanoparticles	nanoparticle	NOUN
cana-5141	159	3	and	and	CCONJ
cana-5141	159	4	polymeric	polymeric	ADJ
cana-5141	159	5	nanoparticles	nanoparticle	NOUN
cana-5141	159	6	also	also	ADV
cana-5141	159	7	hold	hold	VERB
cana-5141	159	8	potential	potential	ADJ
cana-5141	159	9	as	as	ADP
cana-5141	159	10	crispr	crispr	ADJ
cana-5141	159	11	-	-	PUNCT
cana-5141	159	12	cas9	cas9	NOUN
cana-5141	159	13	delivery	delivery	NOUN
cana-5141	159	14	tools	tool	NOUN
cana-5141	159	15	,	,	PUNCT
cana-5141	159	16	having	having	AUX
cana-5141	159	17	been	be	AUX
cana-5141	159	18	extensively	extensively	ADV
cana-5141	159	19	used	use	VERB
cana-5141	159	20	in	in	ADP
cana-5141	159	21	cancer	cancer	NOUN
cana-5141	159	22	and	and	CCONJ
cana-5141	159	23	viral	viral	ADJ
cana-5141	159	24	disease	disease	NOUN
cana-5141	159	25	treatments[52	treatments[52	ADV
cana-5141	159	26	]	]	PUNCT
cana-5141	159	27	.	.	PUNCT
cana-5141	160	1	however	however	ADV
cana-5141	160	2	,	,	PUNCT
cana-5141	160	3	their	their	PRON
cana-5141	160	4	application	application	NOUN
cana-5141	160	5	in	in	ADP
cana-5141	160	6	ad	ad	NOUN
cana-5141	160	7	management	management	NOUN
cana-5141	160	8	remains	remain	VERB
cana-5141	160	9	largely	largely	ADV
cana-5141	160	10	unexplored	unexplored	ADJ
cana-5141	160	11	.	.	PUNCT
cana-5141	161	1	gold	gold	ADJ
cana-5141	161	2	nanoparticles	nanoparticle	NOUN
cana-5141	161	3	represent	represent	VERB
cana-5141	161	4	another	another	DET
cana-5141	161	5	innovative	innovative	ADJ
cana-5141	161	6	approach	approach	NOUN
cana-5141	161	7	.	.	PUNCT
cana-5141	162	1	wang	wang	PROPN
cana-5141	162	2	et	et	PROPN
cana-5141	162	3	al	al	PROPN
cana-5141	162	4	.	.	PROPN
cana-5141	162	5	demonstrated	demonstrate	VERB
cana-5141	162	6	that	that	SCONJ
cana-5141	162	7	crispr	crispr	NOUN
cana-5141	162	8	-	-	PUNCT
cana-5141	162	9	gold	gold	NOUN
cana-5141	162	10	targeting	target	VERB
cana-5141	162	11	the	the	DET
cana-5141	162	12	cxcr4	cxcr4	NOUN
cana-5141	162	13	gene	gene	NOUN
cana-5141	162	14	achieved	achieve	VERB
cana-5141	162	15	3	3	NUM
cana-5141	162	16	-	-	SYM
cana-5141	162	17	4	4	NUM
cana-5141	162	18	%	%	NOUN
cana-5141	162	19	hdr	hdr	NOUN
cana-5141	162	20	efficiency	efficiency	NOUN
cana-5141	162	21	in	in	ADP
cana-5141	162	22	various	various	ADJ
cana-5141	162	23	human	human	ADJ
cana-5141	162	24	cell	cell	NOUN
cana-5141	162	25	types	type	NOUN
cana-5141	162	26	.	.	PUNCT
cana-5141	163	1	a	a	DET
cana-5141	163	2	single	single	ADJ
cana-5141	163	3	local	local	ADJ
cana-5141	163	4	infusion	infusion	NOUN
cana-5141	163	5	of	of	ADP
cana-5141	163	6	crispr	crispr	NOUN
cana-5141	163	7	-	-	PUNCT
cana-5141	163	8	gold	gold	NOUN
cana-5141	163	9	into	into	ADP
cana-5141	163	10	the	the	DET
cana-5141	163	11	muscles	muscle	NOUN
cana-5141	163	12	of	of	ADP
cana-5141	163	13	mdx	mdx	NOUN
cana-5141	163	14	mice	mouse	NOUN
cana-5141	163	15	corrected	correct	VERB
cana-5141	163	16	the	the	DET
cana-5141	163	17	mutated	mutate	VERB
cana-5141	163	18	dystrophin	dystrophin	ADJ
cana-5141	163	19	gene	gene	NOUN
cana-5141	163	20	responsible	responsible	ADJ
cana-5141	163	21	for	for	ADP
cana-5141	163	22	duchenne	duchenne	ADJ
cana-5141	163	23	muscular	muscular	ADJ
cana-5141	163	24	dystrophy	dystrophy	NOUN
cana-5141	163	25	,	,	PUNCT
cana-5141	163	26	without	without	ADP
cana-5141	163	27	significantly	significantly	ADV
cana-5141	163	28	altering	alter	VERB
cana-5141	163	29	the	the	DET
cana-5141	163	30	inflammatory	inflammatory	ADJ
cana-5141	163	31	cytokine	cytokine	NOUN
cana-5141	163	32	profile	profile	NOUN
cana-5141	163	33	,	,	PUNCT
cana-5141	163	34	indicating	indicate	VERB
cana-5141	163	35	low	low	ADJ
cana-5141	163	36	toxicity	toxicity	NOUN
cana-5141	163	37	and	and	CCONJ
cana-5141	163	38	good	good	ADJ
cana-5141	163	39	tolerability	tolerability	NOUN
cana-5141	163	40	[	[	X
cana-5141	163	41	53	53	NUM
cana-5141	163	42	]	]	PUNCT
cana-5141	163	43	.	.	PUNCT
cana-5141	164	1	communications	communication	NOUN
cana-5141	164	2	on	on	ADP
cana-5141	164	3	applied	apply	VERB
cana-5141	164	4	nonlinear	nonlinear	ADJ
cana-5141	164	5	analysis	analysis	NOUN
cana-5141	164	6	issn	issn	NOUN
cana-5141	164	7	:	:	PUNCT
cana-5141	164	8	1074	1074	NUM
cana-5141	164	9	-	-	PUNCT
cana-5141	164	10	133x	133x	NUM
cana-5141	164	11	vol	vol	NOUN
cana-5141	164	12	32	32	NUM
cana-5141	164	13	no	no	NOUN
cana-5141	164	14	.	.	PUNCT
cana-5141	165	1	icmasd	icmasd	NOUN
cana-5141	165	2	(	(	PUNCT
cana-5141	165	3	2025	2025	NUM
cana-5141	165	4	)	)	PUNCT
cana-5141	165	5	1145	1145	NUM
cana-5141	165	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	165	7	recently	recently	ADV
cana-5141	165	8	,	,	PUNCT
cana-5141	165	9	macrovesicles	macrovesicle	NOUN
cana-5141	165	10	have	have	AUX
cana-5141	165	11	emerged	emerge	VERB
cana-5141	165	12	as	as	ADP
cana-5141	165	13	a	a	DET
cana-5141	165	14	novel	novel	ADJ
cana-5141	165	15	method	method	NOUN
cana-5141	165	16	for	for	ADP
cana-5141	165	17	delivering	deliver	VERB
cana-5141	165	18	crispr	crispr	ADJ
cana-5141	165	19	-	-	PUNCT
cana-5141	165	20	cas9	cas9	NOUN
cana-5141	165	21	therapeutics	therapeutic	NOUN
cana-5141	165	22	.	.	PUNCT
cana-5141	166	1	in	in	ADP
cana-5141	166	2	this	this	DET
cana-5141	166	3	approach	approach	NOUN
cana-5141	166	4	,	,	PUNCT
cana-5141	166	5	a	a	DET
cana-5141	166	6	producer	producer	NOUN
cana-5141	166	7	cell	cell	NOUN
cana-5141	166	8	line	line	NOUN
cana-5141	166	9	is	be	AUX
cana-5141	166	10	transfected	transfecte	VERB
cana-5141	166	11	with	with	ADP
cana-5141	166	12	sgrna	sgrna	NOUN
cana-5141	166	13	,	,	PUNCT
cana-5141	166	14	cas9	cas9	NOUN
cana-5141	166	15	protein	protein	NOUN
cana-5141	166	16	,	,	PUNCT
cana-5141	166	17	and	and	CCONJ
cana-5141	166	18	a	a	DET
cana-5141	166	19	micro	micro	NOUN
cana-5141	166	20	vesicleinducing	vesicleinduce	VERB
cana-5141	166	21	protein	protein	NOUN
cana-5141	166	22	(	(	PUNCT
cana-5141	166	23	rab	rab	NOUN
cana-5141	166	24	proteins	protein	NOUN
cana-5141	166	25	)	)	PUNCT
cana-5141	166	26	.	.	PUNCT
cana-5141	167	1	the	the	DET
cana-5141	167	2	cells	cell	NOUN
cana-5141	167	3	then	then	ADV
cana-5141	167	4	produce	produce	VERB
cana-5141	167	5	macrovesicles	macrovesicle	NOUN
cana-5141	167	6	containing	contain	VERB
cana-5141	167	7	the	the	DET
cana-5141	167	8	cas9	cas9	NOUN
cana-5141	167	9	-	-	PUNCT
cana-5141	167	10	sgrna	sgrna	NOUN
cana-5141	167	11	complex	complex	NOUN
cana-5141	167	12	,	,	PUNCT
cana-5141	167	13	which	which	PRON
cana-5141	167	14	are	be	AUX
cana-5141	167	15	harvested	harvest	VERB
cana-5141	167	16	and	and	CCONJ
cana-5141	167	17	used	use	VERB
cana-5141	167	18	to	to	PART
cana-5141	167	19	deliver	deliver	VERB
cana-5141	167	20	the	the	DET
cana-5141	167	21	gene	gene	NOUN
cana-5141	167	22	-	-	PUNCT
cana-5141	167	23	editing	edit	VERB
cana-5141	167	24	payload	payload	NOUN
cana-5141	167	25	to	to	PART
cana-5141	167	26	target	target	VERB
cana-5141	167	27	cells	cell	NOUN
cana-5141	167	28	as	as	SCONJ
cana-5141	167	29	shown	show	VERB
cana-5141	167	30	in	in	ADP
cana-5141	167	31	(	(	PUNCT
cana-5141	167	32	fig.4	fig.4	PROPN
cana-5141	167	33	)	)	PUNCT
cana-5141	168	1	[	[	X
cana-5141	168	2	54	54	NUM
cana-5141	168	3	]	]	PUNCT
cana-5141	168	4	,	,	PUNCT
cana-5141	168	5	[	[	X
cana-5141	168	6	55	55	NUM
cana-5141	168	7	]	]	PUNCT
cana-5141	168	8	.	.	PUNCT
cana-5141	169	1	this	this	DET
cana-5141	169	2	method	method	NOUN
cana-5141	169	3	shows	show	VERB
cana-5141	169	4	promise	promise	NOUN
cana-5141	169	5	for	for	ADP
cana-5141	169	6	future	future	ADJ
cana-5141	169	7	applications	application	NOUN
cana-5141	169	8	in	in	ADP
cana-5141	169	9	gene	gene	NOUN
cana-5141	169	10	therapy	therapy	NOUN
cana-5141	169	11	,	,	PUNCT
cana-5141	169	12	including	include	VERB
cana-5141	169	13	the	the	DET
cana-5141	169	14	treatment	treatment	NOUN
cana-5141	169	15	of	of	ADP
cana-5141	169	16	alzheimer	alzheimer	PROPN
cana-5141	169	17	's	's	PART
cana-5141	169	18	disease	disease	NOUN
cana-5141	169	19	.	.	PUNCT
cana-5141	170	1	fig.4	fig.4	PRON
cana-5141	170	2	schematic	schematic	ADJ
cana-5141	170	3	illustration	illustration	NOUN
cana-5141	170	4	of	of	ADP
cana-5141	170	5	crispr	crispr	ADJ
cana-5141	170	6	/	/	SYM
cana-5141	170	7	cas9	cas9	NOUN
cana-5141	170	8	delivery	delivery	NOUN
cana-5141	170	9	systems	system	NOUN
cana-5141	170	10	using	use	VERB
cana-5141	170	11	various	various	ADJ
cana-5141	170	12	vectors	vector	NOUN
cana-5141	170	13	.	.	PUNCT
cana-5141	171	1	different	different	ADJ
cana-5141	171	2	delivery	delivery	NOUN
cana-5141	171	3	systems	system	NOUN
cana-5141	171	4	such	such	ADJ
cana-5141	171	5	as	as	ADP
cana-5141	171	6	liposomes	liposome	NOUN
cana-5141	171	7	,	,	PUNCT
cana-5141	171	8	nanoparticles	nanoparticle	NOUN
cana-5141	171	9	,	,	PUNCT
cana-5141	171	10	and	and	CCONJ
cana-5141	171	11	microvesicles	microvesicle	NOUN
cana-5141	171	12	are	be	AUX
cana-5141	171	13	used	use	VERB
cana-5141	171	14	to	to	PART
cana-5141	171	15	transport	transport	VERB
cana-5141	171	16	crispr	crispr	ADJ
cana-5141	171	17	/	/	SYM
cana-5141	171	18	cas9	cas9	NOUN
cana-5141	171	19	components	component	NOUN
cana-5141	171	20	,	,	PUNCT
cana-5141	171	21	including	include	VERB
cana-5141	171	22	cas9	cas9	NOUN
cana-5141	171	23	/	/	SYM
cana-5141	171	24	sgrna	sgrna	NOUN
cana-5141	171	25	plasmid	plasmid	NOUN
cana-5141	171	26	,	,	PUNCT
cana-5141	171	27	cas9	cas9	NOUN
cana-5141	171	28	mrna	mrna	PROPN
cana-5141	171	29	,	,	PUNCT
cana-5141	171	30	and	and	CCONJ
cana-5141	171	31	cas9	cas9	PROPN
cana-5141	171	32	/	/	SYM
cana-5141	171	33	sgrna	sgrna	PROPN
cana-5141	171	34	ribonucleoprotein	ribonucleoprotein	NOUN
cana-5141	171	35	(	(	PUNCT
cana-5141	171	36	rnp	rnp	PROPN
cana-5141	171	37	)	)	PUNCT
cana-5141	171	38	.	.	PUNCT
cana-5141	172	1	following	follow	VERB
cana-5141	172	2	internalization	internalization	NOUN
cana-5141	172	3	,	,	PUNCT
cana-5141	172	4	the	the	DET
cana-5141	172	5	plasmid	plasmid	ADJ
cana-5141	172	6	dna	dna	NOUN
cana-5141	172	7	is	be	AUX
cana-5141	172	8	transcribed	transcribe	VERB
cana-5141	172	9	into	into	ADP
cana-5141	172	10	mrna	mrna	PROPN
cana-5141	172	11	in	in	ADP
cana-5141	172	12	the	the	DET
cana-5141	172	13	nucleus	nucleus	NOUN
cana-5141	172	14	,	,	PUNCT
cana-5141	172	15	which	which	PRON
cana-5141	172	16	is	be	AUX
cana-5141	172	17	then	then	ADV
cana-5141	172	18	translated	translate	VERB
cana-5141	172	19	into	into	ADP
cana-5141	172	20	the	the	DET
cana-5141	172	21	cas9	cas9	NOUN
cana-5141	172	22	protein	protein	NOUN
cana-5141	172	23	in	in	ADP
cana-5141	172	24	the	the	DET
cana-5141	172	25	cytosol	cytosol	NOUN
cana-5141	172	26	.	.	PUNCT
cana-5141	173	1	the	the	DET
cana-5141	173	2	cas9	cas9	NOUN
cana-5141	173	3	protein	protein	NOUN
cana-5141	173	4	interacts	interact	VERB
cana-5141	173	5	with	with	ADP
cana-5141	173	6	sgrna	sgrna	NOUN
cana-5141	173	7	to	to	PART
cana-5141	173	8	form	form	VERB
cana-5141	173	9	the	the	DET
cana-5141	173	10	cas9	cas9	NOUN
cana-5141	173	11	rnp	rnp	PROPN
cana-5141	173	12	complex	complex	NOUN
cana-5141	173	13	,	,	PUNCT
cana-5141	173	14	facilitating	facilitate	VERB
cana-5141	173	15	genome	genome	NOUN
cana-5141	173	16	editing	editing	NOUN
cana-5141	173	17	within	within	ADP
cana-5141	173	18	the	the	DET
cana-5141	173	19	nucleus	nucleus	NOUN
cana-5141	173	20	.	.	PUNCT
cana-5141	174	1	7	7	X
cana-5141	174	2	.	.	X
cana-5141	174	3	synergies	synergy	NOUN
cana-5141	174	4	between	between	ADP
cana-5141	174	5	crispr	crispr	PROPN
cana-5141	174	6	/	/	SYM
cana-5141	174	7	cas9	cas9	PROPN
cana-5141	174	8	&	&	CCONJ
cana-5141	174	9	immunotherapies	immunotherapie	VERB
cana-5141	174	10	the	the	DET
cana-5141	174	11	combination	combination	NOUN
cana-5141	174	12	of	of	ADP
cana-5141	174	13	immunotherapy	immunotherapy	NOUN
cana-5141	174	14	and	and	CCONJ
cana-5141	174	15	crispr	crispr	ADJ
cana-5141	174	16	/	/	SYM
cana-5141	174	17	cas9	cas9	NOUN
cana-5141	174	18	gene	gene	NOUN
cana-5141	174	19	editing	edit	VERB
cana-5141	174	20	technology	technology	NOUN
cana-5141	174	21	offers	offer	VERB
cana-5141	174	22	novel	novel	ADJ
cana-5141	174	23	approaches	approach	NOUN
cana-5141	174	24	to	to	ADP
cana-5141	174	25	the	the	DET
cana-5141	174	26	treatment	treatment	NOUN
cana-5141	174	27	of	of	ADP
cana-5141	174	28	alzheimer	alzheimer	PROPN
cana-5141	174	29	's	's	PART
cana-5141	174	30	disease	disease	NOUN
cana-5141	174	31	(	(	PUNCT
cana-5141	174	32	ad	ad	NOUN
cana-5141	174	33	)	)	PUNCT
cana-5141	174	34	.	.	PUNCT
cana-5141	175	1	in	in	ADP
cana-5141	175	2	order	order	NOUN
cana-5141	175	3	to	to	PART
cana-5141	175	4	fight	fight	VERB
cana-5141	175	5	the	the	DET
cana-5141	175	6	illness	illness	NOUN
cana-5141	175	7	,	,	PUNCT
cana-5141	175	8	these	these	DET
cana-5141	175	9	tactics	tactic	NOUN
cana-5141	175	10	seek	seek	VERB
cana-5141	175	11	to	to	PART
cana-5141	175	12	combine	combine	VERB
cana-5141	175	13	the	the	DET
cana-5141	175	14	accuracy	accuracy	NOUN
cana-5141	175	15	of	of	ADP
cana-5141	175	16	genome	genome	NOUN
cana-5141	175	17	editing	editing	NOUN
cana-5141	175	18	with	with	ADP
cana-5141	175	19	the	the	DET
cana-5141	175	20	strength	strength	NOUN
cana-5141	175	21	of	of	ADP
cana-5141	175	22	immune	immune	ADJ
cana-5141	175	23	responses	response	NOUN
cana-5141	175	24	.	.	PUNCT
cana-5141	176	1	7.1	7.1	NUM
cana-5141	176	2	crispr	crispr	ADJ
cana-5141	176	3	/	/	SYM
cana-5141	176	4	cas9	cas9	NOUN
cana-5141	176	5	and	and	CCONJ
cana-5141	176	6	immunotherapy	immunotherapy	NOUN
cana-5141	176	7	synergistic	synergistic	ADJ
cana-5141	176	8	mechanisms	mechanism	NOUN
cana-5141	176	9	the	the	DET
cana-5141	176	10	amyloid	amyloid	NOUN
cana-5141	176	11	precursor	precursor	NOUN
cana-5141	176	12	protein	protein	NOUN
cana-5141	176	13	(	(	PUNCT
cana-5141	176	14	app	app	NOUN
cana-5141	176	15	)	)	PUNCT
cana-5141	176	16	and	and	CCONJ
cana-5141	176	17	presenilin	presenilin	PROPN
cana-5141	176	18	(	(	PUNCT
cana-5141	176	19	psen	psen	NOUN
cana-5141	176	20	)	)	PUNCT
cana-5141	176	21	genes	gene	NOUN
cana-5141	176	22	are	be	AUX
cana-5141	176	23	two	two	NUM
cana-5141	176	24	examples	example	NOUN
cana-5141	176	25	of	of	ADP
cana-5141	176	26	genes	gene	NOUN
cana-5141	176	27	linked	link	VERB
cana-5141	176	28	to	to	ADP
cana-5141	176	29	alzheimer	alzheimer	PROPN
cana-5141	176	30	's	's	PART
cana-5141	176	31	disease	disease	NOUN
cana-5141	176	32	that	that	PRON
cana-5141	176	33	may	may	AUX
cana-5141	176	34	be	be	AUX
cana-5141	176	35	directly	directly	ADV
cana-5141	176	36	edited	edit	VERB
cana-5141	176	37	using	use	VERB
cana-5141	176	38	crispr	crispr	NOUN
cana-5141	176	39	/	/	SYM
cana-5141	176	40	cas9	cas9	NOUN
cana-5141	176	41	.	.	PUNCT
cana-5141	177	1	these	these	DET
cana-5141	177	2	specific	specific	ADJ
cana-5141	177	3	changes	change	NOUN
cana-5141	177	4	can	can	AUX
cana-5141	177	5	communications	communication	NOUN
cana-5141	177	6	on	on	ADP
cana-5141	177	7	applied	apply	VERB
cana-5141	177	8	nonlinear	nonlinear	ADJ
cana-5141	177	9	analysis	analysis	NOUN
cana-5141	177	10	issn	issn	NOUN
cana-5141	177	11	:	:	PUNCT
cana-5141	177	12	1074	1074	NUM
cana-5141	177	13	-	-	PUNCT
cana-5141	177	14	133x	133x	NUM
cana-5141	177	15	vol	vol	NOUN
cana-5141	177	16	32	32	NUM
cana-5141	177	17	no	no	NOUN
cana-5141	177	18	.	.	PUNCT
cana-5141	178	1	icmasd	icmasd	NOUN
cana-5141	178	2	(	(	PUNCT
cana-5141	178	3	2025	2025	NUM
cana-5141	178	4	)	)	PUNCT
cana-5141	178	5	1146	1146	NUM
cana-5141	178	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	178	7	lessen	lessen	VERB
cana-5141	178	8	the	the	DET
cana-5141	178	9	development	development	NOUN
cana-5141	178	10	of	of	ADP
cana-5141	178	11	neurofibrillary	neurofibrillary	ADJ
cana-5141	178	12	tangles	tangle	NOUN
cana-5141	178	13	and	and	CCONJ
cana-5141	178	14	amyloid	amyloid	NOUN
cana-5141	178	15	-	-	PUNCT
cana-5141	178	16	beta	beta	NOUN
cana-5141	178	17	plaques	plaque	NOUN
cana-5141	178	18	,	,	PUNCT
cana-5141	178	19	two	two	NUM
cana-5141	178	20	characteristics	characteristic	NOUN
cana-5141	178	21	of	of	ADP
cana-5141	178	22	ad	ad	NOUN
cana-5141	178	23	.	.	PUNCT
cana-5141	179	1	crispr	crispr	PROPN
cana-5141	179	2	may	may	AUX
cana-5141	179	3	improve	improve	VERB
cana-5141	179	4	the	the	DET
cana-5141	179	5	effectiveness	effectiveness	NOUN
cana-5141	179	6	of	of	ADP
cana-5141	179	7	immunotherapy	immunotherapy	NOUN
cana-5141	179	8	strategies	strategy	NOUN
cana-5141	179	9	that	that	PRON
cana-5141	179	10	depend	depend	VERB
cana-5141	179	11	on	on	ADP
cana-5141	179	12	the	the	DET
cana-5141	179	13	immune	immune	ADJ
cana-5141	179	14	system	system	NOUN
cana-5141	179	15	's	's	PART
cana-5141	179	16	capacity	capacity	NOUN
cana-5141	179	17	to	to	PART
cana-5141	179	18	identify	identify	VERB
cana-5141	179	19	and	and	CCONJ
cana-5141	179	20	eradicate	eradicate	VERB
cana-5141	179	21	these	these	DET
cana-5141	179	22	abnormal	abnormal	ADJ
cana-5141	179	23	aggregates	aggregate	NOUN
cana-5141	179	24	by	by	ADP
cana-5141	179	25	changing	change	VERB
cana-5141	179	26	the	the	DET
cana-5141	179	27	genetic	genetic	ADJ
cana-5141	179	28	composition[56	composition[56	NOUN
cana-5141	179	29	]	]	PUNCT
cana-5141	179	30	.	.	PUNCT
cana-5141	180	1	additionally	additionally	ADV
cana-5141	180	2	,	,	PUNCT
cana-5141	180	3	the	the	DET
cana-5141	180	4	overall	overall	ADJ
cana-5141	180	5	efficacy	efficacy	NOUN
cana-5141	180	6	of	of	ADP
cana-5141	180	7	immunotherapy	immunotherapy	NOUN
cana-5141	180	8	can	can	AUX
cana-5141	180	9	be	be	AUX
cana-5141	180	10	increased	increase	VERB
cana-5141	180	11	by	by	ADP
cana-5141	180	12	using	use	VERB
cana-5141	180	13	crispr	crispr	ADJ
cana-5141	180	14	/	/	SYM
cana-5141	180	15	cas9	cas9	NOUN
cana-5141	180	16	gene	gene	NOUN
cana-5141	180	17	editing	edit	VERB
cana-5141	180	18	to	to	PART
cana-5141	180	19	modify	modify	VERB
cana-5141	180	20	immune	immune	ADJ
cana-5141	180	21	cell	cell	NOUN
cana-5141	180	22	activity	activity	NOUN
cana-5141	180	23	.	.	PUNCT
cana-5141	181	1	for	for	ADP
cana-5141	181	2	example	example	NOUN
cana-5141	181	3	,	,	PUNCT
cana-5141	181	4	improving	improve	VERB
cana-5141	181	5	the	the	DET
cana-5141	181	6	brain	brain	NOUN
cana-5141	181	7	's	's	PART
cana-5141	181	8	innate	innate	ADJ
cana-5141	181	9	immune	immune	ADJ
cana-5141	181	10	cells	cell	NOUN
cana-5141	181	11	'	'	PART
cana-5141	181	12	(	(	PUNCT
cana-5141	181	13	microglia	microglia	ADJ
cana-5141	181	14	)	)	PUNCT
cana-5141	181	15	response	response	NOUN
cana-5141	181	16	can	can	AUX
cana-5141	181	17	result	result	VERB
cana-5141	181	18	in	in	ADP
cana-5141	181	19	improved	improved	ADJ
cana-5141	181	20	amyloid	amyloid	NOUN
cana-5141	181	21	plaque	plaque	NOUN
cana-5141	181	22	removal[57	removal[57	NOUN
cana-5141	181	23	]	]	PUNCT
cana-5141	181	24	.	.	PUNCT
cana-5141	182	1	by	by	ADP
cana-5141	182	2	enabling	enable	VERB
cana-5141	182	3	genetic	genetic	ADJ
cana-5141	182	4	changes	change	NOUN
cana-5141	182	5	that	that	PRON
cana-5141	182	6	increase	increase	VERB
cana-5141	182	7	microglia	microglia	NOUN
cana-5141	182	8	's	's	PART
cana-5141	182	9	phagocytic	phagocytic	ADJ
cana-5141	182	10	activity	activity	NOUN
cana-5141	182	11	,	,	PUNCT
cana-5141	182	12	crispr	crispr	PROPN
cana-5141	182	13	can	can	AUX
cana-5141	182	14	help	help	VERB
cana-5141	182	15	them	they	PRON
cana-5141	182	16	play	play	VERB
cana-5141	182	17	a	a	DET
cana-5141	182	18	part	part	NOUN
cana-5141	182	19	in	in	ADP
cana-5141	182	20	the	the	DET
cana-5141	182	21	immune	immune	ADJ
cana-5141	182	22	response	response	NOUN
cana-5141	182	23	against	against	ADP
cana-5141	182	24	alzheimer	alzheimer	PROPN
cana-5141	182	25	's	's	PART
cana-5141	182	26	disease	disease	NOUN
cana-5141	182	27	.	.	PUNCT
cana-5141	183	1	this	this	DET
cana-5141	183	2	two	two	NUM
cana-5141	183	3	-	-	PUNCT
cana-5141	183	4	pronged	pronged	ADJ
cana-5141	183	5	strategy	strategy	NOUN
cana-5141	183	6	could	could	AUX
cana-5141	183	7	potentially	potentially	ADV
cana-5141	183	8	address	address	VERB
cana-5141	183	9	some	some	PRON
cana-5141	183	10	of	of	ADP
cana-5141	183	11	the	the	DET
cana-5141	183	12	drawbacks	drawback	NOUN
cana-5141	183	13	of	of	ADP
cana-5141	183	14	immunotherapies	immunotherapy	NOUN
cana-5141	183	15	alone	alone	ADV
cana-5141	183	16	,	,	PUNCT
cana-5141	183	17	which	which	PRON
cana-5141	183	18	might	might	AUX
cana-5141	183	19	be	be	AUX
cana-5141	183	20	less	less	ADV
cana-5141	183	21	successful	successful	ADJ
cana-5141	183	22	when	when	SCONJ
cana-5141	183	23	specific	specific	ADJ
cana-5141	183	24	genetic	genetic	ADJ
cana-5141	183	25	variables	variable	NOUN
cana-5141	183	26	are	be	AUX
cana-5141	183	27	present[58	present[58	NOUN
cana-5141	183	28	]	]	PUNCT
cana-5141	183	29	.	.	PUNCT
cana-5141	184	1	8	8	X
cana-5141	184	2	.	.	X
cana-5141	184	3	challenges	challenge	NOUN
cana-5141	184	4	in	in	ADP
cana-5141	184	5	crispr	crispr	ADJ
cana-5141	184	6	therapy	therapy	NOUN
cana-5141	184	7	for	for	ADP
cana-5141	184	8	alzheimer	alzheimer	PROPN
cana-5141	184	9	disease	disease	NOUN
cana-5141	184	10	although	although	SCONJ
cana-5141	184	11	site	site	NOUN
cana-5141	184	12	-	-	PUNCT
cana-5141	184	13	specific	specific	ADJ
cana-5141	184	14	gene	gene	NOUN
cana-5141	184	15	editing	editing	NOUN
cana-5141	184	16	and	and	CCONJ
cana-5141	184	17	other	other	ADJ
cana-5141	184	18	applications	application	NOUN
cana-5141	184	19	have	have	AUX
cana-5141	184	20	shown	show	VERB
cana-5141	184	21	significant	significant	ADJ
cana-5141	184	22	promise	promise	NOUN
cana-5141	184	23	with	with	ADP
cana-5141	184	24	the	the	DET
cana-5141	184	25	crispr	crispr	ADJ
cana-5141	184	26	/	/	SYM
cana-5141	184	27	cas9	cas9	NOUN
cana-5141	184	28	system	system	NOUN
cana-5141	184	29	,	,	PUNCT
cana-5141	184	30	there	there	PRON
cana-5141	184	31	are	be	VERB
cana-5141	184	32	a	a	DET
cana-5141	184	33	number	number	NOUN
cana-5141	184	34	of	of	ADP
cana-5141	184	35	aspects	aspect	NOUN
cana-5141	184	36	that	that	PRON
cana-5141	184	37	affect	affect	VERB
cana-5141	184	38	its	its	PRON
cana-5141	184	39	effectiveness	effectiveness	NOUN
cana-5141	184	40	that	that	PRON
cana-5141	184	41	need	need	VERB
cana-5141	184	42	to	to	PART
cana-5141	184	43	be	be	AUX
cana-5141	184	44	taken	take	VERB
cana-5141	184	45	into	into	ADP
cana-5141	184	46	consideration	consideration	NOUN
cana-5141	184	47	,	,	PUNCT
cana-5141	184	48	particularly	particularly	ADV
cana-5141	184	49	if	if	SCONJ
cana-5141	184	50	it	it	PRON
cana-5141	184	51	is	be	AUX
cana-5141	184	52	to	to	PART
cana-5141	184	53	be	be	AUX
cana-5141	184	54	utilized	utilize	VERB
cana-5141	184	55	for	for	ADP
cana-5141	184	56	in	in	ADP
cana-5141	184	57	vivo	vivo	ADJ
cana-5141	184	58	human	human	ADJ
cana-5141	184	59	gene	gene	NOUN
cana-5141	184	60	therapy	therapy	NOUN
cana-5141	184	61	.	.	PUNCT
cana-5141	185	1	these	these	DET
cana-5141	185	2	elements	element	NOUN
cana-5141	185	3	include	include	VERB
cana-5141	185	4	cas9	cas9	NOUN
cana-5141	185	5	activity	activity	NOUN
cana-5141	185	6	,	,	PUNCT
cana-5141	185	7	off	off	ADP
cana-5141	185	8	-	-	PUNCT
cana-5141	185	9	target	target	NOUN
cana-5141	185	10	cutting	cutting	NOUN
cana-5141	185	11	,	,	PUNCT
cana-5141	185	12	sgrna	sgrna	ADJ
cana-5141	185	13	design	design	NOUN
cana-5141	185	14	,	,	PUNCT
cana-5141	185	15	incidence	incidence	NOUN
cana-5141	185	16	/	/	SYM
cana-5141	185	17	efficiency	efficiency	NOUN
cana-5141	185	18	of	of	ADP
cana-5141	185	19	hdr	hdr	NOUN
cana-5141	185	20	vs.	vs.	ADP
cana-5141	185	21	nhej	nhej	ADJ
cana-5141	185	22	,	,	PUNCT
cana-5141	185	23	target	target	VERB
cana-5141	185	24	dna	dna	NOUN
cana-5141	185	25	site	site	NOUN
cana-5141	185	26	selection	selection	NOUN
cana-5141	185	27	,	,	PUNCT
cana-5141	185	28	and	and	CCONJ
cana-5141	185	29	delivery	delivery	NOUN
cana-5141	185	30	strategy	strategy	NOUN
cana-5141	185	31	.	.	PUNCT
cana-5141	186	1	8.1	8.1	NUM
cana-5141	186	2	delivery	delivery	NOUN
cana-5141	186	3	to	to	ADP
cana-5141	186	4	the	the	DET
cana-5141	186	5	brain	brain	NOUN
cana-5141	186	6	:	:	PUNCT
cana-5141	186	7	the	the	DET
cana-5141	186	8	blood	blood	NOUN
cana-5141	186	9	-	-	PUNCT
cana-5141	186	10	brain	brain	NOUN
cana-5141	186	11	barrier	barrier	NOUN
cana-5141	186	12	(	(	PUNCT
cana-5141	186	13	bbb	bbb	NOUN
cana-5141	186	14	)	)	PUNCT
cana-5141	186	15	is	be	AUX
cana-5141	186	16	a	a	DET
cana-5141	186	17	protective	protective	ADJ
cana-5141	186	18	layer	layer	NOUN
cana-5141	186	19	of	of	ADP
cana-5141	186	20	cells	cell	NOUN
cana-5141	186	21	that	that	PRON
cana-5141	186	22	prevents	prevent	VERB
cana-5141	186	23	harmful	harmful	ADJ
cana-5141	186	24	substances	substance	NOUN
cana-5141	186	25	from	from	ADP
cana-5141	186	26	entering	enter	VERB
cana-5141	186	27	the	the	DET
cana-5141	186	28	brain	brain	NOUN
cana-5141	186	29	while	while	SCONJ
cana-5141	186	30	also	also	ADV
cana-5141	186	31	limiting	limit	VERB
cana-5141	186	32	the	the	DET
cana-5141	186	33	delivery	delivery	NOUN
cana-5141	186	34	of	of	ADP
cana-5141	186	35	therapeutic	therapeutic	ADJ
cana-5141	186	36	agents	agent	NOUN
cana-5141	186	37	,	,	PUNCT
cana-5141	186	38	including	include	VERB
cana-5141	186	39	crispr	crispr	ADJ
cana-5141	186	40	components	component	NOUN
cana-5141	186	41	.	.	PUNCT
cana-5141	187	1	this	this	PRON
cana-5141	187	2	makes	make	VERB
cana-5141	187	3	it	it	PRON
cana-5141	187	4	difficult	difficult	ADJ
cana-5141	187	5	to	to	PART
cana-5141	187	6	effectively	effectively	ADV
cana-5141	187	7	deliver	deliver	VERB
cana-5141	187	8	crispr	crispr	NOUN
cana-5141	187	9	-	-	PUNCT
cana-5141	187	10	based	base	VERB
cana-5141	187	11	treatments	treatment	NOUN
cana-5141	187	12	for	for	ADP
cana-5141	187	13	alzheimer	alzheimer	PROPN
cana-5141	187	14	's	's	PART
cana-5141	187	15	disease	disease	NOUN
cana-5141	187	16	(	(	PUNCT
cana-5141	187	17	ad	ad	NOUN
cana-5141	187	18	)	)	PUNCT
cana-5141	187	19	because	because	SCONJ
cana-5141	187	20	the	the	DET
cana-5141	187	21	crispr	crispr	ADJ
cana-5141	187	22	machinery	machinery	NOUN
cana-5141	187	23	(	(	PUNCT
cana-5141	187	24	such	such	ADJ
cana-5141	187	25	as	as	ADP
cana-5141	187	26	the	the	DET
cana-5141	187	27	cas9	cas9	NOUN
cana-5141	187	28	protein	protein	NOUN
cana-5141	187	29	and	and	CCONJ
cana-5141	187	30	guide	guide	VERB
cana-5141	187	31	rna	rna	PROPN
cana-5141	187	32	)	)	PUNCT
cana-5141	187	33	needs	need	VERB
cana-5141	187	34	to	to	PART
cana-5141	187	35	cross	cross	VERB
cana-5141	187	36	the	the	DET
cana-5141	187	37	bbb	bbb	NOUN
cana-5141	187	38	to	to	PART
cana-5141	187	39	reach	reach	VERB
cana-5141	187	40	the	the	DET
cana-5141	187	41	brain	brain	NOUN
cana-5141	187	42	cells	cell	NOUN
cana-5141	187	43	.	.	PUNCT
cana-5141	188	1	the	the	DET
cana-5141	188	2	bbb	bbb	PROPN
cana-5141	188	3	’s	’s	PART
cana-5141	188	4	selective	selective	ADJ
cana-5141	188	5	permeability	permeability	NOUN
cana-5141	188	6	means	mean	VERB
cana-5141	188	7	that	that	SCONJ
cana-5141	188	8	most	most	ADJ
cana-5141	188	9	drugs	drug	NOUN
cana-5141	188	10	or	or	CCONJ
cana-5141	188	11	therapies	therapy	NOUN
cana-5141	188	12	struggle	struggle	VERB
cana-5141	188	13	to	to	PART
cana-5141	188	14	reach	reach	VERB
cana-5141	188	15	their	their	PRON
cana-5141	188	16	targets	target	NOUN
cana-5141	188	17	in	in	ADP
cana-5141	188	18	the	the	DET
cana-5141	188	19	brain	brain	NOUN
cana-5141	188	20	,	,	PUNCT
cana-5141	188	21	which	which	PRON
cana-5141	188	22	is	be	AUX
cana-5141	188	23	a	a	DET
cana-5141	188	24	major	major	ADJ
cana-5141	188	25	hurdle	hurdle	NOUN
cana-5141	188	26	in	in	ADP
cana-5141	188	27	developing	develop	VERB
cana-5141	188	28	effective	effective	ADJ
cana-5141	188	29	gene	gene	NOUN
cana-5141	188	30	-	-	PUNCT
cana-5141	188	31	editing	edit	VERB
cana-5141	188	32	therapies	therapy	NOUN
cana-5141	188	33	for	for	ADP
cana-5141	188	34	ad[59	ad[59	NOUN
cana-5141	188	35	]	]	X
cana-5141	188	36	.	.	PUNCT
cana-5141	189	1	8.2	8.2	NUM
cana-5141	189	2	target	target	NOUN
cana-5141	189	3	dna	dna	NOUN
cana-5141	189	4	site	site	NOUN
cana-5141	189	5	selection	selection	NOUN
cana-5141	189	6	choosing	choose	VERB
cana-5141	189	7	appropriate	appropriate	ADJ
cana-5141	189	8	target	target	NOUN
cana-5141	189	9	dna	dna	NOUN
cana-5141	189	10	locations	location	NOUN
cana-5141	189	11	for	for	ADP
cana-5141	189	12	crispr	crispr	ADJ
cana-5141	189	13	-	-	PUNCT
cana-5141	189	14	cas9	cas9	NOUN
cana-5141	189	15	application	application	NOUN
cana-5141	189	16	in	in	ADP
cana-5141	189	17	alzheimer	alzheimer	PROPN
cana-5141	189	18	's	's	PART
cana-5141	189	19	disease	disease	NOUN
cana-5141	189	20	(	(	PUNCT
cana-5141	189	21	ad	ad	NOUN
cana-5141	189	22	)	)	PUNCT
cana-5141	189	23	is	be	AUX
cana-5141	189	24	difficult	difficult	ADJ
cana-5141	189	25	for	for	ADP
cana-5141	189	26	a	a	DET
cana-5141	189	27	number	number	NOUN
cana-5141	189	28	of	of	ADP
cana-5141	189	29	reasons	reason	NOUN
cana-5141	189	30	.	.	PUNCT
cana-5141	190	1	initially	initially	ADV
cana-5141	190	2	,	,	PUNCT
cana-5141	190	3	the	the	DET
cana-5141	190	4	requirement	requirement	NOUN
cana-5141	190	5	for	for	ADP
cana-5141	190	6	a	a	DET
cana-5141	190	7	protospacer	protospacer	NOUN
cana-5141	190	8	adjacent	adjacent	ADJ
cana-5141	190	9	motif	motif	NOUN
cana-5141	190	10	(	(	PUNCT
cana-5141	190	11	pam	pam	NOUN
cana-5141	190	12	)	)	PUNCT
cana-5141	190	13	sequence	sequence	NOUN
cana-5141	190	14	(	(	PUNCT
cana-5141	190	15	usually	usually	ADV
cana-5141	190	16	"	"	PUNCT
cana-5141	190	17	ngg	ngg	NOUN
cana-5141	190	18	"	"	PUNCT
cana-5141	190	19	)	)	PUNCT
cana-5141	190	20	restricts	restrict	VERB
cana-5141	190	21	the	the	DET
cana-5141	190	22	target	target	NOUN
cana-5141	190	23	locations	location	NOUN
cana-5141	190	24	that	that	PRON
cana-5141	190	25	are	be	AUX
cana-5141	190	26	available	available	ADJ
cana-5141	190	27	inside	inside	ADP
cana-5141	190	28	pertinent	pertinent	ADJ
cana-5141	190	29	genes	gene	NOUN
cana-5141	190	30	.	.	PUNCT
cana-5141	191	1	given	give	VERB
cana-5141	191	2	the	the	DET
cana-5141	191	3	intricate	intricate	ADJ
cana-5141	191	4	genetic	genetic	ADJ
cana-5141	191	5	makeup	makeup	NOUN
cana-5141	191	6	of	of	ADP
cana-5141	191	7	ad	ad	NOUN
cana-5141	191	8	,	,	PUNCT
cana-5141	191	9	which	which	PRON
cana-5141	191	10	includes	include	VERB
cana-5141	191	11	several	several	ADJ
cana-5141	191	12	genes	gene	NOUN
cana-5141	191	13	and	and	CCONJ
cana-5141	191	14	interactions	interaction	NOUN
cana-5141	191	15	,	,	PUNCT
cana-5141	191	16	this	this	DET
cana-5141	191	17	restriction	restriction	NOUN
cana-5141	191	18	is	be	AUX
cana-5141	191	19	especially	especially	ADV
cana-5141	191	20	important	important	ADJ
cana-5141	191	21	.	.	PUNCT
cana-5141	192	1	furthermore	furthermore	ADV
cana-5141	192	2	,	,	PUNCT
cana-5141	192	3	there	there	PRON
cana-5141	192	4	is	be	VERB
cana-5141	192	5	a	a	DET
cana-5141	192	6	risk	risk	NOUN
cana-5141	192	7	of	of	ADP
cana-5141	192	8	off	off	ADP
cana-5141	192	9	-	-	PUNCT
cana-5141	192	10	target	target	NOUN
cana-5141	192	11	consequences	consequence	NOUN
cana-5141	192	12	as	as	ADP
cana-5141	192	13	comparable	comparable	ADJ
cana-5141	192	14	genome	genome	NOUN
cana-5141	192	15	sequences	sequence	NOUN
cana-5141	192	16	may	may	AUX
cana-5141	192	17	result	result	VERB
cana-5141	192	18	in	in	ADP
cana-5141	192	19	accidental	accidental	ADJ
cana-5141	192	20	changes	change	NOUN
cana-5141	192	21	that	that	PRON
cana-5141	192	22	could	could	AUX
cana-5141	192	23	impair	impair	VERB
cana-5141	192	24	vital	vital	ADJ
cana-5141	192	25	neural	neural	NOUN
cana-5141	192	26	activities[60	activities[60	NOUN
cana-5141	192	27	]	]	X
cana-5141	192	28	.	.	PUNCT
cana-5141	193	1	since	since	SCONJ
cana-5141	193	2	epigenetic	epigenetic	ADJ
cana-5141	193	3	alterations	alteration	NOUN
cana-5141	193	4	such	such	ADJ
cana-5141	193	5	dna	dna	PROPN
cana-5141	193	6	methylation	methylation	NOUN
cana-5141	193	7	are	be	AUX
cana-5141	193	8	common	common	ADJ
cana-5141	193	9	in	in	ADP
cana-5141	193	10	ad	ad	NOUN
cana-5141	193	11	pathophysiology	pathophysiology	NOUN
cana-5141	193	12	,	,	PUNCT
cana-5141	193	13	they	they	PRON
cana-5141	193	14	make	make	VERB
cana-5141	193	15	site	site	NOUN
cana-5141	193	16	selection	selection	NOUN
cana-5141	193	17	even	even	ADV
cana-5141	193	18	more	more	ADV
cana-5141	193	19	difficult	difficult	ADJ
cana-5141	193	20	by	by	ADP
cana-5141	193	21	affecting	affect	VERB
cana-5141	193	22	target	target	NOUN
cana-5141	193	23	regions	region	NOUN
cana-5141	193	24	'	'	PART
cana-5141	193	25	accessibility[61	accessibility[61	NOUN
cana-5141	193	26	]	]	PUNCT
cana-5141	193	27	.	.	PUNCT
cana-5141	194	1	8.3	8.3	NUM
cana-5141	194	2	off	off	ADP
cana-5141	194	3	targeting	target	VERB
cana-5141	194	4	communications	communication	NOUN
cana-5141	194	5	on	on	ADP
cana-5141	194	6	applied	apply	VERB
cana-5141	194	7	nonlinear	nonlinear	ADJ
cana-5141	194	8	analysis	analysis	NOUN
cana-5141	194	9	issn	issn	NOUN
cana-5141	194	10	:	:	PUNCT
cana-5141	194	11	1074	1074	NUM
cana-5141	194	12	-	-	PUNCT
cana-5141	194	13	133x	133x	NUM
cana-5141	194	14	vol	vol	NOUN
cana-5141	194	15	32	32	NUM
cana-5141	194	16	no	no	NOUN
cana-5141	194	17	.	.	PUNCT
cana-5141	195	1	icmasd	icmasd	NOUN
cana-5141	195	2	(	(	PUNCT
cana-5141	195	3	2025	2025	NUM
cana-5141	195	4	)	)	PUNCT
cana-5141	195	5	1147	1147	NUM
cana-5141	195	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	195	7	in	in	ADP
cana-5141	195	8	alzheimer	alzheimer	PROPN
cana-5141	195	9	's	's	PART
cana-5141	195	10	disease	disease	NOUN
cana-5141	195	11	(	(	PUNCT
cana-5141	195	12	ad	ad	NOUN
cana-5141	195	13	)	)	PUNCT
cana-5141	195	14	,	,	PUNCT
cana-5141	195	15	the	the	DET
cana-5141	195	16	brain	brain	NOUN
cana-5141	195	17	's	's	PART
cana-5141	195	18	complex	complex	ADJ
cana-5141	195	19	genetic	genetic	ADJ
cana-5141	195	20	landscape	landscape	NOUN
cana-5141	195	21	increases	increase	VERB
cana-5141	195	22	the	the	DET
cana-5141	195	23	risk	risk	NOUN
cana-5141	195	24	of	of	ADP
cana-5141	195	25	these	these	DET
cana-5141	195	26	offtarget	offtarget	NOUN
cana-5141	195	27	modifications	modification	NOUN
cana-5141	195	28	,	,	PUNCT
cana-5141	195	29	which	which	PRON
cana-5141	195	30	can	can	AUX
cana-5141	195	31	disrupt	disrupt	VERB
cana-5141	195	32	critical	critical	ADJ
cana-5141	195	33	genes	gene	NOUN
cana-5141	195	34	and	and	CCONJ
cana-5141	195	35	potentially	potentially	ADV
cana-5141	195	36	worsen	worsen	VERB
cana-5141	195	37	disease	disease	NOUN
cana-5141	195	38	symptoms	symptom	NOUN
cana-5141	195	39	or	or	CCONJ
cana-5141	195	40	cause	cause	VERB
cana-5141	195	41	new	new	ADJ
cana-5141	195	42	issues	issue	NOUN
cana-5141	195	43	.	.	PUNCT
cana-5141	196	1	ensuring	ensure	VERB
cana-5141	196	2	precise	precise	ADJ
cana-5141	196	3	gene	gene	NOUN
cana-5141	196	4	editing	editing	NOUN
cana-5141	196	5	is	be	AUX
cana-5141	196	6	vital	vital	ADJ
cana-5141	196	7	,	,	PUNCT
cana-5141	196	8	as	as	SCONJ
cana-5141	196	9	even	even	ADV
cana-5141	196	10	small	small	ADJ
cana-5141	196	11	,	,	PUNCT
cana-5141	196	12	unintended	unintended	ADJ
cana-5141	196	13	changes	change	NOUN
cana-5141	196	14	in	in	ADP
cana-5141	196	15	the	the	DET
cana-5141	196	16	dna	dna	NOUN
cana-5141	196	17	can	can	AUX
cana-5141	196	18	have	have	VERB
cana-5141	196	19	significant	significant	ADJ
cana-5141	196	20	consequences	consequence	NOUN
cana-5141	196	21	in	in	ADP
cana-5141	196	22	sensitive	sensitive	ADJ
cana-5141	196	23	brain	brain	NOUN
cana-5141	196	24	cells	cell	NOUN
cana-5141	196	25	,	,	PUNCT
cana-5141	196	26	making	make	VERB
cana-5141	196	27	it	it	PRON
cana-5141	196	28	crucial	crucial	ADJ
cana-5141	196	29	to	to	PART
cana-5141	196	30	improve	improve	VERB
cana-5141	196	31	the	the	DET
cana-5141	196	32	accuracy	accuracy	NOUN
cana-5141	196	33	of	of	ADP
cana-5141	196	34	crispr	crispr	ADJ
cana-5141	196	35	systems	system	NOUN
cana-5141	196	36	for	for	ADP
cana-5141	196	37	safe	safe	ADJ
cana-5141	196	38	and	and	CCONJ
cana-5141	196	39	effective	effective	ADJ
cana-5141	196	40	treatments[62	treatments[62	NOUN
cana-5141	196	41	]	]	PUNCT
cana-5141	196	42	.	.	PUNCT
cana-5141	197	1	8.4	8.4	NUM
cana-5141	197	2	efficient	efficient	ADJ
cana-5141	197	3	delivery	delivery	NOUN
cana-5141	197	4	vehicles	vehicle	NOUN
cana-5141	197	5	efficient	efficient	ADJ
cana-5141	197	6	delivery	delivery	NOUN
cana-5141	197	7	of	of	ADP
cana-5141	197	8	crispr	crispr	ADJ
cana-5141	197	9	components	component	NOUN
cana-5141	197	10	to	to	PART
cana-5141	197	11	target	target	VERB
cana-5141	197	12	cells	cell	NOUN
cana-5141	197	13	is	be	AUX
cana-5141	197	14	a	a	DET
cana-5141	197	15	major	major	ADJ
cana-5141	197	16	challenge	challenge	NOUN
cana-5141	197	17	,	,	PUNCT
cana-5141	197	18	particularly	particularly	ADV
cana-5141	197	19	in	in	ADP
cana-5141	197	20	the	the	DET
cana-5141	197	21	context	context	NOUN
cana-5141	197	22	of	of	ADP
cana-5141	197	23	alzheimer	alzheimer	PROPN
cana-5141	197	24	's	's	PART
cana-5141	197	25	disease	disease	NOUN
cana-5141	197	26	(	(	PUNCT
cana-5141	197	27	ad	ad	NOUN
cana-5141	197	28	)	)	PUNCT
cana-5141	197	29	.	.	PUNCT
cana-5141	198	1	viral	viral	ADJ
cana-5141	198	2	vectors	vector	NOUN
cana-5141	198	3	,	,	PUNCT
cana-5141	198	4	such	such	ADJ
cana-5141	198	5	as	as	ADP
cana-5141	198	6	adeno	adeno	NOUN
cana-5141	198	7	-	-	PUNCT
cana-5141	198	8	associated	associate	VERB
cana-5141	198	9	viruses	virus	NOUN
cana-5141	198	10	(	(	PUNCT
cana-5141	198	11	aavs	aavs	ADV
cana-5141	198	12	)	)	PUNCT
cana-5141	198	13	and	and	CCONJ
cana-5141	198	14	lentiviruses	lentiviruse	NOUN
cana-5141	198	15	,	,	PUNCT
cana-5141	198	16	are	be	AUX
cana-5141	198	17	commonly	commonly	ADV
cana-5141	198	18	used	use	VERB
cana-5141	198	19	for	for	ADP
cana-5141	198	20	gene	gene	NOUN
cana-5141	198	21	delivery	delivery	NOUN
cana-5141	198	22	but	but	CCONJ
cana-5141	198	23	have	have	VERB
cana-5141	198	24	limitations	limitation	NOUN
cana-5141	198	25	.	.	PUNCT
cana-5141	199	1	one	one	NUM
cana-5141	199	2	issue	issue	NOUN
cana-5141	199	3	is	be	AUX
cana-5141	199	4	the	the	DET
cana-5141	199	5	size	size	NOUN
cana-5141	199	6	constraint	constraint	NOUN
cana-5141	199	7	:	:	PUNCT
cana-5141	199	8	the	the	DET
cana-5141	199	9	cas9	cas9	NOUN
cana-5141	199	10	protein	protein	NOUN
cana-5141	199	11	and	and	CCONJ
cana-5141	199	12	guide	guide	VERB
cana-5141	199	13	rna	rna	NOUN
cana-5141	199	14	are	be	AUX
cana-5141	199	15	often	often	ADV
cana-5141	199	16	too	too	ADV
cana-5141	199	17	large	large	ADJ
cana-5141	199	18	to	to	PART
cana-5141	199	19	fit	fit	VERB
cana-5141	199	20	within	within	ADP
cana-5141	199	21	the	the	DET
cana-5141	199	22	packaging	packaging	NOUN
cana-5141	199	23	capacity	capacity	NOUN
cana-5141	199	24	of	of	ADP
cana-5141	199	25	aavs	aavs	PROPN
cana-5141	199	26	.	.	PUNCT
cana-5141	200	1	additionally	additionally	ADV
cana-5141	200	2	,	,	PUNCT
cana-5141	200	3	these	these	DET
cana-5141	200	4	viral	viral	ADJ
cana-5141	200	5	vectors	vector	NOUN
cana-5141	200	6	can	can	AUX
cana-5141	200	7	trigger	trigger	VERB
cana-5141	200	8	immune	immune	ADJ
cana-5141	200	9	responses	response	NOUN
cana-5141	200	10	in	in	ADP
cana-5141	200	11	the	the	DET
cana-5141	200	12	body	body	NOUN
cana-5141	200	13	,	,	PUNCT
cana-5141	200	14	which	which	PRON
cana-5141	200	15	not	not	PART
cana-5141	200	16	only	only	ADV
cana-5141	200	17	reduces	reduce	VERB
cana-5141	200	18	their	their	PRON
cana-5141	200	19	effectiveness	effectiveness	NOUN
cana-5141	200	20	but	but	CCONJ
cana-5141	200	21	can	can	AUX
cana-5141	200	22	also	also	ADV
cana-5141	200	23	pose	pose	VERB
cana-5141	200	24	safety	safety	NOUN
cana-5141	200	25	risks	risk	NOUN
cana-5141	200	26	.	.	PUNCT
cana-5141	201	1	non	non	ADJ
cana-5141	201	2	-	-	ADJ
cana-5141	201	3	viral	viral	ADJ
cana-5141	201	4	vectors	vector	NOUN
cana-5141	201	5	,	,	PUNCT
cana-5141	201	6	like	like	ADP
cana-5141	201	7	lipid	lipid	NOUN
cana-5141	201	8	nanoparticles	nanoparticle	NOUN
cana-5141	201	9	(	(	PUNCT
cana-5141	201	10	lnps	lnps	PROPN
cana-5141	201	11	)	)	PUNCT
cana-5141	201	12	and	and	CCONJ
cana-5141	201	13	electroporation	electroporation	NOUN
cana-5141	201	14	,	,	PUNCT
cana-5141	201	15	are	be	AUX
cana-5141	201	16	being	be	AUX
cana-5141	201	17	explored	explore	VERB
cana-5141	201	18	as	as	ADP
cana-5141	201	19	alternatives	alternative	NOUN
cana-5141	201	20	.	.	PUNCT
cana-5141	202	1	while	while	SCONJ
cana-5141	202	2	lnps	lnps	PROPN
cana-5141	202	3	are	be	AUX
cana-5141	202	4	more	more	ADV
cana-5141	202	5	versatile	versatile	ADJ
cana-5141	202	6	,	,	PUNCT
cana-5141	202	7	they	they	PRON
cana-5141	202	8	may	may	AUX
cana-5141	202	9	have	have	VERB
cana-5141	202	10	low	low	ADJ
cana-5141	202	11	efficiency	efficiency	NOUN
cana-5141	202	12	in	in	ADP
cana-5141	202	13	delivering	deliver	VERB
cana-5141	202	14	crispr	crispr	ADJ
cana-5141	202	15	components	component	NOUN
cana-5141	202	16	to	to	ADP
cana-5141	202	17	specific	specific	ADJ
cana-5141	202	18	cell	cell	NOUN
cana-5141	202	19	types	type	NOUN
cana-5141	202	20	,	,	PUNCT
cana-5141	202	21	particularly	particularly	ADV
cana-5141	202	22	in	in	ADP
cana-5141	202	23	the	the	DET
cana-5141	202	24	brain	brain	NOUN
cana-5141	202	25	.	.	PUNCT
cana-5141	203	1	electroporation	electroporation	NOUN
cana-5141	203	2	,	,	PUNCT
cana-5141	203	3	on	on	ADP
cana-5141	203	4	the	the	DET
cana-5141	203	5	other	other	ADJ
cana-5141	203	6	hand	hand	NOUN
cana-5141	203	7	,	,	PUNCT
cana-5141	203	8	is	be	AUX
cana-5141	203	9	invasive	invasive	ADJ
cana-5141	203	10	and	and	CCONJ
cana-5141	203	11	unsuitable	unsuitable	ADJ
cana-5141	203	12	for	for	ADP
cana-5141	203	13	systemic	systemic	ADJ
cana-5141	203	14	delivery	delivery	NOUN
cana-5141	203	15	,	,	PUNCT
cana-5141	203	16	limiting	limit	VERB
cana-5141	203	17	its	its	PRON
cana-5141	203	18	use	use	NOUN
cana-5141	203	19	in	in	ADP
cana-5141	203	20	treating	treat	VERB
cana-5141	203	21	widespread	widespread	ADJ
cana-5141	203	22	conditions	condition	NOUN
cana-5141	203	23	like	like	ADP
cana-5141	203	24	ad[63	ad[63	PROPN
cana-5141	203	25	]	]	PUNCT
cana-5141	203	26	.	.	PUNCT
cana-5141	204	1	9	9	X
cana-5141	204	2	.	.	X
cana-5141	204	3	applications	application	NOUN
cana-5141	204	4	of	of	ADP
cana-5141	204	5	crispr	crispr	NOUN
cana-5141	204	6	/	/	SYM
cana-5141	204	7	cas9	cas9	NOUN
cana-5141	204	8	:	:	PUNCT
cana-5141	204	9	early	early	ADJ
cana-5141	204	10	-	-	PUNCT
cana-5141	204	11	onset	onset	NOUN
cana-5141	204	12	alzheimer	alzheimer	NOUN
cana-5141	204	13	’s	’s	PART
cana-5141	204	14	disease	disease	NOUN
cana-5141	204	15	(	(	PUNCT
cana-5141	204	16	ad	ad	NOUN
cana-5141	204	17	)	)	PUNCT
cana-5141	204	18	is	be	AUX
cana-5141	204	19	primarily	primarily	ADV
cana-5141	204	20	caused	cause	VERB
cana-5141	204	21	by	by	ADP
cana-5141	204	22	over	over	ADP
cana-5141	204	23	200	200	NUM
cana-5141	204	24	genetic	genetic	ADJ
cana-5141	204	25	mutations	mutation	NOUN
cana-5141	204	26	.	.	PUNCT
cana-5141	205	1	the	the	DET
cana-5141	205	2	crispr	crispr	ADJ
cana-5141	205	3	-	-	PUNCT
cana-5141	205	4	cas9	cas9	NOUN
cana-5141	205	5	system	system	NOUN
cana-5141	205	6	enables	enable	VERB
cana-5141	205	7	precise	precise	ADJ
cana-5141	205	8	establishment	establishment	NOUN
cana-5141	205	9	of	of	ADP
cana-5141	205	10	these	these	DET
cana-5141	205	11	mutations	mutation	NOUN
cana-5141	205	12	in	in	ADP
cana-5141	205	13	cellular	cellular	ADJ
cana-5141	205	14	and	and	CCONJ
cana-5141	205	15	animal	animal	NOUN
cana-5141	205	16	models	model	NOUN
cana-5141	205	17	,	,	PUNCT
cana-5141	205	18	effectively	effectively	ADV
cana-5141	205	19	mimicking	mimic	VERB
cana-5141	205	20	ad	ad	NOUN
cana-5141	205	21	pathogenesis	pathogenesis	NOUN
cana-5141	205	22	.	.	PUNCT
cana-5141	206	1	this	this	DET
cana-5141	206	2	technology	technology	NOUN
cana-5141	206	3	facilitates	facilitate	VERB
cana-5141	206	4	the	the	DET
cana-5141	206	5	study	study	NOUN
cana-5141	206	6	of	of	ADP
cana-5141	206	7	dynamic	dynamic	ADJ
cana-5141	206	8	biological	biological	ADJ
cana-5141	206	9	processes	process	NOUN
cana-5141	206	10	,	,	PUNCT
cana-5141	206	11	explores	explore	VERB
cana-5141	206	12	synergistic	synergistic	ADJ
cana-5141	206	13	gene	gene	NOUN
cana-5141	206	14	interactions	interaction	NOUN
cana-5141	206	15	through	through	ADP
cana-5141	206	16	multi	multi	ADJ
cana-5141	206	17	-	-	ADJ
cana-5141	206	18	gene	gene	ADJ
cana-5141	206	19	editing	editing	NOUN
cana-5141	206	20	,	,	PUNCT
cana-5141	206	21	and	and	CCONJ
cana-5141	206	22	surpasses	surpass	VERB
cana-5141	206	23	traditional	traditional	ADJ
cana-5141	206	24	methods	method	NOUN
cana-5141	206	25	in	in	ADP
cana-5141	206	26	speed	speed	NOUN
cana-5141	206	27	,	,	PUNCT
cana-5141	206	28	cost	cost	NOUN
cana-5141	206	29	-	-	PUNCT
cana-5141	206	30	efficiency	efficiency	NOUN
cana-5141	206	31	,	,	PUNCT
cana-5141	206	32	and	and	CCONJ
cana-5141	206	33	reliability	reliability	NOUN
cana-5141	206	34	.	.	PUNCT
cana-5141	207	1	by	by	ADP
cana-5141	207	2	rapidly	rapidly	ADV
cana-5141	207	3	generating	generate	VERB
cana-5141	207	4	numerous	numerous	ADJ
cana-5141	207	5	ad	ad	NOUN
cana-5141	207	6	models	model	NOUN
cana-5141	207	7	,	,	PUNCT
cana-5141	207	8	crispr	crispr	NOUN
cana-5141	207	9	-	-	PUNCT
cana-5141	207	10	cas9	cas9	NOUN
cana-5141	207	11	provides	provide	VERB
cana-5141	207	12	a	a	DET
cana-5141	207	13	transformative	transformative	ADJ
cana-5141	207	14	platform	platform	NOUN
cana-5141	207	15	for	for	ADP
cana-5141	207	16	drug	drug	NOUN
cana-5141	207	17	screening	screening	NOUN
cana-5141	207	18	,	,	PUNCT
cana-5141	207	19	treatment	treatment	NOUN
cana-5141	207	20	development	development	NOUN
cana-5141	207	21	,	,	PUNCT
cana-5141	207	22	and	and	CCONJ
cana-5141	207	23	advancing	advance	VERB
cana-5141	207	24	our	our	PRON
cana-5141	207	25	understanding	understanding	NOUN
cana-5141	207	26	of	of	ADP
cana-5141	207	27	ad	ad	NOUN
cana-5141	207	28	pathophysiology	pathophysiology	NOUN
cana-5141	207	29	,	,	PUNCT
cana-5141	207	30	significantly	significantly	ADV
cana-5141	207	31	accelerating	accelerate	VERB
cana-5141	207	32	basic	basic	ADJ
cana-5141	207	33	research	research	NOUN
cana-5141	207	34	in	in	ADP
cana-5141	207	35	the	the	DET
cana-5141	207	36	field	field	NOUN
cana-5141	207	37	.	.	PUNCT
cana-5141	208	1	9.1	9.1	NUM
cana-5141	208	2	crispr	crispr	ADJ
cana-5141	208	3	/	/	SYM
cana-5141	208	4	cas9	cas9	NOUN
cana-5141	208	5	in	in	ADP
cana-5141	208	6	precision	precision	NOUN
cana-5141	208	7	therapy	therapy	NOUN
cana-5141	208	8	crispr	crispr	ADJ
cana-5141	208	9	/	/	SYM
cana-5141	208	10	cas9	cas9	NOUN
cana-5141	208	11	technology	technology	NOUN
cana-5141	208	12	is	be	AUX
cana-5141	208	13	a	a	DET
cana-5141	208	14	promising	promising	ADJ
cana-5141	208	15	tool	tool	NOUN
cana-5141	208	16	for	for	ADP
cana-5141	208	17	targeted	target	VERB
cana-5141	208	18	therapy	therapy	NOUN
cana-5141	208	19	in	in	ADP
cana-5141	208	20	alzheimer	alzheimer	PROPN
cana-5141	208	21	’s	’s	PART
cana-5141	208	22	disease	disease	NOUN
cana-5141	208	23	(	(	PUNCT
cana-5141	208	24	ad	ad	NOUN
cana-5141	208	25	)	)	PUNCT
cana-5141	208	26	.	.	PUNCT
cana-5141	209	1	it	it	PRON
cana-5141	209	2	allows	allow	VERB
cana-5141	209	3	precise	precise	ADJ
cana-5141	209	4	editing	editing	NOUN
cana-5141	209	5	of	of	ADP
cana-5141	209	6	genes	gene	NOUN
cana-5141	209	7	associated	associate	VERB
cana-5141	209	8	with	with	ADP
cana-5141	209	9	ad	ad	NOUN
cana-5141	209	10	pathogenesis	pathogenesis	NOUN
cana-5141	209	11	,	,	PUNCT
cana-5141	209	12	such	such	ADJ
cana-5141	209	13	as	as	ADP
cana-5141	209	14	app	app	NOUN
cana-5141	209	15	,	,	PUNCT
cana-5141	209	16	psen1	psen1	ADJ
cana-5141	209	17	,	,	PUNCT
cana-5141	209	18	and	and	CCONJ
cana-5141	209	19	psen2	psen2	NOUN
cana-5141	209	20	.	.	PUNCT
cana-5141	210	1	by	by	ADP
cana-5141	210	2	correcting	correct	VERB
cana-5141	210	3	pathogenic	pathogenic	ADJ
cana-5141	210	4	mutations	mutation	NOUN
cana-5141	210	5	or	or	CCONJ
cana-5141	210	6	silencing	silence	VERB
cana-5141	210	7	harmful	harmful	ADJ
cana-5141	210	8	gene	gene	NOUN
cana-5141	210	9	expressions	expression	NOUN
cana-5141	210	10	,	,	PUNCT
cana-5141	210	11	crispr	crispr	ADJ
cana-5141	210	12	/	/	SYM
cana-5141	210	13	cas9	cas9	NOUN
cana-5141	210	14	can	can	AUX
cana-5141	210	15	potentially	potentially	ADV
cana-5141	210	16	reduce	reduce	VERB
cana-5141	210	17	the	the	DET
cana-5141	210	18	production	production	NOUN
cana-5141	210	19	of	of	ADP
cana-5141	210	20	toxic	toxic	ADJ
cana-5141	210	21	amyloid	amyloid	NOUN
cana-5141	210	22	-	-	PUNCT
cana-5141	210	23	beta	beta	NOUN
cana-5141	210	24	plaques	plaque	NOUN
cana-5141	210	25	and	and	CCONJ
cana-5141	210	26	tau	tau	PROPN
cana-5141	210	27	tangles	tangle	NOUN
cana-5141	210	28	,	,	PUNCT
cana-5141	210	29	the	the	DET
cana-5141	210	30	hallmarks	hallmark	NOUN
cana-5141	210	31	of	of	ADP
cana-5141	210	32	ad	ad	NOUN
cana-5141	210	33	.	.	PUNCT
cana-5141	211	1	additionally	additionally	ADV
cana-5141	211	2	,	,	PUNCT
cana-5141	211	3	it	it	PRON
cana-5141	211	4	enables	enable	VERB
cana-5141	211	5	the	the	DET
cana-5141	211	6	introduction	introduction	NOUN
cana-5141	211	7	of	of	ADP
cana-5141	211	8	protective	protective	ADJ
cana-5141	211	9	genetic	genetic	ADJ
cana-5141	211	10	variants	variant	NOUN
cana-5141	211	11	or	or	CCONJ
cana-5141	211	12	the	the	DET
cana-5141	211	13	regulation	regulation	NOUN
cana-5141	211	14	of	of	ADP
cana-5141	211	15	pathways	pathway	NOUN
cana-5141	211	16	involved	involve	VERB
cana-5141	211	17	in	in	ADP
cana-5141	211	18	neuroinflammation	neuroinflammation	NOUN
cana-5141	211	19	and	and	CCONJ
cana-5141	211	20	neuronal	neuronal	ADJ
cana-5141	211	21	survival	survival	NOUN
cana-5141	211	22	,	,	PUNCT
cana-5141	211	23	paving	pave	VERB
cana-5141	211	24	the	the	DET
cana-5141	211	25	way	way	NOUN
cana-5141	211	26	for	for	ADP
cana-5141	211	27	personalized	personalized	ADJ
cana-5141	211	28	and	and	CCONJ
cana-5141	211	29	effective	effective	ADJ
cana-5141	211	30	treatments	treatment	NOUN
cana-5141	211	31	for	for	ADP
cana-5141	211	32	ad[64	ad[64	PROPN
cana-5141	211	33	]	]	X
cana-5141	211	34	.	.	PUNCT
cana-5141	212	1	9.2	9.2	NUM
cana-5141	212	2	crispr	crispr	ADJ
cana-5141	212	3	/	/	SYM
cana-5141	212	4	cas9	cas9	NOUN
cana-5141	212	5	in	in	ADP
cana-5141	212	6	the	the	DET
cana-5141	212	7	development	development	NOUN
cana-5141	212	8	of	of	ADP
cana-5141	212	9	alzheimer	alzheimer	PROPN
cana-5141	212	10	's	's	PART
cana-5141	212	11	disease	disease	NOUN
cana-5141	212	12	models	model	VERB
cana-5141	212	13	three	three	NUM
cana-5141	212	14	essential	essential	ADJ
cana-5141	212	15	amino	amino	ADJ
cana-5141	212	16	acids	acid	NOUN
cana-5141	212	17	—	—	PUNCT
cana-5141	212	18	g676r	g676r	NOUN
cana-5141	212	19	,	,	PUNCT
cana-5141	212	20	f681y	f681y	PROPN
cana-5141	212	21	,	,	PUNCT
cana-5141	212	22	and	and	CCONJ
cana-5141	212	23	r684h	r684h	PROPN
cana-5141	212	24	—	—	PUNCT
cana-5141	212	25	that	that	PRON
cana-5141	212	26	distinguish	distinguish	VERB
cana-5141	212	27	the	the	DET
cana-5141	212	28	human	human	NOUN
cana-5141	212	29	and	and	CCONJ
cana-5141	212	30	rat	rat	NOUN
cana-5141	212	31	app	app	NOUN
cana-5141	212	32	sequences	sequence	NOUN
cana-5141	212	33	were	be	AUX
cana-5141	212	34	shown	show	VERB
cana-5141	212	35	to	to	PART
cana-5141	212	36	differ	differ	VERB
cana-5141	212	37	by	by	ADP
cana-5141	212	38	researchers	researcher	NOUN
cana-5141	212	39	using	use	VERB
cana-5141	212	40	computer	computer	NOUN
cana-5141	212	41	modelling	modelling	NOUN
cana-5141	212	42	.	.	PUNCT
cana-5141	213	1	these	these	DET
cana-5141	213	2	variations	variation	NOUN
cana-5141	213	3	affected	affect	VERB
cana-5141	213	4	app	app	PROPN
cana-5141	213	5	’s	’s	PART
cana-5141	213	6	binding	bind	VERB
cana-5141	213	7	affinity	affinity	NOUN
cana-5141	213	8	for	for	ADP
cana-5141	213	9	β	β	NOUN
cana-5141	213	10	-	-	NOUN
cana-5141	213	11	secretase	secretase	ADJ
cana-5141	213	12	bace1	bace1	NOUN
cana-5141	213	13	,	,	PUNCT
cana-5141	213	14	influencing	influence	VERB
cana-5141	213	15	aβ	aβ	ADP
cana-5141	213	16	synthesis	synthesis	NOUN
cana-5141	213	17	.	.	PUNCT
cana-5141	214	1	using	use	VERB
cana-5141	214	2	crispr	crispr	ADJ
cana-5141	214	3	-	-	PUNCT
cana-5141	214	4	cas9	cas9	NOUN
cana-5141	214	5	technology	technology	NOUN
cana-5141	214	6	,	,	PUNCT
cana-5141	214	7	they	they	PRON
cana-5141	214	8	created	create	VERB
cana-5141	214	9	a	a	DET
cana-5141	214	10	humanized	humanize	VERB
cana-5141	214	11	app	app	NOUN
cana-5141	214	12	rodent	rodent	NOUN
cana-5141	214	13	model	model	NOUN
cana-5141	214	14	(	(	PUNCT
cana-5141	214	15	apphu	apphu	PROPN
cana-5141	214	16	/	/	SYM
cana-5141	214	17	hu	hu	PROPN
cana-5141	214	18	)	)	PUNCT
cana-5141	214	19	by	by	ADP
cana-5141	214	20	introducing	introduce	VERB
cana-5141	214	21	these	these	DET
cana-5141	214	22	amino	amino	NOUN
cana-5141	214	23	acid	acid	NOUN
cana-5141	214	24	substitutions	substitution	NOUN
cana-5141	214	25	into	into	ADP
cana-5141	214	26	the	the	DET
cana-5141	214	27	mouse	mouse	NOUN
cana-5141	214	28	genome	genome	NOUN
cana-5141	214	29	.	.	PUNCT
cana-5141	215	1	additionally	additionally	ADV
cana-5141	215	2	,	,	PUNCT
cana-5141	215	3	they	they	PRON
cana-5141	215	4	developed	develop	VERB
cana-5141	215	5	a	a	DET
cana-5141	215	6	double	double	ADJ
cana-5141	215	7	knock	knock	NOUN
cana-5141	215	8	-	-	PUNCT
cana-5141	215	9	in	in	ADP
cana-5141	215	10	communications	communication	NOUN
cana-5141	215	11	on	on	ADP
cana-5141	215	12	applied	apply	VERB
cana-5141	215	13	nonlinear	nonlinear	ADJ
cana-5141	215	14	analysis	analysis	NOUN
cana-5141	215	15	issn	issn	NOUN
cana-5141	215	16	:	:	PUNCT
cana-5141	215	17	1074	1074	NUM
cana-5141	215	18	-	-	PUNCT
cana-5141	215	19	133x	133x	NUM
cana-5141	215	20	vol	vol	NOUN
cana-5141	215	21	32	32	NUM
cana-5141	215	22	no	no	NOUN
cana-5141	215	23	.	.	PUNCT
cana-5141	216	1	icmasd	icmasd	NOUN
cana-5141	216	2	(	(	PUNCT
cana-5141	216	3	2025	2025	NUM
cana-5141	216	4	)	)	PUNCT
cana-5141	216	5	1148	1148	NUM
cana-5141	216	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	216	7	apphu	apphu	PROPN
cana-5141	216	8	/	/	SYM
cana-5141	216	9	hu	hu	PROPN
cana-5141	216	10	;	;	PUNCT
cana-5141	216	11	psen1m139	psen1m139	PROPN
cana-5141	216	12	t	t	NOUN
cana-5141	216	13	ad	ad	NOUN
cana-5141	216	14	model	model	NOUN
cana-5141	216	15	by	by	ADP
cana-5141	216	16	incorporating	incorporate	VERB
cana-5141	216	17	the	the	DET
cana-5141	216	18	m139	m139	PROPN
cana-5141	216	19	t	t	NOUN
cana-5141	216	20	mutation	mutation	NOUN
cana-5141	216	21	,	,	PUNCT
cana-5141	216	22	associated	associate	VERB
cana-5141	216	23	with	with	ADP
cana-5141	216	24	earlyonset	earlyonset	NOUN
cana-5141	216	25	familial	familial	ADJ
cana-5141	216	26	alzheimer	alzheimer	PROPN
cana-5141	216	27	’s	’s	PART
cana-5141	216	28	disease	disease	NOUN
cana-5141	216	29	,	,	PUNCT
cana-5141	216	30	into	into	ADP
cana-5141	216	31	the	the	DET
cana-5141	216	32	psen1	psen1	ADJ
cana-5141	216	33	gene	gene	NOUN
cana-5141	216	34	of	of	ADP
cana-5141	216	35	mice	mouse	NOUN
cana-5141	216	36	.	.	PUNCT
cana-5141	217	1	both	both	CCONJ
cana-5141	217	2	the	the	DET
cana-5141	217	3	humanized	humanize	VERB
cana-5141	217	4	app	app	NOUN
cana-5141	217	5	mouse	mouse	PROPN
cana-5141	217	6	and	and	CCONJ
cana-5141	217	7	rat	rat	NOUN
cana-5141	217	8	models	model	NOUN
cana-5141	217	9	produced	produce	VERB
cana-5141	217	10	about	about	ADP
cana-5141	217	11	three	three	NUM
cana-5141	217	12	times	time	NOUN
cana-5141	217	13	more	more	ADJ
cana-5141	217	14	aβ	aβ	NOUN
cana-5141	217	15	than	than	ADP
cana-5141	217	16	wild	wild	ADJ
cana-5141	217	17	type	type	NOUN
cana-5141	217	18	,	,	PUNCT
cana-5141	217	19	confirming	confirm	VERB
cana-5141	217	20	the	the	DET
cana-5141	217	21	computer	computer	NOUN
cana-5141	217	22	model	model	NOUN
cana-5141	217	23	's	's	PART
cana-5141	217	24	predictions	prediction	NOUN
cana-5141	217	25	.	.	PUNCT
cana-5141	218	1	this	this	PRON
cana-5141	218	2	increased	increase	VERB
cana-5141	218	3	aβ	aβ	PRON
cana-5141	218	4	production	production	NOUN
cana-5141	218	5	was	be	AUX
cana-5141	218	6	due	due	ADJ
cana-5141	218	7	to	to	ADP
cana-5141	218	8	the	the	DET
cana-5141	218	9	enhanced	enhanced	ADJ
cana-5141	218	10	cleavage	cleavage	NOUN
cana-5141	218	11	efficiency	efficiency	NOUN
cana-5141	218	12	of	of	ADP
cana-5141	218	13	bace1	bace1	NOUN
cana-5141	218	14	by	by	ADP
cana-5141	218	15	the	the	DET
cana-5141	218	16	humanized	humanize	VERB
cana-5141	218	17	app	app	NOUN
cana-5141	218	18	sequence	sequence	NOUN
cana-5141	218	19	.	.	PUNCT
cana-5141	219	1	these	these	DET
cana-5141	219	2	new	new	ADJ
cana-5141	219	3	humanized	humanize	VERB
cana-5141	219	4	app	app	NOUN
cana-5141	219	5	rodent	rodent	NOUN
cana-5141	219	6	models	model	NOUN
cana-5141	219	7	more	more	ADV
cana-5141	219	8	accurately	accurately	ADV
cana-5141	219	9	replicate	replicate	VERB
cana-5141	219	10	human	human	ADJ
cana-5141	219	11	ad	ad	NOUN
cana-5141	219	12	aβ	aβ	DET
cana-5141	219	13	pathology	pathology	NOUN
cana-5141	219	14	,	,	PUNCT
cana-5141	219	15	offering	offer	VERB
cana-5141	219	16	greater	great	ADJ
cana-5141	219	17	physiological	physiological	ADJ
cana-5141	219	18	relevance	relevance	NOUN
cana-5141	219	19	compared	compare	VERB
cana-5141	219	20	to	to	ADP
cana-5141	219	21	previous	previous	ADJ
cana-5141	219	22	transgenic	transgenic	NOUN
cana-5141	219	23	overexpression	overexpression	NOUN
cana-5141	219	24	models	model	NOUN
cana-5141	219	25	[	[	X
cana-5141	219	26	65	65	NUM
cana-5141	219	27	]	]	PUNCT
cana-5141	219	28	.	.	PUNCT
cana-5141	220	1	9.3	9.3	NUM
cana-5141	220	2	crispr	crispr	ADJ
cana-5141	220	3	/	/	SYM
cana-5141	220	4	cas9	cas9	NOUN
cana-5141	220	5	in	in	ADP
cana-5141	220	6	screening	screen	VERB
cana-5141	220	7	alzheimer	alzheimer	PROPN
cana-5141	220	8	's	's	PART
cana-5141	220	9	disease	disease	NOUN
cana-5141	220	10	pathogenic	pathogenic	ADJ
cana-5141	220	11	genes	gene	NOUN
cana-5141	220	12	a	a	DET
cana-5141	220	13	study	study	NOUN
cana-5141	220	14	used	use	VERB
cana-5141	220	15	crispr	crispr	ADJ
cana-5141	220	16	-	-	PUNCT
cana-5141	220	17	cas9	cas9	NOUN
cana-5141	220	18	technology	technology	NOUN
cana-5141	220	19	to	to	PART
cana-5141	220	20	delete	delete	VERB
cana-5141	220	21	the	the	DET
cana-5141	220	22	3	3	NUM
cana-5141	220	23	'	'	PART
cana-5141	220	24	untranslated	untranslated	ADJ
cana-5141	220	25	region	region	NOUN
cana-5141	220	26	(	(	PUNCT
cana-5141	220	27	3'-utr	3'-utr	NOUN
cana-5141	220	28	)	)	PUNCT
cana-5141	220	29	of	of	ADP
cana-5141	220	30	the	the	DET
cana-5141	220	31	app	app	NOUN
cana-5141	220	32	gene	gene	NOUN
cana-5141	220	33	in	in	ADP
cana-5141	220	34	an	an	DET
cana-5141	220	35	app	app	NOUN
cana-5141	220	36	knock	knock	VERB
cana-5141	220	37	-	-	PUNCT
cana-5141	220	38	in	in	ADP
cana-5141	220	39	mouse	mouse	NOUN
cana-5141	220	40	model	model	NOUN
cana-5141	220	41	with	with	ADP
cana-5141	220	42	three	three	NUM
cana-5141	220	43	fad	fad	NOUN
cana-5141	220	44	mutations	mutation	NOUN
cana-5141	220	45	and	and	CCONJ
cana-5141	220	46	a	a	DET
cana-5141	220	47	humanized	humanize	VERB
cana-5141	220	48	aβ	aβ	NOUN
cana-5141	220	49	sequence	sequence	NOUN
cana-5141	220	50	.	.	PUNCT
cana-5141	221	1	the	the	DET
cana-5141	221	2	researchers	researcher	NOUN
cana-5141	221	3	found	find	VERB
cana-5141	221	4	that	that	SCONJ
cana-5141	221	5	greater	great	ADJ
cana-5141	221	6	deletion	deletion	NOUN
cana-5141	221	7	of	of	ADP
cana-5141	221	8	the	the	DET
cana-5141	221	9	app	app	NOUN
cana-5141	221	10	3'-utr	3'-utr	PROPN
cana-5141	221	11	led	lead	VERB
cana-5141	221	12	to	to	PART
cana-5141	221	13	reduced	reduced	VERB
cana-5141	221	14	aβ	aβ	PRON
cana-5141	221	15	deposition	deposition	NOUN
cana-5141	221	16	in	in	ADP
cana-5141	221	17	the	the	DET
cana-5141	221	18	brain	brain	NOUN
cana-5141	221	19	,	,	PUNCT
cana-5141	221	20	due	due	ADP
cana-5141	221	21	to	to	ADP
cana-5141	221	22	lower	low	ADJ
cana-5141	221	23	transcriptional	transcriptional	ADJ
cana-5141	221	24	and	and	CCONJ
cana-5141	221	25	translational	translational	ADJ
cana-5141	221	26	levels	level	NOUN
cana-5141	221	27	of	of	ADP
cana-5141	221	28	app	app	PROPN
cana-5141	221	29	.	.	PUNCT
cana-5141	222	1	further	further	ADJ
cana-5141	222	2	analysis	analysis	NOUN
cana-5141	222	3	identified	identify	VERB
cana-5141	222	4	a	a	DET
cana-5141	222	5	critical	critical	ADJ
cana-5141	222	6	34	34	NUM
cana-5141	222	7	bp	bp	PROPN
cana-5141	222	8	deletion	deletion	NOUN
cana-5141	222	9	near	near	ADP
cana-5141	222	10	the	the	DET
cana-5141	222	11	conserved	conserved	ADJ
cana-5141	222	12	52	52	NUM
cana-5141	222	13	bp	bp	NOUN
cana-5141	222	14	sequence	sequence	NOUN
cana-5141	222	15	in	in	ADP
cana-5141	222	16	the	the	DET
cana-5141	222	17	3'-utr	3'-utr	NOUN
cana-5141	222	18	,	,	PUNCT
cana-5141	222	19	significantly	significantly	ADV
cana-5141	222	20	reducing	reduce	VERB
cana-5141	222	21	aβ	aβ	PRON
cana-5141	222	22	pathology[66	pathology[66	NOUN
cana-5141	222	23	]	]	PUNCT
cana-5141	222	24	.	.	PUNCT
cana-5141	223	1	crispr	crispr	ADJ
cana-5141	223	2	-	-	PUNCT
cana-5141	223	3	cas9	cas9	NOUN
cana-5141	223	4	enhances	enhance	VERB
cana-5141	223	5	ad	ad	NOUN
cana-5141	223	6	gene	gene	NOUN
cana-5141	223	7	screening	screen	VERB
cana-5141	223	8	by	by	ADP
cana-5141	223	9	enabling	enable	VERB
cana-5141	223	10	precise	precise	ADJ
cana-5141	223	11	gene	gene	NOUN
cana-5141	223	12	editing	editing	NOUN
cana-5141	223	13	,	,	PUNCT
cana-5141	223	14	improving	improve	VERB
cana-5141	223	15	experimental	experimental	ADJ
cana-5141	223	16	accuracy	accuracy	NOUN
cana-5141	223	17	,	,	PUNCT
cana-5141	223	18	and	and	CCONJ
cana-5141	223	19	facilitating	facilitate	VERB
cana-5141	223	20	gene	gene	NOUN
cana-5141	223	21	expression	expression	NOUN
cana-5141	223	22	regulation	regulation	NOUN
cana-5141	223	23	.	.	PUNCT
cana-5141	224	1	it	it	PRON
cana-5141	224	2	also	also	ADV
cana-5141	224	3	offers	offer	VERB
cana-5141	224	4	a	a	DET
cana-5141	224	5	tool	tool	NOUN
cana-5141	224	6	for	for	ADP
cana-5141	224	7	correcting	correct	VERB
cana-5141	224	8	mutations	mutation	NOUN
cana-5141	224	9	in	in	ADP
cana-5141	224	10	genes	gene	NOUN
cana-5141	224	11	associated	associate	VERB
cana-5141	224	12	with	with	ADP
cana-5141	224	13	early	early	ADJ
cana-5141	224	14	-	-	PUNCT
cana-5141	224	15	onset	onset	NOUN
cana-5141	224	16	familial	familial	ADJ
cana-5141	224	17	ad	ad	NOUN
cana-5141	224	18	,	,	PUNCT
cana-5141	224	19	such	such	ADJ
cana-5141	224	20	as	as	ADP
cana-5141	224	21	the	the	DET
cana-5141	224	22	app	app	NOUN
cana-5141	224	23	gene	gene	NOUN
cana-5141	224	24	,	,	PUNCT
cana-5141	224	25	to	to	PART
cana-5141	224	26	reduce	reduce	VERB
cana-5141	224	27	aβ	aβ	PRON
cana-5141	224	28	accumulation	accumulation	NOUN
cana-5141	224	29	and	and	CCONJ
cana-5141	224	30	prevent	prevent	VERB
cana-5141	224	31	disease	disease	NOUN
cana-5141	224	32	onset[67	onset[67	NOUN
cana-5141	224	33	]	]	PUNCT
cana-5141	224	34	.	.	PUNCT
cana-5141	225	1	10	10	NUM
cana-5141	225	2	.	.	PUNCT
cana-5141	226	1	future	future	ADJ
cana-5141	226	2	prospect	prospect	NOUN
cana-5141	226	3	the	the	DET
cana-5141	226	4	integration	integration	NOUN
cana-5141	226	5	of	of	ADP
cana-5141	226	6	crispr	crispr	ADJ
cana-5141	226	7	/	/	SYM
cana-5141	226	8	cas9	cas9	NOUN
cana-5141	226	9	gene	gene	NOUN
cana-5141	226	10	-	-	PUNCT
cana-5141	226	11	editing	edit	VERB
cana-5141	226	12	technology	technology	NOUN
cana-5141	226	13	and	and	CCONJ
cana-5141	226	14	artificial	artificial	ADJ
cana-5141	226	15	intelligence	intelligence	NOUN
cana-5141	226	16	(	(	PUNCT
cana-5141	226	17	ai	ai	PROPN
cana-5141	226	18	)	)	PUNCT
cana-5141	226	19	is	be	AUX
cana-5141	226	20	driving	drive	VERB
cana-5141	226	21	innovative	innovative	ADJ
cana-5141	226	22	approaches	approach	NOUN
cana-5141	226	23	in	in	ADP
cana-5141	226	24	the	the	DET
cana-5141	226	25	treatment	treatment	NOUN
cana-5141	226	26	and	and	CCONJ
cana-5141	226	27	understanding	understanding	NOUN
cana-5141	226	28	of	of	ADP
cana-5141	226	29	alzheimer	alzheimer	PROPN
cana-5141	226	30	's	's	PART
cana-5141	226	31	disease	disease	NOUN
cana-5141	226	32	(	(	PUNCT
cana-5141	226	33	ad	ad	NOUN
cana-5141	226	34	)	)	PUNCT
cana-5141	226	35	.	.	PUNCT
cana-5141	227	1	crispr	crispr	PROPN
cana-5141	227	2	enables	enable	VERB
cana-5141	227	3	precise	precise	ADJ
cana-5141	227	4	genetic	genetic	ADJ
cana-5141	227	5	modifications	modification	NOUN
cana-5141	227	6	,	,	PUNCT
cana-5141	227	7	offering	offer	VERB
cana-5141	227	8	hope	hope	NOUN
cana-5141	227	9	for	for	ADP
cana-5141	227	10	correcting	correct	VERB
cana-5141	227	11	mutations	mutation	NOUN
cana-5141	227	12	linked	link	VERB
cana-5141	227	13	to	to	ADP
cana-5141	227	14	early	early	ADJ
cana-5141	227	15	-	-	PUNCT
cana-5141	227	16	onset	onset	NOUN
cana-5141	227	17	ad	ad	NOUN
cana-5141	227	18	and	and	CCONJ
cana-5141	227	19	creating	create	VERB
cana-5141	227	20	more	more	ADV
cana-5141	227	21	accurate	accurate	ADJ
cana-5141	227	22	disease	disease	NOUN
cana-5141	227	23	models	model	NOUN
cana-5141	227	24	.	.	PUNCT
cana-5141	228	1	ai	ai	VERB
cana-5141	228	2	enhances	enhance	NOUN
cana-5141	228	3	this	this	DET
cana-5141	228	4	process	process	NOUN
cana-5141	228	5	by	by	ADP
cana-5141	228	6	analysing	analyse	VERB
cana-5141	228	7	vast	vast	ADJ
cana-5141	228	8	datasets	dataset	NOUN
cana-5141	228	9	to	to	PART
cana-5141	228	10	identify	identify	VERB
cana-5141	228	11	drug	drug	NOUN
cana-5141	228	12	targets	target	NOUN
cana-5141	228	13	,	,	PUNCT
cana-5141	228	14	predict	predict	VERB
cana-5141	228	15	treatment	treatment	NOUN
cana-5141	228	16	outcomes	outcome	NOUN
cana-5141	228	17	,	,	PUNCT
cana-5141	228	18	and	and	CCONJ
cana-5141	228	19	optimize	optimize	VERB
cana-5141	228	20	patient	patient	ADJ
cana-5141	228	21	selection	selection	NOUN
cana-5141	228	22	and	and	CCONJ
cana-5141	228	23	personalized	personalized	ADJ
cana-5141	228	24	treatment	treatment	NOUN
cana-5141	228	25	plans[68	plans[68	NOUN
cana-5141	228	26	]	]	PUNCT
cana-5141	228	27	.	.	PUNCT
cana-5141	229	1	ai	ai	VERB
cana-5141	229	2	tools	tool	NOUN
cana-5141	229	3	like	like	ADP
cana-5141	229	4	deep	deep	ADJ
cana-5141	229	5	crispr	crispr	NOUN
cana-5141	229	6	and	and	CCONJ
cana-5141	229	7	crisot	crisot	ADJ
cana-5141	229	8	further	far	ADV
cana-5141	229	9	refine	refine	VERB
cana-5141	229	10	sgrna	sgrna	ADJ
cana-5141	229	11	design	design	NOUN
cana-5141	229	12	and	and	CCONJ
cana-5141	229	13	predict	predict	VERB
cana-5141	229	14	off	off	ADP
cana-5141	229	15	-	-	PUNCT
cana-5141	229	16	target	target	NOUN
cana-5141	229	17	effects	effect	NOUN
cana-5141	229	18	by	by	ADP
cana-5141	229	19	analysing	analyse	VERB
cana-5141	229	20	genomic	genomic	NOUN
cana-5141	229	21	features	feature	NOUN
cana-5141	229	22	and	and	CCONJ
cana-5141	229	23	using	use	VERB
cana-5141	229	24	machine	machine	NOUN
cana-5141	229	25	learning	learning	NOUN
cana-5141	229	26	models	model	NOUN
cana-5141	229	27	to	to	PART
cana-5141	229	28	predict	predict	VERB
cana-5141	229	29	potential	potential	ADJ
cana-5141	229	30	cleavage	cleavage	NOUN
cana-5141	229	31	sites[69	sites[69	NOUN
cana-5141	229	32	]	]	PUNCT
cana-5141	229	33	.	.	PUNCT
cana-5141	230	1	however	however	ADV
cana-5141	230	2	,	,	PUNCT
cana-5141	230	3	challenges	challenge	NOUN
cana-5141	230	4	such	such	ADJ
cana-5141	230	5	as	as	ADP
cana-5141	230	6	off	off	ADP
cana-5141	230	7	-	-	PUNCT
cana-5141	230	8	target	target	NOUN
cana-5141	230	9	effects	effect	NOUN
cana-5141	230	10	,	,	PUNCT
cana-5141	230	11	data	datum	NOUN
cana-5141	230	12	heterogeneity	heterogeneity	NOUN
cana-5141	230	13	,	,	PUNCT
cana-5141	230	14	and	and	CCONJ
cana-5141	230	15	the	the	DET
cana-5141	230	16	limited	limited	ADJ
cana-5141	230	17	availability	availability	NOUN
cana-5141	230	18	of	of	ADP
cana-5141	230	19	labelled	label	VERB
cana-5141	230	20	data	datum	NOUN
cana-5141	230	21	remain	remain	VERB
cana-5141	230	22	.	.	PUNCT
cana-5141	231	1	future	future	ADJ
cana-5141	231	2	advancements	advancement	NOUN
cana-5141	231	3	will	will	AUX
cana-5141	231	4	focus	focus	VERB
cana-5141	231	5	on	on	ADP
cana-5141	231	6	improving	improve	VERB
cana-5141	231	7	crispr	crispr	ADJ
cana-5141	231	8	delivery	delivery	NOUN
cana-5141	231	9	methods	method	NOUN
cana-5141	231	10	,	,	PUNCT
cana-5141	231	11	refining	refining	NOUN
cana-5141	231	12	ai	ai	VERB
cana-5141	231	13	algorithms	algorithm	NOUN
cana-5141	231	14	,	,	PUNCT
cana-5141	231	15	and	and	CCONJ
cana-5141	231	16	addressing	address	VERB
cana-5141	231	17	ethical	ethical	ADJ
cana-5141	231	18	concerns	concern	NOUN
cana-5141	231	19	to	to	PART
cana-5141	231	20	fully	fully	ADV
cana-5141	231	21	realize	realize	VERB
cana-5141	231	22	the	the	DET
cana-5141	231	23	potential	potential	NOUN
cana-5141	231	24	of	of	ADP
cana-5141	231	25	these	these	DET
cana-5141	231	26	integrated	integrate	VERB
cana-5141	231	27	technologies	technology	NOUN
cana-5141	231	28	in	in	ADP
cana-5141	231	29	alzheimer	alzheimer	PROPN
cana-5141	231	30	's	's	PART
cana-5141	231	31	treatment	treatment	NOUN
cana-5141	231	32	and	and	CCONJ
cana-5141	231	33	gene	gene	NOUN
cana-5141	231	34	editing	edit	VERB
cana-5141	231	35	therapies	therapy	NOUN
cana-5141	231	36	.	.	PUNCT
cana-5141	232	1	conclusion	conclusion	NOUN
cana-5141	232	2	the	the	DET
cana-5141	232	3	therapeutic	therapeutic	ADJ
cana-5141	232	4	landscape	landscape	NOUN
cana-5141	232	5	is	be	AUX
cana-5141	232	6	constantly	constantly	ADV
cana-5141	232	7	being	be	AUX
cana-5141	232	8	shaped	shape	VERB
cana-5141	232	9	by	by	ADP
cana-5141	232	10	developments	development	NOUN
cana-5141	232	11	in	in	ADP
cana-5141	232	12	alzheimer	alzheimer	PROPN
cana-5141	232	13	's	's	PART
cana-5141	232	14	disease	disease	NOUN
cana-5141	232	15	research	research	NOUN
cana-5141	232	16	,	,	PUNCT
cana-5141	232	17	which	which	PRON
cana-5141	232	18	give	give	VERB
cana-5141	232	19	rise	rise	NOUN
cana-5141	232	20	to	to	ADP
cana-5141	232	21	fresh	fresh	ADJ
cana-5141	232	22	optimism	optimism	NOUN
cana-5141	232	23	for	for	ADP
cana-5141	232	24	disease	disease	NOUN
cana-5141	232	25	-	-	PUNCT
cana-5141	232	26	modifying	modify	VERB
cana-5141	232	27	therapies	therapy	NOUN
cana-5141	232	28	.	.	PUNCT
cana-5141	233	1	measurable	measurable	ADJ
cana-5141	233	2	progress	progress	NOUN
cana-5141	233	3	has	have	AUX
cana-5141	233	4	been	be	AUX
cana-5141	233	5	made	make	VERB
cana-5141	233	6	with	with	ADP
cana-5141	233	7	amyloidand	amyloidand	NOUN
cana-5141	233	8	tau	tau	ADV
cana-5141	233	9	-	-	PUNCT
cana-5141	233	10	targeting	target	VERB
cana-5141	233	11	treatments	treatment	NOUN
cana-5141	233	12	as	as	ADV
cana-5141	233	13	well	well	ADV
cana-5141	233	14	as	as	ADP
cana-5141	233	15	precision	precision	NOUN
cana-5141	233	16	medicine	medicine	NOUN
cana-5141	233	17	strategies	strategy	NOUN
cana-5141	233	18	like	like	ADP
cana-5141	233	19	lecanemab	lecanemab	NOUN
cana-5141	233	20	,	,	PUNCT
cana-5141	233	21	while	while	SCONJ
cana-5141	233	22	issues	issue	NOUN
cana-5141	233	23	with	with	ADP
cana-5141	233	24	accessibility	accessibility	NOUN
cana-5141	233	25	and	and	CCONJ
cana-5141	233	26	effectiveness	effectiveness	NOUN
cana-5141	233	27	still	still	ADV
cana-5141	233	28	exist	exist	VERB
cana-5141	233	29	.	.	PUNCT
cana-5141	234	1	with	with	ADP
cana-5141	234	2	its	its	PRON
cana-5141	234	3	ability	ability	NOUN
cana-5141	234	4	to	to	PART
cana-5141	234	5	precisely	precisely	ADV
cana-5141	234	6	target	target	VERB
cana-5141	234	7	genetic	genetic	ADJ
cana-5141	234	8	variables	variable	NOUN
cana-5141	234	9	connected	connect	VERB
cana-5141	234	10	to	to	ADP
cana-5141	234	11	ad	ad	NOUN
cana-5141	234	12	pathogenesis	pathogenesis	NOUN
cana-5141	234	13	,	,	PUNCT
cana-5141	234	14	the	the	DET
cana-5141	234	15	ground	ground	NOUN
cana-5141	234	16	-	-	PUNCT
cana-5141	234	17	breaking	break	VERB
cana-5141	234	18	crispr	crispr	ADJ
cana-5141	234	19	-	-	PUNCT
cana-5141	234	20	cas9	cas9	NOUN
cana-5141	234	21	gene	gene	NOUN
cana-5141	234	22	-	-	PUNCT
cana-5141	234	23	editing	edit	VERB
cana-5141	234	24	technology	technology	NOUN
cana-5141	234	25	is	be	AUX
cana-5141	234	26	an	an	DET
cana-5141	234	27	example	example	NOUN
cana-5141	234	28	of	of	ADP
cana-5141	234	29	the	the	DET
cana-5141	234	30	future	future	ADJ
cana-5141	234	31	frontier	frontier	NOUN
cana-5141	234	32	.	.	PUNCT
cana-5141	235	1	but	but	CCONJ
cana-5141	235	2	there	there	PRON
cana-5141	235	3	are	be	VERB
cana-5141	235	4	challenges	challenge	NOUN
cana-5141	235	5	including	include	VERB
cana-5141	235	6	brain	brain	NOUN
cana-5141	235	7	delivery	delivery	NOUN
cana-5141	235	8	,	,	PUNCT
cana-5141	235	9	off	off	ADP
cana-5141	235	10	-	-	PUNCT
cana-5141	235	11	target	target	NOUN
cana-5141	235	12	effects	effect	NOUN
cana-5141	235	13	,	,	PUNCT
cana-5141	235	14	and	and	CCONJ
cana-5141	235	15	ethical	ethical	ADJ
cana-5141	235	16	issues	issue	NOUN
cana-5141	235	17	that	that	PRON
cana-5141	235	18	need	need	VERB
cana-5141	235	19	to	to	PART
cana-5141	235	20	be	be	AUX
cana-5141	235	21	addressed	address	VERB
cana-5141	235	22	.	.	PUNCT
cana-5141	236	1	combining	combine	VERB
cana-5141	236	2	these	these	DET
cana-5141	236	3	developments	development	NOUN
cana-5141	236	4	with	with	ADP
cana-5141	236	5	enhanced	enhanced	ADJ
cana-5141	236	6	clinical	clinical	ADJ
cana-5141	236	7	trial	trial	NOUN
cana-5141	236	8	designs	design	NOUN
cana-5141	236	9	and	and	CCONJ
cana-5141	236	10	artificial	artificial	ADJ
cana-5141	236	11	intelligence	intelligence	NOUN
cana-5141	236	12	has	have	VERB
cana-5141	236	13	the	the	DET
cana-5141	236	14	potential	potential	NOUN
cana-5141	236	15	to	to	ADP
cana-5141	236	16	communications	communication	NOUN
cana-5141	236	17	on	on	ADP
cana-5141	236	18	applied	apply	VERB
cana-5141	236	19	nonlinear	nonlinear	ADJ
cana-5141	236	20	analysis	analysis	NOUN
cana-5141	236	21	issn	issn	NOUN
cana-5141	236	22	:	:	PUNCT
cana-5141	236	23	1074	1074	NUM
cana-5141	236	24	-	-	PUNCT
cana-5141	236	25	133x	133x	NUM
cana-5141	236	26	vol	vol	NOUN
cana-5141	236	27	32	32	NUM
cana-5141	236	28	no	no	NOUN
cana-5141	236	29	.	.	PUNCT
cana-5141	237	1	icmasd	icmasd	NOUN
cana-5141	237	2	(	(	PUNCT
cana-5141	237	3	2025	2025	NUM
cana-5141	237	4	)	)	PUNCT
cana-5141	237	5	1149	1149	NUM
cana-5141	237	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	237	7	speed	speed	VERB
cana-5141	237	8	up	up	ADP
cana-5141	237	9	research	research	NOUN
cana-5141	237	10	and	and	CCONJ
cana-5141	237	11	improve	improve	VERB
cana-5141	237	12	treatment	treatment	NOUN
cana-5141	237	13	results	result	NOUN
cana-5141	237	14	.	.	PUNCT
cana-5141	238	1	future	future	ADJ
cana-5141	238	2	research	research	NOUN
cana-5141	238	3	should	should	AUX
cana-5141	238	4	concentrate	concentrate	VERB
cana-5141	238	5	on	on	ADP
cana-5141	238	6	improving	improve	VERB
cana-5141	238	7	these	these	DET
cana-5141	238	8	approaches	approach	NOUN
cana-5141	238	9	to	to	PART
cana-5141	238	10	give	give	VERB
cana-5141	238	11	people	people	NOUN
cana-5141	238	12	with	with	ADP
cana-5141	238	13	ad	ad	NOUN
cana-5141	238	14	individualized	individualize	VERB
cana-5141	238	15	,	,	PUNCT
cana-5141	238	16	efficient	efficient	ADJ
cana-5141	238	17	,	,	PUNCT
cana-5141	238	18	and	and	CCONJ
cana-5141	238	19	equitable	equitable	ADJ
cana-5141	238	20	care	care	NOUN
cana-5141	238	21	.	.	PUNCT
cana-5141	239	1	acknowledgements	acknowledgement	NOUN
cana-5141	239	2	we	we	PRON
cana-5141	239	3	would	would	AUX
cana-5141	239	4	like	like	VERB
cana-5141	239	5	to	to	PART
cana-5141	239	6	express	express	VERB
cana-5141	239	7	our	our	PRON
cana-5141	239	8	gratitude	gratitude	NOUN
cana-5141	239	9	to	to	ADP
cana-5141	239	10	vandana	vandana	PROPN
cana-5141	239	11	bhatia	bhatia	PROPN
cana-5141	239	12	,	,	PUNCT
cana-5141	239	13	dr	dr	PROPN
cana-5141	239	14	.	.	PROPN
cana-5141	239	15	vir	vir	PROPN
cana-5141	239	16	vikram	vikram	PROPN
cana-5141	239	17	sharma	sharma	PROPN
cana-5141	239	18	,	,	PUNCT
cana-5141	239	19	dr	dr	PROPN
cana-5141	239	20	.	.	PROPN
cana-5141	239	21	swati	swati	PROPN
cana-5141	239	22	rana	rana	PROPN
cana-5141	239	23	,	,	PUNCT
cana-5141	239	24	shagun	shagun	VERB
cana-5141	239	25	thakur	thakur	PROPN
cana-5141	239	26	,	,	PUNCT
cana-5141	239	27	yavnika	yavnika	PROPN
cana-5141	239	28	minhas	minhas	PROPN
cana-5141	239	29	and	and	CCONJ
cana-5141	239	30	aditya	aditya	PROPN
cana-5141	239	31	rattan	rattan	PROPN
cana-5141	239	32	for	for	ADP
cana-5141	239	33	their	their	PRON
cana-5141	239	34	invaluable	invaluable	ADJ
cana-5141	239	35	contributions	contribution	NOUN
cana-5141	239	36	to	to	ADP
cana-5141	239	37	this	this	DET
cana-5141	239	38	review	review	NOUN
cana-5141	239	39	.	.	PUNCT
cana-5141	240	1	we	we	PRON
cana-5141	240	2	sincerely	sincerely	ADV
cana-5141	240	3	thank	thank	VERB
cana-5141	240	4	vandana	vandana	PROPN
cana-5141	240	5	bhatia	bhatia	PROPN
cana-5141	240	6	,	,	PUNCT
cana-5141	240	7	dr	dr	PROPN
cana-5141	240	8	.	.	PROPN
cana-5141	240	9	vir	vir	PROPN
cana-5141	240	10	vikram	vikram	PROPN
cana-5141	240	11	sharma	sharma	PROPN
cana-5141	240	12	and	and	CCONJ
cana-5141	240	13	dr	dr	PROPN
cana-5141	240	14	.	.	PROPN
cana-5141	240	15	swati	swati	PROPN
cana-5141	240	16	rana	rana	PROPN
cana-5141	240	17	for	for	ADP
cana-5141	240	18	their	their	PRON
cana-5141	240	19	insightful	insightful	ADJ
cana-5141	240	20	discussions	discussion	NOUN
cana-5141	240	21	and	and	CCONJ
cana-5141	240	22	critical	critical	ADJ
cana-5141	240	23	feedback	feedback	NOUN
cana-5141	240	24	,	,	PUNCT
cana-5141	240	25	which	which	PRON
cana-5141	240	26	greatly	greatly	ADV
cana-5141	240	27	enhanced	enhance	VERB
cana-5141	240	28	the	the	DET
cana-5141	240	29	manuscript	manuscript	NOUN
cana-5141	240	30	and	and	CCONJ
cana-5141	240	31	also	also	ADV
cana-5141	240	32	,	,	PUNCT
cana-5141	240	33	we	we	PRON
cana-5141	240	34	acknowledge	acknowledge	VERB
cana-5141	240	35	the	the	DET
cana-5141	240	36	collective	collective	ADJ
cana-5141	240	37	efforts	effort	NOUN
cana-5141	240	38	of	of	ADP
cana-5141	240	39	all	all	DET
cana-5141	240	40	co	co	NOUN
cana-5141	240	41	-	-	NOUN
cana-5141	240	42	authors	author	NOUN
cana-5141	240	43	shagun	shagun	VERB
cana-5141	240	44	thakur	thakur	PROPN
cana-5141	240	45	,	,	PUNCT
cana-5141	240	46	yavnika	yavnika	PROPN
cana-5141	240	47	minhas	minhas	PROPN
cana-5141	240	48	and	and	CCONJ
cana-5141	240	49	aditya	aditya	PROPN
cana-5141	240	50	rattan	rattan	PROPN
cana-5141	240	51	for	for	ADP
cana-5141	240	52	their	their	PRON
cana-5141	240	53	assistance	assistance	NOUN
cana-5141	240	54	in	in	ADP
cana-5141	240	55	literature	literature	NOUN
cana-5141	240	56	searches	search	NOUN
cana-5141	240	57	,	,	PUNCT
cana-5141	240	58	manuscript	manuscript	NOUN
cana-5141	240	59	preparation	preparation	NOUN
cana-5141	240	60	.	.	PUNCT
cana-5141	241	1	author	author	NOUN
cana-5141	241	2	contributions	contributions	PROPN
cana-5141	241	3	vandana	vandana	PROPN
cana-5141	241	4	bhatia	bhatia	PROPN
cana-5141	241	5	and	and	CCONJ
cana-5141	241	6	dr	dr	PROPN
cana-5141	241	7	.	.	PROPN
cana-5141	241	8	swati	swati	PROPN
cana-5141	241	9	rana	rana	PROPN
cana-5141	241	10	conceptualized	conceptualize	VERB
cana-5141	241	11	the	the	DET
cana-5141	241	12	review	review	NOUN
cana-5141	241	13	topic	topic	NOUN
cana-5141	241	14	,	,	PUNCT
cana-5141	241	15	designed	design	VERB
cana-5141	241	16	the	the	DET
cana-5141	241	17	structure	structure	NOUN
cana-5141	241	18	of	of	ADP
cana-5141	241	19	the	the	DET
cana-5141	241	20	manuscript	manuscript	NOUN
cana-5141	241	21	,	,	PUNCT
cana-5141	241	22	and	and	CCONJ
cana-5141	241	23	led	lead	VERB
cana-5141	241	24	the	the	DET
cana-5141	241	25	writing	writing	NOUN
cana-5141	241	26	process	process	NOUN
cana-5141	241	27	.	.	PUNCT
cana-5141	242	1	shagun	shagun	PROPN
cana-5141	242	2	thakur	thakur	PROPN
cana-5141	242	3	and	and	CCONJ
cana-5141	242	4	aditya	aditya	PROPN
cana-5141	242	5	rattan	rattan	PROPN
cana-5141	242	6	conducted	conduct	VERB
cana-5141	242	7	the	the	DET
cana-5141	242	8	primary	primary	ADJ
cana-5141	242	9	literature	literature	NOUN
cana-5141	242	10	search	search	NOUN
cana-5141	242	11	and	and	CCONJ
cana-5141	242	12	data	datum	NOUN
cana-5141	242	13	collection	collection	NOUN
cana-5141	242	14	.	.	PUNCT
cana-5141	243	1	anjali	anjali	PROPN
cana-5141	243	2	chandel	chandel	PROPN
cana-5141	243	3	&	&	CCONJ
cana-5141	243	4	yavnika	yavnika	PROPN
cana-5141	243	5	minhas	minhas	PROPN
cana-5141	243	6	conducted	conduct	VERB
cana-5141	243	7	an	an	DET
cana-5141	243	8	extensive	extensive	ADJ
cana-5141	243	9	literature	literature	NOUN
cana-5141	243	10	review	review	NOUN
cana-5141	243	11	,	,	PUNCT
cana-5141	243	12	contributed	contribute	VERB
cana-5141	243	13	to	to	ADP
cana-5141	243	14	the	the	DET
cana-5141	243	15	writing	writing	NOUN
cana-5141	243	16	of	of	ADP
cana-5141	243	17	the	the	DET
cana-5141	243	18	various	various	ADJ
cana-5141	243	19	section	section	NOUN
cana-5141	243	20	in	in	ADP
cana-5141	243	21	manuscript	manuscript	NOUN
cana-5141	243	22	,	,	PUNCT
cana-5141	243	23	and	and	CCONJ
cana-5141	243	24	assisted	assist	VERB
cana-5141	243	25	in	in	ADP
cana-5141	243	26	refining	refine	VERB
cana-5141	243	27	the	the	DET
cana-5141	243	28	manuscript	manuscript	NOUN
cana-5141	243	29	's	's	PART
cana-5141	243	30	framework	framework	NOUN
cana-5141	243	31	.	.	PUNCT
cana-5141	244	1	dr	dr	PROPN
cana-5141	244	2	.	.	PROPN
cana-5141	244	3	vir	vir	PROPN
cana-5141	244	4	vikram	vikram	PROPN
cana-5141	244	5	sharma	sharma	PROPN
cana-5141	244	6	provided	provide	VERB
cana-5141	244	7	critical	critical	ADJ
cana-5141	244	8	revisions	revision	NOUN
cana-5141	244	9	and	and	CCONJ
cana-5141	244	10	feedback	feedback	NOUN
cana-5141	244	11	,	,	PUNCT
cana-5141	244	12	ensuring	ensure	VERB
cana-5141	244	13	the	the	DET
cana-5141	244	14	accuracy	accuracy	NOUN
cana-5141	244	15	and	and	CCONJ
cana-5141	244	16	scientific	scientific	ADJ
cana-5141	244	17	integrity	integrity	NOUN
cana-5141	244	18	of	of	ADP
cana-5141	244	19	the	the	DET
cana-5141	244	20	content	content	NOUN
cana-5141	244	21	.	.	PUNCT
cana-5141	245	1	all	all	DET
cana-5141	245	2	authors	author	NOUN
cana-5141	245	3	participated	participate	VERB
cana-5141	245	4	in	in	ADP
cana-5141	245	5	reviewing	review	VERB
cana-5141	245	6	and	and	CCONJ
cana-5141	245	7	editing	edit	VERB
cana-5141	245	8	the	the	DET
cana-5141	245	9	manuscript	manuscript	NOUN
cana-5141	245	10	,	,	PUNCT
cana-5141	245	11	approved	approve	VERB
cana-5141	245	12	the	the	DET
cana-5141	245	13	final	final	ADJ
cana-5141	245	14	version	version	NOUN
cana-5141	245	15	,	,	PUNCT
cana-5141	245	16	and	and	CCONJ
cana-5141	245	17	agreed	agree	VERB
cana-5141	245	18	to	to	PART
cana-5141	245	19	be	be	AUX
cana-5141	245	20	accountable	accountable	ADJ
cana-5141	245	21	for	for	ADP
cana-5141	245	22	all	all	DET
cana-5141	245	23	aspects	aspect	NOUN
cana-5141	245	24	of	of	ADP
cana-5141	245	25	the	the	DET
cana-5141	245	26	work	work	NOUN
cana-5141	245	27	.	.	PUNCT
cana-5141	246	1	conflicts	conflict	NOUN
cana-5141	246	2	of	of	ADP
cana-5141	246	3	interest	interest	NOUN
cana-5141	246	4	“	"	PUNCT
cana-5141	246	5	the	the	DET
cana-5141	246	6	authors	author	NOUN
cana-5141	246	7	declare	declare	VERB
cana-5141	246	8	that	that	SCONJ
cana-5141	246	9	they	they	PRON
cana-5141	246	10	have	have	VERB
cana-5141	246	11	no	no	DET
cana-5141	246	12	conflicts	conflict	NOUN
cana-5141	246	13	of	of	ADP
cana-5141	246	14	interest	interest	NOUN
cana-5141	246	15	.	.	PUNCT
cana-5141	246	16	”	"	PUNCT
cana-5141	246	17	.	.	PUNCT
cana-5141	247	1	references	reference	NOUN
cana-5141	247	2	[	[	X
cana-5141	247	3	1	1	X
cana-5141	247	4	]	]	X
cana-5141	247	5	y.	y.	PROPN
cana-5141	247	6	wang	wang	PROPN
cana-5141	247	7	et	et	PROPN
cana-5141	247	8	al	al	PROPN
cana-5141	247	9	.	.	PROPN
cana-5141	247	10	,	,	PUNCT
cana-5141	247	11	‘	'	PUNCT
cana-5141	247	12	upregulation	upregulation	NOUN
cana-5141	247	13	of	of	ADP
cana-5141	247	14	thioredoxin	thioredoxin	PROPN
cana-5141	247	15	-	-	PUNCT
cana-5141	247	16	interacting	interact	VERB
cana-5141	247	17	protein	protein	NOUN
cana-5141	247	18	in	in	ADP
cana-5141	247	19	brain	brain	NOUN
cana-5141	247	20	of	of	ADP
cana-5141	247	21	amyloid	amyloid	NOUN
cana-5141	247	22	-	-	PUNCT
cana-5141	247	23	β	β	X
cana-5141	247	24	protein	protein	NOUN
cana-5141	247	25	precursor	precursor	NOUN
cana-5141	247	26	/	/	SYM
cana-5141	247	27	presenilin	presenilin	PROPN
cana-5141	247	28	1	1	NUM
cana-5141	247	29	transgenic	transgenic	NOUN
cana-5141	247	30	mice	mouse	NOUN
cana-5141	247	31	and	and	CCONJ
cana-5141	247	32	amyloid	amyloid	NOUN
cana-5141	247	33	-	-	PUNCT
cana-5141	247	34	β	β	NOUN
cana-5141	247	35	treated	treat	VERB
cana-5141	247	36	neuronal	neuronal	ADJ
cana-5141	247	37	cells	cell	NOUN
cana-5141	247	38	’	'	PUNCT
cana-5141	247	39	,	,	PUNCT
cana-5141	247	40	journal	journal	NOUN
cana-5141	247	41	of	of	ADP
cana-5141	247	42	alzheimer	alzheimer	PROPN
cana-5141	247	43	’s	’s	PART
cana-5141	247	44	disease	disease	NOUN
cana-5141	247	45	,	,	PUNCT
cana-5141	247	46	vol	vol	NOUN
cana-5141	247	47	.	.	PROPN
cana-5141	248	1	72	72	NUM
cana-5141	248	2	,	,	PUNCT
cana-5141	248	3	no	no	INTJ
cana-5141	248	4	.	.	NOUN
cana-5141	248	5	1	1	NUM
cana-5141	248	6	,	,	PUNCT
cana-5141	248	7	pp	pp	ADJ
cana-5141	248	8	.	.	PUNCT
cana-5141	249	1	139–150	139–150	NUM
cana-5141	249	2	,	,	PUNCT
cana-5141	249	3	oct	oct	PROPN
cana-5141	249	4	.	.	PROPN
cana-5141	249	5	2019	2019	NUM
cana-5141	249	6	,	,	PUNCT
cana-5141	249	7	doi	doi	NOUN
cana-5141	249	8	:	:	PUNCT
cana-5141	249	9	10.3233	10.3233	NUM
cana-5141	249	10	/	/	SYM
cana-5141	249	11	jad190223	jad190223	NOUN
cana-5141	249	12	.	.	PUNCT
cana-5141	250	1	[	[	X
cana-5141	250	2	2	2	X
cana-5141	250	3	]	]	PUNCT
cana-5141	250	4	j.	j.	PROPN
cana-5141	250	5	m.	m.	PROPN
cana-5141	250	6	long	long	PROPN
cana-5141	250	7	and	and	CCONJ
cana-5141	250	8	d.	d.	PROPN
cana-5141	250	9	m.	m.	PROPN
cana-5141	250	10	holtzman	holtzman	PROPN
cana-5141	250	11	,	,	PUNCT
cana-5141	250	12	‘	'	PUNCT
cana-5141	250	13	alzheimer	alzheimer	NOUN
cana-5141	250	14	disease	disease	NOUN
cana-5141	250	15	:	:	PUNCT
cana-5141	250	16	an	an	DET
cana-5141	250	17	update	update	NOUN
cana-5141	250	18	on	on	ADP
cana-5141	250	19	pathobiology	pathobiology	NOUN
cana-5141	250	20	and	and	CCONJ
cana-5141	250	21	treatment	treatment	NOUN
cana-5141	250	22	strategies	strategy	NOUN
cana-5141	250	23	’	'	PUNCT
cana-5141	250	24	,	,	PUNCT
cana-5141	250	25	cell	cell	NOUN
cana-5141	250	26	,	,	PUNCT
cana-5141	250	27	vol	vol	NOUN
cana-5141	250	28	.	.	PROPN
cana-5141	250	29	179	179	NUM
cana-5141	250	30	,	,	PUNCT
cana-5141	250	31	no	no	INTJ
cana-5141	250	32	.	.	NOUN
cana-5141	250	33	2	2	NUM
cana-5141	250	34	,	,	PUNCT
cana-5141	250	35	pp	pp	ADJ
cana-5141	250	36	.	.	PUNCT
cana-5141	251	1	312–339	312–339	NUM
cana-5141	251	2	,	,	PUNCT
cana-5141	251	3	oct	oct	PROPN
cana-5141	251	4	.	.	PROPN
cana-5141	251	5	2019	2019	NUM
cana-5141	251	6	,	,	PUNCT
cana-5141	251	7	doi	doi	NOUN
cana-5141	251	8	:	:	PUNCT
cana-5141	251	9	10.1016	10.1016	NUM
cana-5141	251	10	/	/	SYM
cana-5141	251	11	j.cell.2019.09.001	j.cell.2019.09.001	PROPN
cana-5141	251	12	.	.	PUNCT
cana-5141	252	1	[	[	X
cana-5141	252	2	3	3	X
cana-5141	252	3	]	]	X
cana-5141	252	4	h.	h.	PROPN
cana-5141	252	5	sasaguri	sasaguri	PROPN
cana-5141	252	6	et	et	PROPN
cana-5141	252	7	al	al	PROPN
cana-5141	252	8	.	.	PROPN
cana-5141	252	9	,	,	PUNCT
cana-5141	252	10	‘	'	PUNCT
cana-5141	252	11	<	<	X
cana-5141	252	12	scp	scp	X
cana-5141	252	13	>	>	X
cana-5141	252	14	app</scp	app</scp	PROPN
cana-5141	252	15	>	>	X
cana-5141	252	16	mouse	mouse	NOUN
cana-5141	252	17	models	model	NOUN
cana-5141	252	18	for	for	ADP
cana-5141	252	19	alzheimer	alzheimer	PROPN
cana-5141	252	20	’s	’s	PART
cana-5141	252	21	disease	disease	NOUN
cana-5141	252	22	preclinical	preclinical	ADJ
cana-5141	252	23	studies	study	NOUN
cana-5141	252	24	’	'	PUNCT
cana-5141	252	25	,	,	PUNCT
cana-5141	252	26	embo	embo	PROPN
cana-5141	252	27	j	j	PROPN
cana-5141	252	28	,	,	PUNCT
cana-5141	252	29	vol	vol	NOUN
cana-5141	252	30	.	.	PROPN
cana-5141	252	31	36	36	NUM
cana-5141	252	32	,	,	PUNCT
cana-5141	252	33	no	no	INTJ
cana-5141	252	34	.	.	NOUN
cana-5141	252	35	17	17	NUM
cana-5141	252	36	,	,	PUNCT
cana-5141	252	37	pp	pp	ADJ
cana-5141	252	38	.	.	PUNCT
cana-5141	253	1	2473–2487	2473–2487	NUM
cana-5141	253	2	,	,	PUNCT
cana-5141	253	3	sep	sep	PROPN
cana-5141	253	4	.	.	PROPN
cana-5141	254	1	2017	2017	NUM
cana-5141	254	2	,	,	PUNCT
cana-5141	254	3	doi	doi	NOUN
cana-5141	254	4	:	:	PUNCT
cana-5141	254	5	10.15252	10.15252	NUM
cana-5141	254	6	/	/	SYM
cana-5141	254	7	embj.201797397	embj.201797397	NOUN
cana-5141	254	8	.	.	PUNCT
cana-5141	255	1	[	[	X
cana-5141	255	2	4	4	X
cana-5141	255	3	]	]	PUNCT
cana-5141	255	4	m.	m.	NOUN
cana-5141	255	5	a.	a.	PROPN
cana-5141	255	6	mintun	mintun	PROPN
cana-5141	255	7	et	et	PROPN
cana-5141	255	8	al	al	PROPN
cana-5141	255	9	.	.	PROPN
cana-5141	255	10	,	,	PUNCT
cana-5141	255	11	‘	'	PUNCT
cana-5141	255	12	donanemab	donanemab	NOUN
cana-5141	255	13	in	in	ADP
cana-5141	255	14	early	early	PROPN
cana-5141	255	15	alzheimer	alzheimer	PROPN
cana-5141	255	16	’s	’s	PART
cana-5141	255	17	disease	disease	NOUN
cana-5141	255	18	’	'	PUNCT
cana-5141	255	19	,	,	PUNCT
cana-5141	255	20	new	new	PROPN
cana-5141	255	21	england	england	PROPN
cana-5141	255	22	journal	journal	PROPN
cana-5141	255	23	of	of	ADP
cana-5141	255	24	medicine	medicine	NOUN
cana-5141	255	25	,	,	PUNCT
cana-5141	255	26	vol	vol	NOUN
cana-5141	255	27	.	.	PROPN
cana-5141	255	28	384	384	NUM
cana-5141	255	29	,	,	PUNCT
cana-5141	255	30	no	no	INTJ
cana-5141	255	31	.	.	NOUN
cana-5141	255	32	18	18	NUM
cana-5141	255	33	,	,	PUNCT
cana-5141	255	34	pp	pp	ADJ
cana-5141	255	35	.	.	PUNCT
cana-5141	255	36	1691–1704	1691–1704	NUM
cana-5141	255	37	,	,	PUNCT
cana-5141	255	38	may	may	AUX
cana-5141	255	39	2021	2021	NUM
cana-5141	255	40	,	,	PUNCT
cana-5141	255	41	doi	doi	NOUN
cana-5141	255	42	:	:	PUNCT
cana-5141	255	43	10.1056	10.1056	NUM
cana-5141	255	44	/	/	SYM
cana-5141	255	45	nejmoa2100708	nejmoa2100708	PROPN
cana-5141	255	46	.	.	PUNCT
cana-5141	256	1	[	[	X
cana-5141	256	2	5	5	X
cana-5141	256	3	]	]	PUNCT
cana-5141	256	4	k.	k.	PROPN
cana-5141	256	5	t.	t.	PROPN
cana-5141	256	6	yong	yong	PROPN
cana-5141	256	7	and	and	CCONJ
cana-5141	256	8	s.-h	s.-h	NOUN
cana-5141	256	9	.	.	PUNCT
cana-5141	257	1	cheng	cheng	PROPN
cana-5141	257	2	,	,	PUNCT
cana-5141	257	3	‘	'	PUNCT
cana-5141	257	4	trace	trace	NOUN
cana-5141	257	5	elements	element	NOUN
cana-5141	257	6	and	and	CCONJ
cana-5141	257	7	mild	mild	ADJ
cana-5141	257	8	cognitive	cognitive	ADJ
cana-5141	257	9	impairment	impairment	NOUN
cana-5141	257	10	’	'	PUNCT
cana-5141	257	11	,	,	PUNCT
cana-5141	257	12	2023	2023	NUM
cana-5141	257	13	,	,	PUNCT
cana-5141	257	14	pp	pp	ADJ
cana-5141	257	15	.	.	PUNCT
cana-5141	258	1	15–45	15–45	X
cana-5141	258	2	.	.	PUNCT
cana-5141	259	1	doi	doi	NOUN
cana-5141	259	2	:	:	PUNCT
cana-5141	259	3	10.1007/978	10.1007/978	NUM
cana-5141	259	4	-	-	SYM
cana-5141	259	5	981	981	NUM
cana-5141	259	6	-	-	PUNCT
cana-5141	259	7	99	99	NUM
cana-5141	259	8	-	-	PUNCT
cana-5141	259	9	1513	1513	NUM
cana-5141	259	10	-	-	PUNCT
cana-5141	259	11	2_2	2_2	NUM
cana-5141	259	12	.	.	PUNCT
cana-5141	260	1	[	[	X
cana-5141	260	2	6	6	NUM
cana-5141	260	3	]	]	PUNCT
cana-5141	260	4	g.	g.	PROPN
cana-5141	260	5	e.	e.	PROPN
cana-5141	260	6	vitek	vitek	PROPN
cana-5141	260	7	,	,	PUNCT
cana-5141	260	8	b.	b.	PROPN
cana-5141	260	9	decourt	decourt	PROPN
cana-5141	260	10	,	,	PUNCT
cana-5141	260	11	and	and	CCONJ
cana-5141	260	12	m.	m.	PROPN
cana-5141	260	13	n.	n.	PROPN
cana-5141	260	14	sabbagh	sabbagh	PROPN
cana-5141	260	15	,	,	PUNCT
cana-5141	260	16	‘	'	PUNCT
cana-5141	260	17	lecanemab	lecanemab	NOUN
cana-5141	260	18	(	(	PUNCT
cana-5141	260	19	ban2401	ban2401	NOUN
cana-5141	260	20	):	):	PUNCT
cana-5141	260	21	an	an	DET
cana-5141	260	22	anti	anti	ADJ
cana-5141	260	23	–	–	NOUN
cana-5141	260	24	beta	beta	ADJ
cana-5141	260	25	-	-	PUNCT
cana-5141	260	26	amyloid	amyloid	NOUN
cana-5141	260	27	monoclonal	monoclonal	NOUN
cana-5141	260	28	antibody	antibody	NOUN
cana-5141	260	29	for	for	ADP
cana-5141	260	30	the	the	DET
cana-5141	260	31	treatment	treatment	NOUN
cana-5141	260	32	of	of	ADP
cana-5141	260	33	alzheimer	alzheimer	PROPN
cana-5141	260	34	disease	disease	NOUN
cana-5141	260	35	’	'	PUNCT
cana-5141	260	36	,	,	PUNCT
cana-5141	260	37	expert	expert	NOUN
cana-5141	260	38	opin	opin	NOUN
cana-5141	260	39	investig	investig	NOUN
cana-5141	260	40	drugs	drug	NOUN
cana-5141	260	41	,	,	PUNCT
cana-5141	260	42	vol	vol	NOUN
cana-5141	260	43	.	.	PROPN
cana-5141	261	1	32	32	NUM
cana-5141	261	2	,	,	PUNCT
cana-5141	261	3	no	no	INTJ
cana-5141	261	4	.	.	NOUN
cana-5141	261	5	2	2	NUM
cana-5141	261	6	,	,	PUNCT
cana-5141	261	7	pp	pp	ADJ
cana-5141	261	8	.	.	PUNCT
cana-5141	262	1	89–94	89–94	NUM
cana-5141	262	2	,	,	PUNCT
cana-5141	262	3	feb	feb	PROPN
cana-5141	262	4	.	.	PROPN
cana-5141	262	5	2023	2023	NUM
cana-5141	262	6	,	,	PUNCT
cana-5141	262	7	doi	doi	NOUN
cana-5141	262	8	:	:	PUNCT
cana-5141	262	9	10.1080/13543784.2023.2178414	10.1080/13543784.2023.2178414	NUM
cana-5141	262	10	.	.	X
cana-5141	263	1	communications	communication	NOUN
cana-5141	263	2	on	on	ADP
cana-5141	263	3	applied	apply	VERB
cana-5141	263	4	nonlinear	nonlinear	ADJ
cana-5141	263	5	analysis	analysis	NOUN
cana-5141	263	6	issn	issn	NOUN
cana-5141	263	7	:	:	PUNCT
cana-5141	263	8	1074	1074	NUM
cana-5141	263	9	-	-	PUNCT
cana-5141	263	10	133x	133x	NUM
cana-5141	263	11	vol	vol	NOUN
cana-5141	263	12	32	32	NUM
cana-5141	263	13	no	no	NOUN
cana-5141	263	14	.	.	PUNCT
cana-5141	264	1	icmasd	icmasd	NOUN
cana-5141	264	2	(	(	PUNCT
cana-5141	264	3	2025	2025	NUM
cana-5141	264	4	)	)	PUNCT
cana-5141	264	5	1150	1150	NUM
cana-5141	264	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	265	1	[	[	X
cana-5141	265	2	7	7	X
cana-5141	265	3	]	]	PUNCT
cana-5141	265	4	s.	s.	PROPN
cana-5141	265	5	mead	mead	PROPN
cana-5141	265	6	and	and	CCONJ
cana-5141	265	7	n.	n.	PROPN
cana-5141	265	8	c.	c.	PROPN
cana-5141	265	9	fox	fox	PROPN
cana-5141	265	10	,	,	PUNCT
cana-5141	265	11	‘	'	PUNCT
cana-5141	265	12	lecanemab	lecanemab	NOUN
cana-5141	265	13	slows	slow	VERB
cana-5141	265	14	alzheimer	alzheimer	PROPN
cana-5141	265	15	’s	’s	PART
cana-5141	265	16	disease	disease	NOUN
cana-5141	265	17	:	:	PUNCT
cana-5141	265	18	hope	hope	NOUN
cana-5141	265	19	and	and	CCONJ
cana-5141	265	20	challenges	challenge	NOUN
cana-5141	265	21	’	'	PUNCT
cana-5141	265	22	,	,	PUNCT
cana-5141	265	23	lancet	lancet	PROPN
cana-5141	265	24	neurol	neurol	NOUN
cana-5141	265	25	,	,	PUNCT
cana-5141	265	26	vol	vol	NOUN
cana-5141	265	27	.	.	PROPN
cana-5141	266	1	22	22	NUM
cana-5141	266	2	,	,	PUNCT
cana-5141	266	3	no	no	INTJ
cana-5141	266	4	.	.	NOUN
cana-5141	266	5	2	2	NUM
cana-5141	266	6	,	,	PUNCT
cana-5141	266	7	pp	pp	ADJ
cana-5141	266	8	.	.	PUNCT
cana-5141	267	1	106–108	106–108	NUM
cana-5141	267	2	,	,	PUNCT
cana-5141	267	3	feb	feb	PROPN
cana-5141	267	4	.	.	PROPN
cana-5141	267	5	2023	2023	NUM
cana-5141	267	6	,	,	PUNCT
cana-5141	267	7	doi	doi	NOUN
cana-5141	267	8	:	:	PUNCT
cana-5141	267	9	10.1016	10.1016	NUM
cana-5141	267	10	/	/	SYM
cana-5141	267	11	s1474	s1474	NOUN
cana-5141	267	12	-	-	PROPN
cana-5141	267	13	4422(22)005294	4422(22)005294	NUM
cana-5141	267	14	.	.	PUNCT
cana-5141	268	1	[	[	X
cana-5141	268	2	8	8	NUM
cana-5141	268	3	]	]	X
cana-5141	268	4	a.	a.	NOUN
cana-5141	268	5	bhardwaj	bhardwaj	PROPN
cana-5141	268	6	and	and	CCONJ
cana-5141	268	7	v.	v.	ADP
cana-5141	268	8	nain	nain	NOUN
cana-5141	268	9	,	,	PUNCT
cana-5141	268	10	‘	'	PUNCT
cana-5141	268	11	talens	talen	NOUN
cana-5141	268	12	—	—	PUNCT
cana-5141	268	13	an	an	DET
cana-5141	268	14	indispensable	indispensable	ADJ
cana-5141	268	15	tool	tool	NOUN
cana-5141	268	16	in	in	ADP
cana-5141	268	17	the	the	DET
cana-5141	268	18	era	era	NOUN
cana-5141	268	19	of	of	ADP
cana-5141	268	20	crispr	crispr	NOUN
cana-5141	268	21	:	:	PUNCT
cana-5141	268	22	a	a	DET
cana-5141	268	23	mini	mini	ADJ
cana-5141	268	24	review	review	NOUN
cana-5141	268	25	’	'	PUNCT
cana-5141	268	26	,	,	PUNCT
cana-5141	268	27	journal	journal	NOUN
cana-5141	268	28	of	of	ADP
cana-5141	268	29	genetic	genetic	ADJ
cana-5141	268	30	engineering	engineering	NOUN
cana-5141	268	31	and	and	CCONJ
cana-5141	268	32	biotechnology	biotechnology	NOUN
cana-5141	268	33	,	,	PUNCT
cana-5141	268	34	vol	vol	NOUN
cana-5141	268	35	.	.	PROPN
cana-5141	268	36	19	19	NUM
cana-5141	268	37	,	,	PUNCT
cana-5141	268	38	no	no	INTJ
cana-5141	268	39	.	.	NOUN
cana-5141	268	40	1	1	NUM
cana-5141	268	41	,	,	PUNCT
cana-5141	268	42	p.	p.	NOUN
cana-5141	268	43	125	125	NUM
cana-5141	268	44	,	,	PUNCT
cana-5141	268	45	dec	dec	PROPN
cana-5141	268	46	.	.	PROPN
cana-5141	268	47	2021	2021	NUM
cana-5141	268	48	,	,	PUNCT
cana-5141	268	49	doi	doi	NOUN
cana-5141	268	50	:	:	PUNCT
cana-5141	268	51	10.1186	10.1186	NUM
cana-5141	268	52	/	/	SYM
cana-5141	268	53	s43141	s43141	NOUN
cana-5141	268	54	-	-	PUNCT
cana-5141	268	55	021	021	NUM
cana-5141	268	56	-	-	PUNCT
cana-5141	268	57	00225	00225	NUM
cana-5141	268	58	-	-	PUNCT
cana-5141	268	59	z.	z.	PROPN
cana-5141	269	1	[	[	X
cana-5141	269	2	9	9	NUM
cana-5141	269	3	]	]	X
cana-5141	269	4	d.	d.	PROPN
cana-5141	269	5	gupta	gupta	PROPN
cana-5141	269	6	et	et	PROPN
cana-5141	269	7	al	al	PROPN
cana-5141	269	8	.	.	PROPN
cana-5141	269	9	,	,	PUNCT
cana-5141	269	10	‘	'	PUNCT
cana-5141	269	11	crispr	crispr	ADJ
cana-5141	269	12	-	-	PUNCT
cana-5141	269	13	cas9	cas9	NOUN
cana-5141	269	14	system	system	NOUN
cana-5141	269	15	:	:	PUNCT
cana-5141	269	16	a	a	DET
cana-5141	269	17	new	new	ADJ
cana-5141	269	18	-	-	PUNCT
cana-5141	269	19	fangled	fangled	ADJ
cana-5141	269	20	dawn	dawn	NOUN
cana-5141	269	21	in	in	ADP
cana-5141	269	22	gene	gene	NOUN
cana-5141	269	23	editing	editing	NOUN
cana-5141	269	24	’	'	PUNCT
cana-5141	269	25	,	,	PUNCT
cana-5141	269	26	life	life	NOUN
cana-5141	269	27	sci	sci	PROPN
cana-5141	269	28	,	,	PUNCT
cana-5141	269	29	vol	vol	NOUN
cana-5141	269	30	.	.	PROPN
cana-5141	269	31	232	232	NUM
cana-5141	269	32	,	,	PUNCT
cana-5141	269	33	p.	p.	NOUN
cana-5141	269	34	116636	116636	NUM
cana-5141	269	35	,	,	PUNCT
cana-5141	269	36	sep	sep	PROPN
cana-5141	269	37	.	.	PROPN
cana-5141	269	38	2019	2019	NUM
cana-5141	269	39	,	,	PUNCT
cana-5141	269	40	doi	doi	NOUN
cana-5141	269	41	:	:	PUNCT
cana-5141	269	42	10.1016	10.1016	NUM
cana-5141	269	43	/	/	SYM
cana-5141	269	44	j.lfs.2019.116636	j.lfs.2019.116636	NOUN
cana-5141	269	45	.	.	PUNCT
cana-5141	270	1	[	[	X
cana-5141	270	2	10	10	NUM
cana-5141	270	3	]	]	X
cana-5141	270	4	b.	b.	PROPN
cana-5141	270	5	györgy	györgy	PROPN
cana-5141	270	6	et	et	PROPN
cana-5141	270	7	al	al	PROPN
cana-5141	270	8	.	.	PROPN
cana-5141	270	9	,	,	PUNCT
cana-5141	270	10	‘	'	PUNCT
cana-5141	270	11	crispr	crispr	ADJ
cana-5141	270	12	/	/	SYM
cana-5141	270	13	cas9	cas9	NOUN
cana-5141	270	14	mediated	mediate	VERB
cana-5141	270	15	disruption	disruption	NOUN
cana-5141	270	16	of	of	ADP
cana-5141	270	17	the	the	DET
cana-5141	270	18	swedish	swedish	PROPN
cana-5141	270	19	app	app	PROPN
cana-5141	270	20	allele	allele	PROPN
cana-5141	270	21	as	as	ADP
cana-5141	270	22	a	a	DET
cana-5141	270	23	therapeutic	therapeutic	ADJ
cana-5141	270	24	approach	approach	NOUN
cana-5141	270	25	for	for	ADP
cana-5141	270	26	early	early	ADJ
cana-5141	270	27	-	-	PUNCT
cana-5141	270	28	onset	onset	NOUN
cana-5141	270	29	alzheimer	alzheimer	PROPN
cana-5141	270	30	’s	’s	PART
cana-5141	270	31	disease	disease	NOUN
cana-5141	270	32	’	'	PUNCT
cana-5141	270	33	,	,	PUNCT
cana-5141	270	34	mol	mol	ADP
cana-5141	270	35	ther	ther	ADV
cana-5141	270	36	nucleic	nucleic	ADJ
cana-5141	270	37	acids	acid	NOUN
cana-5141	270	38	,	,	PUNCT
cana-5141	270	39	vol	vol	NOUN
cana-5141	270	40	.	.	PROPN
cana-5141	270	41	11	11	NUM
cana-5141	270	42	,	,	PUNCT
cana-5141	270	43	pp	pp	ADJ
cana-5141	270	44	.	.	PUNCT
cana-5141	271	1	429–440	429–440	NUM
cana-5141	271	2	,	,	PUNCT
cana-5141	271	3	jun	jun	PROPN
cana-5141	271	4	.	.	PROPN
cana-5141	271	5	2018	2018	NUM
cana-5141	271	6	,	,	PUNCT
cana-5141	271	7	doi	doi	NOUN
cana-5141	271	8	:	:	PUNCT
cana-5141	271	9	10.1016	10.1016	NUM
cana-5141	271	10	/	/	SYM
cana-5141	271	11	j.omtn.2018.03.007	j.omtn.2018.03.007	NOUN
cana-5141	271	12	.	.	PUNCT
cana-5141	272	1	[	[	X
cana-5141	272	2	11	11	NUM
cana-5141	272	3	]	]	X
cana-5141	272	4	e.	e.	PROPN
cana-5141	272	5	konstantinidis	konstantinidis	PROPN
cana-5141	272	6	et	et	PROPN
cana-5141	272	7	al	al	PROPN
cana-5141	272	8	.	.	PROPN
cana-5141	272	9	,	,	PUNCT
cana-5141	272	10	‘	'	PUNCT
cana-5141	272	11	crispr	crispr	ADJ
cana-5141	272	12	-	-	PUNCT
cana-5141	272	13	cas9	cas9	NOUN
cana-5141	272	14	treatment	treatment	NOUN
cana-5141	272	15	partially	partially	ADV
cana-5141	272	16	restores	restore	VERB
cana-5141	272	17	amyloid	amyloid	NOUN
cana-5141	272	18	-	-	PUNCT
cana-5141	272	19	β	β	NOUN
cana-5141	272	20	42/40	42/40	NUM
cana-5141	272	21	in	in	ADP
cana-5141	272	22	human	human	ADJ
cana-5141	272	23	fibroblasts	fibroblast	NOUN
cana-5141	272	24	with	with	ADP
cana-5141	272	25	the	the	DET
cana-5141	272	26	alzheimer	alzheimer	PROPN
cana-5141	272	27	’s	’s	PART
cana-5141	272	28	disease	disease	NOUN
cana-5141	272	29	psen1	psen1	ADJ
cana-5141	272	30	m146l	m146l	NOUN
cana-5141	272	31	mutation	mutation	NOUN
cana-5141	272	32	’	'	PUNCT
cana-5141	272	33	,	,	PUNCT
cana-5141	272	34	mol	mol	ADP
cana-5141	272	35	ther	ther	ADV
cana-5141	272	36	nucleic	nucleic	ADJ
cana-5141	272	37	acids	acid	NOUN
cana-5141	272	38	,	,	PUNCT
cana-5141	272	39	vol	vol	NOUN
cana-5141	272	40	.	.	PROPN
cana-5141	272	41	28	28	NUM
cana-5141	272	42	,	,	PUNCT
cana-5141	272	43	pp	pp	ADJ
cana-5141	272	44	.	.	PUNCT
cana-5141	273	1	450–461	450–461	NUM
cana-5141	273	2	,	,	PUNCT
cana-5141	273	3	jun	jun	PROPN
cana-5141	273	4	.	.	PROPN
cana-5141	273	5	2022	2022	NUM
cana-5141	273	6	,	,	PUNCT
cana-5141	273	7	doi	doi	NOUN
cana-5141	273	8	:	:	PUNCT
cana-5141	273	9	10.1016	10.1016	NUM
cana-5141	273	10	/	/	SYM
cana-5141	273	11	j.omtn.2022.03.022	j.omtn.2022.03.022	PROPN
cana-5141	273	12	.	.	PUNCT
cana-5141	274	1	[	[	X
cana-5141	274	2	12	12	NUM
cana-5141	274	3	]	]	PUNCT
cana-5141	274	4	a.	a.	NOUN
cana-5141	274	5	guyon	guyon	PROPN
cana-5141	274	6	,	,	PUNCT
cana-5141	274	7	j.	j.	PROPN
cana-5141	274	8	rousseau	rousseau	PROPN
cana-5141	274	9	,	,	PUNCT
cana-5141	274	10	g.	g.	PROPN
cana-5141	274	11	lamothe	lamothe	PROPN
cana-5141	274	12	,	,	PUNCT
cana-5141	274	13	and	and	CCONJ
cana-5141	274	14	j.	j.	PROPN
cana-5141	274	15	p.	p.	PROPN
cana-5141	274	16	tremblay	tremblay	PROPN
cana-5141	274	17	,	,	PUNCT
cana-5141	274	18	‘	'	PUNCT
cana-5141	274	19	the	the	DET
cana-5141	274	20	protective	protective	ADJ
cana-5141	274	21	mutation	mutation	NOUN
cana-5141	274	22	a673	a673	PROPN
cana-5141	274	23	t	t	PROPN
cana-5141	274	24	in	in	ADP
cana-5141	274	25	amyloid	amyloid	NOUN
cana-5141	274	26	precursor	precursor	NOUN
cana-5141	274	27	protein	protein	NOUN
cana-5141	274	28	gene	gene	NOUN
cana-5141	274	29	decreases	decrease	VERB
cana-5141	274	30	aβ	aβ	PRON
cana-5141	274	31	peptides	peptide	NOUN
cana-5141	274	32	production	production	NOUN
cana-5141	274	33	for	for	ADP
cana-5141	274	34	14	14	NUM
cana-5141	274	35	forms	form	NOUN
cana-5141	274	36	of	of	ADP
cana-5141	274	37	familial	familial	ADJ
cana-5141	274	38	alzheimer	alzheimer	PROPN
cana-5141	274	39	’s	’s	PART
cana-5141	274	40	disease	disease	NOUN
cana-5141	274	41	in	in	ADP
cana-5141	274	42	sh	sh	PROPN
cana-5141	274	43	-	-	PUNCT
cana-5141	274	44	sy5y	sy5y	PROPN
cana-5141	274	45	cells	cell	NOUN
cana-5141	274	46	’	'	PUNCT
cana-5141	274	47	,	,	PUNCT
cana-5141	274	48	plos	plos	PROPN
cana-5141	274	49	one	one	NUM
cana-5141	274	50	,	,	PUNCT
cana-5141	274	51	vol	vol	NOUN
cana-5141	274	52	.	.	PROPN
cana-5141	274	53	15	15	NUM
cana-5141	274	54	,	,	PUNCT
cana-5141	274	55	no	no	INTJ
cana-5141	274	56	.	.	NOUN
cana-5141	274	57	12	12	NUM
cana-5141	274	58	,	,	PUNCT
cana-5141	274	59	p.	p.	NOUN
cana-5141	274	60	e0237122	e0237122	PROPN
cana-5141	274	61	,	,	PUNCT
cana-5141	274	62	dec	dec	PROPN
cana-5141	274	63	.	.	PROPN
cana-5141	274	64	2020	2020	NUM
cana-5141	274	65	,	,	PUNCT
cana-5141	274	66	doi	doi	NOUN
cana-5141	274	67	:	:	PUNCT
cana-5141	274	68	10.1371	10.1371	NUM
cana-5141	274	69	/	/	SYM
cana-5141	274	70	journal.pone.0237122	journal.pone.0237122	PROPN
cana-5141	274	71	.	.	PUNCT
cana-5141	275	1	[	[	X
cana-5141	275	2	13	13	NUM
cana-5141	275	3	]	]	X
cana-5141	275	4	y.	y.	PROPN
cana-5141	275	5	duan	duan	PROPN
cana-5141	275	6	et	et	PROPN
cana-5141	275	7	al	al	PROPN
cana-5141	275	8	.	.	PROPN
cana-5141	275	9	,	,	PUNCT
cana-5141	275	10	‘	'	PUNCT
cana-5141	275	11	brain	brain	NOUN
cana-5141	275	12	-	-	PUNCT
cana-5141	275	13	wide	wide	ADJ
cana-5141	275	14	cas9	cas9	NOUN
cana-5141	275	15	-	-	PUNCT
cana-5141	275	16	mediated	mediate	VERB
cana-5141	275	17	cleavage	cleavage	NOUN
cana-5141	275	18	of	of	ADP
cana-5141	275	19	a	a	DET
cana-5141	275	20	gene	gene	NOUN
cana-5141	275	21	causing	cause	VERB
cana-5141	275	22	familial	familial	ADJ
cana-5141	275	23	alzheimer	alzheimer	NOUN
cana-5141	275	24	’s	’s	PART
cana-5141	275	25	disease	disease	NOUN
cana-5141	275	26	alleviates	alleviate	VERB
cana-5141	275	27	amyloid	amyloid	NOUN
cana-5141	275	28	-	-	PUNCT
cana-5141	275	29	related	relate	VERB
cana-5141	275	30	pathologies	pathology	NOUN
cana-5141	275	31	in	in	ADP
cana-5141	275	32	mice	mouse	NOUN
cana-5141	275	33	’	'	PUNCT
cana-5141	275	34	,	,	PUNCT
cana-5141	275	35	nat	nat	PROPN
cana-5141	275	36	biomed	biome	VERB
cana-5141	275	37	eng	eng	PROPN
cana-5141	275	38	,	,	PUNCT
cana-5141	275	39	vol	vol	NOUN
cana-5141	275	40	.	.	PROPN
cana-5141	276	1	6	6	NUM
cana-5141	276	2	,	,	PUNCT
cana-5141	276	3	no	no	INTJ
cana-5141	276	4	.	.	NOUN
cana-5141	276	5	2	2	NUM
cana-5141	276	6	,	,	PUNCT
cana-5141	276	7	pp	pp	ADJ
cana-5141	276	8	.	.	PUNCT
cana-5141	277	1	168–180	168–180	NUM
cana-5141	277	2	,	,	PUNCT
cana-5141	277	3	jul	jul	PROPN
cana-5141	277	4	.	.	PROPN
cana-5141	277	5	2021	2021	NUM
cana-5141	277	6	,	,	PUNCT
cana-5141	277	7	doi	doi	NOUN
cana-5141	277	8	:	:	PUNCT
cana-5141	277	9	10.1038	10.1038	NUM
cana-5141	277	10	/	/	SYM
cana-5141	277	11	s41551	s41551	NOUN
cana-5141	277	12	-	-	PUNCT
cana-5141	277	13	021	021	NUM
cana-5141	277	14	-	-	PUNCT
cana-5141	277	15	00759	00759	NUM
cana-5141	277	16	-	-	PUNCT
cana-5141	277	17	0	0	NUM
cana-5141	277	18	.	.	PUNCT
cana-5141	278	1	[	[	X
cana-5141	278	2	14	14	NUM
cana-5141	278	3	]	]	X
cana-5141	278	4	j.	j.	PROPN
cana-5141	278	5	eoh	eoh	PROPN
cana-5141	278	6	and	and	CCONJ
cana-5141	278	7	l.	l.	PROPN
cana-5141	278	8	gu	gu	PROPN
cana-5141	278	9	,	,	PUNCT
cana-5141	278	10	‘	'	PUNCT
cana-5141	278	11	biomaterials	biomaterial	NOUN
cana-5141	278	12	as	as	ADP
cana-5141	278	13	vectors	vector	NOUN
cana-5141	278	14	for	for	ADP
cana-5141	278	15	the	the	DET
cana-5141	278	16	delivery	delivery	NOUN
cana-5141	278	17	of	of	ADP
cana-5141	278	18	crispr	crispr	NOUN
cana-5141	278	19	–	–	PUNCT
cana-5141	278	20	cas9	cas9	NOUN
cana-5141	278	21	’	'	PUNCT
cana-5141	278	22	,	,	PUNCT
cana-5141	278	23	biomater	biomater	PROPN
cana-5141	278	24	sci	sci	PROPN
cana-5141	278	25	,	,	PUNCT
cana-5141	278	26	vol	vol	NOUN
cana-5141	278	27	.	.	PROPN
cana-5141	278	28	7	7	NUM
cana-5141	278	29	,	,	PUNCT
cana-5141	278	30	no	no	INTJ
cana-5141	278	31	.	.	NOUN
cana-5141	278	32	4	4	NUM
cana-5141	278	33	,	,	PUNCT
cana-5141	278	34	pp	pp	ADJ
cana-5141	278	35	.	.	PUNCT
cana-5141	278	36	1240–1261	1240–1261	NUM
cana-5141	278	37	,	,	PUNCT
cana-5141	278	38	2019	2019	NUM
cana-5141	278	39	,	,	PUNCT
cana-5141	278	40	doi	doi	NOUN
cana-5141	278	41	:	:	PUNCT
cana-5141	278	42	10.1039	10.1039	NUM
cana-5141	278	43	/	/	SYM
cana-5141	278	44	c8bm01310a	c8bm01310a	PROPN
cana-5141	278	45	.	.	PUNCT
cana-5141	279	1	[	[	X
cana-5141	279	2	15	15	NUM
cana-5141	279	3	]	]	X
cana-5141	279	4	f.	f.	PROPN
cana-5141	279	5	chen	chen	PROPN
cana-5141	279	6	et	et	PROPN
cana-5141	279	7	al	al	PROPN
cana-5141	279	8	.	.	PROPN
cana-5141	279	9	,	,	PUNCT
cana-5141	279	10	‘	'	PUNCT
cana-5141	279	11	crispr	crispr	ADJ
cana-5141	279	12	/	/	SYM
cana-5141	279	13	cas9	cas9	NOUN
cana-5141	279	14	-	-	PUNCT
cana-5141	279	15	mediated	mediate	VERB
cana-5141	279	16	cyslt1r	cyslt1r	NOUN
cana-5141	279	17	deletion	deletion	NOUN
cana-5141	279	18	reverses	reverse	VERB
cana-5141	279	19	synaptic	synaptic	ADJ
cana-5141	279	20	failure	failure	NOUN
cana-5141	279	21	,	,	PUNCT
cana-5141	279	22	amyloidosis	amyloidosis	NOUN
cana-5141	279	23	and	and	CCONJ
cana-5141	279	24	cognitive	cognitive	ADJ
cana-5141	279	25	impairment	impairment	NOUN
cana-5141	279	26	in	in	ADP
cana-5141	279	27	app	app	PROPN
cana-5141	279	28	/	/	SYM
cana-5141	279	29	ps1	ps1	NOUN
cana-5141	279	30	mice	mouse	NOUN
cana-5141	279	31	’	'	PUNCT
cana-5141	279	32	,	,	PUNCT
cana-5141	279	33	aging	aging	NOUN
cana-5141	279	34	,	,	PUNCT
cana-5141	279	35	vol	vol	NOUN
cana-5141	279	36	.	.	PROPN
cana-5141	279	37	13	13	NUM
cana-5141	279	38	,	,	PUNCT
cana-5141	279	39	no	no	INTJ
cana-5141	279	40	.	.	NOUN
cana-5141	279	41	5	5	NUM
cana-5141	279	42	,	,	PUNCT
cana-5141	279	43	pp	pp	ADJ
cana-5141	279	44	.	.	PUNCT
cana-5141	279	45	6634	6634	NUM
cana-5141	279	46	–	–	PUNCT
cana-5141	279	47	6661	6661	NUM
cana-5141	279	48	,	,	PUNCT
cana-5141	279	49	mar	mar	PROPN
cana-5141	279	50	.	.	PROPN
cana-5141	279	51	2021	2021	NUM
cana-5141	279	52	,	,	PUNCT
cana-5141	279	53	doi	doi	NOUN
cana-5141	279	54	:	:	PUNCT
cana-5141	279	55	10.18632	10.18632	NUM
cana-5141	279	56	/	/	SYM
cana-5141	279	57	aging.202501	aging.202501	PROPN
cana-5141	279	58	.	.	PUNCT
cana-5141	280	1	[	[	X
cana-5141	280	2	16	16	NUM
cana-5141	280	3	]	]	PUNCT
cana-5141	280	4	s.	s.	PROPN
cana-5141	280	5	p.	p.	NOUN
cana-5141	280	6	salloway	salloway	NOUN
cana-5141	280	7	et	et	PROPN
cana-5141	280	8	al	al	PROPN
cana-5141	280	9	.	.	PROPN
cana-5141	280	10	,	,	PUNCT
cana-5141	280	11	‘	'	PUNCT
cana-5141	280	12	advancing	advance	VERB
cana-5141	280	13	combination	combination	NOUN
cana-5141	280	14	therapy	therapy	NOUN
cana-5141	280	15	for	for	ADP
cana-5141	280	16	alzheimer	alzheimer	PROPN
cana-5141	280	17	’s	’s	PART
cana-5141	280	18	disease	disease	NOUN
cana-5141	280	19	’	'	PUNCT
cana-5141	280	20	,	,	PUNCT
cana-5141	280	21	alzheimer	alzheimer	PROPN
cana-5141	280	22	’s	’s	PART
cana-5141	280	23	&	&	CCONJ
cana-5141	280	24	dementia	dementia	PROPN
cana-5141	280	25	:	:	PUNCT
cana-5141	280	26	translational	translational	ADJ
cana-5141	280	27	research	research	PROPN
cana-5141	280	28	&	&	CCONJ
cana-5141	280	29	clinical	clinical	ADJ
cana-5141	280	30	interventions	intervention	NOUN
cana-5141	280	31	,	,	PUNCT
cana-5141	280	32	vol	vol	NOUN
cana-5141	280	33	.	.	PROPN
cana-5141	280	34	6	6	NUM
cana-5141	280	35	,	,	PUNCT
cana-5141	280	36	no	no	INTJ
cana-5141	280	37	.	.	NOUN
cana-5141	280	38	1	1	NUM
cana-5141	280	39	,	,	PUNCT
cana-5141	280	40	jan	jan	PROPN
cana-5141	280	41	.	.	PROPN
cana-5141	280	42	2020	2020	NUM
cana-5141	280	43	,	,	PUNCT
cana-5141	280	44	doi	doi	NOUN
cana-5141	280	45	:	:	PUNCT
cana-5141	280	46	10.1002	10.1002	NUM
cana-5141	280	47	/	/	SYM
cana-5141	280	48	trc2.12073	trc2.12073	NUM
cana-5141	280	49	.	.	PUNCT
cana-5141	281	1	[	[	X
cana-5141	281	2	17	17	NUM
cana-5141	281	3	]	]	X
cana-5141	282	1	c.	c.	PROPN
cana-5141	282	2	h.	h.	PROPN
cana-5141	282	3	van	van	PROPN
cana-5141	282	4	dyck	dyck	PROPN
cana-5141	282	5	et	et	PROPN
cana-5141	282	6	al	al	PROPN
cana-5141	282	7	.	.	PROPN
cana-5141	282	8	,	,	PUNCT
cana-5141	282	9	‘	'	PUNCT
cana-5141	282	10	lecanemab	lecanemab	NOUN
cana-5141	282	11	in	in	ADP
cana-5141	282	12	early	early	PROPN
cana-5141	282	13	alzheimer	alzheimer	PROPN
cana-5141	282	14	’s	’s	PART
cana-5141	282	15	disease	disease	NOUN
cana-5141	282	16	’	'	PUNCT
cana-5141	282	17	,	,	PUNCT
cana-5141	282	18	new	new	PROPN
cana-5141	282	19	england	england	PROPN
cana-5141	282	20	journal	journal	PROPN
cana-5141	282	21	of	of	ADP
cana-5141	282	22	medicine	medicine	NOUN
cana-5141	282	23	,	,	PUNCT
cana-5141	282	24	vol	vol	NOUN
cana-5141	282	25	.	.	PROPN
cana-5141	283	1	388	388	NUM
cana-5141	283	2	,	,	PUNCT
cana-5141	283	3	no	no	INTJ
cana-5141	283	4	.	.	NOUN
cana-5141	283	5	1	1	NUM
cana-5141	283	6	,	,	PUNCT
cana-5141	283	7	pp	pp	ADJ
cana-5141	283	8	.	.	PUNCT
cana-5141	284	1	9–21	9–21	PROPN
cana-5141	284	2	,	,	PUNCT
cana-5141	284	3	jan	jan	PROPN
cana-5141	284	4	.	.	PROPN
cana-5141	284	5	2023	2023	NUM
cana-5141	284	6	,	,	PUNCT
cana-5141	284	7	doi	doi	NOUN
cana-5141	284	8	:	:	PUNCT
cana-5141	284	9	10.1056	10.1056	NUM
cana-5141	284	10	/	/	SYM
cana-5141	284	11	nejmoa2212948	nejmoa2212948	PROPN
cana-5141	284	12	.	.	PUNCT
cana-5141	285	1	[	[	X
cana-5141	285	2	18	18	NUM
cana-5141	285	3	]	]	PUNCT
cana-5141	285	4	m.	m.	NOUN
cana-5141	285	5	canevelli	canevelli	PROPN
cana-5141	285	6	,	,	PUNCT
cana-5141	285	7	p.	p.	PROPN
cana-5141	285	8	d.	d.	PROPN
cana-5141	285	9	rossi	rossi	PROPN
cana-5141	285	10	,	,	PUNCT
cana-5141	285	11	p.	p.	NOUN
cana-5141	285	12	astrone	astrone	NOUN
cana-5141	285	13	,	,	PUNCT
cana-5141	285	14	e.	e.	PROPN
cana-5141	285	15	consorti	consorti	PROPN
cana-5141	285	16	,	,	PUNCT
cana-5141	285	17	n.	n.	PROPN
cana-5141	285	18	vanacore	vanacore	NOUN
cana-5141	285	19	,	,	PUNCT
cana-5141	285	20	and	and	CCONJ
cana-5141	285	21	m.	m.	NOUN
cana-5141	285	22	cesari	cesari	PROPN
cana-5141	285	23	,	,	PUNCT
cana-5141	285	24	‘	'	PUNCT
cana-5141	285	25	“	"	PUNCT
cana-5141	285	26	real	real	ADJ
cana-5141	285	27	world	world	NOUN
cana-5141	285	28	”	"	PUNCT
cana-5141	285	29	eligibility	eligibility	NOUN
cana-5141	285	30	for	for	ADP
cana-5141	285	31	aducanumab	aducanumab	NOUN
cana-5141	285	32	’	'	PUNCT
cana-5141	285	33	,	,	PUNCT
cana-5141	285	34	j	j	PROPN
cana-5141	285	35	am	be	AUX
cana-5141	285	36	geriatr	geriatr	ADJ
cana-5141	285	37	soc	soc	NOUN
cana-5141	285	38	,	,	PUNCT
cana-5141	285	39	vol	vol	NOUN
cana-5141	285	40	.	.	PROPN
cana-5141	286	1	69	69	NUM
cana-5141	286	2	,	,	PUNCT
cana-5141	286	3	no	no	INTJ
cana-5141	286	4	.	.	NOUN
cana-5141	286	5	10	10	NUM
cana-5141	286	6	,	,	PUNCT
cana-5141	286	7	pp	pp	ADJ
cana-5141	286	8	.	.	PUNCT
cana-5141	287	1	2995–2998	2995–2998	NUM
cana-5141	287	2	,	,	PUNCT
cana-5141	287	3	oct	oct	PROPN
cana-5141	287	4	.	.	PROPN
cana-5141	287	5	2021	2021	NUM
cana-5141	287	6	,	,	PUNCT
cana-5141	287	7	doi	doi	NOUN
cana-5141	287	8	:	:	PUNCT
cana-5141	287	9	10.1111	10.1111	NUM
cana-5141	287	10	/	/	SYM
cana-5141	287	11	jgs.17390	jgs.17390	NOUN
cana-5141	287	12	.	.	PUNCT
cana-5141	288	1	[	[	X
cana-5141	288	2	19	19	NUM
cana-5141	288	3	]	]	X
cana-5141	288	4	r.	r.	PROPN
cana-5141	288	5	r.	r.	PROPN
cana-5141	288	6	pittock	pittock	PROPN
cana-5141	288	7	et	et	PROPN
cana-5141	288	8	al	al	PROPN
cana-5141	288	9	.	.	PROPN
cana-5141	288	10	,	,	PUNCT
cana-5141	288	11	‘	'	PUNCT
cana-5141	288	12	eligibility	eligibility	NOUN
cana-5141	288	13	for	for	ADP
cana-5141	288	14	anti	anti	ADJ
cana-5141	288	15	-	-	ADJ
cana-5141	288	16	amyloid	amyloid	ADJ
cana-5141	288	17	treatment	treatment	NOUN
cana-5141	288	18	in	in	ADP
cana-5141	288	19	a	a	DET
cana-5141	288	20	population	population	NOUN
cana-5141	288	21	-	-	PUNCT
cana-5141	288	22	based	base	VERB
cana-5141	288	23	study	study	NOUN
cana-5141	288	24	of	of	ADP
cana-5141	288	25	cognitive	cognitive	ADJ
cana-5141	288	26	aging	aging	NOUN
cana-5141	288	27	’	'	PUNCT
cana-5141	288	28	,	,	PUNCT
cana-5141	288	29	neurology	neurology	NOUN
cana-5141	288	30	,	,	PUNCT
cana-5141	288	31	vol	vol	NOUN
cana-5141	288	32	.	.	PROPN
cana-5141	289	1	101	101	NUM
cana-5141	289	2	,	,	PUNCT
cana-5141	289	3	no	no	INTJ
cana-5141	289	4	.	.	NOUN
cana-5141	289	5	19	19	NUM
cana-5141	289	6	,	,	PUNCT
cana-5141	289	7	nov	nov	PROPN
cana-5141	289	8	.	.	PROPN
cana-5141	289	9	2023	2023	NUM
cana-5141	289	10	,	,	PUNCT
cana-5141	289	11	doi	doi	NOUN
cana-5141	289	12	:	:	PUNCT
cana-5141	289	13	10.1212	10.1212	NUM
cana-5141	289	14	/	/	SYM
cana-5141	289	15	wnl.0000000000207770	wnl.0000000000207770	NOUN
cana-5141	289	16	.	.	PUNCT
cana-5141	290	1	[	[	X
cana-5141	290	2	20	20	NUM
cana-5141	290	3	]	]	X
cana-5141	290	4	n.	n.	PROPN
cana-5141	290	5	r.	r.	PROPN
cana-5141	290	6	barthélemy	barthélemy	PROPN
cana-5141	290	7	et	et	PROPN
cana-5141	290	8	al	al	PROPN
cana-5141	290	9	.	.	PROPN
cana-5141	290	10	,	,	PUNCT
cana-5141	290	11	‘	'	PUNCT
cana-5141	290	12	a	a	DET
cana-5141	290	13	soluble	soluble	ADJ
cana-5141	290	14	phosphorylated	phosphorylate	VERB
cana-5141	290	15	tau	tau	NOUN
cana-5141	290	16	signature	signature	NOUN
cana-5141	290	17	links	link	NOUN
cana-5141	290	18	tau	tau	PROPN
cana-5141	290	19	,	,	PUNCT
cana-5141	290	20	amyloid	amyloid	NOUN
cana-5141	290	21	and	and	CCONJ
cana-5141	290	22	the	the	DET
cana-5141	290	23	evolution	evolution	NOUN
cana-5141	290	24	of	of	ADP
cana-5141	290	25	stages	stage	NOUN
cana-5141	290	26	of	of	ADP
cana-5141	290	27	dominantly	dominantly	ADV
cana-5141	290	28	inherited	inherit	VERB
cana-5141	290	29	alzheimer	alzheimer	PROPN
cana-5141	290	30	’s	’s	PART
cana-5141	290	31	disease	disease	NOUN
cana-5141	290	32	’	'	PUNCT
cana-5141	290	33	,	,	PUNCT
cana-5141	290	34	nat	nat	PROPN
cana-5141	290	35	med	me	VERB
cana-5141	290	36	,	,	PUNCT
cana-5141	290	37	vol	vol	NOUN
cana-5141	290	38	.	.	PROPN
cana-5141	291	1	26	26	NUM
cana-5141	291	2	,	,	PUNCT
cana-5141	291	3	no	no	INTJ
cana-5141	291	4	.	.	NOUN
cana-5141	291	5	3	3	NUM
cana-5141	291	6	,	,	PUNCT
cana-5141	291	7	pp	pp	ADJ
cana-5141	291	8	.	.	PUNCT
cana-5141	292	1	398–407	398–407	NUM
cana-5141	292	2	,	,	PUNCT
cana-5141	292	3	mar	mar	PROPN
cana-5141	292	4	.	.	PROPN
cana-5141	292	5	2020	2020	NUM
cana-5141	292	6	,	,	PUNCT
cana-5141	292	7	doi	doi	NOUN
cana-5141	292	8	:	:	PUNCT
cana-5141	292	9	10.1038	10.1038	NUM
cana-5141	292	10	/	/	SYM
cana-5141	292	11	s41591	s41591	VERB
cana-5141	292	12	-	-	PUNCT
cana-5141	292	13	020	020	NUM
cana-5141	292	14	-	-	PUNCT
cana-5141	292	15	0781	0781	NUM
cana-5141	292	16	-	-	PUNCT
cana-5141	292	17	z.	z.	PROPN
cana-5141	293	1	[	[	X
cana-5141	293	2	21	21	NUM
cana-5141	293	3	]	]	X
cana-5141	293	4	m.	m.	NOUN
cana-5141	293	5	a.	a.	PROPN
cana-5141	293	6	mintun	mintun	PROPN
cana-5141	293	7	et	et	PROPN
cana-5141	293	8	al	al	PROPN
cana-5141	293	9	.	.	PROPN
cana-5141	293	10	,	,	PUNCT
cana-5141	293	11	‘	'	PUNCT
cana-5141	293	12	donanemab	donanemab	NOUN
cana-5141	293	13	in	in	ADP
cana-5141	293	14	early	early	PROPN
cana-5141	293	15	alzheimer	alzheimer	PROPN
cana-5141	293	16	’s	’s	PART
cana-5141	293	17	disease	disease	NOUN
cana-5141	293	18	’	'	PUNCT
cana-5141	293	19	,	,	PUNCT
cana-5141	293	20	new	new	PROPN
cana-5141	293	21	england	england	PROPN
cana-5141	293	22	journal	journal	PROPN
cana-5141	293	23	of	of	ADP
cana-5141	293	24	medicine	medicine	NOUN
cana-5141	293	25	,	,	PUNCT
cana-5141	293	26	vol	vol	NOUN
cana-5141	293	27	.	.	PROPN
cana-5141	293	28	384	384	NUM
cana-5141	293	29	,	,	PUNCT
cana-5141	293	30	no	no	INTJ
cana-5141	293	31	.	.	NOUN
cana-5141	293	32	18	18	NUM
cana-5141	293	33	,	,	PUNCT
cana-5141	293	34	pp	pp	ADJ
cana-5141	293	35	.	.	PUNCT
cana-5141	293	36	1691–1704	1691–1704	NUM
cana-5141	293	37	,	,	PUNCT
cana-5141	293	38	may	may	AUX
cana-5141	293	39	2021	2021	NUM
cana-5141	293	40	,	,	PUNCT
cana-5141	293	41	doi	doi	NOUN
cana-5141	293	42	:	:	PUNCT
cana-5141	293	43	10.1056	10.1056	NUM
cana-5141	293	44	/	/	SYM
cana-5141	293	45	nejmoa2100708	nejmoa2100708	PROPN
cana-5141	293	46	.	.	PUNCT
cana-5141	294	1	communications	communication	NOUN
cana-5141	294	2	on	on	ADP
cana-5141	294	3	applied	apply	VERB
cana-5141	294	4	nonlinear	nonlinear	ADJ
cana-5141	294	5	analysis	analysis	NOUN
cana-5141	294	6	issn	issn	NOUN
cana-5141	294	7	:	:	PUNCT
cana-5141	294	8	1074	1074	NUM
cana-5141	294	9	-	-	PUNCT
cana-5141	294	10	133x	133x	NUM
cana-5141	294	11	vol	vol	NOUN
cana-5141	294	12	32	32	NUM
cana-5141	294	13	no	no	NOUN
cana-5141	294	14	.	.	PUNCT
cana-5141	295	1	icmasd	icmasd	NOUN
cana-5141	295	2	(	(	PUNCT
cana-5141	295	3	2025	2025	NUM
cana-5141	295	4	)	)	PUNCT
cana-5141	295	5	1151	1151	NUM
cana-5141	295	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	296	1	[	[	X
cana-5141	296	2	22	22	NUM
cana-5141	296	3	]	]	PUNCT
cana-5141	296	4	s.	s.	PROPN
cana-5141	296	5	salloway	salloway	PROPN
cana-5141	296	6	et	et	PROPN
cana-5141	296	7	al	al	PROPN
cana-5141	296	8	.	.	PROPN
cana-5141	296	9	,	,	PUNCT
cana-5141	296	10	‘	'	PUNCT
cana-5141	296	11	a	a	DET
cana-5141	296	12	trial	trial	NOUN
cana-5141	296	13	of	of	ADP
cana-5141	296	14	gantenerumab	gantenerumab	NOUN
cana-5141	296	15	or	or	CCONJ
cana-5141	296	16	solanezumab	solanezumab	NOUN
cana-5141	296	17	in	in	ADP
cana-5141	296	18	dominantly	dominantly	ADV
cana-5141	296	19	inherited	inherit	VERB
cana-5141	296	20	alzheimer	alzheimer	PROPN
cana-5141	296	21	’s	’s	PART
cana-5141	296	22	disease	disease	NOUN
cana-5141	296	23	’	'	PUNCT
cana-5141	296	24	,	,	PUNCT
cana-5141	296	25	nat	nat	PROPN
cana-5141	296	26	med	me	VERB
cana-5141	296	27	,	,	PUNCT
cana-5141	296	28	vol	vol	NOUN
cana-5141	296	29	.	.	PROPN
cana-5141	296	30	27	27	NUM
cana-5141	296	31	,	,	PUNCT
cana-5141	296	32	no	no	INTJ
cana-5141	296	33	.	.	NOUN
cana-5141	296	34	7	7	NUM
cana-5141	296	35	,	,	PUNCT
cana-5141	296	36	pp	pp	ADJ
cana-5141	296	37	.	.	PUNCT
cana-5141	297	1	1187–1196	1187–1196	NUM
cana-5141	297	2	,	,	PUNCT
cana-5141	297	3	jul	jul	PROPN
cana-5141	297	4	.	.	PROPN
cana-5141	297	5	2021	2021	NUM
cana-5141	297	6	,	,	PUNCT
cana-5141	297	7	doi	doi	NOUN
cana-5141	297	8	:	:	PUNCT
cana-5141	297	9	10.1038	10.1038	NUM
cana-5141	297	10	/	/	SYM
cana-5141	297	11	s41591	s41591	VERB
cana-5141	297	12	-	-	PUNCT
cana-5141	297	13	021	021	NUM
cana-5141	297	14	-	-	PUNCT
cana-5141	297	15	01369	01369	NUM
cana-5141	297	16	-	-	PUNCT
cana-5141	297	17	8	8	NUM
cana-5141	297	18	.	.	PUNCT
cana-5141	298	1	[	[	X
cana-5141	298	2	23	23	NUM
cana-5141	298	3	]	]	PUNCT
cana-5141	298	4	j.	j.	PROPN
cana-5141	298	5	yang	yang	PROPN
cana-5141	298	6	,	,	PUNCT
cana-5141	298	7	y.	y.	PROPN
cana-5141	298	8	guo	guo	PROPN
cana-5141	298	9	,	,	PUNCT
cana-5141	298	10	m.	m.	NOUN
cana-5141	298	11	pistolozzi	pistolozzi	PROPN
cana-5141	298	12	,	,	PUNCT
cana-5141	298	13	and	and	CCONJ
cana-5141	298	14	j.	j.	PROPN
cana-5141	298	15	yan	yan	PROPN
cana-5141	298	16	,	,	PUNCT
cana-5141	298	17	‘	'	PUNCT
cana-5141	298	18	research	research	NOUN
cana-5141	298	19	progress	progress	NOUN
cana-5141	298	20	of	of	ADP
cana-5141	298	21	multi	multi	ADJ
cana-5141	298	22	-	-	ADJ
cana-5141	298	23	functional	functional	ADJ
cana-5141	298	24	fluorescent	fluorescent	NOUN
cana-5141	298	25	probes	probe	NOUN
cana-5141	298	26	for	for	ADP
cana-5141	298	27	alzheimer	alzheimer	PROPN
cana-5141	298	28	’s	’s	PART
cana-5141	298	29	disease	disease	NOUN
cana-5141	298	30	monitoring	monitoring	NOUN
cana-5141	298	31	’	'	PUNCT
cana-5141	298	32	,	,	PUNCT
cana-5141	298	33	dyes	dye	NOUN
cana-5141	298	34	and	and	CCONJ
cana-5141	298	35	pigments	pigment	NOUN
cana-5141	298	36	,	,	PUNCT
cana-5141	298	37	vol	vol	NOUN
cana-5141	298	38	.	.	NOUN
cana-5141	298	39	193	193	NUM
cana-5141	298	40	,	,	PUNCT
cana-5141	298	41	p.	p.	NOUN
cana-5141	298	42	109466	109466	NUM
cana-5141	298	43	,	,	PUNCT
cana-5141	298	44	sep	sep	PROPN
cana-5141	298	45	.	.	PROPN
cana-5141	298	46	2021	2021	NUM
cana-5141	298	47	,	,	PUNCT
cana-5141	298	48	doi	doi	NOUN
cana-5141	298	49	:	:	PUNCT
cana-5141	298	50	10.1016	10.1016	NUM
cana-5141	298	51	/	/	SYM
cana-5141	298	52	j.dyepig.2021.109466	j.dyepig.2021.109466	NOUN
cana-5141	298	53	.	.	PUNCT
cana-5141	299	1	[	[	X
cana-5141	299	2	24	24	NUM
cana-5141	299	3	]	]	X
cana-5141	299	4	d.	d.	PROPN
cana-5141	299	5	angioni	angioni	PROPN
cana-5141	299	6	et	et	PROPN
cana-5141	299	7	al	al	PROPN
cana-5141	299	8	.	.	PROPN
cana-5141	299	9	,	,	PUNCT
cana-5141	299	10	‘	'	PUNCT
cana-5141	299	11	clinical	clinical	ADJ
cana-5141	299	12	meaningfulness	meaningfulness	NOUN
cana-5141	299	13	in	in	ADP
cana-5141	299	14	alzheimer	alzheimer	PROPN
cana-5141	299	15	’s	’s	PART
cana-5141	299	16	disease	disease	NOUN
cana-5141	299	17	clinical	clinical	ADJ
cana-5141	299	18	trials	trial	NOUN
cana-5141	299	19	.	.	PUNCT
cana-5141	300	1	a	a	DET
cana-5141	300	2	report	report	NOUN
cana-5141	300	3	from	from	ADP
cana-5141	300	4	the	the	DET
cana-5141	300	5	eu	eu	PROPN
cana-5141	300	6	-	-	PROPN
cana-5141	300	7	us	us	PROPN
cana-5141	300	8	ctad	ctad	PROPN
cana-5141	300	9	task	task	PROPN
cana-5141	300	10	force	force	PROPN
cana-5141	300	11	’	'	PUNCT
cana-5141	300	12	,	,	PUNCT
cana-5141	300	13	j	j	PROPN
cana-5141	300	14	prev	prev	PROPN
cana-5141	300	15	alzheimers	alzheimers	PROPN
cana-5141	300	16	dis	dis	PROPN
cana-5141	300	17	,	,	PUNCT
cana-5141	300	18	2024	2024	NUM
cana-5141	300	19	,	,	PUNCT
cana-5141	300	20	doi	doi	NOUN
cana-5141	300	21	:	:	PUNCT
cana-5141	300	22	10.14283	10.14283	NUM
cana-5141	300	23	/	/	SYM
cana-5141	300	24	jpad.2024.112	jpad.2024.112	PROPN
cana-5141	300	25	.	.	PUNCT
cana-5141	301	1	[	[	X
cana-5141	301	2	25	25	NUM
cana-5141	301	3	]	]	X
cana-5141	301	4	s.	s.	PROPN
cana-5141	301	5	budd	budd	PROPN
cana-5141	301	6	haeberlein	haeberlein	PROPN
cana-5141	301	7	et	et	PROPN
cana-5141	301	8	al	al	PROPN
cana-5141	301	9	.	.	PROPN
cana-5141	301	10	,	,	PUNCT
cana-5141	301	11	‘	'	PUNCT
cana-5141	301	12	two	two	NUM
cana-5141	301	13	randomized	randomized	ADJ
cana-5141	301	14	phase	phase	NOUN
cana-5141	301	15	3	3	NUM
cana-5141	301	16	studies	study	NOUN
cana-5141	301	17	of	of	ADP
cana-5141	301	18	aducanumab	aducanumab	NOUN
cana-5141	301	19	in	in	ADP
cana-5141	301	20	early	early	PROPN
cana-5141	301	21	alzheimer	alzheimer	PROPN
cana-5141	301	22	’s	’s	PART
cana-5141	301	23	disease	disease	NOUN
cana-5141	301	24	’	'	PUNCT
cana-5141	301	25	,	,	PUNCT
cana-5141	301	26	j	j	PROPN
cana-5141	301	27	prev	prev	PROPN
cana-5141	301	28	alzheimers	alzheimers	PROPN
cana-5141	301	29	dis	dis	PROPN
cana-5141	301	30	,	,	PUNCT
cana-5141	301	31	2022	2022	NUM
cana-5141	301	32	,	,	PUNCT
cana-5141	301	33	doi	doi	NOUN
cana-5141	301	34	:	:	PUNCT
cana-5141	301	35	10.14283	10.14283	NUM
cana-5141	301	36	/	/	SYM
cana-5141	301	37	jpad.2022.30	jpad.2022.30	NOUN
cana-5141	301	38	.	.	PUNCT
cana-5141	302	1	[	[	X
cana-5141	302	2	26	26	NUM
cana-5141	302	3	]	]	X
cana-5141	302	4	c.	c.	PROPN
cana-5141	302	5	j.	j.	PROPN
cana-5141	302	6	swanson	swanson	PROPN
cana-5141	302	7	et	et	PROPN
cana-5141	302	8	al	al	PROPN
cana-5141	302	9	.	.	PROPN
cana-5141	302	10	,	,	PUNCT
cana-5141	302	11	‘	'	PUNCT
cana-5141	302	12	a	a	DET
cana-5141	302	13	randomized	randomized	ADJ
cana-5141	302	14	,	,	PUNCT
cana-5141	302	15	double	double	ADJ
cana-5141	302	16	-	-	PUNCT
cana-5141	302	17	blind	blind	ADJ
cana-5141	302	18	,	,	PUNCT
cana-5141	302	19	phase	phase	NOUN
cana-5141	302	20	2b	2b	NUM
cana-5141	302	21	proof	proof	NOUN
cana-5141	302	22	-	-	PUNCT
cana-5141	302	23	of	of	ADP
cana-5141	302	24	-	-	PUNCT
cana-5141	302	25	concept	concept	NOUN
cana-5141	302	26	clinical	clinical	ADJ
cana-5141	302	27	trial	trial	NOUN
cana-5141	302	28	in	in	ADP
cana-5141	302	29	early	early	PROPN
cana-5141	302	30	alzheimer	alzheimer	PROPN
cana-5141	302	31	’s	’s	PART
cana-5141	302	32	disease	disease	NOUN
cana-5141	302	33	with	with	ADP
cana-5141	302	34	lecanemab	lecanemab	NOUN
cana-5141	302	35	,	,	PUNCT
cana-5141	302	36	an	an	DET
cana-5141	302	37	anti	anti	ADJ
cana-5141	302	38	-	-	ADJ
cana-5141	302	39	aβ	aβ	ADJ
cana-5141	302	40	protofibril	protofibril	ADJ
cana-5141	302	41	antibody	antibody	NOUN
cana-5141	302	42	’	'	PUNCT
cana-5141	302	43	,	,	PUNCT
cana-5141	302	44	alzheimers	alzheimers	PROPN
cana-5141	302	45	res	re	VERB
cana-5141	302	46	ther	ther	ADV
cana-5141	302	47	,	,	PUNCT
cana-5141	302	48	vol	vol	NOUN
cana-5141	302	49	.	.	PROPN
cana-5141	302	50	13	13	NUM
cana-5141	302	51	,	,	PUNCT
cana-5141	302	52	no	no	INTJ
cana-5141	302	53	.	.	NOUN
cana-5141	302	54	1	1	NUM
cana-5141	302	55	,	,	PUNCT
cana-5141	302	56	p.	p.	NOUN
cana-5141	302	57	80	80	NUM
cana-5141	302	58	,	,	PUNCT
cana-5141	302	59	apr	apr	NOUN
cana-5141	302	60	.	.	PROPN
cana-5141	302	61	2021	2021	NUM
cana-5141	302	62	,	,	PUNCT
cana-5141	302	63	doi	doi	NOUN
cana-5141	302	64	:	:	PUNCT
cana-5141	302	65	10.1186	10.1186	NUM
cana-5141	302	66	/	/	SYM
cana-5141	302	67	s13195	s13195	NOUN
cana-5141	302	68	-	-	PUNCT
cana-5141	302	69	021	021	NUM
cana-5141	302	70	-	-	PUNCT
cana-5141	302	71	00813	00813	NUM
cana-5141	302	72	-	-	SYM
cana-5141	302	73	8	8	NUM
cana-5141	302	74	.	.	PUNCT
cana-5141	303	1	[	[	X
cana-5141	303	2	27	27	NUM
cana-5141	303	3	]	]	X
cana-5141	303	4	l.	l.	PROPN
cana-5141	303	5	fan	fan	PROPN
cana-5141	303	6	et	et	PROPN
cana-5141	303	7	al	al	PROPN
cana-5141	303	8	.	.	PROPN
cana-5141	303	9	,	,	PUNCT
cana-5141	303	10	‘	'	PUNCT
cana-5141	303	11	new	new	ADJ
cana-5141	303	12	insights	insight	NOUN
cana-5141	303	13	into	into	ADP
cana-5141	303	14	the	the	DET
cana-5141	303	15	pathogenesis	pathogenesis	NOUN
cana-5141	303	16	of	of	ADP
cana-5141	303	17	alzheimer	alzheimer	PROPN
cana-5141	303	18	’s	’s	PART
cana-5141	303	19	disease	disease	NOUN
cana-5141	303	20	’	'	PUNCT
cana-5141	303	21	,	,	PUNCT
cana-5141	303	22	front	front	ADJ
cana-5141	303	23	neurol	neurol	NOUN
cana-5141	303	24	,	,	PUNCT
cana-5141	303	25	vol	vol	NOUN
cana-5141	303	26	.	.	PROPN
cana-5141	303	27	10	10	NUM
cana-5141	303	28	,	,	PUNCT
cana-5141	303	29	jan	jan	PROPN
cana-5141	303	30	.	.	PROPN
cana-5141	303	31	2020	2020	NUM
cana-5141	303	32	,	,	PUNCT
cana-5141	303	33	doi	doi	NOUN
cana-5141	303	34	:	:	PUNCT
cana-5141	303	35	10.3389	10.3389	NUM
cana-5141	303	36	/	/	SYM
cana-5141	303	37	fneur.2019.01312	fneur.2019.01312	NOUN
cana-5141	303	38	.	.	PUNCT
cana-5141	304	1	[	[	X
cana-5141	304	2	28	28	NUM
cana-5141	304	3	]	]	X
cana-5141	304	4	c.	c.	PROPN
cana-5141	304	5	r.	r.	PROPN
cana-5141	304	6	harrington	harrington	PROPN
cana-5141	304	7	and	and	CCONJ
cana-5141	304	8	c.	c.	PROPN
cana-5141	304	9	m.	m.	PROPN
cana-5141	304	10	wischik	wischik	PROPN
cana-5141	304	11	,	,	PUNCT
cana-5141	304	12	‘	'	PUNCT
cana-5141	304	13	molecular	molecular	ADJ
cana-5141	304	14	pathobiology	pathobiology	NOUN
cana-5141	304	15	of	of	ADP
cana-5141	304	16	alzheimer	alzheimer	PROPN
cana-5141	304	17	’s	’s	PART
cana-5141	304	18	disease	disease	NOUN
cana-5141	304	19	’	'	PUNCT
cana-5141	304	20	,	,	PUNCT
cana-5141	304	21	in	in	ADP
cana-5141	304	22	dementia	dementia	PROPN
cana-5141	304	23	,	,	PUNCT
cana-5141	304	24	boston	boston	PROPN
cana-5141	304	25	,	,	PUNCT
cana-5141	304	26	ma	ma	PROPN
cana-5141	304	27	:	:	PUNCT
cana-5141	304	28	springer	springer	NOUN
cana-5141	304	29	us	we	PRON
cana-5141	304	30	,	,	PUNCT
cana-5141	304	31	1994	1994	NUM
cana-5141	304	32	,	,	PUNCT
cana-5141	304	33	pp	pp	ADJ
cana-5141	304	34	.	.	PUNCT
cana-5141	305	1	209–238	209–238	NUM
cana-5141	305	2	.	.	PUNCT
cana-5141	306	1	doi	doi	NOUN
cana-5141	306	2	:	:	PUNCT
cana-5141	306	3	10.1007/978	10.1007/978	NUM
cana-5141	306	4	-	-	SYM
cana-5141	306	5	1	1	NUM
cana-5141	306	6	-	-	PUNCT
cana-5141	306	7	4615	4615	NUM
cana-5141	306	8	-	-	PUNCT
cana-5141	306	9	68056_13	68056_13	NOUN
cana-5141	306	10	.	.	PUNCT
cana-5141	307	1	[	[	X
cana-5141	307	2	29	29	NUM
cana-5141	307	3	]	]	X
cana-5141	307	4	l.	l.	PROPN
cana-5141	307	5	g.	g.	PROPN
cana-5141	307	6	apostolova	apostolova	PROPN
cana-5141	307	7	and	and	CCONJ
cana-5141	307	8	j.	j.	PROPN
cana-5141	307	9	l.	l.	PROPN
cana-5141	307	10	cummings	cummings	PROPN
cana-5141	307	11	,	,	PUNCT
cana-5141	307	12	‘	'	PUNCT
cana-5141	307	13	the	the	DET
cana-5141	307	14	pathogenesis	pathogenesis	NOUN
cana-5141	307	15	of	of	ADP
cana-5141	307	16	alzheimer	alzheimer	PROPN
cana-5141	307	17	’s	’s	PART
cana-5141	307	18	disease	disease	NOUN
cana-5141	307	19	:	:	PUNCT
cana-5141	307	20	general	general	ADJ
cana-5141	307	21	overview	overview	NOUN
cana-5141	307	22	’	'	PUNCT
cana-5141	307	23	,	,	PUNCT
cana-5141	307	24	in	in	ADP
cana-5141	307	25	protein	protein	NOUN
cana-5141	307	26	misfolding	misfolding	NOUN
cana-5141	307	27	,	,	PUNCT
cana-5141	307	28	aggregation	aggregation	NOUN
cana-5141	307	29	,	,	PUNCT
cana-5141	307	30	and	and	CCONJ
cana-5141	307	31	conformational	conformational	ADJ
cana-5141	307	32	diseases	disease	NOUN
cana-5141	307	33	,	,	PUNCT
cana-5141	307	34	boston	boston	PROPN
cana-5141	307	35	,	,	PUNCT
cana-5141	307	36	ma	ma	PROPN
cana-5141	307	37	:	:	PUNCT
cana-5141	307	38	springer	springer	NOUN
cana-5141	307	39	us	we	PRON
cana-5141	307	40	,	,	PUNCT
cana-5141	307	41	pp	pp	ADP
cana-5141	307	42	.	.	PUNCT
cana-5141	308	1	3–29	3–29	INTJ
cana-5141	308	2	.	.	PUNCT
cana-5141	309	1	doi	doi	NOUN
cana-5141	309	2	:	:	PUNCT
cana-5141	309	3	10.1007/978	10.1007/978	NUM
cana-5141	309	4	-	-	SYM
cana-5141	309	5	0	0	NUM
cana-5141	309	6	-	-	PUNCT
cana-5141	309	7	387	387	NUM
cana-5141	309	8	-	-	PUNCT
cana-5141	309	9	36534	36534	NUM
cana-5141	309	10	-	-	SYM
cana-5141	309	11	3_1	3_1	NUM
cana-5141	309	12	.	.	PUNCT
cana-5141	310	1	[	[	X
cana-5141	310	2	30	30	NUM
cana-5141	310	3	]	]	X
cana-5141	310	4	o.	o.	PROPN
cana-5141	310	5	sheppard	sheppard	PROPN
cana-5141	310	6	and	and	CCONJ
cana-5141	310	7	m.	m.	PROPN
cana-5141	310	8	coleman	coleman	PROPN
cana-5141	310	9	,	,	PUNCT
cana-5141	310	10	‘	'	PUNCT
cana-5141	310	11	alzheimer	alzheimer	X
cana-5141	310	12	’s	’s	PART
cana-5141	310	13	disease	disease	NOUN
cana-5141	310	14	:	:	PUNCT
cana-5141	310	15	etiology	etiology	NOUN
cana-5141	310	16	,	,	PUNCT
cana-5141	310	17	neuropathology	neuropathology	NOUN
cana-5141	310	18	and	and	CCONJ
cana-5141	310	19	pathogenesis	pathogenesis	NOUN
cana-5141	310	20	’	'	PUNCT
cana-5141	310	21	,	,	PUNCT
cana-5141	310	22	in	in	ADP
cana-5141	310	23	alzheimer	alzheimer	PROPN
cana-5141	310	24	’s	’s	PART
cana-5141	310	25	disease	disease	NOUN
cana-5141	310	26	:	:	PUNCT
cana-5141	310	27	drug	drug	NOUN
cana-5141	310	28	discovery	discovery	NOUN
cana-5141	310	29	,	,	PUNCT
cana-5141	310	30	exon	exon	NOUN
cana-5141	310	31	publications	publication	NOUN
cana-5141	310	32	,	,	PUNCT
cana-5141	310	33	2020	2020	NUM
cana-5141	310	34	,	,	PUNCT
cana-5141	310	35	pp	pp	ADP
cana-5141	310	36	.	.	PUNCT
cana-5141	311	1	1–22	1–22	NOUN
cana-5141	311	2	.	.	PUNCT
cana-5141	312	1	doi	doi	NOUN
cana-5141	312	2	:	:	PUNCT
cana-5141	312	3	10.36255	10.36255	NUM
cana-5141	312	4	/	/	SYM
cana-5141	312	5	exonpublications.alzheimersdisease.2020.ch1	exonpublications.alzheimersdisease.2020.ch1	X
cana-5141	312	6	.	.	PUNCT
cana-5141	313	1	[	[	X
cana-5141	313	2	31	31	NUM
cana-5141	313	3	]	]	PUNCT
cana-5141	313	4	c.	c.	PROPN
cana-5141	313	5	f.	f.	PROPN
cana-5141	313	6	m.	m.	PROPN
cana-5141	313	7	huffels	huffels	PROPN
cana-5141	313	8	,	,	PUNCT
cana-5141	313	9	j.	j.	PROPN
cana-5141	313	10	middeldorp	middeldorp	PROPN
cana-5141	313	11	,	,	PUNCT
cana-5141	313	12	and	and	CCONJ
cana-5141	313	13	e.	e.	PROPN
cana-5141	313	14	m.	m.	PROPN
cana-5141	313	15	hol	hol	PROPN
cana-5141	313	16	,	,	PUNCT
cana-5141	313	17	‘	'	PUNCT
cana-5141	313	18	aß	aß	ADP
cana-5141	313	19	pathology	pathology	NOUN
cana-5141	313	20	and	and	CCONJ
cana-5141	313	21	neuron	neuron	PROPN
cana-5141	313	22	–	–	PUNCT
cana-5141	313	23	glia	glia	NOUN
cana-5141	313	24	interactions	interaction	NOUN
cana-5141	313	25	:	:	PUNCT
cana-5141	313	26	a	a	DET
cana-5141	313	27	synaptocentric	synaptocentric	ADJ
cana-5141	313	28	view	view	NOUN
cana-5141	313	29	’	'	PUNCT
cana-5141	313	30	,	,	PUNCT
cana-5141	313	31	neurochem	neurochem	PROPN
cana-5141	313	32	res	re	NOUN
cana-5141	313	33	,	,	PUNCT
cana-5141	313	34	vol	vol	NOUN
cana-5141	313	35	.	.	PROPN
cana-5141	313	36	48	48	NUM
cana-5141	313	37	,	,	PUNCT
cana-5141	313	38	no	no	INTJ
cana-5141	313	39	.	.	NOUN
cana-5141	313	40	4	4	NUM
cana-5141	313	41	,	,	PUNCT
cana-5141	313	42	pp	pp	ADJ
cana-5141	313	43	.	.	PUNCT
cana-5141	314	1	1026–1046	1026–1046	NUM
cana-5141	314	2	,	,	PUNCT
cana-5141	314	3	apr	apr	PROPN
cana-5141	314	4	.	.	PROPN
cana-5141	315	1	2023	2023	NUM
cana-5141	315	2	,	,	PUNCT
cana-5141	315	3	doi	doi	NOUN
cana-5141	315	4	:	:	PUNCT
cana-5141	315	5	10.1007	10.1007	NUM
cana-5141	315	6	/	/	SYM
cana-5141	315	7	s11064	s11064	PROPN
cana-5141	315	8	-	-	PUNCT
cana-5141	315	9	022	022	NUM
cana-5141	315	10	-	-	PUNCT
cana-5141	315	11	03699	03699	NUM
cana-5141	315	12	-	-	SYM
cana-5141	315	13	6	6	NUM
cana-5141	315	14	.	.	PUNCT
cana-5141	316	1	[	[	X
cana-5141	316	2	32	32	NUM
cana-5141	316	3	]	]	PUNCT
cana-5141	316	4	j.	j.	PROPN
cana-5141	316	5	weller	weller	PROPN
cana-5141	316	6	and	and	CCONJ
cana-5141	316	7	a.	a.	PROPN
cana-5141	316	8	budson	budson	PROPN
cana-5141	316	9	,	,	PUNCT
cana-5141	316	10	‘	'	PUNCT
cana-5141	316	11	current	current	ADJ
cana-5141	316	12	understanding	understanding	NOUN
cana-5141	316	13	of	of	ADP
cana-5141	316	14	alzheimer	alzheimer	PROPN
cana-5141	316	15	’s	’s	PART
cana-5141	316	16	disease	disease	NOUN
cana-5141	316	17	diagnosis	diagnosis	NOUN
cana-5141	316	18	and	and	CCONJ
cana-5141	316	19	treatment	treatment	NOUN
cana-5141	316	20	’	'	PUNCT
cana-5141	316	21	,	,	PUNCT
cana-5141	316	22	f1000res	f1000res	PROPN
cana-5141	316	23	,	,	PUNCT
cana-5141	316	24	vol	vol	NOUN
cana-5141	316	25	.	.	PROPN
cana-5141	316	26	7	7	NUM
cana-5141	316	27	,	,	PUNCT
cana-5141	316	28	p.	p.	NOUN
cana-5141	316	29	1161	1161	NUM
cana-5141	316	30	,	,	PUNCT
cana-5141	316	31	jul	jul	PROPN
cana-5141	316	32	.	.	PROPN
cana-5141	316	33	2018	2018	NUM
cana-5141	316	34	,	,	PUNCT
cana-5141	316	35	doi	doi	NOUN
cana-5141	316	36	:	:	PUNCT
cana-5141	316	37	10.12688	10.12688	NUM
cana-5141	316	38	/	/	SYM
cana-5141	316	39	f1000research.14506.1	f1000research.14506.1	NOUN
cana-5141	316	40	.	.	PUNCT
cana-5141	317	1	[	[	X
cana-5141	317	2	33	33	NUM
cana-5141	317	3	]	]	PUNCT
cana-5141	317	4	b.	b.	PROPN
cana-5141	317	5	györgy	györgy	PROPN
cana-5141	317	6	et	et	PROPN
cana-5141	317	7	al	al	PROPN
cana-5141	317	8	.	.	PROPN
cana-5141	317	9	,	,	PUNCT
cana-5141	317	10	‘	'	PUNCT
cana-5141	317	11	crispr	crispr	ADJ
cana-5141	317	12	/	/	SYM
cana-5141	317	13	cas9	cas9	NOUN
cana-5141	317	14	mediated	mediate	VERB
cana-5141	317	15	disruption	disruption	NOUN
cana-5141	317	16	of	of	ADP
cana-5141	317	17	the	the	DET
cana-5141	317	18	swedish	swedish	PROPN
cana-5141	317	19	app	app	PROPN
cana-5141	317	20	allele	allele	PROPN
cana-5141	317	21	as	as	ADP
cana-5141	317	22	a	a	DET
cana-5141	317	23	therapeutic	therapeutic	ADJ
cana-5141	317	24	approach	approach	NOUN
cana-5141	317	25	for	for	ADP
cana-5141	317	26	early	early	ADJ
cana-5141	317	27	-	-	PUNCT
cana-5141	317	28	onset	onset	NOUN
cana-5141	317	29	alzheimer	alzheimer	PROPN
cana-5141	317	30	’s	’s	PART
cana-5141	317	31	disease	disease	NOUN
cana-5141	317	32	’	'	PUNCT
cana-5141	317	33	,	,	PUNCT
cana-5141	317	34	mol	mol	ADP
cana-5141	317	35	ther	ther	ADV
cana-5141	317	36	nucleic	nucleic	ADJ
cana-5141	317	37	acids	acid	NOUN
cana-5141	317	38	,	,	PUNCT
cana-5141	317	39	vol	vol	NOUN
cana-5141	317	40	.	.	PROPN
cana-5141	317	41	11	11	NUM
cana-5141	317	42	,	,	PUNCT
cana-5141	317	43	pp	pp	ADJ
cana-5141	317	44	.	.	PUNCT
cana-5141	318	1	429–440	429–440	NUM
cana-5141	318	2	,	,	PUNCT
cana-5141	318	3	jun	jun	PROPN
cana-5141	318	4	.	.	PROPN
cana-5141	318	5	2018	2018	NUM
cana-5141	318	6	,	,	PUNCT
cana-5141	318	7	doi	doi	NOUN
cana-5141	318	8	:	:	PUNCT
cana-5141	318	9	10.1016	10.1016	NUM
cana-5141	318	10	/	/	SYM
cana-5141	318	11	j.omtn.2018.03.007	j.omtn.2018.03.007	NOUN
cana-5141	318	12	.	.	PUNCT
cana-5141	319	1	[	[	X
cana-5141	319	2	34	34	NUM
cana-5141	319	3	]	]	PUNCT
cana-5141	319	4	s.	s.	PROPN
cana-5141	319	5	p.	p.	PROPN
cana-5141	319	6	raikwar	raikwar	ADV
cana-5141	319	7	et	et	PROPN
cana-5141	319	8	al	al	PROPN
cana-5141	319	9	.	.	PROPN
cana-5141	319	10	,	,	PUNCT
cana-5141	319	11	‘	'	PUNCT
cana-5141	319	12	neuro	neuro	NOUN
cana-5141	319	13	-	-	PUNCT
cana-5141	319	14	immuno	immuno	ADJ
cana-5141	319	15	-	-	PUNCT
cana-5141	319	16	geneand	geneand	NOUN
cana-5141	319	17	genome	genome	NOUN
cana-5141	319	18	-	-	PUNCT
cana-5141	319	19	editing	editing	NOUN
cana-5141	319	20	-	-	PUNCT
cana-5141	319	21	therapy	therapy	NOUN
cana-5141	319	22	for	for	ADP
cana-5141	319	23	alzheimer	alzheimer	PROPN
cana-5141	319	24	’s	’s	PART
cana-5141	319	25	disease	disease	NOUN
cana-5141	319	26	:	:	PUNCT
cana-5141	319	27	are	be	AUX
cana-5141	319	28	we	we	PRON
cana-5141	319	29	there	there	ADV
cana-5141	319	30	yet	yet	ADV
cana-5141	319	31	?	?	PUNCT
cana-5141	319	32	’	'	PUNCT
cana-5141	319	33	,	,	PUNCT
cana-5141	319	34	journal	journal	NOUN
cana-5141	319	35	of	of	ADP
cana-5141	319	36	alzheimer	alzheimer	PROPN
cana-5141	319	37	’s	’s	PART
cana-5141	319	38	disease	disease	NOUN
cana-5141	319	39	,	,	PUNCT
cana-5141	319	40	vol	vol	NOUN
cana-5141	319	41	.	.	PROPN
cana-5141	319	42	65	65	NUM
cana-5141	319	43	,	,	PUNCT
cana-5141	319	44	no	no	INTJ
cana-5141	319	45	.	.	NOUN
cana-5141	319	46	2	2	NUM
cana-5141	319	47	,	,	PUNCT
cana-5141	319	48	pp	pp	ADJ
cana-5141	319	49	.	.	PUNCT
cana-5141	320	1	321–344	321–344	NUM
cana-5141	320	2	,	,	PUNCT
cana-5141	320	3	aug	aug	PROPN
cana-5141	320	4	.	.	PROPN
cana-5141	320	5	2018	2018	NUM
cana-5141	320	6	,	,	PUNCT
cana-5141	320	7	doi	doi	NOUN
cana-5141	320	8	:	:	PUNCT
cana-5141	320	9	10.3233	10.3233	NUM
cana-5141	320	10	/	/	SYM
cana-5141	320	11	jad-180422	jad-180422	NOUN
cana-5141	320	12	.	.	PUNCT
cana-5141	321	1	[	[	X
cana-5141	321	2	35	35	NUM
cana-5141	321	3	]	]	X
cana-5141	321	4	h.	h.	PROPN
cana-5141	321	5	park	park	PROPN
cana-5141	321	6	et	et	PROPN
cana-5141	321	7	al	al	PROPN
cana-5141	321	8	.	.	PROPN
cana-5141	321	9	,	,	PUNCT
cana-5141	321	10	‘	'	PUNCT
cana-5141	321	11	in	in	ADP
cana-5141	321	12	vivo	vivo	ADJ
cana-5141	321	13	neuronal	neuronal	ADJ
cana-5141	321	14	gene	gene	NOUN
cana-5141	321	15	editing	edit	VERB
cana-5141	321	16	via	via	ADP
cana-5141	321	17	crispr	crispr	ADJ
cana-5141	321	18	–	–	PUNCT
cana-5141	321	19	cas9	cas9	NOUN
cana-5141	321	20	amphiphilic	amphiphilic	ADJ
cana-5141	321	21	nanocomplexes	nanocomplexe	NOUN
cana-5141	321	22	alleviates	alleviate	VERB
cana-5141	321	23	deficits	deficit	NOUN
cana-5141	321	24	in	in	ADP
cana-5141	321	25	mouse	mouse	NOUN
cana-5141	321	26	models	model	NOUN
cana-5141	321	27	of	of	ADP
cana-5141	321	28	alzheimer	alzheimer	PROPN
cana-5141	321	29	’s	’s	PART
cana-5141	321	30	disease	disease	NOUN
cana-5141	321	31	’	'	PUNCT
cana-5141	321	32	,	,	PUNCT
cana-5141	321	33	nat	nat	PROPN
cana-5141	321	34	neurosci	neurosci	PROPN
cana-5141	321	35	,	,	PUNCT
cana-5141	321	36	vol	vol	NOUN
cana-5141	321	37	.	.	PROPN
cana-5141	321	38	22	22	NUM
cana-5141	321	39	,	,	PUNCT
cana-5141	321	40	no	no	INTJ
cana-5141	321	41	.	.	NOUN
cana-5141	321	42	4	4	NUM
cana-5141	321	43	,	,	PUNCT
cana-5141	321	44	pp	pp	ADJ
cana-5141	321	45	.	.	PUNCT
cana-5141	322	1	524–528	524–528	NUM
cana-5141	322	2	,	,	PUNCT
cana-5141	322	3	apr	apr	NOUN
cana-5141	322	4	.	.	PROPN
cana-5141	322	5	2019	2019	NUM
cana-5141	322	6	,	,	PUNCT
cana-5141	322	7	doi	doi	NOUN
cana-5141	322	8	:	:	PUNCT
cana-5141	322	9	10.1038	10.1038	NUM
cana-5141	322	10	/	/	SYM
cana-5141	322	11	s41593	s41593	PROPN
cana-5141	322	12	-	-	PUNCT
cana-5141	322	13	019	019	NUM
cana-5141	322	14	-	-	PUNCT
cana-5141	322	15	0352	0352	NUM
cana-5141	322	16	-	-	SYM
cana-5141	322	17	0	0	NUM
cana-5141	322	18	.	.	PUNCT
cana-5141	323	1	[	[	X
cana-5141	323	2	36	36	NUM
cana-5141	323	3	]	]	X
cana-5141	323	4	c.	c.	PROPN
cana-5141	323	5	wang	wang	PROPN
cana-5141	323	6	et	et	PROPN
cana-5141	323	7	al	al	PROPN
cana-5141	323	8	.	.	PROPN
cana-5141	323	9	,	,	PUNCT
cana-5141	323	10	‘	'	PUNCT
cana-5141	323	11	gain	gain	NOUN
cana-5141	323	12	of	of	ADP
cana-5141	323	13	toxic	toxic	ADJ
cana-5141	323	14	apolipoprotein	apolipoprotein	ADJ
cana-5141	323	15	e4	e4	PROPN
cana-5141	323	16	effects	effect	NOUN
cana-5141	323	17	in	in	ADP
cana-5141	323	18	human	human	ADJ
cana-5141	323	19	ipsc	ipsc	NOUN
cana-5141	323	20	-	-	PUNCT
cana-5141	323	21	derived	derive	VERB
cana-5141	323	22	neurons	neuron	NOUN
cana-5141	323	23	is	be	AUX
cana-5141	323	24	ameliorated	ameliorate	VERB
cana-5141	323	25	by	by	ADP
cana-5141	323	26	a	a	DET
cana-5141	323	27	small	small	ADJ
cana-5141	323	28	-	-	PUNCT
cana-5141	323	29	molecule	molecule	NOUN
cana-5141	323	30	structure	structure	NOUN
cana-5141	323	31	corrector	corrector	NOUN
cana-5141	323	32	’	'	PUNCT
cana-5141	323	33	,	,	PUNCT
cana-5141	323	34	nat	nat	PROPN
cana-5141	323	35	med	me	VERB
cana-5141	323	36	,	,	PUNCT
cana-5141	323	37	vol	vol	NOUN
cana-5141	323	38	.	.	PROPN
cana-5141	324	1	24	24	NUM
cana-5141	324	2	,	,	PUNCT
cana-5141	324	3	no	no	INTJ
cana-5141	324	4	.	.	NOUN
cana-5141	324	5	5	5	NUM
cana-5141	324	6	,	,	PUNCT
cana-5141	324	7	pp	pp	ADJ
cana-5141	324	8	.	.	PUNCT
cana-5141	325	1	647–657	647–657	NUM
cana-5141	325	2	,	,	PUNCT
cana-5141	325	3	may	may	PROPN
cana-5141	325	4	2018	2018	NUM
cana-5141	325	5	,	,	PUNCT
cana-5141	325	6	doi	doi	NOUN
cana-5141	325	7	:	:	PUNCT
cana-5141	325	8	10.1038	10.1038	NUM
cana-5141	325	9	/	/	SYM
cana-5141	325	10	s41591	s41591	VERB
cana-5141	325	11	-	-	PUNCT
cana-5141	325	12	018	018	NUM
cana-5141	325	13	-	-	PUNCT
cana-5141	325	14	0004	0004	NUM
cana-5141	325	15	-	-	PUNCT
cana-5141	325	16	z.	z.	PROPN
cana-5141	325	17	communications	communication	NOUN
cana-5141	325	18	on	on	ADP
cana-5141	325	19	applied	apply	VERB
cana-5141	325	20	nonlinear	nonlinear	ADJ
cana-5141	325	21	analysis	analysis	NOUN
cana-5141	325	22	issn	issn	NOUN
cana-5141	325	23	:	:	PUNCT
cana-5141	325	24	1074	1074	NUM
cana-5141	325	25	-	-	PUNCT
cana-5141	325	26	133x	133x	NUM
cana-5141	325	27	vol	vol	NOUN
cana-5141	325	28	32	32	NUM
cana-5141	325	29	no	no	NOUN
cana-5141	325	30	.	.	PUNCT
cana-5141	326	1	icmasd	icmasd	NOUN
cana-5141	326	2	(	(	PUNCT
cana-5141	326	3	2025	2025	NUM
cana-5141	326	4	)	)	PUNCT
cana-5141	326	5	1152	1152	NUM
cana-5141	326	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	327	1	[	[	X
cana-5141	327	2	37	37	NUM
cana-5141	327	3	]	]	X
cana-5141	327	4	j.	j.	PROPN
cana-5141	327	5	sun	sun	PROPN
cana-5141	327	6	et	et	PROPN
cana-5141	327	7	al	al	PROPN
cana-5141	327	8	.	.	PROPN
cana-5141	327	9	,	,	PUNCT
cana-5141	327	10	‘	'	PUNCT
cana-5141	327	11	crispr	crispr	ADJ
cana-5141	327	12	/	/	SYM
cana-5141	327	13	cas9	cas9	NOUN
cana-5141	327	14	editing	editing	NOUN
cana-5141	327	15	of	of	ADP
cana-5141	327	16	app	app	PROPN
cana-5141	327	17	c	c	X
cana-5141	327	18	-	-	PUNCT
cana-5141	327	19	terminus	terminus	NOUN
cana-5141	327	20	attenuates	attenuate	VERB
cana-5141	327	21	β	β	NOUN
cana-5141	327	22	-	-	NOUN
cana-5141	327	23	cleavage	cleavage	NOUN
cana-5141	327	24	and	and	CCONJ
cana-5141	327	25	promotes	promote	VERB
cana-5141	327	26	α	α	DET
cana-5141	327	27	-	-	NOUN
cana-5141	327	28	cleavage	cleavage	NOUN
cana-5141	327	29	’	'	PUNCT
cana-5141	327	30	,	,	PUNCT
cana-5141	327	31	nat	nat	PROPN
cana-5141	327	32	commun	commun	PROPN
cana-5141	327	33	,	,	PUNCT
cana-5141	327	34	vol	vol	NOUN
cana-5141	327	35	.	.	PROPN
cana-5141	328	1	10	10	NUM
cana-5141	328	2	,	,	PUNCT
cana-5141	328	3	no	no	INTJ
cana-5141	328	4	.	.	NOUN
cana-5141	328	5	1	1	NUM
cana-5141	328	6	,	,	PUNCT
cana-5141	328	7	p.	p.	NOUN
cana-5141	328	8	53	53	NUM
cana-5141	328	9	,	,	PUNCT
cana-5141	328	10	jan	jan	PROPN
cana-5141	328	11	.	.	PROPN
cana-5141	328	12	2019	2019	NUM
cana-5141	328	13	,	,	PUNCT
cana-5141	328	14	doi	doi	NOUN
cana-5141	328	15	:	:	PUNCT
cana-5141	328	16	10.1038	10.1038	NUM
cana-5141	328	17	/	/	SYM
cana-5141	328	18	s41467	s41467	NOUN
cana-5141	328	19	-	-	PUNCT
cana-5141	328	20	018	018	NUM
cana-5141	328	21	-	-	PUNCT
cana-5141	328	22	079718	079718	NUM
cana-5141	328	23	.	.	PUNCT
cana-5141	329	1	[	[	X
cana-5141	329	2	38	38	NUM
cana-5141	329	3	]	]	PUNCT
cana-5141	329	4	s.	s.	PROPN
cana-5141	329	5	bhardwaj	bhardwaj	PROPN
cana-5141	329	6	et	et	PROPN
cana-5141	329	7	al	al	PROPN
cana-5141	329	8	.	.	PROPN
cana-5141	329	9	,	,	PUNCT
cana-5141	329	10	‘	'	PUNCT
cana-5141	329	11	crispr	crispr	ADJ
cana-5141	329	12	/	/	SYM
cana-5141	329	13	cas9	cas9	NOUN
cana-5141	329	14	gene	gene	NOUN
cana-5141	329	15	editing	editing	NOUN
cana-5141	329	16	:	:	PUNCT
cana-5141	329	17	new	new	ADJ
cana-5141	329	18	hope	hope	NOUN
cana-5141	329	19	for	for	ADP
cana-5141	329	20	alzheimer	alzheimer	PROPN
cana-5141	329	21	’s	’s	PART
cana-5141	329	22	disease	disease	NOUN
cana-5141	329	23	therapeutics	therapeutic	NOUN
cana-5141	329	24	’	'	PUNCT
cana-5141	329	25	,	,	PUNCT
cana-5141	329	26	j	j	PROPN
cana-5141	329	27	adv	adv	PROPN
cana-5141	329	28	res	re	NOUN
cana-5141	329	29	,	,	PUNCT
cana-5141	329	30	vol	vol	NOUN
cana-5141	329	31	.	.	PROPN
cana-5141	329	32	40	40	NUM
cana-5141	329	33	,	,	PUNCT
cana-5141	329	34	pp	pp	ADJ
cana-5141	329	35	.	.	PUNCT
cana-5141	330	1	207–221	207–221	NUM
cana-5141	330	2	,	,	PUNCT
cana-5141	330	3	sep	sep	PROPN
cana-5141	330	4	.	.	PROPN
cana-5141	330	5	2022	2022	NUM
cana-5141	330	6	,	,	PUNCT
cana-5141	330	7	doi	doi	NOUN
cana-5141	330	8	:	:	PUNCT
cana-5141	330	9	10.1016	10.1016	NUM
cana-5141	330	10	/	/	SYM
cana-5141	330	11	j.jare.2021.07.001	j.jare.2021.07.001	PROPN
cana-5141	330	12	.	.	PUNCT
cana-5141	331	1	[	[	X
cana-5141	331	2	39	39	NUM
cana-5141	331	3	]	]	PUNCT
cana-5141	331	4	m.	m.	NOUN
cana-5141	331	5	naeem	naeem	PROPN
cana-5141	331	6	,	,	PUNCT
cana-5141	331	7	s.	s.	PROPN
cana-5141	331	8	majeed	majeed	PROPN
cana-5141	331	9	,	,	PUNCT
cana-5141	331	10	m.	m.	NOUN
cana-5141	331	11	z.	z.	PROPN
cana-5141	331	12	hoque	hoque	PROPN
cana-5141	331	13	,	,	PUNCT
cana-5141	331	14	and	and	CCONJ
cana-5141	331	15	i.	i.	PROPN
cana-5141	331	16	ahmad	ahmad	PROPN
cana-5141	331	17	,	,	PUNCT
cana-5141	331	18	‘	'	PUNCT
cana-5141	331	19	latest	late	ADJ
cana-5141	331	20	developed	develop	VERB
cana-5141	331	21	strategies	strategy	NOUN
cana-5141	331	22	to	to	PART
cana-5141	331	23	minimize	minimize	VERB
cana-5141	331	24	the	the	DET
cana-5141	331	25	off	off	ADP
cana-5141	331	26	-	-	PUNCT
cana-5141	331	27	target	target	NOUN
cana-5141	331	28	effects	effect	NOUN
cana-5141	331	29	in	in	ADP
cana-5141	331	30	crispr	crispr	NOUN
cana-5141	331	31	-	-	PUNCT
cana-5141	331	32	cas	cas	NOUN
cana-5141	331	33	-	-	PUNCT
cana-5141	331	34	mediated	mediate	VERB
cana-5141	331	35	genome	genome	NOUN
cana-5141	331	36	editing	editing	NOUN
cana-5141	331	37	’	'	PUNCT
cana-5141	331	38	,	,	PUNCT
cana-5141	331	39	cells	cell	NOUN
cana-5141	331	40	,	,	PUNCT
cana-5141	331	41	vol	vol	NOUN
cana-5141	331	42	.	.	NOUN
cana-5141	331	43	9	9	NUM
cana-5141	331	44	,	,	PUNCT
cana-5141	331	45	no	no	INTJ
cana-5141	331	46	.	.	NOUN
cana-5141	331	47	7	7	NUM
cana-5141	331	48	,	,	PUNCT
cana-5141	331	49	p.	p.	NOUN
cana-5141	331	50	1608	1608	NUM
cana-5141	331	51	,	,	PUNCT
cana-5141	331	52	jul	jul	PROPN
cana-5141	331	53	.	.	PROPN
cana-5141	331	54	2020	2020	NUM
cana-5141	331	55	,	,	PUNCT
cana-5141	331	56	doi	doi	NOUN
cana-5141	331	57	:	:	PUNCT
cana-5141	331	58	10.3390	10.3390	NUM
cana-5141	331	59	/	/	SYM
cana-5141	331	60	cells9071608	cells9071608	PROPN
cana-5141	331	61	.	.	PUNCT
cana-5141	332	1	[	[	X
cana-5141	332	2	40	40	NUM
cana-5141	332	3	]	]	PUNCT
cana-5141	332	4	m.	m.	NOUN
cana-5141	332	5	haeussler	haeussler	NOUN
cana-5141	332	6	et	et	PROPN
cana-5141	332	7	al	al	PROPN
cana-5141	332	8	.	.	PROPN
cana-5141	332	9	,	,	PUNCT
cana-5141	332	10	‘	'	PUNCT
cana-5141	332	11	evaluation	evaluation	NOUN
cana-5141	332	12	of	of	ADP
cana-5141	332	13	off	off	ADP
cana-5141	332	14	-	-	PUNCT
cana-5141	332	15	target	target	NOUN
cana-5141	332	16	and	and	CCONJ
cana-5141	332	17	on	on	ADP
cana-5141	332	18	-	-	PUNCT
cana-5141	332	19	target	target	NOUN
cana-5141	332	20	scoring	scoring	NOUN
cana-5141	332	21	algorithms	algorithm	NOUN
cana-5141	332	22	and	and	CCONJ
cana-5141	332	23	integration	integration	NOUN
cana-5141	332	24	into	into	ADP
cana-5141	332	25	the	the	DET
cana-5141	332	26	guide	guide	NOUN
cana-5141	332	27	rna	rna	NOUN
cana-5141	332	28	selection	selection	NOUN
cana-5141	332	29	tool	tool	NOUN
cana-5141	332	30	crispor	crispor	NOUN
cana-5141	332	31	’	'	PUNCT
cana-5141	332	32	,	,	PUNCT
cana-5141	332	33	genome	genome	NOUN
cana-5141	332	34	biol	biol	NOUN
cana-5141	332	35	,	,	PUNCT
cana-5141	332	36	vol	vol	NOUN
cana-5141	332	37	.	.	PROPN
cana-5141	332	38	17	17	NUM
cana-5141	332	39	,	,	PUNCT
cana-5141	332	40	no	no	INTJ
cana-5141	332	41	.	.	NOUN
cana-5141	332	42	1	1	NUM
cana-5141	332	43	,	,	PUNCT
cana-5141	332	44	p.	p.	NOUN
cana-5141	332	45	148	148	NUM
cana-5141	332	46	,	,	PUNCT
cana-5141	332	47	dec	dec	PROPN
cana-5141	332	48	.	.	PROPN
cana-5141	332	49	2016	2016	NUM
cana-5141	332	50	,	,	PUNCT
cana-5141	332	51	doi	doi	NOUN
cana-5141	332	52	:	:	PUNCT
cana-5141	332	53	10.1186	10.1186	NUM
cana-5141	332	54	/	/	SYM
cana-5141	332	55	s13059	s13059	NOUN
cana-5141	332	56	-	-	PUNCT
cana-5141	332	57	016	016	NUM
cana-5141	332	58	-	-	PUNCT
cana-5141	332	59	1012	1012	NUM
cana-5141	332	60	-	-	SYM
cana-5141	332	61	2	2	NUM
cana-5141	332	62	.	.	PUNCT
cana-5141	333	1	[	[	X
cana-5141	333	2	41	41	NUM
cana-5141	333	3	]	]	X
cana-5141	333	4	r.	r.	PROPN
cana-5141	333	5	barrangou	barrangou	PROPN
cana-5141	333	6	et	et	PROPN
cana-5141	333	7	al	al	PROPN
cana-5141	333	8	.	.	PROPN
cana-5141	333	9	,	,	PUNCT
cana-5141	333	10	‘	'	PUNCT
cana-5141	333	11	crispr	crispr	NOUN
cana-5141	333	12	provides	provide	VERB
cana-5141	333	13	acquired	acquire	VERB
cana-5141	333	14	resistance	resistance	NOUN
cana-5141	333	15	against	against	ADP
cana-5141	333	16	viruses	virus	NOUN
cana-5141	333	17	in	in	ADP
cana-5141	333	18	prokaryotes	prokaryote	NOUN
cana-5141	333	19	’	'	PUNCT
cana-5141	333	20	,	,	PUNCT
cana-5141	333	21	science	science	NOUN
cana-5141	333	22	(	(	PUNCT
cana-5141	333	23	1979	1979	NUM
cana-5141	333	24	)	)	PUNCT
cana-5141	333	25	,	,	PUNCT
cana-5141	333	26	vol	vol	NOUN
cana-5141	333	27	.	.	PROPN
cana-5141	333	28	315	315	NUM
cana-5141	333	29	,	,	PUNCT
cana-5141	333	30	no	no	NOUN
cana-5141	333	31	.	.	NOUN
cana-5141	333	32	5819	5819	NUM
cana-5141	333	33	,	,	PUNCT
cana-5141	333	34	pp	pp	ADP
cana-5141	333	35	.	.	PUNCT
cana-5141	333	36	1709–1712	1709–1712	NOUN
cana-5141	333	37	,	,	PUNCT
cana-5141	333	38	mar	mar	PROPN
cana-5141	333	39	.	.	PROPN
cana-5141	333	40	2007	2007	NUM
cana-5141	333	41	,	,	PUNCT
cana-5141	333	42	doi	doi	NOUN
cana-5141	333	43	:	:	PUNCT
cana-5141	333	44	10.1126	10.1126	NUM
cana-5141	333	45	/	/	SYM
cana-5141	333	46	science.1138140	science.1138140	NOUN
cana-5141	333	47	.	.	PUNCT
cana-5141	334	1	[	[	X
cana-5141	334	2	42	42	NUM
cana-5141	334	3	]	]	PUNCT
cana-5141	334	4	m.	m.	NOUN
cana-5141	334	5	jinek	jinek	NOUN
cana-5141	334	6	,	,	PUNCT
cana-5141	334	7	k.	k.	PROPN
cana-5141	334	8	chylinski	chylinski	PROPN
cana-5141	334	9	,	,	PUNCT
cana-5141	334	10	i.	i.	PROPN
cana-5141	334	11	fonfara	fonfara	PROPN
cana-5141	334	12	,	,	PUNCT
cana-5141	334	13	m.	m.	PROPN
cana-5141	334	14	hauer	hauer	PROPN
cana-5141	334	15	,	,	PUNCT
cana-5141	334	16	j.	j.	PROPN
cana-5141	334	17	a.	a.	PROPN
cana-5141	334	18	doudna	doudna	PROPN
cana-5141	334	19	,	,	PUNCT
cana-5141	334	20	and	and	CCONJ
cana-5141	334	21	e.	e.	PROPN
cana-5141	334	22	charpentier	charpentier	PROPN
cana-5141	334	23	,	,	PUNCT
cana-5141	334	24	‘	'	PUNCT
cana-5141	334	25	a	a	DET
cana-5141	334	26	programmable	programmable	ADJ
cana-5141	334	27	dual	dual	ADJ
cana-5141	334	28	-	-	PUNCT
cana-5141	334	29	rna	rna	NOUN
cana-5141	334	30	–	–	PUNCT
cana-5141	334	31	guided	guide	VERB
cana-5141	334	32	dna	dna	NOUN
cana-5141	334	33	endonuclease	endonuclease	NOUN
cana-5141	334	34	in	in	ADP
cana-5141	334	35	adaptive	adaptive	ADJ
cana-5141	334	36	bacterial	bacterial	ADJ
cana-5141	334	37	immunity	immunity	NOUN
cana-5141	334	38	’	'	PUNCT
cana-5141	334	39	,	,	PUNCT
cana-5141	334	40	science	science	NOUN
cana-5141	334	41	(	(	PUNCT
cana-5141	334	42	1979	1979	NUM
cana-5141	334	43	)	)	PUNCT
cana-5141	334	44	,	,	PUNCT
cana-5141	334	45	vol	vol	NOUN
cana-5141	334	46	.	.	PROPN
cana-5141	334	47	337	337	NUM
cana-5141	334	48	,	,	PUNCT
cana-5141	334	49	no	no	INTJ
cana-5141	334	50	.	.	NOUN
cana-5141	334	51	6096	6096	NUM
cana-5141	334	52	,	,	PUNCT
cana-5141	334	53	pp	pp	ADV
cana-5141	334	54	.	.	PUNCT
cana-5141	335	1	816–821	816–821	NUM
cana-5141	335	2	,	,	PUNCT
cana-5141	335	3	aug	aug	PROPN
cana-5141	335	4	.	.	PROPN
cana-5141	335	5	2012	2012	NUM
cana-5141	335	6	,	,	PUNCT
cana-5141	335	7	doi	doi	NOUN
cana-5141	335	8	:	:	PUNCT
cana-5141	335	9	10.1126	10.1126	NUM
cana-5141	335	10	/	/	SYM
cana-5141	335	11	science.1225829	science.1225829	PROPN
cana-5141	335	12	.	.	PUNCT
cana-5141	336	1	[	[	X
cana-5141	336	2	43	43	NUM
cana-5141	336	3	]	]	X
cana-5141	336	4	h.	h.	PROPN
cana-5141	336	5	nishimasu	nishimasu	VERB
cana-5141	336	6	et	et	PROPN
cana-5141	336	7	al	al	PROPN
cana-5141	336	8	.	.	PROPN
cana-5141	336	9	,	,	PUNCT
cana-5141	336	10	‘	'	PUNCT
cana-5141	336	11	crystal	crystal	NOUN
cana-5141	336	12	structure	structure	NOUN
cana-5141	336	13	of	of	ADP
cana-5141	336	14	cas9	cas9	NOUN
cana-5141	336	15	in	in	ADP
cana-5141	336	16	complex	complex	NOUN
cana-5141	336	17	with	with	ADP
cana-5141	336	18	guide	guide	NOUN
cana-5141	336	19	rna	rna	NOUN
cana-5141	336	20	and	and	CCONJ
cana-5141	336	21	target	target	PROPN
cana-5141	336	22	dna	dna	NOUN
cana-5141	336	23	’	'	PUNCT
cana-5141	336	24	,	,	PUNCT
cana-5141	336	25	cell	cell	NOUN
cana-5141	336	26	,	,	PUNCT
cana-5141	336	27	vol	vol	NOUN
cana-5141	336	28	.	.	PROPN
cana-5141	337	1	156	156	NUM
cana-5141	337	2	,	,	PUNCT
cana-5141	337	3	no	no	INTJ
cana-5141	337	4	.	.	NOUN
cana-5141	337	5	5	5	NUM
cana-5141	337	6	,	,	PUNCT
cana-5141	337	7	pp	pp	ADJ
cana-5141	337	8	.	.	PUNCT
cana-5141	338	1	935–949	935–949	NUM
cana-5141	338	2	,	,	PUNCT
cana-5141	338	3	feb	feb	PROPN
cana-5141	338	4	.	.	PROPN
cana-5141	338	5	2014	2014	NUM
cana-5141	338	6	,	,	PUNCT
cana-5141	338	7	doi	doi	NOUN
cana-5141	338	8	:	:	PUNCT
cana-5141	338	9	10.1016	10.1016	NUM
cana-5141	338	10	/	/	SYM
cana-5141	338	11	j.cell.2014.02.001	j.cell.2014.02.001	PROPN
cana-5141	338	12	.	.	PUNCT
cana-5141	339	1	[	[	X
cana-5141	339	2	44	44	NUM
cana-5141	339	3	]	]	PUNCT
cana-5141	339	4	m.	m.	NOUN
cana-5141	339	5	niuz	niuz	NOUN
cana-5141	339	6	,	,	PUNCT
cana-5141	339	7	m.	m.	PROPN
cana-5141	339	8	khan	khan	PROPN
cana-5141	339	9	,	,	PUNCT
cana-5141	339	10	m.	m.	NOUN
cana-5141	339	11	niuz	niuz	PROPN
cana-5141	339	12	morshed	morshe	VERB
cana-5141	339	13	khan	khan	PROPN
cana-5141	339	14	,	,	PUNCT
cana-5141	339	15	k.	k.	PROPN
cana-5141	339	16	khaldun	khaldun	PROPN
cana-5141	339	17	islam	islam	PROPN
cana-5141	339	18	,	,	PUNCT
cana-5141	339	19	a.	a.	NOUN
cana-5141	339	20	ashraf	ashraf	PROPN
cana-5141	339	21	,	,	PUNCT
cana-5141	339	22	and	and	CCONJ
cana-5141	339	23	n.	n.	PROPN
cana-5141	339	24	chandra	chandra	PROPN
cana-5141	339	25	barman	barman	PROPN
cana-5141	339	26	,	,	PUNCT
cana-5141	339	27	‘	'	PUNCT
cana-5141	339	28	a	a	DET
cana-5141	339	29	review	review	NOUN
cana-5141	339	30	on	on	ADP
cana-5141	339	31	genome	genome	NOUN
cana-5141	339	32	editing	editing	NOUN
cana-5141	339	33	by	by	ADP
cana-5141	339	34	crispr	crispr	ADJ
cana-5141	339	35	-	-	PUNCT
cana-5141	339	36	cas9	cas9	NOUN
cana-5141	339	37	technique	technique	NOUN
cana-5141	339	38	for	for	ADP
cana-5141	339	39	cancer	cancer	NOUN
cana-5141	339	40	treatment	treatment	NOUN
cana-5141	339	41	wcrj	wcrj	NOUN
cana-5141	339	42	2020	2020	NUM
cana-5141	339	43	;	;	PUNCT
cana-5141	339	44	7	7	NUM
cana-5141	339	45	:	:	PUNCT
cana-5141	339	46	e1510	e1510	ADJ
cana-5141	339	47	’	'	PUNCT
cana-5141	339	48	.	.	PUNCT
cana-5141	340	1	[	[	X
cana-5141	340	2	45	45	NUM
cana-5141	340	3	]	]	PUNCT
cana-5141	340	4	m.	m.	NOUN
cana-5141	340	5	chen	chen	PROPN
cana-5141	340	6	,	,	PUNCT
cana-5141	340	7	a.	a.	PROPN
cana-5141	340	8	mao	mao	PROPN
cana-5141	340	9	,	,	PUNCT
cana-5141	340	10	m.	m.	PROPN
cana-5141	340	11	xu	xu	PROPN
cana-5141	340	12	,	,	PUNCT
cana-5141	340	13	q.	q.	PROPN
cana-5141	340	14	weng	weng	PROPN
cana-5141	340	15	,	,	PUNCT
cana-5141	340	16	j.	j.	PROPN
cana-5141	340	17	mao	mao	PROPN
cana-5141	340	18	,	,	PUNCT
cana-5141	340	19	and	and	CCONJ
cana-5141	340	20	j.	j.	PROPN
cana-5141	340	21	ji	ji	PROPN
cana-5141	340	22	,	,	PUNCT
cana-5141	340	23	‘	'	PUNCT
cana-5141	340	24	crispr	crispr	NOUN
cana-5141	340	25	-	-	PUNCT
cana-5141	340	26	cas9	cas9	NOUN
cana-5141	340	27	for	for	ADP
cana-5141	340	28	cancer	cancer	NOUN
cana-5141	340	29	therapy	therapy	NOUN
cana-5141	340	30	:	:	PUNCT
cana-5141	340	31	opportunities	opportunity	NOUN
cana-5141	340	32	and	and	CCONJ
cana-5141	340	33	challenges	challenge	NOUN
cana-5141	340	34	’	'	PUNCT
cana-5141	340	35	,	,	PUNCT
cana-5141	340	36	cancer	cancer	NOUN
cana-5141	340	37	lett	lett	PROPN
cana-5141	340	38	,	,	PUNCT
cana-5141	340	39	vol	vol	NOUN
cana-5141	340	40	.	.	PROPN
cana-5141	340	41	447	447	NUM
cana-5141	340	42	,	,	PUNCT
cana-5141	340	43	pp	pp	ADJ
cana-5141	340	44	.	.	PUNCT
cana-5141	341	1	48–55	48–55	NUM
cana-5141	341	2	,	,	PUNCT
cana-5141	341	3	apr	apr	NOUN
cana-5141	341	4	.	.	PROPN
cana-5141	341	5	2019	2019	NUM
cana-5141	341	6	,	,	PUNCT
cana-5141	341	7	doi	doi	NOUN
cana-5141	341	8	:	:	PUNCT
cana-5141	341	9	10.1016	10.1016	NUM
cana-5141	341	10	/	/	SYM
cana-5141	341	11	j.canlet.2019.01.017	j.canlet.2019.01.017	PROPN
cana-5141	341	12	.	.	PUNCT
cana-5141	342	1	[	[	X
cana-5141	342	2	46	46	NUM
cana-5141	342	3	]	]	X
cana-5141	342	4	e.	e.	PROPN
cana-5141	342	5	s.	s.	PROPN
cana-5141	342	6	lander	lander	PROPN
cana-5141	342	7	,	,	PUNCT
cana-5141	342	8	‘	'	PUNCT
cana-5141	342	9	the	the	DET
cana-5141	342	10	heroes	hero	NOUN
cana-5141	342	11	of	of	ADP
cana-5141	342	12	crispr	crispr	NOUN
cana-5141	342	13	’	'	PUNCT
cana-5141	342	14	,	,	PUNCT
cana-5141	342	15	cell	cell	NOUN
cana-5141	342	16	,	,	PUNCT
cana-5141	342	17	vol	vol	NOUN
cana-5141	342	18	.	.	NOUN
cana-5141	342	19	164	164	NUM
cana-5141	342	20	,	,	PUNCT
cana-5141	342	21	no	no	INTJ
cana-5141	342	22	.	.	PUNCT
cana-5141	343	1	1–2	1–2	NUM
cana-5141	343	2	,	,	PUNCT
cana-5141	343	3	pp	pp	ADJ
cana-5141	343	4	.	.	PUNCT
cana-5141	344	1	18–28	18–28	NUM
cana-5141	344	2	,	,	PUNCT
cana-5141	344	3	jan	jan	PROPN
cana-5141	344	4	.	.	PROPN
cana-5141	344	5	2016	2016	NUM
cana-5141	344	6	,	,	PUNCT
cana-5141	344	7	doi	doi	NOUN
cana-5141	344	8	:	:	PUNCT
cana-5141	344	9	10.1016	10.1016	NUM
cana-5141	344	10	/	/	SYM
cana-5141	344	11	j.cell.2015.12.041	j.cell.2015.12.041	NOUN
cana-5141	344	12	.	.	PUNCT
cana-5141	345	1	[	[	X
cana-5141	345	2	47	47	NUM
cana-5141	345	3	]	]	X
cana-5141	345	4	i.	i.	PROPN
cana-5141	345	5	maggio	maggio	PROPN
cana-5141	345	6	,	,	PUNCT
cana-5141	345	7	m.	m.	NOUN
cana-5141	345	8	holkers	holkers	PROPN
cana-5141	345	9	,	,	PUNCT
cana-5141	345	10	j.	j.	PROPN
cana-5141	345	11	liu	liu	PROPN
cana-5141	345	12	,	,	PUNCT
cana-5141	345	13	j.	j.	PROPN
cana-5141	345	14	m.	m.	PROPN
cana-5141	345	15	janssen	janssen	PROPN
cana-5141	345	16	,	,	PUNCT
cana-5141	345	17	x.	x.	PROPN
cana-5141	345	18	chen	chen	PROPN
cana-5141	345	19	,	,	PUNCT
cana-5141	345	20	and	and	CCONJ
cana-5141	345	21	m.	m.	PROPN
cana-5141	345	22	a.	a.	PROPN
cana-5141	345	23	f.	f.	PROPN
cana-5141	345	24	v.	v.	PROPN
cana-5141	345	25	gonçalves	gonçalves	PROPN
cana-5141	345	26	,	,	PUNCT
cana-5141	345	27	‘	'	PUNCT
cana-5141	345	28	adenoviral	adenoviral	ADJ
cana-5141	345	29	vector	vector	NOUN
cana-5141	345	30	delivery	delivery	NOUN
cana-5141	345	31	of	of	ADP
cana-5141	345	32	rna	rna	NOUN
cana-5141	345	33	-	-	PUNCT
cana-5141	345	34	guided	guide	VERB
cana-5141	345	35	crispr	crispr	ADJ
cana-5141	345	36	/	/	SYM
cana-5141	345	37	cas9	cas9	NOUN
cana-5141	345	38	nuclease	nuclease	NOUN
cana-5141	345	39	complexes	complex	NOUN
cana-5141	345	40	induces	induce	VERB
cana-5141	345	41	targeted	target	VERB
cana-5141	345	42	mutagenesis	mutagenesis	NOUN
cana-5141	345	43	in	in	ADP
cana-5141	345	44	a	a	DET
cana-5141	345	45	diverse	diverse	ADJ
cana-5141	345	46	array	array	NOUN
cana-5141	345	47	of	of	ADP
cana-5141	345	48	human	human	ADJ
cana-5141	345	49	cells	cell	NOUN
cana-5141	345	50	’	'	PUNCT
cana-5141	345	51	,	,	PUNCT
cana-5141	345	52	sci	sci	PROPN
cana-5141	345	53	rep	rep	PROPN
cana-5141	345	54	,	,	PUNCT
cana-5141	345	55	vol	vol	NOUN
cana-5141	345	56	.	.	PROPN
cana-5141	345	57	4	4	NUM
cana-5141	345	58	,	,	PUNCT
cana-5141	345	59	no	no	INTJ
cana-5141	345	60	.	.	NOUN
cana-5141	345	61	1	1	NUM
cana-5141	345	62	,	,	PUNCT
cana-5141	345	63	p.	p.	NOUN
cana-5141	345	64	5105	5105	NUM
cana-5141	345	65	,	,	PUNCT
cana-5141	345	66	may	may	AUX
cana-5141	345	67	2014	2014	NUM
cana-5141	345	68	,	,	PUNCT
cana-5141	345	69	doi	doi	NOUN
cana-5141	345	70	:	:	PUNCT
cana-5141	345	71	10.1038	10.1038	NUM
cana-5141	345	72	/	/	SYM
cana-5141	345	73	srep05105	srep05105	PROPN
cana-5141	345	74	.	.	PUNCT
cana-5141	346	1	[	[	X
cana-5141	346	2	48	48	NUM
cana-5141	346	3	]	]	PUNCT
cana-5141	346	4	d.	d.	PROPN
cana-5141	346	5	h.	h.	PROPN
cana-5141	346	6	patel	patel	PROPN
cana-5141	346	7	and	and	CCONJ
cana-5141	346	8	a.	a.	NOUN
cana-5141	346	9	misra	misra	PROPN
cana-5141	346	10	,	,	PUNCT
cana-5141	346	11	‘	'	PUNCT
cana-5141	346	12	gene	gene	NOUN
cana-5141	346	13	delivery	delivery	NOUN
cana-5141	346	14	using	use	VERB
cana-5141	346	15	viral	viral	ADJ
cana-5141	346	16	vectors	vector	NOUN
cana-5141	346	17	’	'	PUNCT
cana-5141	346	18	,	,	PUNCT
cana-5141	346	19	in	in	ADP
cana-5141	346	20	challenges	challenge	NOUN
cana-5141	346	21	in	in	ADP
cana-5141	346	22	delivery	delivery	NOUN
cana-5141	346	23	of	of	ADP
cana-5141	346	24	therapeutic	therapeutic	ADJ
cana-5141	346	25	genomics	genomic	NOUN
cana-5141	346	26	and	and	CCONJ
cana-5141	346	27	proteomics	proteomic	NOUN
cana-5141	346	28	,	,	PUNCT
cana-5141	346	29	elsevier	elsevier	NOUN
cana-5141	346	30	,	,	PUNCT
cana-5141	346	31	2011	2011	NUM
cana-5141	346	32	,	,	PUNCT
cana-5141	346	33	pp	pp	ADJ
cana-5141	346	34	.	.	PUNCT
cana-5141	347	1	207–270	207–270	NUM
cana-5141	347	2	.	.	PUNCT
cana-5141	348	1	doi	doi	NOUN
cana-5141	348	2	:	:	PUNCT
cana-5141	348	3	10.1016	10.1016	NUM
cana-5141	348	4	/	/	SYM
cana-5141	348	5	b978	b978	PROPN
cana-5141	348	6	-	-	PUNCT
cana-5141	348	7	012	012	NUM
cana-5141	348	8	-	-	PUNCT
cana-5141	348	9	384964	384964	NUM
cana-5141	348	10	-	-	PUNCT
cana-5141	348	11	9.00005	9.00005	NUM
cana-5141	348	12	-	-	SYM
cana-5141	348	13	0	0	NUM
cana-5141	348	14	.	.	PUNCT
cana-5141	349	1	[	[	X
cana-5141	349	2	49	49	NUM
cana-5141	349	3	]	]	PUNCT
cana-5141	349	4	l.	l.	PROPN
cana-5141	349	5	li	li	PROPN
cana-5141	349	6	,	,	PUNCT
cana-5141	349	7	z.-y	z.-y	NOUN
cana-5141	349	8	.	.	PUNCT
cana-5141	350	1	he	he	PRON
cana-5141	350	2	,	,	PUNCT
cana-5141	350	3	x.-w	x.-w	PROPN
cana-5141	350	4	.	.	PUNCT
cana-5141	351	1	wei	wei	PROPN
cana-5141	351	2	,	,	PUNCT
cana-5141	351	3	g.-p	g.-p	PROPN
cana-5141	351	4	.	.	PUNCT
cana-5141	352	1	gao	gao	PROPN
cana-5141	352	2	,	,	PUNCT
cana-5141	352	3	and	and	CCONJ
cana-5141	352	4	y.-q	y.-q	PROPN
cana-5141	352	5	.	.	PUNCT
cana-5141	353	1	wei	wei	PROPN
cana-5141	353	2	,	,	PUNCT
cana-5141	353	3	‘	'	PUNCT
cana-5141	353	4	challenges	challenge	NOUN
cana-5141	353	5	in	in	ADP
cana-5141	353	6	crispr	crispr	ADJ
cana-5141	353	7	/	/	SYM
cana-5141	353	8	cas9	cas9	NOUN
cana-5141	353	9	delivery	delivery	NOUN
cana-5141	353	10	:	:	PUNCT
cana-5141	353	11	potential	potential	ADJ
cana-5141	353	12	roles	role	NOUN
cana-5141	353	13	of	of	ADP
cana-5141	353	14	nonviral	nonviral	ADJ
cana-5141	353	15	vectors	vector	NOUN
cana-5141	353	16	’	'	PUNCT
cana-5141	353	17	,	,	PUNCT
cana-5141	353	18	hum	hum	ADJ
cana-5141	353	19	gene	gene	PROPN
cana-5141	353	20	ther	ther	ADV
cana-5141	353	21	,	,	PUNCT
cana-5141	353	22	vol	vol	NOUN
cana-5141	353	23	.	.	PROPN
cana-5141	353	24	26	26	NUM
cana-5141	353	25	,	,	PUNCT
cana-5141	353	26	no	no	INTJ
cana-5141	353	27	.	.	NOUN
cana-5141	353	28	7	7	NUM
cana-5141	353	29	,	,	PUNCT
cana-5141	353	30	pp	pp	ADJ
cana-5141	353	31	.	.	PUNCT
cana-5141	354	1	452–462	452–462	NUM
cana-5141	354	2	,	,	PUNCT
cana-5141	354	3	jul	jul	PROPN
cana-5141	354	4	.	.	PROPN
cana-5141	354	5	2015	2015	NUM
cana-5141	354	6	,	,	PUNCT
cana-5141	354	7	doi	doi	NOUN
cana-5141	354	8	:	:	PUNCT
cana-5141	354	9	10.1089	10.1089	NUM
cana-5141	354	10	/	/	SYM
cana-5141	354	11	hum.2015.069	hum.2015.069	NOUN
cana-5141	354	12	.	.	PUNCT
cana-5141	355	1	[	[	X
cana-5141	355	2	50	50	NUM
cana-5141	355	3	]	]	PUNCT
cana-5141	355	4	j.	j.	PROPN
cana-5141	355	5	zhou	zhou	PROPN
cana-5141	355	6	,	,	PUNCT
cana-5141	355	7	q.	q.	PROPN
cana-5141	355	8	xu	xu	PROPN
cana-5141	355	9	,	,	PUNCT
cana-5141	355	10	j.	j.	PROPN
cana-5141	355	11	yao	yao	PROPN
cana-5141	355	12	,	,	PUNCT
cana-5141	355	13	s.	s.	PROPN
cana-5141	355	14	yu	yu	PROPN
cana-5141	355	15	,	,	PUNCT
cana-5141	355	16	and	and	CCONJ
cana-5141	355	17	s.	s.	PROPN
cana-5141	355	18	cao	cao	PROPN
cana-5141	355	19	,	,	PUNCT
cana-5141	355	20	‘	'	PUNCT
cana-5141	355	21	crispr	crispr	ADJ
cana-5141	355	22	/	/	SYM
cana-5141	355	23	cas9	cas9	NOUN
cana-5141	355	24	genome	genome	NOUN
cana-5141	355	25	editing	editing	NOUN
cana-5141	355	26	technique	technique	NOUN
cana-5141	355	27	and	and	CCONJ
cana-5141	355	28	its	its	PRON
cana-5141	355	29	application	application	NOUN
cana-5141	355	30	in	in	ADP
cana-5141	355	31	site	site	NOUN
cana-5141	355	32	-	-	PUNCT
cana-5141	355	33	directed	direct	VERB
cana-5141	355	34	genome	genome	NOUN
cana-5141	355	35	modification	modification	NOUN
cana-5141	355	36	of	of	ADP
cana-5141	355	37	animals	animal	NOUN
cana-5141	355	38	.	.	PUNCT
cana-5141	355	39	’	'	PUNCT
cana-5141	355	40	,	,	PUNCT
cana-5141	355	41	yi	yi	PROPN
cana-5141	355	42	chuan	chuan	PROPN
cana-5141	355	43	,	,	PUNCT
cana-5141	355	44	vol	vol	NOUN
cana-5141	355	45	.	.	PROPN
cana-5141	355	46	37	37	NUM
cana-5141	355	47	,	,	PUNCT
cana-5141	355	48	no	no	INTJ
cana-5141	355	49	.	.	NOUN
cana-5141	355	50	10	10	NUM
cana-5141	355	51	,	,	PUNCT
cana-5141	355	52	pp	pp	PROPN
cana-5141	355	53	.	.	PUNCT
cana-5141	355	54	1011–20	1011–20	NUM
cana-5141	355	55	,	,	PUNCT
cana-5141	355	56	oct	oct	PROPN
cana-5141	355	57	.	.	PROPN
cana-5141	355	58	2015	2015	NUM
cana-5141	355	59	,	,	PUNCT
cana-5141	355	60	doi	doi	NOUN
cana-5141	355	61	:	:	PUNCT
cana-5141	355	62	10.16288	10.16288	NUM
cana-5141	355	63	/	/	SYM
cana-5141	355	64	j.yczz.15	j.yczz.15	NOUN
cana-5141	355	65	-	-	PUNCT
cana-5141	355	66	066	066	NUM
cana-5141	355	67	.	.	PUNCT
cana-5141	356	1	communications	communication	NOUN
cana-5141	356	2	on	on	ADP
cana-5141	356	3	applied	apply	VERB
cana-5141	356	4	nonlinear	nonlinear	ADJ
cana-5141	356	5	analysis	analysis	NOUN
cana-5141	356	6	issn	issn	NOUN
cana-5141	356	7	:	:	PUNCT
cana-5141	356	8	1074	1074	NUM
cana-5141	356	9	-	-	PUNCT
cana-5141	356	10	133x	133x	NUM
cana-5141	356	11	vol	vol	NOUN
cana-5141	356	12	32	32	NUM
cana-5141	356	13	no	no	NOUN
cana-5141	356	14	.	.	PUNCT
cana-5141	357	1	icmasd	icmasd	NOUN
cana-5141	357	2	(	(	PUNCT
cana-5141	357	3	2025	2025	NUM
cana-5141	357	4	)	)	PUNCT
cana-5141	357	5	1153	1153	NUM
cana-5141	357	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	358	1	[	[	X
cana-5141	358	2	51	51	NUM
cana-5141	358	3	]	]	PUNCT
cana-5141	358	4	l.	l.	PROPN
cana-5141	358	5	qu	qu	PROPN
cana-5141	358	6	,	,	PUNCT
cana-5141	358	7	h.	h.	PROPN
cana-5141	358	8	li	li	PROPN
cana-5141	358	9	,	,	PUNCT
cana-5141	358	10	y.	y.	PROPN
cana-5141	358	11	jiang	jiang	PROPN
cana-5141	358	12	,	,	PUNCT
cana-5141	358	13	and	and	CCONJ
cana-5141	358	14	c.	c.	PROPN
cana-5141	358	15	dong	dong	PROPN
cana-5141	358	16	,	,	PUNCT
cana-5141	358	17	‘	'	PUNCT
cana-5141	358	18	the	the	DET
cana-5141	358	19	molecular	molecular	ADJ
cana-5141	358	20	mechanism	mechanism	NOUN
cana-5141	358	21	of	of	ADP
cana-5141	358	22	crispr	crispr	ADJ
cana-5141	358	23	/	/	SYM
cana-5141	358	24	cas9	cas9	NOUN
cana-5141	358	25	system	system	NOUN
cana-5141	358	26	and	and	CCONJ
cana-5141	358	27	its	its	PRON
cana-5141	358	28	application	application	NOUN
cana-5141	358	29	in	in	ADP
cana-5141	358	30	gene	gene	NOUN
cana-5141	358	31	therapy	therapy	NOUN
cana-5141	358	32	of	of	ADP
cana-5141	358	33	human	human	ADJ
cana-5141	358	34	diseases	disease	NOUN
cana-5141	358	35	.	.	PUNCT
cana-5141	358	36	’	'	PUNCT
cana-5141	358	37	,	,	PUNCT
cana-5141	358	38	yi	yi	PROPN
cana-5141	358	39	chuan	chuan	PROPN
cana-5141	358	40	,	,	PUNCT
cana-5141	358	41	vol	vol	NOUN
cana-5141	358	42	.	.	PROPN
cana-5141	358	43	37	37	NUM
cana-5141	358	44	,	,	PUNCT
cana-5141	358	45	no	no	INTJ
cana-5141	358	46	.	.	NOUN
cana-5141	358	47	10	10	NUM
cana-5141	358	48	,	,	PUNCT
cana-5141	358	49	pp	pp	ADJ
cana-5141	358	50	.	.	PUNCT
cana-5141	359	1	974–82	974–82	NOUN
cana-5141	359	2	,	,	PUNCT
cana-5141	359	3	oct	oct	PROPN
cana-5141	359	4	.	.	PROPN
cana-5141	359	5	2015	2015	NUM
cana-5141	359	6	,	,	PUNCT
cana-5141	359	7	doi	doi	NOUN
cana-5141	359	8	:	:	PUNCT
cana-5141	359	9	10.16288	10.16288	NUM
cana-5141	359	10	/	/	SYM
cana-5141	359	11	j.yczz.15	j.yczz.15	PROPN
cana-5141	359	12	-	-	PUNCT
cana-5141	359	13	109	109	NUM
cana-5141	359	14	.	.	PUNCT
cana-5141	360	1	[	[	X
cana-5141	360	2	52	52	NUM
cana-5141	360	3	]	]	PUNCT
cana-5141	360	4	s.	s.	PROPN
cana-5141	360	5	aghamiri	aghamiri	PROPN
cana-5141	360	6	et	et	PROPN
cana-5141	360	7	al	al	PROPN
cana-5141	360	8	.	.	PROPN
cana-5141	360	9	,	,	PUNCT
cana-5141	360	10	‘	'	PUNCT
cana-5141	360	11	nanoparticles	nanoparticle	NOUN
cana-5141	360	12	-	-	PUNCT
cana-5141	360	13	mediated	mediate	VERB
cana-5141	360	14	crispr	crispr	ADJ
cana-5141	360	15	/	/	SYM
cana-5141	360	16	cas9	cas9	NOUN
cana-5141	360	17	delivery	delivery	NOUN
cana-5141	360	18	:	:	PUNCT
cana-5141	360	19	recent	recent	ADJ
cana-5141	360	20	advances	advance	NOUN
cana-5141	360	21	in	in	ADP
cana-5141	360	22	cancer	cancer	NOUN
cana-5141	360	23	treatment	treatment	NOUN
cana-5141	360	24	’	'	PUNCT
cana-5141	360	25	,	,	PUNCT
cana-5141	360	26	j	j	PROPN
cana-5141	360	27	drug	drug	NOUN
cana-5141	360	28	deliv	deliv	VERB
cana-5141	360	29	sci	sci	PROPN
cana-5141	360	30	technol	technol	PROPN
cana-5141	360	31	,	,	PUNCT
cana-5141	360	32	vol	vol	NOUN
cana-5141	360	33	.	.	PROPN
cana-5141	360	34	56	56	NUM
cana-5141	360	35	,	,	PUNCT
cana-5141	360	36	p.	p.	NOUN
cana-5141	360	37	101533	101533	NUM
cana-5141	360	38	,	,	PUNCT
cana-5141	360	39	apr	apr	PROPN
cana-5141	360	40	.	.	PROPN
cana-5141	360	41	2020	2020	NUM
cana-5141	360	42	,	,	PUNCT
cana-5141	360	43	doi	doi	NOUN
cana-5141	360	44	:	:	PUNCT
cana-5141	360	45	10.1016	10.1016	NUM
cana-5141	360	46	/	/	SYM
cana-5141	360	47	j.jddst.2020.101533	j.jddst.2020.101533	PROPN
cana-5141	360	48	.	.	PUNCT
cana-5141	361	1	[	[	X
cana-5141	361	2	53	53	NUM
cana-5141	361	3	]	]	X
cana-5141	361	4	d.	d.	PROPN
cana-5141	361	5	wang	wang	PROPN
cana-5141	361	6	,	,	PUNCT
cana-5141	361	7	f.	f.	PROPN
cana-5141	361	8	zhang	zhang	PROPN
cana-5141	361	9	,	,	PUNCT
cana-5141	361	10	and	and	CCONJ
cana-5141	361	11	g.	g.	PROPN
cana-5141	361	12	gao	gao	PROPN
cana-5141	361	13	,	,	PUNCT
cana-5141	361	14	‘	'	PUNCT
cana-5141	361	15	crispr	crispr	NOUN
cana-5141	361	16	-	-	PUNCT
cana-5141	361	17	based	base	VERB
cana-5141	361	18	therapeutic	therapeutic	ADJ
cana-5141	361	19	genome	genome	NOUN
cana-5141	361	20	editing	editing	NOUN
cana-5141	361	21	:	:	PUNCT
cana-5141	361	22	strategies	strategy	NOUN
cana-5141	361	23	and	and	CCONJ
cana-5141	361	24	in	in	ADP
cana-5141	361	25	vivo	vivo	ADJ
cana-5141	361	26	delivery	delivery	NOUN
cana-5141	361	27	by	by	ADP
cana-5141	361	28	aav	aav	PROPN
cana-5141	361	29	vectors	vector	NOUN
cana-5141	361	30	’	'	PUNCT
cana-5141	361	31	,	,	PUNCT
cana-5141	361	32	apr	apr	PROPN
cana-5141	361	33	.	.	PROPN
cana-5141	361	34	02	02	NUM
cana-5141	361	35	,	,	PUNCT
cana-5141	361	36	2020	2020	NUM
cana-5141	361	37	,	,	PUNCT
cana-5141	361	38	cell	cell	NOUN
cana-5141	361	39	press	press	NOUN
cana-5141	361	40	.	.	PUNCT
cana-5141	362	1	doi	doi	NOUN
cana-5141	362	2	:	:	PUNCT
cana-5141	362	3	10.1016	10.1016	NUM
cana-5141	362	4	/	/	SYM
cana-5141	362	5	j.cell.2020.03.023	j.cell.2020.03.023	NOUN
cana-5141	362	6	.	.	PUNCT
cana-5141	363	1	[	[	X
cana-5141	363	2	54	54	NUM
cana-5141	363	3	]	]	PUNCT
cana-5141	363	4	l.	l.	PROPN
cana-5141	363	5	cong	cong	PROPN
cana-5141	363	6	et	et	PROPN
cana-5141	363	7	al	al	PROPN
cana-5141	363	8	.	.	PROPN
cana-5141	363	9	,	,	PUNCT
cana-5141	363	10	‘	'	PUNCT
cana-5141	363	11	multiplex	multiplex	NOUN
cana-5141	363	12	genome	genome	NOUN
cana-5141	363	13	engineering	engineering	NOUN
cana-5141	363	14	using	use	VERB
cana-5141	363	15	crispr	crispr	ADJ
cana-5141	363	16	/	/	SYM
cana-5141	363	17	cas	cas	NOUN
cana-5141	363	18	systems	system	NOUN
cana-5141	363	19	’	'	PUNCT
cana-5141	363	20	,	,	PUNCT
cana-5141	363	21	science	science	NOUN
cana-5141	363	22	(	(	PUNCT
cana-5141	363	23	1979	1979	NUM
cana-5141	363	24	)	)	PUNCT
cana-5141	363	25	,	,	PUNCT
cana-5141	363	26	vol	vol	NOUN
cana-5141	363	27	.	.	PROPN
cana-5141	363	28	339	339	NUM
cana-5141	363	29	,	,	PUNCT
cana-5141	363	30	no	no	NOUN
cana-5141	363	31	.	.	NOUN
cana-5141	363	32	6121	6121	NUM
cana-5141	363	33	,	,	PUNCT
cana-5141	363	34	pp	pp	ADJ
cana-5141	363	35	.	.	PUNCT
cana-5141	364	1	819–823	819–823	NUM
cana-5141	364	2	,	,	PUNCT
cana-5141	364	3	feb	feb	PROPN
cana-5141	364	4	.	.	PROPN
cana-5141	364	5	2013	2013	NUM
cana-5141	364	6	,	,	PUNCT
cana-5141	364	7	doi	doi	NOUN
cana-5141	364	8	:	:	PUNCT
cana-5141	364	9	10.1126	10.1126	NUM
cana-5141	364	10	/	/	SYM
cana-5141	364	11	science.1231143	science.1231143	PROPN
cana-5141	364	12	.	.	PUNCT
cana-5141	365	1	[	[	X
cana-5141	365	2	55	55	NUM
cana-5141	365	3	]	]	X
cana-5141	365	4	c.	c.	PROPN
cana-5141	365	5	liu	liu	PROPN
cana-5141	365	6	,	,	PUNCT
cana-5141	365	7	l.	l.	PROPN
cana-5141	365	8	zhang	zhang	PROPN
cana-5141	365	9	,	,	PUNCT
cana-5141	365	10	h.	h.	PROPN
cana-5141	365	11	liu	liu	PROPN
cana-5141	365	12	,	,	PUNCT
cana-5141	365	13	and	and	CCONJ
cana-5141	365	14	k.	k.	PROPN
cana-5141	365	15	cheng	cheng	PROPN
cana-5141	365	16	,	,	PUNCT
cana-5141	365	17	‘	'	PUNCT
cana-5141	365	18	delivery	delivery	NOUN
cana-5141	365	19	strategies	strategy	NOUN
cana-5141	365	20	of	of	ADP
cana-5141	365	21	the	the	DET
cana-5141	365	22	crispr	crispr	ADJ
cana-5141	365	23	-	-	PUNCT
cana-5141	365	24	cas9	cas9	NOUN
cana-5141	365	25	geneediting	geneedite	VERB
cana-5141	365	26	system	system	NOUN
cana-5141	365	27	for	for	ADP
cana-5141	365	28	therapeutic	therapeutic	ADJ
cana-5141	365	29	applications	application	NOUN
cana-5141	365	30	’	'	PUNCT
cana-5141	365	31	,	,	PUNCT
cana-5141	365	32	journal	journal	NOUN
cana-5141	365	33	of	of	ADP
cana-5141	365	34	controlled	control	VERB
cana-5141	365	35	release	release	NOUN
cana-5141	365	36	,	,	PUNCT
cana-5141	365	37	vol	vol	NOUN
cana-5141	365	38	.	.	PROPN
cana-5141	365	39	266	266	NUM
cana-5141	365	40	,	,	PUNCT
cana-5141	365	41	pp	pp	ADJ
cana-5141	365	42	.	.	PUNCT
cana-5141	366	1	17	17	NUM
cana-5141	366	2	–	–	SYM
cana-5141	366	3	26	26	NUM
cana-5141	366	4	,	,	PUNCT
cana-5141	366	5	nov	nov	PROPN
cana-5141	366	6	.	.	PROPN
cana-5141	366	7	2017	2017	NUM
cana-5141	366	8	,	,	PUNCT
cana-5141	366	9	doi	doi	NOUN
cana-5141	366	10	:	:	PUNCT
cana-5141	366	11	10.1016	10.1016	NUM
cana-5141	366	12	/	/	SYM
cana-5141	366	13	j.jconrel.2017.09.012	j.jconrel.2017.09.012	PROPN
cana-5141	366	14	.	.	PUNCT
cana-5141	367	1	[	[	X
cana-5141	367	2	56	56	NUM
cana-5141	367	3	]	]	X
cana-5141	367	4	l.	l.	PROPN
cana-5141	367	5	m.	m.	PROPN
cana-5141	367	6	de	de	PROPN
cana-5141	367	7	plano	plano	PROPN
cana-5141	367	8	,	,	PUNCT
cana-5141	367	9	g.	g.	PROPN
cana-5141	367	10	calabrese	calabrese	PROPN
cana-5141	367	11	,	,	PUNCT
cana-5141	367	12	s.	s.	PROPN
cana-5141	367	13	conoci	conoci	PROPN
cana-5141	367	14	,	,	PUNCT
cana-5141	367	15	s.	s.	PROPN
cana-5141	367	16	p.	p.	PROPN
cana-5141	367	17	p.	p.	PROPN
cana-5141	367	18	guglielmino	guglielmino	PROPN
cana-5141	367	19	,	,	PUNCT
cana-5141	367	20	s.	s.	PROPN
cana-5141	367	21	oddo	oddo	PROPN
cana-5141	367	22	,	,	PUNCT
cana-5141	367	23	and	and	CCONJ
cana-5141	367	24	a.	a.	NOUN
cana-5141	367	25	caccamo	caccamo	PROPN
cana-5141	367	26	,	,	PUNCT
cana-5141	367	27	‘	'	PUNCT
cana-5141	367	28	applications	application	NOUN
cana-5141	367	29	of	of	ADP
cana-5141	367	30	crispr	crispr	NOUN
cana-5141	367	31	-	-	PUNCT
cana-5141	367	32	cas9	cas9	NOUN
cana-5141	367	33	in	in	ADP
cana-5141	367	34	alzheimer	alzheimer	PROPN
cana-5141	367	35	’s	’s	PART
cana-5141	367	36	disease	disease	NOUN
cana-5141	367	37	and	and	CCONJ
cana-5141	367	38	related	related	ADJ
cana-5141	367	39	disorders	disorder	NOUN
cana-5141	367	40	’	'	PUNCT
cana-5141	367	41	,	,	PUNCT
cana-5141	367	42	int	int	PROPN
cana-5141	367	43	j	j	PROPN
cana-5141	367	44	mol	mol	ADP
cana-5141	367	45	sci	sci	PROPN
cana-5141	367	46	,	,	PUNCT
cana-5141	367	47	vol	vol	NOUN
cana-5141	367	48	.	.	PROPN
cana-5141	367	49	23	23	NUM
cana-5141	367	50	,	,	PUNCT
cana-5141	367	51	no	no	INTJ
cana-5141	367	52	.	.	NOUN
cana-5141	367	53	15	15	NUM
cana-5141	367	54	,	,	PUNCT
cana-5141	367	55	p.	p.	NOUN
cana-5141	367	56	8714	8714	NUM
cana-5141	367	57	,	,	PUNCT
cana-5141	367	58	aug	aug	PROPN
cana-5141	367	59	.	.	PROPN
cana-5141	367	60	2022	2022	NUM
cana-5141	367	61	,	,	PUNCT
cana-5141	367	62	doi	doi	NOUN
cana-5141	367	63	:	:	PUNCT
cana-5141	367	64	10.3390	10.3390	NUM
cana-5141	367	65	/	/	SYM
cana-5141	367	66	ijms23158714	ijms23158714	PROPN
cana-5141	367	67	.	.	PUNCT
cana-5141	368	1	[	[	X
cana-5141	368	2	57	57	NUM
cana-5141	368	3	]	]	PUNCT
cana-5141	368	4	h.	h.	PROPN
cana-5141	368	5	park	park	PROPN
cana-5141	368	6	and	and	CCONJ
cana-5141	368	7	j.	j.	PROPN
cana-5141	368	8	kim	kim	PROPN
cana-5141	368	9	,	,	PUNCT
cana-5141	368	10	‘	'	PUNCT
cana-5141	368	11	activation	activation	NOUN
cana-5141	368	12	of	of	ADP
cana-5141	368	13	melatonin	melatonin	NOUN
cana-5141	368	14	receptor	receptor	NOUN
cana-5141	368	15	1	1	NUM
cana-5141	368	16	by	by	ADP
cana-5141	368	17	crispr‐cas9	crispr‐cas9	NOUN
cana-5141	368	18	activator	activator	NOUN
cana-5141	368	19	ameliorates	ameliorate	VERB
cana-5141	368	20	cognitive	cognitive	ADJ
cana-5141	368	21	deficits	deficit	NOUN
cana-5141	368	22	in	in	ADP
cana-5141	368	23	an	an	DET
cana-5141	368	24	alzheimer	alzheimer	X
cana-5141	368	25	’s	’s	PART
cana-5141	368	26	disease	disease	PROPN
cana-5141	368	27	mouse	mouse	PROPN
cana-5141	368	28	model	model	NOUN
cana-5141	368	29	’	'	PUNCT
cana-5141	368	30	,	,	PUNCT
cana-5141	368	31	j	j	PROPN
cana-5141	368	32	pineal	pineal	NOUN
cana-5141	368	33	res	re	NOUN
cana-5141	368	34	,	,	PUNCT
cana-5141	368	35	vol	vol	NOUN
cana-5141	368	36	.	.	PROPN
cana-5141	369	1	72	72	NUM
cana-5141	369	2	,	,	PUNCT
cana-5141	369	3	no	no	INTJ
cana-5141	369	4	.	.	NOUN
cana-5141	369	5	3	3	NUM
cana-5141	369	6	,	,	PUNCT
cana-5141	369	7	apr	apr	NOUN
cana-5141	369	8	.	.	PROPN
cana-5141	370	1	2022	2022	NUM
cana-5141	370	2	,	,	PUNCT
cana-5141	370	3	doi	doi	NOUN
cana-5141	370	4	:	:	PUNCT
cana-5141	370	5	10.1111	10.1111	NUM
cana-5141	370	6	/	/	SYM
cana-5141	370	7	jpi.12787	jpi.12787	NOUN
cana-5141	370	8	.	.	PUNCT
cana-5141	371	1	[	[	X
cana-5141	371	2	58	58	NUM
cana-5141	371	3	]	]	X
cana-5141	371	4	n.	n.	PROPN
cana-5141	371	5	thapar	thapar	PROPN
cana-5141	371	6	,	,	PUNCT
cana-5141	371	7	m.	m.	PROPN
cana-5141	371	8	a.	a.	PROPN
cana-5141	371	9	f.	f.	PROPN
cana-5141	371	10	eid	eid	PROPN
cana-5141	371	11	,	,	PUNCT
cana-5141	371	12	n.	n.	PROPN
cana-5141	371	13	raj	raj	PROPN
cana-5141	371	14	,	,	PUNCT
cana-5141	371	15	t.	t.	PROPN
cana-5141	371	16	kantas	kantas	PROPN
cana-5141	371	17	,	,	PUNCT
cana-5141	371	18	h.	h.	PROPN
cana-5141	371	19	s.	s.	PROPN
cana-5141	371	20	billing	billing	PROPN
cana-5141	371	21	,	,	PUNCT
cana-5141	371	22	and	and	CCONJ
cana-5141	371	23	d.	d.	PROPN
cana-5141	371	24	sadhu	sadhu	PROPN
cana-5141	371	25	,	,	PUNCT
cana-5141	371	26	‘	'	PUNCT
cana-5141	371	27	application	application	NOUN
cana-5141	371	28	of	of	ADP
cana-5141	371	29	crispr	crispr	NOUN
cana-5141	371	30	/	/	SYM
cana-5141	371	31	cas9	cas9	NOUN
cana-5141	371	32	in	in	ADP
cana-5141	371	33	the	the	DET
cana-5141	371	34	management	management	NOUN
cana-5141	371	35	of	of	ADP
cana-5141	371	36	alzheimer	alzheimer	PROPN
cana-5141	371	37	’s	’s	PART
cana-5141	371	38	disease	disease	NOUN
cana-5141	371	39	and	and	CCONJ
cana-5141	371	40	parkinson	parkinson	NOUN
cana-5141	371	41	’s	’s	PART
cana-5141	371	42	disease	disease	NOUN
cana-5141	371	43	:	:	PUNCT
cana-5141	371	44	a	a	DET
cana-5141	371	45	review	review	NOUN
cana-5141	371	46	’	'	PUNCT
cana-5141	371	47	,	,	PUNCT
cana-5141	371	48	annals	annal	NOUN
cana-5141	371	49	of	of	ADP
cana-5141	371	50	medicine	medicine	NOUN
cana-5141	371	51	&	&	CCONJ
cana-5141	371	52	surgery	surgery	NOUN
cana-5141	371	53	,	,	PUNCT
cana-5141	371	54	vol	vol	NOUN
cana-5141	371	55	.	.	PROPN
cana-5141	371	56	86	86	NUM
cana-5141	371	57	,	,	PUNCT
cana-5141	371	58	no	no	INTJ
cana-5141	371	59	.	.	NOUN
cana-5141	371	60	1	1	NUM
cana-5141	371	61	,	,	PUNCT
cana-5141	371	62	pp	pp	ADJ
cana-5141	371	63	.	.	PUNCT
cana-5141	372	1	329–335	329–335	NUM
cana-5141	372	2	,	,	PUNCT
cana-5141	372	3	jan	jan	PROPN
cana-5141	372	4	.	.	PROPN
cana-5141	372	5	2024	2024	NUM
cana-5141	372	6	,	,	PUNCT
cana-5141	372	7	doi	doi	NOUN
cana-5141	372	8	:	:	PUNCT
cana-5141	372	9	10.1097	10.1097	NUM
cana-5141	372	10	/	/	SYM
cana-5141	372	11	ms9.0000000000001500	ms9.0000000000001500	NOUN
cana-5141	372	12	.	.	PUNCT
cana-5141	373	1	[	[	X
cana-5141	373	2	59	59	NUM
cana-5141	373	3	]	]	PUNCT
cana-5141	373	4	m.	m.	NOUN
cana-5141	373	5	adli	adli	PROPN
cana-5141	373	6	,	,	PUNCT
cana-5141	373	7	‘	'	PUNCT
cana-5141	373	8	the	the	DET
cana-5141	373	9	crispr	crispr	ADJ
cana-5141	373	10	tool	tool	NOUN
cana-5141	373	11	kit	kit	NOUN
cana-5141	373	12	for	for	ADP
cana-5141	373	13	genome	genome	NOUN
cana-5141	373	14	editing	editing	NOUN
cana-5141	373	15	and	and	CCONJ
cana-5141	373	16	beyond	beyond	ADP
cana-5141	373	17	’	'	PUNCT
cana-5141	373	18	,	,	PUNCT
cana-5141	373	19	nat	nat	PROPN
cana-5141	373	20	commun	commun	PROPN
cana-5141	373	21	,	,	PUNCT
cana-5141	373	22	vol	vol	NOUN
cana-5141	373	23	.	.	PROPN
cana-5141	373	24	9	9	NUM
cana-5141	373	25	,	,	PUNCT
cana-5141	373	26	no	no	INTJ
cana-5141	373	27	.	.	NOUN
cana-5141	373	28	1	1	NUM
cana-5141	373	29	,	,	PUNCT
cana-5141	373	30	p.	p.	NOUN
cana-5141	373	31	1911	1911	NUM
cana-5141	373	32	,	,	PUNCT
cana-5141	373	33	may	may	AUX
cana-5141	373	34	2018	2018	NUM
cana-5141	373	35	,	,	PUNCT
cana-5141	373	36	doi	doi	NOUN
cana-5141	373	37	:	:	PUNCT
cana-5141	373	38	10.1038	10.1038	NUM
cana-5141	373	39	/	/	SYM
cana-5141	373	40	s41467	s41467	NOUN
cana-5141	373	41	-	-	PUNCT
cana-5141	373	42	018	018	NUM
cana-5141	373	43	-	-	PUNCT
cana-5141	373	44	04252	04252	NUM
cana-5141	373	45	-	-	PUNCT
cana-5141	373	46	2	2	NUM
cana-5141	373	47	.	.	PUNCT
cana-5141	374	1	[	[	X
cana-5141	374	2	60	60	NUM
cana-5141	374	3	]	]	X
cana-5141	374	4	c.	c.	PROPN
cana-5141	374	5	guo	guo	PROPN
cana-5141	374	6	,	,	PUNCT
cana-5141	374	7	x.	x.	PROPN
cana-5141	374	8	ma	ma	PROPN
cana-5141	374	9	,	,	PUNCT
cana-5141	374	10	f.	f.	PROPN
cana-5141	374	11	gao	gao	PROPN
cana-5141	374	12	,	,	PUNCT
cana-5141	374	13	and	and	CCONJ
cana-5141	374	14	y.	y.	PROPN
cana-5141	374	15	guo	guo	PROPN
cana-5141	374	16	,	,	PUNCT
cana-5141	374	17	‘	'	PUNCT
cana-5141	374	18	off	off	ADP
cana-5141	374	19	-	-	PUNCT
cana-5141	374	20	target	target	NOUN
cana-5141	374	21	effects	effect	NOUN
cana-5141	374	22	in	in	ADP
cana-5141	374	23	crispr	crispr	ADJ
cana-5141	374	24	/	/	SYM
cana-5141	374	25	cas9	cas9	NOUN
cana-5141	374	26	gene	gene	NOUN
cana-5141	374	27	editing	edit	VERB
cana-5141	374	28	’	'	PUNCT
cana-5141	374	29	,	,	PUNCT
cana-5141	374	30	front	front	ADJ
cana-5141	374	31	bioeng	bioeng	PROPN
cana-5141	374	32	biotechnol	biotechnol	NOUN
cana-5141	374	33	,	,	PUNCT
cana-5141	374	34	vol	vol	NOUN
cana-5141	374	35	.	.	PROPN
cana-5141	374	36	11	11	NUM
cana-5141	374	37	,	,	PUNCT
cana-5141	374	38	mar	mar	PROPN
cana-5141	374	39	.	.	PROPN
cana-5141	374	40	2023	2023	NUM
cana-5141	374	41	,	,	PUNCT
cana-5141	374	42	doi	doi	NOUN
cana-5141	374	43	:	:	PUNCT
cana-5141	374	44	10.3389	10.3389	NUM
cana-5141	374	45	/	/	SYM
cana-5141	374	46	fbioe.2023.1143157	fbioe.2023.1143157	NOUN
cana-5141	374	47	.	.	PUNCT
cana-5141	375	1	[	[	X
cana-5141	375	2	61	61	NUM
cana-5141	375	3	]	]	PUNCT
cana-5141	375	4	l.	l.	PROPN
cana-5141	375	5	zhang	zhang	PROPN
cana-5141	375	6	,	,	PUNCT
cana-5141	375	7	y.	y.	PROPN
cana-5141	375	8	liu	liu	PROPN
cana-5141	375	9	,	,	PUNCT
cana-5141	375	10	y.	y.	PROPN
cana-5141	375	11	lu	lu	PROPN
cana-5141	375	12	,	,	PUNCT
cana-5141	375	13	and	and	CCONJ
cana-5141	375	14	g.	g.	PROPN
cana-5141	375	15	wang	wang	PROPN
cana-5141	375	16	,	,	PUNCT
cana-5141	375	17	‘	'	PUNCT
cana-5141	375	18	targeting	target	VERB
cana-5141	375	19	epigenetics	epigenetic	NOUN
cana-5141	375	20	as	as	ADP
cana-5141	375	21	a	a	DET
cana-5141	375	22	promising	promising	ADJ
cana-5141	375	23	therapeutic	therapeutic	ADJ
cana-5141	375	24	strategy	strategy	NOUN
cana-5141	375	25	for	for	ADP
cana-5141	375	26	treatment	treatment	NOUN
cana-5141	375	27	of	of	ADP
cana-5141	375	28	neurodegenerative	neurodegenerative	ADJ
cana-5141	375	29	diseases	disease	NOUN
cana-5141	375	30	’	'	PUNCT
cana-5141	375	31	,	,	PUNCT
cana-5141	375	32	biochem	biochem	PROPN
cana-5141	375	33	pharmacol	pharmacol	NOUN
cana-5141	375	34	,	,	PUNCT
cana-5141	375	35	vol	vol	NOUN
cana-5141	375	36	.	.	PROPN
cana-5141	375	37	206	206	NUM
cana-5141	375	38	,	,	PUNCT
cana-5141	375	39	p.	p.	NOUN
cana-5141	375	40	115295	115295	NUM
cana-5141	375	41	,	,	PUNCT
cana-5141	375	42	dec	dec	PROPN
cana-5141	375	43	.	.	PROPN
cana-5141	375	44	2022	2022	NUM
cana-5141	375	45	,	,	PUNCT
cana-5141	375	46	doi	doi	NOUN
cana-5141	375	47	:	:	PUNCT
cana-5141	375	48	10.1016	10.1016	NUM
cana-5141	375	49	/	/	SYM
cana-5141	375	50	j.bcp.2022.115295	j.bcp.2022.115295	NOUN
cana-5141	375	51	.	.	PUNCT
cana-5141	376	1	[	[	X
cana-5141	376	2	62	62	NUM
cana-5141	376	3	]	]	X
cana-5141	376	4	n.	n.	PROPN
cana-5141	376	5	thapar	thapar	PROPN
cana-5141	376	6	,	,	PUNCT
cana-5141	376	7	m.	m.	PROPN
cana-5141	376	8	a.	a.	PROPN
cana-5141	376	9	f.	f.	PROPN
cana-5141	376	10	eid	eid	PROPN
cana-5141	376	11	,	,	PUNCT
cana-5141	376	12	n.	n.	PROPN
cana-5141	376	13	raj	raj	PROPN
cana-5141	376	14	,	,	PUNCT
cana-5141	376	15	t.	t.	PROPN
cana-5141	376	16	kantas	kantas	PROPN
cana-5141	376	17	,	,	PUNCT
cana-5141	376	18	h.	h.	PROPN
cana-5141	376	19	s.	s.	PROPN
cana-5141	376	20	billing	billing	PROPN
cana-5141	376	21	,	,	PUNCT
cana-5141	376	22	and	and	CCONJ
cana-5141	376	23	d.	d.	PROPN
cana-5141	376	24	sadhu	sadhu	PROPN
cana-5141	376	25	,	,	PUNCT
cana-5141	376	26	‘	'	PUNCT
cana-5141	376	27	application	application	NOUN
cana-5141	376	28	of	of	ADP
cana-5141	376	29	crispr	crispr	NOUN
cana-5141	376	30	/	/	SYM
cana-5141	376	31	cas9	cas9	NOUN
cana-5141	376	32	in	in	ADP
cana-5141	376	33	the	the	DET
cana-5141	376	34	management	management	NOUN
cana-5141	376	35	of	of	ADP
cana-5141	376	36	alzheimer	alzheimer	PROPN
cana-5141	376	37	’s	’s	PART
cana-5141	376	38	disease	disease	NOUN
cana-5141	376	39	and	and	CCONJ
cana-5141	376	40	parkinson	parkinson	NOUN
cana-5141	376	41	’s	’s	PART
cana-5141	376	42	disease	disease	NOUN
cana-5141	376	43	:	:	PUNCT
cana-5141	376	44	a	a	DET
cana-5141	376	45	review	review	NOUN
cana-5141	376	46	’	'	PUNCT
cana-5141	376	47	,	,	PUNCT
cana-5141	376	48	annals	annal	NOUN
cana-5141	376	49	of	of	ADP
cana-5141	376	50	medicine	medicine	NOUN
cana-5141	376	51	&	&	CCONJ
cana-5141	376	52	surgery	surgery	NOUN
cana-5141	376	53	,	,	PUNCT
cana-5141	376	54	vol	vol	NOUN
cana-5141	376	55	.	.	PROPN
cana-5141	376	56	86	86	NUM
cana-5141	376	57	,	,	PUNCT
cana-5141	376	58	no	no	INTJ
cana-5141	376	59	.	.	NOUN
cana-5141	376	60	1	1	NUM
cana-5141	376	61	,	,	PUNCT
cana-5141	376	62	pp	pp	ADJ
cana-5141	376	63	.	.	PUNCT
cana-5141	377	1	329–335	329–335	NUM
cana-5141	377	2	,	,	PUNCT
cana-5141	377	3	jan	jan	PROPN
cana-5141	377	4	.	.	PROPN
cana-5141	377	5	2024	2024	NUM
cana-5141	377	6	,	,	PUNCT
cana-5141	377	7	doi	doi	NOUN
cana-5141	377	8	:	:	PUNCT
cana-5141	377	9	10.1097	10.1097	NUM
cana-5141	377	10	/	/	SYM
cana-5141	377	11	ms9.0000000000001500	ms9.0000000000001500	NOUN
cana-5141	377	12	.	.	PUNCT
cana-5141	378	1	[	[	X
cana-5141	378	2	63	63	NUM
cana-5141	378	3	]	]	PUNCT
cana-5141	378	4	z.	z.	PROPN
cana-5141	378	5	song	song	PROPN
cana-5141	378	6	,	,	PUNCT
cana-5141	378	7	y.	y.	PROPN
cana-5141	378	8	tao	tao	PROPN
cana-5141	378	9	,	,	PUNCT
cana-5141	378	10	y.	y.	PROPN
cana-5141	378	11	liu	liu	PROPN
cana-5141	378	12	,	,	PUNCT
cana-5141	378	13	and	and	CCONJ
cana-5141	378	14	j.	j.	PROPN
cana-5141	378	15	li	li	PROPN
cana-5141	378	16	,	,	PUNCT
cana-5141	378	17	‘	'	PUNCT
cana-5141	378	18	advances	advance	NOUN
cana-5141	378	19	in	in	ADP
cana-5141	378	20	delivery	delivery	NOUN
cana-5141	378	21	systems	system	NOUN
cana-5141	378	22	for	for	ADP
cana-5141	378	23	crispr	crispr	ADJ
cana-5141	378	24	/	/	SYM
cana-5141	378	25	cas	cas	ADJ
cana-5141	378	26	-	-	PUNCT
cana-5141	378	27	mediated	mediate	VERB
cana-5141	378	28	cancer	cancer	NOUN
cana-5141	378	29	treatment	treatment	NOUN
cana-5141	378	30	:	:	PUNCT
cana-5141	378	31	a	a	DET
cana-5141	378	32	focus	focus	NOUN
cana-5141	378	33	on	on	ADP
cana-5141	378	34	viral	viral	ADJ
cana-5141	378	35	vectors	vector	NOUN
cana-5141	378	36	and	and	CCONJ
cana-5141	378	37	extracellular	extracellular	ADJ
cana-5141	378	38	vesicles	vesicle	NOUN
cana-5141	378	39	’	'	PUNCT
cana-5141	378	40	,	,	PUNCT
cana-5141	378	41	front	front	ADJ
cana-5141	378	42	immunol	immunol	NOUN
cana-5141	378	43	,	,	PUNCT
cana-5141	378	44	vol	vol	NOUN
cana-5141	378	45	.	.	PROPN
cana-5141	378	46	15	15	NUM
cana-5141	378	47	,	,	PUNCT
cana-5141	378	48	aug	aug	PROPN
cana-5141	378	49	.	.	PROPN
cana-5141	378	50	2024	2024	NUM
cana-5141	378	51	,	,	PUNCT
cana-5141	378	52	doi	doi	NOUN
cana-5141	378	53	:	:	PUNCT
cana-5141	378	54	10.3389	10.3389	NUM
cana-5141	378	55	/	/	SYM
cana-5141	378	56	fimmu.2024.1444437	fimmu.2024.1444437	NOUN
cana-5141	378	57	.	.	PUNCT
cana-5141	379	1	[	[	X
cana-5141	379	2	64	64	NUM
cana-5141	379	3	]	]	PUNCT
cana-5141	379	4	x.	x.	NOUN
cana-5141	379	5	zhang	zhang	PROPN
cana-5141	379	6	,	,	PUNCT
cana-5141	379	7	‘	'	PUNCT
cana-5141	379	8	application	application	NOUN
cana-5141	379	9	of	of	ADP
cana-5141	379	10	crispr	crispr	ADJ
cana-5141	379	11	/	/	SYM
cana-5141	379	12	cas9	cas9	NOUN
cana-5141	379	13	gene	gene	NOUN
cana-5141	379	14	-	-	PUNCT
cana-5141	379	15	editing	edit	VERB
cana-5141	379	16	technology	technology	NOUN
cana-5141	379	17	in	in	ADP
cana-5141	379	18	alzheimers	alzheimers	PROPN
cana-5141	379	19	disease	disease	NOUN
cana-5141	379	20	’	'	PUNCT
cana-5141	379	21	,	,	PUNCT
cana-5141	379	22	theoretical	theoretical	ADJ
cana-5141	379	23	and	and	CCONJ
cana-5141	379	24	natural	natural	ADJ
cana-5141	379	25	science	science	NOUN
cana-5141	379	26	,	,	PUNCT
cana-5141	379	27	vol	vol	NOUN
cana-5141	379	28	.	.	PROPN
cana-5141	379	29	54	54	NUM
cana-5141	379	30	,	,	PUNCT
cana-5141	379	31	no	no	INTJ
cana-5141	379	32	.	.	NOUN
cana-5141	379	33	1	1	NUM
cana-5141	379	34	,	,	PUNCT
cana-5141	379	35	pp	pp	ADJ
cana-5141	379	36	.	.	PUNCT
cana-5141	379	37	63–68	63–68	NUM
cana-5141	379	38	,	,	PUNCT
cana-5141	379	39	oct	oct	PROPN
cana-5141	379	40	.	.	PROPN
cana-5141	379	41	2024	2024	NUM
cana-5141	379	42	,	,	PUNCT
cana-5141	379	43	doi	doi	NOUN
cana-5141	379	44	:	:	PUNCT
cana-5141	379	45	10.54254/27538818/54/2024au0120	10.54254/27538818/54/2024au0120	NUM
cana-5141	379	46	.	.	PUNCT
cana-5141	379	47	communications	communication	NOUN
cana-5141	379	48	on	on	ADP
cana-5141	379	49	applied	apply	VERB
cana-5141	379	50	nonlinear	nonlinear	ADJ
cana-5141	379	51	analysis	analysis	NOUN
cana-5141	379	52	issn	issn	NOUN
cana-5141	379	53	:	:	PUNCT
cana-5141	379	54	1074	1074	NUM
cana-5141	379	55	-	-	PUNCT
cana-5141	379	56	133x	133x	NUM
cana-5141	379	57	vol	vol	NOUN
cana-5141	379	58	32	32	NUM
cana-5141	379	59	no	no	NOUN
cana-5141	379	60	.	.	PUNCT
cana-5141	380	1	icmasd	icmasd	NOUN
cana-5141	380	2	(	(	PUNCT
cana-5141	380	3	2025	2025	NUM
cana-5141	380	4	)	)	PUNCT
cana-5141	380	5	1154	1154	NUM
cana-5141	380	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5141	381	1	[	[	X
cana-5141	381	2	65	65	NUM
cana-5141	381	3	]	]	X
cana-5141	381	4	a.	a.	NOUN
cana-5141	381	5	arabi	arabi	PROPN
cana-5141	381	6	,	,	PUNCT
cana-5141	381	7	s.	s.	PROPN
cana-5141	381	8	a.	a.	PROPN
cana-5141	381	9	karimi	karimi	PROPN
cana-5141	381	10	,	,	PUNCT
cana-5141	381	11	i.	i.	PROPN
cana-5141	381	12	salehi	salehi	PROPN
cana-5141	381	13	,	,	PUNCT
cana-5141	381	14	r.	r.	PROPN
cana-5141	381	15	haddadi	haddadi	PROPN
cana-5141	381	16	,	,	PUNCT
cana-5141	381	17	and	and	CCONJ
cana-5141	381	18	a.	a.	NOUN
cana-5141	381	19	komaki	komaki	PROPN
cana-5141	381	20	,	,	PUNCT
cana-5141	381	21	‘	'	PUNCT
cana-5141	381	22	effects	effect	NOUN
cana-5141	381	23	of	of	ADP
cana-5141	381	24	sesamin	sesamin	NOUN
cana-5141	381	25	on	on	ADP
cana-5141	381	26	aβ1	aβ1	NOUN
cana-5141	381	27	-	-	PUNCT
cana-5141	381	28	42induced	42induce	VERB
cana-5141	381	29	oxidative	oxidative	ADJ
cana-5141	381	30	stress	stress	NOUN
cana-5141	381	31	and	and	CCONJ
cana-5141	381	32	ltp	ltp	PROPN
cana-5141	381	33	impairment	impairment	NOUN
cana-5141	381	34	in	in	ADP
cana-5141	381	35	a	a	DET
cana-5141	381	36	rat	rat	NOUN
cana-5141	381	37	model	model	NOUN
cana-5141	381	38	of	of	ADP
cana-5141	381	39	alzheimer	alzheimer	PROPN
cana-5141	381	40	’s	’s	PART
cana-5141	381	41	disease	disease	NOUN
cana-5141	381	42	’	'	PUNCT
cana-5141	381	43	,	,	PUNCT
cana-5141	381	44	metab	metab	ADJ
cana-5141	381	45	brain	brain	NOUN
cana-5141	381	46	dis	dis	PROPN
cana-5141	381	47	,	,	PUNCT
cana-5141	381	48	vol	vol	NOUN
cana-5141	381	49	.	.	PROPN
cana-5141	382	1	38	38	NUM
cana-5141	382	2	,	,	PUNCT
cana-5141	382	3	no	no	INTJ
cana-5141	382	4	.	.	NOUN
cana-5141	382	5	5	5	NUM
cana-5141	382	6	,	,	PUNCT
cana-5141	382	7	pp	pp	ADJ
cana-5141	382	8	.	.	PUNCT
cana-5141	382	9	1503–1511	1503–1511	NUM
cana-5141	382	10	,	,	PUNCT
cana-5141	382	11	jun	jun	PROPN
cana-5141	382	12	.	.	PROPN
cana-5141	382	13	2023	2023	NUM
cana-5141	382	14	,	,	PUNCT
cana-5141	382	15	doi	doi	NOUN
cana-5141	382	16	:	:	PUNCT
cana-5141	382	17	10.1007	10.1007	NUM
cana-5141	382	18	/	/	SYM
cana-5141	382	19	s11011	s11011	NOUN
cana-5141	382	20	-	-	PUNCT
cana-5141	382	21	023	023	NUM
cana-5141	382	22	-	-	PUNCT
cana-5141	382	23	01191	01191	NUM
cana-5141	382	24	-	-	PUNCT
cana-5141	382	25	w.	w.	NOUN
cana-5141	383	1	[	[	X
cana-5141	383	2	66	66	NUM
cana-5141	383	3	]	]	PUNCT
cana-5141	383	4	k.	k.	PROPN
cana-5141	383	5	nagata	nagata	PROPN
cana-5141	383	6	et	et	PROPN
cana-5141	383	7	al	al	PROPN
cana-5141	383	8	.	.	PROPN
cana-5141	383	9	,	,	PUNCT
cana-5141	383	10	‘	'	PUNCT
cana-5141	383	11	generation	generation	NOUN
cana-5141	383	12	of	of	ADP
cana-5141	383	13	app	app	NOUN
cana-5141	383	14	knock	knock	VERB
cana-5141	383	15	-	-	PUNCT
cana-5141	383	16	in	in	ADP
cana-5141	383	17	mice	mouse	NOUN
cana-5141	383	18	reveals	reveal	VERB
cana-5141	383	19	deletion	deletion	NOUN
cana-5141	383	20	mutations	mutation	NOUN
cana-5141	383	21	protective	protective	ADJ
cana-5141	383	22	against	against	ADP
cana-5141	383	23	alzheimer	alzheimer	PROPN
cana-5141	383	24	’s	’s	PART
cana-5141	383	25	disease	disease	NOUN
cana-5141	383	26	-	-	PUNCT
cana-5141	383	27	like	like	ADJ
cana-5141	383	28	pathology	pathology	NOUN
cana-5141	383	29	’	'	PUNCT
cana-5141	383	30	,	,	PUNCT
cana-5141	383	31	nat	nat	PROPN
cana-5141	383	32	commun	commun	PROPN
cana-5141	383	33	,	,	PUNCT
cana-5141	383	34	vol	vol	NOUN
cana-5141	383	35	.	.	PROPN
cana-5141	384	1	9	9	NUM
cana-5141	384	2	,	,	PUNCT
cana-5141	384	3	no	no	INTJ
cana-5141	384	4	.	.	NOUN
cana-5141	384	5	1	1	NUM
cana-5141	384	6	,	,	PUNCT
cana-5141	384	7	p.	p.	NOUN
cana-5141	384	8	1800	1800	NUM
cana-5141	384	9	,	,	PUNCT
cana-5141	384	10	may	may	AUX
cana-5141	384	11	2018	2018	NUM
cana-5141	384	12	,	,	PUNCT
cana-5141	384	13	doi	doi	NOUN
cana-5141	384	14	:	:	PUNCT
cana-5141	384	15	10.1038	10.1038	NUM
cana-5141	384	16	/	/	SYM
cana-5141	384	17	s41467	s41467	NOUN
cana-5141	384	18	-	-	PUNCT
cana-5141	384	19	018	018	NUM
cana-5141	384	20	-	-	PUNCT
cana-5141	384	21	04238	04238	NUM
cana-5141	384	22	-	-	PUNCT
cana-5141	384	23	0	0	NUM
cana-5141	384	24	.	.	PUNCT
cana-5141	385	1	[	[	X
cana-5141	385	2	67	67	NUM
cana-5141	385	3	]	]	PUNCT
cana-5141	385	4	l.	l.	PROPN
cana-5141	385	5	lu	lu	PROPN
cana-5141	385	6	,	,	PUNCT
cana-5141	385	7	x.	x.	PROPN
cana-5141	385	8	yu	yu	PROPN
cana-5141	385	9	,	,	PUNCT
cana-5141	385	10	y.	y.	PROPN
cana-5141	385	11	cai	cai	PROPN
cana-5141	385	12	,	,	PUNCT
cana-5141	385	13	m.	m.	NOUN
cana-5141	385	14	sun	sun	PROPN
cana-5141	385	15	,	,	PUNCT
cana-5141	385	16	and	and	CCONJ
cana-5141	385	17	h.	h.	PROPN
cana-5141	385	18	yang	yang	PROPN
cana-5141	385	19	,	,	PUNCT
cana-5141	385	20	‘	'	PUNCT
cana-5141	385	21	application	application	NOUN
cana-5141	385	22	of	of	ADP
cana-5141	385	23	crispr	crispr	NOUN
cana-5141	385	24	/	/	SYM
cana-5141	385	25	cas9	cas9	NOUN
cana-5141	385	26	in	in	ADP
cana-5141	385	27	alzheimer	alzheimer	PROPN
cana-5141	385	28	’s	’s	PART
cana-5141	385	29	disease	disease	NOUN
cana-5141	385	30	’	'	PUNCT
cana-5141	385	31	,	,	PUNCT
cana-5141	385	32	front	front	ADJ
cana-5141	385	33	neurosci	neurosci	NOUN
cana-5141	385	34	,	,	PUNCT
cana-5141	385	35	vol	vol	NOUN
cana-5141	385	36	.	.	PROPN
cana-5141	385	37	15	15	NUM
cana-5141	385	38	,	,	PUNCT
cana-5141	385	39	dec	dec	PROPN
cana-5141	385	40	.	.	PROPN
cana-5141	385	41	2021	2021	NUM
cana-5141	385	42	,	,	PUNCT
cana-5141	385	43	doi	doi	NOUN
cana-5141	385	44	:	:	PUNCT
cana-5141	385	45	10.3389	10.3389	NUM
cana-5141	385	46	/	/	SYM
cana-5141	385	47	fnins.2021.803894	fnins.2021.803894	NOUN
cana-5141	385	48	.	.	PUNCT
cana-5141	386	1	[	[	X
cana-5141	386	2	68	68	NUM
cana-5141	386	3	]	]	PUNCT
cana-5141	386	4	t.	t.	X
cana-5141	386	5	doherty	doherty	PROPN
cana-5141	386	6	et	et	PROPN
cana-5141	386	7	al	al	PROPN
cana-5141	386	8	.	.	PROPN
cana-5141	386	9	,	,	PUNCT
cana-5141	386	10	‘	'	PUNCT
cana-5141	386	11	artificial	artificial	ADJ
cana-5141	386	12	intelligence	intelligence	NOUN
cana-5141	386	13	for	for	ADP
cana-5141	386	14	dementia	dementia	NOUN
cana-5141	386	15	drug	drug	NOUN
cana-5141	386	16	discovery	discovery	PROPN
cana-5141	386	17	and	and	CCONJ
cana-5141	386	18	trials	trial	NOUN
cana-5141	386	19	optimization	optimization	NOUN
cana-5141	386	20	’	'	PUNCT
cana-5141	386	21	,	,	PUNCT
cana-5141	386	22	alzheimer	alzheimer	PROPN
cana-5141	386	23	’s	’s	PART
cana-5141	386	24	&	&	CCONJ
cana-5141	386	25	dementia	dementia	PROPN
cana-5141	386	26	,	,	PUNCT
cana-5141	386	27	vol	vol	NOUN
cana-5141	386	28	.	.	PROPN
cana-5141	386	29	19	19	NUM
cana-5141	386	30	,	,	PUNCT
cana-5141	386	31	no	no	INTJ
cana-5141	386	32	.	.	NOUN
cana-5141	386	33	12	12	NUM
cana-5141	386	34	,	,	PUNCT
cana-5141	386	35	pp	pp	ADJ
cana-5141	386	36	.	.	PUNCT
cana-5141	387	1	5922–5933	5922–5933	NUM
cana-5141	387	2	,	,	PUNCT
cana-5141	387	3	dec	dec	PROPN
cana-5141	387	4	.	.	PROPN
cana-5141	387	5	2023	2023	NUM
cana-5141	387	6	,	,	PUNCT
cana-5141	387	7	doi	doi	NOUN
cana-5141	387	8	:	:	PUNCT
cana-5141	387	9	10.1002	10.1002	NUM
cana-5141	387	10	/	/	SYM
cana-5141	387	11	alz.13428	alz.13428	X
cana-5141	387	12	.	.	PUNCT
cana-5141	388	1	[	[	X
cana-5141	388	2	69	69	NUM
cana-5141	388	3	]	]	PUNCT
cana-5141	388	4	q.	q.	PROPN
cana-5141	388	5	chen	chen	PROPN
cana-5141	388	6	et	et	PROPN
cana-5141	388	7	al	al	PROPN
cana-5141	388	8	.	.	PROPN
cana-5141	388	9	,	,	PUNCT
cana-5141	388	10	‘	'	PUNCT
cana-5141	388	11	genome	genome	NOUN
cana-5141	388	12	-	-	PUNCT
cana-5141	388	13	wide	wide	ADJ
cana-5141	388	14	crispr	crispr	ADJ
cana-5141	388	15	off	off	ADP
cana-5141	388	16	-	-	PUNCT
cana-5141	388	17	target	target	NOUN
cana-5141	388	18	prediction	prediction	NOUN
cana-5141	388	19	and	and	CCONJ
cana-5141	388	20	optimization	optimization	NOUN
cana-5141	388	21	using	use	VERB
cana-5141	388	22	rnadna	rnadna	NOUN
cana-5141	388	23	interaction	interaction	NOUN
cana-5141	388	24	fingerprints	fingerprint	NOUN
cana-5141	388	25	’	'	PUNCT
cana-5141	388	26	,	,	PUNCT
cana-5141	388	27	nat	nat	PROPN
cana-5141	388	28	commun	commun	PROPN
cana-5141	388	29	,	,	PUNCT
cana-5141	388	30	vol	vol	NOUN
cana-5141	388	31	.	.	PROPN
cana-5141	389	1	14	14	NUM
cana-5141	389	2	,	,	PUNCT
cana-5141	389	3	no	no	INTJ
cana-5141	389	4	.	.	NOUN
cana-5141	389	5	1	1	NUM
cana-5141	389	6	,	,	PUNCT
cana-5141	389	7	p.	p.	NOUN
cana-5141	389	8	7521	7521	NUM
cana-5141	389	9	,	,	PUNCT
cana-5141	389	10	nov	nov	PROPN
cana-5141	389	11	.	.	PROPN
cana-5141	389	12	2023	2023	NUM
cana-5141	389	13	,	,	PUNCT
cana-5141	389	14	doi	doi	NOUN
cana-5141	389	15	:	:	PUNCT
cana-5141	389	16	10.1038	10.1038	NUM
cana-5141	389	17	/	/	SYM
cana-5141	389	18	s41467	s41467	NOUN
cana-5141	389	19	-	-	PUNCT
cana-5141	389	20	023	023	NUM
cana-5141	389	21	-	-	PUNCT
cana-5141	389	22	42695	42695	NUM
cana-5141	389	23	-	-	SYM
cana-5141	389	24	4	4	NUM
cana-5141	389	25	.	.	PUNCT